"Bivalirudin";"CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O";"* Normal renal function: 25 min (in normal conditions)
* Creatinine clearance 10-29mL/min: 57min
* Dialysis-dependant patients: 3.5h";"B01AE06";"Prothrombin";"F2";"yes";"inhibitor"
"Goserelin";"CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O";"4-5 hours";"L02AE03";"Lutropin-choriogonadotropic hormone receptor";"LHCGR";"yes";"agonist"
"Goserelin";"CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O";"4-5 hours";"L02AE03";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"agonist"
"Desmopressin";"NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O";"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [L1184].";"H01BA02";"Vasopressin V2 receptor";"AVPR2";"yes";"agonist"
"Desmopressin";"NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O";"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [L1184].";"H01BA02";"Vasopressin V1a receptor";"AVPR1A";"yes";""
"Desmopressin";"NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O";"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [L1184].";"H01BA02";"Vasopressin V1b receptor";"AVPR1B";"yes";""
"Cetrorelix";"CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O";"~62.8 hours";"H01CC02";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"antagonist"
"Cetrorelix";"CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O";"~62.8 hours";"H01CC02";"Lutropin-choriogonadotropic hormone receptor";"LHCGR";"unknown";""
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"S01XA18";"Calcium signal-modulating cyclophilin ligand";"CAMLG";"yes";"binder"
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"L04AD01";"Calcium signal-modulating cyclophilin ligand";"CAMLG";"yes";"binder"
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"S01XA18";"Calcineurin subunit B type 2";"PPP3R2";"yes";"inhibitor"
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"L04AD01";"Calcineurin subunit B type 2";"PPP3R2";"yes";"inhibitor"
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"S01XA18";"Peptidyl-prolyl cis-trans isomerase A";"PPIA";"unknown";""
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"L04AD01";"Peptidyl-prolyl cis-trans isomerase A";"PPIA";"unknown";""
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"S01XA18";"Peptidyl-prolyl cis-trans isomerase F, mitochondrial";"PPIF";"unknown";"binder"
"Cyclosporine";"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C";"Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.";"L04AD01";"Peptidyl-prolyl cis-trans isomerase F, mitochondrial";"PPIF";"unknown";"binder"
"Octreotide";"[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O";"";"H01CB02";"Somatostatin receptor type 1";"SSTR1";"yes";""
"Octreotide";"[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O";"";"H01CB02";"Somatostatin receptor type 5";"SSTR5";"yes";""
"Octreotide";"[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O";"";"H01CB02";"Somatostatin receptor type 2";"SSTR2";"yes";"binder"
"Abarelix";"CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O";"13.2 &plusmn; 3.2 days";"L02BX01";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"antagonist"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Alanine--glyoxylate aminotransferase 2, mitochondrial";"AGXT2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glutamate decarboxylase 1";"GAD1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Cystathionine beta-synthase";"CBS";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Kynureninase";"KYNU";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine hydroxymethyltransferase, cytosolic";"SHMT1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Cysteine desulfurase, mitochondrial";"NFS1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Aspartate aminotransferase, cytoplasmic";"GOT1";"unknown";"activator"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Ornithine aminotransferase, mitochondrial";"OAT";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Ornithine decarboxylase";"ODC1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial";"AADAT";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"4-aminobutyrate aminotransferase, mitochondrial";"ABAT";"unknown";"inhibitor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Pyridoxine-5'-phosphate oxidase";"PNPO";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Sphingosine-1-phosphate lyase 1";"SGPL1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Tyrosine aminotransferase";"TAT";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Kynurenine--oxoglutarate transaminase 1";"CCBL1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Threonine synthase-like 1";"THNSL1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glycogen phosphorylase, liver form";"PYGL";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine palmitoyltransferase 2";"SPTLC2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Cysteine sulfinic acid decarboxylase";"CSAD";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Histidine decarboxylase";"HDC";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Arginine decarboxylase";"AZIN2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"L-serine dehydratase/L-threonine deaminase";"SDS";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial";"GCAT";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glycine dehydrogenase [decarboxylating], mitochondrial";"GLDC";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Alanine aminotransferase 1";"GPT";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Phosphoserine aminotransferase";"PSAT1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"5-aminolevulinate synthase, nonspecific, mitochondrial";"ALAS1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine--pyruvate aminotransferase";"AGXT";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Pyridoxal phosphate phosphatase";"PDXP";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine palmitoyltransferase 1";"SPTLC1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Cystathionine gamma-lyase";"CTH";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Branched-chain-amino-acid aminotransferase, cytosolic";"BCAT1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Branched-chain-amino-acid aminotransferase, mitochondrial";"BCAT2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Proline synthase co-transcribed bacterial homolog protein";"PROSC";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Formimidoyltransferase-cyclodeaminase";"FTCD";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Aspartate aminotransferase, mitochondrial";"GOT2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glycogen phosphorylase, brain form";"PYGB";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glycogen phosphorylase, muscle form";"PYGM";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Aromatic-L-amino-acid decarboxylase";"DDC";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Aspartate aminotransferase";"GIG18";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"GAD1 protein";"GAD1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine hydroxymethyltransferase";"";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Selenocysteine lyase variant";"";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Phosphorylase";"";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Ornithine aminotransferase variant";"";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"5-aminolevulinate synthase";"ALAS1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glutamate decarboxylase 2 (Pancreatic islets and brain, 65kDa)";"GAD2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"DDC protein";"DDC";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Pyridoxal-dependent decarboxylase domain-containing protein 1";"PDXDC1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Kynurenine--oxoglutarate transaminase 3";"CCBL2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glutamate decarboxylase-like protein 1";"GADL1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Selenocysteine lyase";"SCLY";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Immunoglobulin superfamily member 10";"IGSF10";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"5-phosphohydroxy-L-lysine phospho-lyase";"PHYKPL";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glutamate decarboxylase 1 (Brain, 67kDa)";"GAD1";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine hydroxymethyltransferase, mitochondrial";"SHMT2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"5-aminolevulinate synthase, erythroid-specific, mitochondrial";"ALAS2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Alanine aminotransferase 2";"GPT2";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Molybdenum cofactor sulfurase";"MOCOS";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine dehydratase-like";"SDSL";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"P-selectin cytoplasmic tail-associated protein (PCAP)";"pcap";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Hepatic peroxysomal alanine:glyoxylate aminotransferase";"";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine racemase";"SRR";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"O-phosphoseryl-tRNA(Sec) selenium transferase";"SEPSECS";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Serine palmitoyltransferase 3";"SPTLC3";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Glutamic acid decarboxylase";"GAD65";"unknown";"cofactor"
"Pyridoxal Phosphate";"CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O";"";"A11HA06";"Alanine-glyoxylate aminotransferase homolog";"TLH6";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03AE01";"Methionine synthase";"MTR";"yes";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA51";"Methionine synthase";"MTR";"yes";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA01";"Methionine synthase";"MTR";"yes";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03AE01";"Methylmalonyl-CoA mutase, mitochondrial";"MUT";"yes";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA51";"Methylmalonyl-CoA mutase, mitochondrial";"MUT";"yes";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA01";"Methylmalonyl-CoA mutase, mitochondrial";"MUT";"yes";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03AE01";"Methionine synthase reductase";"MTRR";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA51";"Methionine synthase reductase";"MTRR";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA01";"Methionine synthase reductase";"MTRR";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03AE01";"Methylmalonic aciduria type A protein, mitochondrial";"MMAA";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA51";"Methylmalonic aciduria type A protein, mitochondrial";"MMAA";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA01";"Methylmalonic aciduria type A protein, mitochondrial";"MMAA";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03AE01";"Methylmalonic aciduria and homocystinuria type C protein";"MMACHC";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA51";"Methylmalonic aciduria and homocystinuria type C protein";"MMACHC";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA01";"Methylmalonic aciduria and homocystinuria type C protein";"MMACHC";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03AE01";"Methylenetetrahydrofolate reductase";"MTHFR";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA51";"Methylenetetrahydrofolate reductase";"MTHFR";"unknown";"cofactor"
"Cyanocobalamin";"[C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO";"Approximately 6 days (400 days in the liver).";"B03BA01";"Methylenetetrahydrofolate reductase";"MTHFR";"unknown";"cofactor"
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"Glycine N-methyltransferase";"GNMT";"unknown";"cofactor"
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"S-adenosylmethionine decarboxylase proenzyme";"AMD1";"unknown";"cofactor"
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"S-adenosylmethionine synthase isoform type-2";"MAT2A";"unknown";"cofactor"
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"Cystathionine beta-synthase";"CBS";"unknown";"activator"
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"S-adenosylmethionine synthase isoform type-1";"MAT1A";"unknown";"cofactor"
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"Catechol O-methyltransferase";"COMT";"unknown";"cofactor"
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1";"CMTR1";"unknown";""
"Ademetionine";"[H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O";"";"A16AA02";"Arsenite methyltransferase";"AS3MT";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Propionyl-CoA carboxylase beta chain, mitochondrial";"PCCB";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Biotin--protein ligase";"HLCS";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Sodium-dependent multivitamin transporter";"SLC5A6";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial";"MCCC2";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Acetyl-CoA carboxylase 2";"ACACB";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial";"MCCC1";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Pyruvate carboxylase, mitochondrial";"PC";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Propionyl-CoA carboxylase alpha chain, mitochondrial";"PCCA";"unknown";""
"Biotin";"[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2";"";"A11HA05";"Acetyl-CoA carboxylase 1";"ACACA";"unknown";""
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Choline-phosphate cytidylyltransferase B";"PCYT1B";"unknown";"product of"
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Acetylcholinesterase";"ACHE";"unknown";"product of"
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Choline-phosphate cytidylyltransferase A";"PCYT1A";"unknown";"product of"
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Phospholipase D2";"PLD2";"unknown";"product of"
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Cholinesterase";"BCHE";"unknown";"product of"
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Phospholipase D1";"PLD1";"unknown";"product of"
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Phosphoethanolamine/phosphocholine phosphatase";"PHOSPHO1";"unknown";"product of"
"Choline";"C[N+](C)(C)CCO";"";"N02BA03";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";""
"L-Lysine";"NCCCC[C@H](N)C(O)=O";"";"B05XB03";"High affinity cationic amino acid transporter 1";"SLC7A1";"unknown";""
"L-Lysine";"NCCCC[C@H](N)C(O)=O";"";"B05XB03";"Cationic amino acid transporter 4";"SLC7A4";"unknown";""
"L-Lysine";"NCCCC[C@H](N)C(O)=O";"";"B05XB03";"Cationic amino acid transporter 3";"SLC7A3";"unknown";""
"L-Lysine";"NCCCC[C@H](N)C(O)=O";"";"B05XB03";"Low affinity cationic amino acid transporter 2";"SLC7A2";"unknown";""
"L-Lysine";"NCCCC[C@H](N)C(O)=O";"";"B05XB03";"Lysine--tRNA ligase";"KARS";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Nitric oxide synthase, endothelial";"NOS3";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Cationic amino acid transporter 3";"SLC7A3";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Arginine decarboxylase";"AZIN2";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Argininosuccinate lyase";"ASL";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Nitric oxide synthase, inducible";"NOS2";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"High affinity cationic amino acid transporter 1";"SLC7A1";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Arginase-2, mitochondrial";"ARG2";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Cationic amino acid transporter 4";"SLC7A4";"unknown";""
"L-Arginine";"N[C@@H](CCCNC(N)=N)C(O)=O";"";"B05XB01";"Argininosuccinate synthase";"ASS1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Lactase-phlorizin hydrolase";"LCT";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Lactase-phlorizin hydrolase";"LCT";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Lactase-phlorizin hydrolase";"LCT";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Lactase-phlorizin hydrolase";"LCT";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Hyaluronate lyase";"";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Hyaluronate lyase";"";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Hyaluronate lyase";"";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Hyaluronate lyase";"";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Xylose isomerase";"xylA";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Xylose isomerase";"xylA";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Xylose isomerase";"xylA";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Xylose isomerase";"xylA";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2";"PLOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2";"PLOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2";"PLOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2";"PLOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Phytanoyl-CoA dioxygenase, peroxisomal";"PHYH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Phytanoyl-CoA dioxygenase, peroxisomal";"PHYH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Phytanoyl-CoA dioxygenase, peroxisomal";"PHYH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Phytanoyl-CoA dioxygenase, peroxisomal";"PHYH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3";"PLOD3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3";"PLOD3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3";"PLOD3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3";"PLOD3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Gamma-butyrobetaine dioxygenase";"BBOX1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Gamma-butyrobetaine dioxygenase";"BBOX1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Gamma-butyrobetaine dioxygenase";"BBOX1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Gamma-butyrobetaine dioxygenase";"BBOX1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Dopamine beta-hydroxylase";"DBH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Dopamine beta-hydroxylase";"DBH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Dopamine beta-hydroxylase";"DBH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Dopamine beta-hydroxylase";"DBH";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Peptidyl-glycine alpha-amidating monooxygenase";"PAM";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Peptidyl-glycine alpha-amidating monooxygenase";"PAM";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Peptidyl-glycine alpha-amidating monooxygenase";"PAM";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Peptidyl-glycine alpha-amidating monooxygenase";"PAM";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Prolyl 4-hydroxylase subunit alpha-1";"P4HA1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Prolyl 4-hydroxylase subunit alpha-1";"P4HA1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Prolyl 4-hydroxylase subunit alpha-1";"P4HA1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Prolyl 4-hydroxylase subunit alpha-1";"P4HA1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Prolyl 3-hydroxylase 1";"P3H1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Prolyl 3-hydroxylase 1";"P3H1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Prolyl 3-hydroxylase 1";"P3H1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Prolyl 3-hydroxylase 1";"P3H1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2";"OGFOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2";"OGFOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2";"OGFOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2";"OGFOD2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2";"ALKBH2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2";"ALKBH2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2";"ALKBH2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2";"ALKBH2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Prolyl 3-hydroxylase 2";"P3H2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Prolyl 3-hydroxylase 2";"P3H2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Prolyl 3-hydroxylase 2";"P3H2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Prolyl 3-hydroxylase 2";"P3H2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Prolyl 3-hydroxylase 3";"P3H3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Prolyl 3-hydroxylase 3";"P3H3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Prolyl 3-hydroxylase 3";"P3H3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Prolyl 3-hydroxylase 3";"P3H3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1";"OGFOD1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1";"OGFOD1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1";"OGFOD1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1";"OGFOD1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Egl nine homolog 2";"EGLN2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Egl nine homolog 2";"EGLN2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Egl nine homolog 2";"EGLN2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Egl nine homolog 2";"EGLN2";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3";"ALKBH3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3";"ALKBH3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3";"ALKBH3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3";"ALKBH3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Lysine-specific demethylase 5D";"KDM5D";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Lysine-specific demethylase 5D";"KDM5D";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Lysine-specific demethylase 5D";"KDM5D";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Lysine-specific demethylase 5D";"KDM5D";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Egl nine homolog 1";"EGLN1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Egl nine homolog 1";"EGLN1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Egl nine homolog 1";"EGLN1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Egl nine homolog 1";"EGLN1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Solute carrier family 23 member 1";"SLC23A1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Solute carrier family 23 member 1";"SLC23A1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Solute carrier family 23 member 1";"SLC23A1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Solute carrier family 23 member 1";"SLC23A1";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1";"PLOD1";"unknown";"activator"
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1";"PLOD1";"unknown";"activator"
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1";"PLOD1";"unknown";"activator"
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1";"PLOD1";"unknown";"activator"
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Egl nine homolog 3";"EGLN3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Egl nine homolog 3";"EGLN3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Egl nine homolog 3";"EGLN3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Egl nine homolog 3";"EGLN3";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Trimethyllysine dioxygenase, mitochondrial";"TMLHE";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Trimethyllysine dioxygenase, mitochondrial";"TMLHE";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Trimethyllysine dioxygenase, mitochondrial";"TMLHE";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Trimethyllysine dioxygenase, mitochondrial";"TMLHE";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GB01";"Transmembrane prolyl 4-hydroxylase";"P4HTM";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"A11GA01";"Transmembrane prolyl 4-hydroxylase";"P4HTM";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"S01XA15";"Transmembrane prolyl 4-hydroxylase";"P4HTM";"unknown";""
"Vitamin C";"[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO";"16 days (3.4 hours in people who have excess levels of vitamin C)";"G01AD03";"Transmembrane prolyl 4-hydroxylase";"P4HTM";"unknown";""
"L-Glutamine";"N[C@@H](CCC(N)=O)C(O)=O";"The half life of elimination is 1 h [FDA Label].";"A16AA03";"CTP synthase 1";"CTPS1";"unknown";"antagonist"
"L-Glutamine";"N[C@@H](CCC(N)=O)C(O)=O";"The half life of elimination is 1 h [FDA Label].";"A16AA03";"Amidophosphoribosyltransferase";"PPAT";"unknown";"product of"
"L-Glutamine";"N[C@@H](CCC(N)=O)C(O)=O";"The half life of elimination is 1 h [FDA Label].";"A16AA03";"Glutamine synthetase";"GLUL";"unknown";"product of"
"Methionine";"CSCC[C@H](N)C(O)=O";"";"V03AB26";"Methionine synthase reductase";"MTRR";"unknown";"product of"
"Methionine";"CSCC[C@H](N)C(O)=O";"";"V03AB26";"Methionine synthase";"MTR";"unknown";"product of"
"Methionine";"CSCC[C@H](N)C(O)=O";"";"V03AB26";"Methionine aminopeptidase 2";"METAP2";"unknown";"product of"
"Methionine";"CSCC[C@H](N)C(O)=O";"";"V03AB26";"Betaine--homocysteine S-methyltransferase 1";"BHMT";"unknown";"product of"
"Methionine";"CSCC[C@H](N)C(O)=O";"";"V03AB26";"S-methylmethionine--homocysteine S-methyltransferase BHMT2";"BHMT2";"unknown";"product of"
"Calcitriol";"C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"5-8 hours";"A11CC04";"Vitamin D3 receptor";"VDR";"yes";"antagonist"
"Calcitriol";"C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"5-8 hours";"D05AX03";"Vitamin D3 receptor";"VDR";"yes";"antagonist"
"Calcitriol";"C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"5-8 hours";"A11CC04";"Homeobox protein Hox-A10";"HOXA10";"unknown";""
"Calcitriol";"C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"5-8 hours";"D05AX03";"Homeobox protein Hox-A10";"HOXA10";"unknown";""
"Calcitriol";"C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"5-8 hours";"A11CC04";"Vitamin D-binding protein";"GC";"unknown";""
"Calcitriol";"C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"5-8 hours";"D05AX03";"Vitamin D-binding protein";"GC";"unknown";""
"Riboflavin";"CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1";"66-84 minutes";"A11HA04";"Riboflavin kinase";"RFK";"yes";"ligand"
"Riboflavin";"CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1";"66-84 minutes";"A11HA04";"Riboflavin synthase";"ribC";"yes";"other"
"Riboflavin";"CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1";"66-84 minutes";"A11HA04";"Flavin reductase (NADPH)";"BLVRB";"yes";"product of"
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Metabotropic glutamate receptor 1";"GRM1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Metabotropic glutamate receptor 4";"GRM4";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, kainate 4";"GRIK4";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, kainate 5";"GRIK5";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Metabotropic glutamate receptor 7";"GRM7";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Metabotropic glutamate receptor 8";"GRM8";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Excitatory amino acid transporter 5";"SLC1A7";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"5-oxoprolinase";"OPLAH";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Phosphoribosylformylglycinamidine synthase";"PFAS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Branched-chain-amino-acid aminotransferase, mitochondrial";"BCAT2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, delta-2";"GRID2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, NMDA 3B";"GRIN3B";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial";"GATB";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutaminase kidney isoform, mitochondrial";"GLS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Aspartate aminotransferase, mitochondrial";"GOT2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Bifunctional glutamate/proline--tRNA ligase";"EPRS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Asparagine synthetase [glutamine-hydrolyzing]";"ASNS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamine synthetase";"GLUL";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Aspartate aminotransferase, cytoplasmic";"GOT1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Tyrosine aminotransferase";"TAT";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Alanine aminotransferase 1";"GPT";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Vitamin K-dependent gamma-carboxylase";"GGCX";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Excitatory amino acid transporter 1";"SLC1A3";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Excitatory amino acid transporter 2";"SLC1A2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Excitatory amino acid transporter 3";"SLC1A1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate--cysteine ligase catalytic subunit";"GCLC";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Excitatory amino acid transporter 4";"SLC1A6";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate dehydrogenase 2, mitochondrial";"GLUD2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"GMP synthase [glutamine-hydrolyzing]";"GMPS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Branched-chain-amino-acid aminotransferase, cytosolic";"BCAT1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"4-aminobutyrate aminotransferase, mitochondrial";"ABAT";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Folylpolyglutamate synthase, mitochondrial";"FPGS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamyl aminopeptidase";"ENPEP";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, NMDA 2C";"GRIN2C";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Aspartate aminotransferase";"GIG18";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Probable glutamate--tRNA ligase, mitochondrial";"EARS2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Lengsin";"LGSN";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamine-dependent NAD(+) synthetase";"NADSYN1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Kynurenine--oxoglutarate transaminase 3";"CCBL2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"N-acetylglutamate synthase, mitochondrial";"NAGS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial";"AADAT";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Alanine aminotransferase 2";"GPT2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Mitochondrial glutamate carrier 2";"SLC25A18";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Mitochondrial glutamate carrier 1";"SLC25A22";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Alpha-aminoadipic semialdehyde synthase, mitochondrial";"AASS";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutaminase liver isoform, mitochondrial";"GLS2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Aspartyl aminopeptidase";"DNPEP";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, delta-1";"GRID1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Cystine/glutamate transporter";"SLC7A11";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Carboxypeptidase Q";"CPQ";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Phosphoserine aminotransferase";"PSAT1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate dehydrogenase 1, mitochondrial";"GLUD1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, kainate 1";"GRIK1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor 1";"GRIA1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate--cysteine ligase regulatory subunit";"GCLM";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate carboxypeptidase 2";"FOLH1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate decarboxylase 2";"GAD2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate decarboxylase 1";"GAD1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Formimidoyltransferase-cyclodeaminase";"FTCD";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor 2";"GRIA2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor 3";"GRIA3";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor 4";"GRIA4";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Delta-1-pyrroline-5-carboxylate synthase";"ALDH18A1";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";""
"Glutamic Acid";"N[C@@H](CCC(O)=O)C(O)=O";"";"A09AB01";"Glutamate receptor ionotropic, kainate 3";"GRIK3";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Microsomal glutathione S-transferase 3";"MGST3";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Thioredoxin domain-containing protein 12";"TXNDC12";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase A1";"GSTA1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase A2";"GSTA2";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Microsomal glutathione S-transferase 1";"MGST1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"S-formylglutathione hydrolase";"ESD";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Gamma-glutamyltranspeptidase 1";"GGT1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase Mu 2";"GSTM2";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutaredoxin-1";"GLRX";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Phospholipid hydroperoxide glutathione peroxidase, mitochondrial";"GPX4";"unknown";"cofactor"
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase Mu 5";"GSTM5";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione peroxidase 6";"GPX6";"unknown";"cofactor"
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Hydroxyacylglutathione hydrolase, mitochondrial";"HAGH";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione peroxidase";"GPX1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Probable glutathione peroxidase 8";"GPX8";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione peroxidase 7";"GPX7";"unknown";"cofactor"
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Microsomal glutathione S-transferase 2";"MGST2";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase omega-2";"GSTO2";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutaredoxin-2, mitochondrial";"GLRX2";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Lactoylglutathione lyase";"GLO1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Leukotriene C4 synthase";"LTC4S";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione reductase, mitochondrial";"GSR";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione synthetase";"GSS";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase Mu 1";"GSTM1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase kappa 1";"GSTK1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase A3";"GSTA3";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase Mu 3";"GSTM3";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase A4";"GSTA4";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase Mu 4";"GSTM4";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase A5";"GSTA5";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase omega-1";"GSTO1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione peroxidase 1";"GPX1";"unknown";"cofactor"
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione peroxidase 2";"GPX2";"unknown";"cofactor"
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione S-transferase theta-1";"GSTT1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Maleylacetoacetate isomerase";"GSTZ1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Epididymal secretory glutathione peroxidase";"GPX5";"unknown";"cofactor"
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Glutathione peroxidase 3";"GPX3";"unknown";"cofactor"
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Aldose reductase";"AKR1B1";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Matrix metalloproteinase-9";"MMP9";"unknown";""
"Glutathione";"N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O";"";"V03AB32";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial";"GCAT";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"5-aminolevulinate synthase, nonspecific, mitochondrial";"ALAS1";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"5-aminolevulinate synthase, erythroid-specific, mitochondrial";"ALAS2";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine cleavage system H protein, mitochondrial";"GCSH";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine--tRNA ligase";"GARS";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"antagonist"
"Glycine";"NCC(O)=O";"";"B05CX03";"Bile acid-CoA:amino acid N-acyltransferase";"BAAT";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"N-arachidonyl glycine receptor";"GPR18";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glutathione synthetase";"GSS";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glutamate receptor ionotropic, NMDA 2C";"GRIN2C";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Serine hydroxymethyltransferase";"";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine N-acyltransferase";"GLYAT";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Proton-coupled amino acid transporter 1";"SLC36A1";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Serine hydroxymethyltransferase, mitochondrial";"SHMT2";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine N-acyltransferase-like protein 2";"GLYATL2";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine N-acyltransferase-like protein 1";"GLYATL1";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Alanine--glyoxylate aminotransferase 2, mitochondrial";"AGXT2";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Vesicular inhibitory amino acid transporter";"SLC32A1";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Peroxisomal sarcosine oxidase";"PIPOX";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Sodium- and chloride-dependent glycine transporter 2";"SLC6A5";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glutamate receptor ionotropic, NMDA 3B";"GRIN3B";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine dehydrogenase [decarboxylating], mitochondrial";"GLDC";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Sodium- and chloride-dependent glycine transporter 1";"SLC6A9";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Serine--pyruvate aminotransferase";"AGXT";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine receptor subunit beta";"GLRB";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Serine hydroxymethyltransferase, cytosolic";"SHMT1";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine receptor subunit alpha-3";"GLRA3";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine receptor subunit alpha-2";"GLRA2";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine N-methyltransferase";"GNMT";"unknown";""
"Glycine";"NCC(O)=O";"";"B05CX03";"Glycine amidinotransferase, mitochondrial";"GATM";"unknown";""
"Calcidiol";"C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"288 hours";"A11CC06";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"L-Tryptophan";"N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O";"";"N06AX02";"Tryptophan--tRNA ligase, mitochondrial";"WARS2";"unknown";"inhibitor"
"L-Tryptophan";"N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O";"";"N06AX02";"Tryptophan--tRNA ligase";"trpS";"unknown";"inhibitor"
"L-Tryptophan";"N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O";"";"N06AX02";"Tryptophan--tRNA ligase, cytoplasmic";"WARS";"unknown";"inhibitor"
"Thiamine";"CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N";"";"A11DA01";"Thiamin pyrophosphokinase 1";"TPK1";"yes";"ligand"
"Thiamine";"CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N";"";"A11DA01";"Thiamine transporter 1";"SLC19A2";"unknown";"binder"
"Ergocalciferol";"CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"19 to 48 hours (however, stored in fat deposits in body for prolonged periods).";"A11CC01";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03AE01";"Folate receptor beta";"FOLR2";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03AE02";"Folate receptor beta";"FOLR2";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03BB51";"Folate receptor beta";"FOLR2";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03BB01";"Folate receptor beta";"FOLR2";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03AE01";"Folate receptor gamma";"FOLR3";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03AE02";"Folate receptor gamma";"FOLR3";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03BB51";"Folate receptor gamma";"FOLR3";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03BB01";"Folate receptor gamma";"FOLR3";"unknown";"binder"
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03AE01";"Folate receptor alpha";"FOLR1";"unknown";""
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03AE02";"Folate receptor alpha";"FOLR1";"unknown";""
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03BB51";"Folate receptor alpha";"FOLR1";"unknown";""
"Folic Acid";"NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1";"";"B03BB01";"Folate receptor alpha";"FOLR1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinol dehydrogenase 12";"RDH12";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinol dehydrogenase 12";"RDH12";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinol dehydrogenase 12";"RDH12";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinol dehydrogenase 12";"RDH12";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinol dehydrogenase 12";"RDH12";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Short-chain dehydrogenase/reductase 3";"DHRS3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Short-chain dehydrogenase/reductase 3";"DHRS3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Short-chain dehydrogenase/reductase 3";"DHRS3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Short-chain dehydrogenase/reductase 3";"DHRS3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Short-chain dehydrogenase/reductase 3";"DHRS3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Aldehyde dehydrogenase family 1 member A3";"ALDH1A3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Aldehyde dehydrogenase family 1 member A3";"ALDH1A3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Aldehyde dehydrogenase family 1 member A3";"ALDH1A3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Aldehyde dehydrogenase family 1 member A3";"ALDH1A3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Aldehyde dehydrogenase family 1 member A3";"ALDH1A3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"All-trans-retinol 13,14-reductase";"RETSAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"All-trans-retinol 13,14-reductase";"RETSAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"All-trans-retinol 13,14-reductase";"RETSAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"All-trans-retinol 13,14-reductase";"RETSAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"All-trans-retinol 13,14-reductase";"RETSAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinol dehydrogenase 11";"RDH11";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinol dehydrogenase 11";"RDH11";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinol dehydrogenase 11";"RDH11";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinol dehydrogenase 11";"RDH11";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinol dehydrogenase 11";"RDH11";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Dehydrogenase/reductase SDR family member 4";"DHRS4";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Dehydrogenase/reductase SDR family member 4";"DHRS4";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Dehydrogenase/reductase SDR family member 4";"DHRS4";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Dehydrogenase/reductase SDR family member 4";"DHRS4";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Dehydrogenase/reductase SDR family member 4";"DHRS4";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinol dehydrogenase 14";"RDH14";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinol dehydrogenase 14";"RDH14";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinol dehydrogenase 14";"RDH14";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinol dehydrogenase 14";"RDH14";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinol dehydrogenase 14";"RDH14";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinol dehydrogenase 8";"RDH8";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinol dehydrogenase 8";"RDH8";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinol dehydrogenase 8";"RDH8";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinol dehydrogenase 8";"RDH8";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinol dehydrogenase 8";"RDH8";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Lecithin retinol acyltransferase";"LRAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Lecithin retinol acyltransferase";"LRAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Lecithin retinol acyltransferase";"LRAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Lecithin retinol acyltransferase";"LRAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Lecithin retinol acyltransferase";"LRAT";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinol-binding protein 1";"RBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinol-binding protein 1";"RBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinol-binding protein 1";"RBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinol-binding protein 1";"RBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinol-binding protein 1";"RBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"11-cis retinol dehydrogenase";"RDH5";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"11-cis retinol dehydrogenase";"RDH5";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"11-cis retinol dehydrogenase";"RDH5";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"11-cis retinol dehydrogenase";"RDH5";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"11-cis retinol dehydrogenase";"RDH5";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinol dehydrogenase 13";"RDH13";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinol dehydrogenase 13";"RDH13";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinol dehydrogenase 13";"RDH13";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinol dehydrogenase 13";"RDH13";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinol dehydrogenase 13";"RDH13";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinol-binding protein 3";"RBP3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinol-binding protein 3";"RBP3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinol-binding protein 3";"RBP3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinol-binding protein 3";"RBP3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinol-binding protein 3";"RBP3";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Retinaldehyde-binding protein 1";"RLBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Retinaldehyde-binding protein 1";"RLBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Retinaldehyde-binding protein 1";"RLBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Retinaldehyde-binding protein 1";"RLBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Retinaldehyde-binding protein 1";"RLBP1";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Apolipoprotein D";"APOD";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Apolipoprotein D";"APOD";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Apolipoprotein D";"APOD";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Apolipoprotein D";"APOD";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Apolipoprotein D";"APOD";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"R01AX02";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"D10AD02";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"A11CA01";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"S01XA02";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Vitamin A";"C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C";"1.9 hours";"V04CB01";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Pyridoxine";"CC1=C(O)C(CO)=C(CO)C=N1";"15-20 days";"A11HA02";"Pyridoxal kinase";"PDXK";"yes";"ligand"
"Lipoic Acid";"OC(=O)CCCC[C@@H]1CCSS1";"";"A16AX01";"Lipoyltransferase 1, mitochondrial";"LIPT1";"unknown";""
"Lipoic Acid";"OC(=O)CCCC[C@@H]1CCSS1";"";"A16AX01";"Lipoyl synthase, mitochondrial";"LIAS";"unknown";""
"Lipoic Acid";"OC(=O)CCCC[C@@H]1CCSS1";"";"A16AX01";"Sodium-dependent multivitamin transporter";"SLC5A6";"unknown";""
"Cholecalciferol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"Several weeks";"M05BB08";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Cholecalciferol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"Several weeks";"M05BB04";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Cholecalciferol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"Several weeks";"A11CC05";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Cholecalciferol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"Several weeks";"M05BB05";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Cholecalciferol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"Several weeks";"M05BB03";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Cholecalciferol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"Several weeks";"M05BX53";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Cholecalciferol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C";"Several weeks";"M05BB07";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Vitamin K-dependent gamma-carboxylase";"GGCX";"yes";"cofactor"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Vitamin K epoxide reductase complex subunit 1";"VKORC1";"yes";"cofactor"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Vitamin K epoxide reductase complex subunit 1-like protein 1";"VKORC1L1";"yes";"cofactor"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Prothrombin";"F2";"unknown";"activator"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Coagulation factor VII";"F7";"unknown";"activator"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Coagulation factor IX";"F9";"unknown";"activator"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Coagulation factor X";"F10";"unknown";"activator"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Vitamin K-dependent protein C";"PROC";"unknown";"activator"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Vitamin K-dependent protein S";"PROS1";"unknown";"activator"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Vitamin K-dependent protein Z";"PROZ";"unknown";"activator"
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Ribosyldihydronicotinamide dehydrogenase [quinone]";"NQO2";"unknown";""
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"NAD(P)H dehydrogenase [quinone] 1";"NQO1";"unknown";""
"Menadione";"CC1=CC(=O)C2=CC=CC=C2C1=O";"";"B02BA02";"Osteocalcin";"BGLAP";"unknown";"agonist"
"Pravastatin";"[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC";"77 hours";"C10AA03";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Pravastatin";"[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC";"77 hours";"C10BX02";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Pravastatin";"[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC";"77 hours";"C10BA03";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Fluvoxamine";"COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F";"15.6 hours [FDA Label].";"N06AB08";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Fluvoxamine";"COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F";"15.6 hours [FDA Label].";"N06AB08";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C09DX02";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C10BX10";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C09DB08";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C09DX01";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C09DB01";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C09DA03";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C09CA03";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Valsartan";"CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O";"The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.";"C09DX04";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C10BX04";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09AA05";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C10BX06";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09BA05";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09BB07";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09BB05";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C10BX04";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09AA05";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C10BX06";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09BA05";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09BB07";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Ramipril";"[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC";"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours and that of the terminal elimination phase is > 50 hours. Two elimination phases occur as a result of ramiprilat's potent binding to ACE and slow dissociation from the enzyme. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.";"C09BB05";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Masoprocol";"C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1";"";"L01XX10";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Masoprocol";"C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1";"";"L01XX10";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Flunisolide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.8 hours";"R01AD04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Flunisolide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.8 hours";"R03BA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Baclofen";"NCC(CC(O)=O)C1=CC=C(Cl)C=C1";"2.5-4 hours";"M03BX01";"Gamma-aminobutyric acid type B receptor subunit 1";"GABBR1";"yes";"agonist"
"Baclofen";"NCC(CC(O)=O)C1=CC=C(Cl)C=C1";"2.5-4 hours";"M03BX01";"Gamma-aminobutyric acid type B receptor subunit 2";"GABBR2";"yes";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"negative modulator"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Cocaine- and amphetamine-regulated transcript protein";"CARTPT";"yes";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Trace amine-associated receptor 1";"TAAR1";"yes";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"stimulator"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Alpha adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Alpha adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Alpha adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Alpha adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Alpha adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Alpha adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Beta adrenergic receptor";"ADRB1";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Beta adrenergic receptor";"ADRB2";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Beta adrenergic receptor";"ADRB3";"unknown";"agonist"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"D(2) dopamine receptor";"DRD2";"unknown";"binder"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"binder"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Monoamine oxidase";"MAOA";"yes";"inhibitor"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"Monoamine oxidase";"MAOB";"yes";"inhibitor"
"Amphetamine";"CC(N)CC1=CC=CC=C1";"The half life for adults in the fasted state was found to be 11.25 hr.";"N06BA01";"vesicular monoamine transporter 2 (VMAT2)";"VMAT2";"yes";""
"Pentagastrin";"CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O";"10 minutes or less";"V04CG04";"Gastrin/cholecystokinin type B receptor";"CCKBR";"yes";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"yes";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"yes";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"yes";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-5";"CHRNA5";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-6";"CHRNA6";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-9";"CHRNA9";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit beta-3";"CHRNB3";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";"agonist"
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Cytochrome P450 19A1";"CYP19A1";"unknown";""
"Nicotine";"CN1CCC[C@H]1C1=CN=CC=C1";"Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours";"N07BA01";"Choline O-acetyltransferase";"CHAT";"unknown";""
"Cevimeline";"CC1O[C@@]2(CS1)CN1CCC2CC1";"5 &plusmn; 1 hours";"N07AX03";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"agonist"
"Cevimeline";"CC1O[C@@]2(CS1)CN1CCC2CC1";"5 &plusmn; 1 hours";"N07AX03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA06";"Translocator protein";"TSPO";"unknown";"other"
"Lorazepam";"OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2";"Parenteral administration = 14±5 hours;
Oral administration = 2 hours.";"N05BA56";"Translocator protein";"TSPO";"unknown";"other"
"Esmolol";"COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1";"Rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.";"C07AB09";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bortezomib";"CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O";"The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.";"L01XX32";"Proteasome subunit beta type-5";"PSMB5";"yes";"inhibitor"
"Bortezomib";"CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O";"The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.";"L01XX32";"Proteasome subunit beta type-1";"PSMB1";"yes";"inhibitor"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Ethchlorvynol";"[H]C(Cl)=CC(O)(CC)C#C";"Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.";"N05CM08";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Phentermine";"CC(C)(N)CC1=CC=CC=C1";"16 to 31 hours";"A08AA01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Phentermine";"CC(C)(N)CC1=CC=CC=C1";"16 to 31 hours";"A08AA01";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Phentermine";"CC(C)(N)CC1=CC=CC=C1";"16 to 31 hours";"A08AA01";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Phentermine";"CC(C)(N)CC1=CC=CC=C1";"16 to 31 hours";"A08AA01";"Amine oxidase [flavin-containing] A";"MAOA";"yes";"antagonist"
"Phentermine";"CC(C)(N)CC1=CC=CC=C1";"16 to 31 hours";"A08AA01";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Delta-type opioid receptor";"OPRD1";"no";"agonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Delta-type opioid receptor";"OPRD1";"no";"agonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Alpha-7 nicotinic cholinergic receptor subunit";"CHRNA7";"unknown";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Alpha-7 nicotinic cholinergic receptor subunit";"CHRNA7";"unknown";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX52";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Tramadol";"COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C";"Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.";"N02AX02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Vidarabine";"NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"";"J05AB03";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Vidarabine";"NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"";"S01AD06";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Vidarabine";"NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"";"J05AB03";"Thymidine kinase";"TK";"yes";"inducer"
"Vidarabine";"NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"";"S01AD06";"Thymidine kinase";"TK";"yes";"inducer"
"Vidarabine";"NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"";"J05AB03";"Thymidine kinase";"TK";"yes";"inducer"
"Vidarabine";"NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"";"S01AD06";"Thymidine kinase";"TK";"yes";"inducer"
"Betaxolol";"CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1";"14-22 hours";"C07AB05";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Betaxolol";"CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1";"14-22 hours";"S01ED52";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Betaxolol";"CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1";"14-22 hours";"S01ED02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Betaxolol";"CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1";"14-22 hours";"C07AB05";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Betaxolol";"CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1";"14-22 hours";"S01ED52";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Betaxolol";"CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1";"14-22 hours";"S01ED02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Fluconazole";"OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1";"30 hours (range 20-50 hours)";"D01AC15";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Fluconazole";"OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1";"30 hours (range 20-50 hours)";"J02AC01";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Fluconazole";"OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1";"30 hours (range 20-50 hours)";"J01RA07";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Long-chain-fatty-acid--CoA ligase 4";"ACSL4";"no";"inhibitor"
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Plasminogen activator inhibitor 1";"SERPINE1";"unknown";"antagonist"
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Equilibrative nucleoside transporter 1";"SLC29A1";"no";"inhibitor"
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Estrogen-related receptor gamma";"ESRRG";"no";"inverse agonist"
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Steroid hormone receptor ERR1";"ESRRA";"no";"inverse agonist"
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Troglitazone";"CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O";"16-34 hours";"A10BG01";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Oseltamivir";"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1";"1 to 3 hours in most subjects after oral administration.";"J05AH02";"Neuraminidase";"NA";"yes";"inhibitor"
"Oseltamivir";"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1";"1 to 3 hours in most subjects after oral administration.";"J05AH02";"Liver carboxylesterase 1";"CES1";"yes";"other"
"Oseltamivir";"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1";"1 to 3 hours in most subjects after oral administration.";"J05AH02";"Sialidase-1";"NEU1";"unknown";"inhibitor"
"Oseltamivir";"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1";"1 to 3 hours in most subjects after oral administration.";"J05AH02";"Sialidase-2";"NEU2";"unknown";"inhibitor"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"D10AF52";"Motilin receptor";"MLNR";"no";"agonist"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"J01FA01";"Motilin receptor";"MLNR";"no";"agonist"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"D10AF02";"Motilin receptor";"MLNR";"no";"agonist"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"S01AA17";"Motilin receptor";"MLNR";"no";"agonist"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"D10AF52";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"no";"inhibitor"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"J01FA01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"no";"inhibitor"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"D10AF02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"no";"inhibitor"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"S01AA17";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"no";"inhibitor"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"D10AF52";"Serum albumin";"ALB";"no";"binder"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"J01FA01";"Serum albumin";"ALB";"no";"binder"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"D10AF02";"Serum albumin";"ALB";"no";"binder"
"Erythromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O";"0.8 - 3 hours";"S01AA17";"Serum albumin";"ALB";"no";"binder"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Methionine synthase";"MTR";"yes";"cofactor"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Methionine synthase";"MTR";"yes";"cofactor"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Methionine synthase";"MTR";"yes";"cofactor"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Methylmalonyl-CoA mutase, mitochondrial";"MUT";"yes";"cofactor"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Methylmalonyl-CoA mutase, mitochondrial";"MUT";"yes";"cofactor"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Methylmalonyl-CoA mutase, mitochondrial";"MUT";"yes";"cofactor"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Methionine synthase reductase";"MTRR";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Methionine synthase reductase";"MTRR";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Methionine synthase reductase";"MTRR";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Methylmalonic aciduria type A protein, mitochondrial";"MMAA";"unknown";"other/unknown"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Methylmalonic aciduria type A protein, mitochondrial";"MMAA";"unknown";"other/unknown"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Methylmalonic aciduria type A protein, mitochondrial";"MMAA";"unknown";"other/unknown"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Transcobalamin-1";"TCN1";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Transcobalamin-1";"TCN1";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Transcobalamin-1";"TCN1";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Protein amnionless";"AMN";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Protein amnionless";"AMN";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Protein amnionless";"AMN";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Cubilin";"CUBN";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Cubilin";"CUBN";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Cubilin";"CUBN";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial";"MMAB";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial";"MMAB";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial";"MMAB";"unknown";"other"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA03";"Methylmalonic aciduria and homocystinuria type C protein";"MMACHC";"unknown";"other/unknown"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"V03AB33";"Methylmalonic aciduria and homocystinuria type C protein";"MMACHC";"unknown";"other/unknown"
"Hydroxocobalamin";"[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]";"Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)";"B03BA53";"Methylmalonic aciduria and homocystinuria type C protein";"MMACHC";"unknown";"other/unknown"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Adenosine receptor A1";"ADORA1";"yes";"antagonistmultitarget"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Adenosine receptor A1";"ADORA1";"yes";"antagonistmultitarget"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Adenosine receptor A1";"ADORA1";"yes";"antagonistmultitarget"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonistmultitarget"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonistmultitarget"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonistmultitarget"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Ryanodine receptor 1";"RYR1";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Ryanodine receptor 1";"RYR1";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Ryanodine receptor 1";"RYR1";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE1A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE1A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE1A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE1B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE1B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE1B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE1C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE1C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE1C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE10A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE10A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE10A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE4A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE4A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE4A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE4B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE4B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE4B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE4C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE4C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE4C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE4D";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE4D";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE4D";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE7B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE7B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE7B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE2A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE2A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE2A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE3A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE3A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE3A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE3B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE3B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE3B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE5A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE5A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE5A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE6C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE6C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE6C";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE11A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE11A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE11A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE7A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE7A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE7A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE8A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE8A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE8A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE8B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE8B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE8B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE9A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE9A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE9A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE6A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE6A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE6A";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Cyclic nucleotide phosphodiesterase";"PDE6B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Cyclic nucleotide phosphodiesterase";"PDE6B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Cyclic nucleotide phosphodiesterase";"PDE6B";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"DNA-dependent protein kinase catalytic subunit";"PRKDC";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"DNA-dependent protein kinase catalytic subunit";"PRKDC";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"DNA-dependent protein kinase catalytic subunit";"PRKDC";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform";"PIK3CD";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform";"PIK3CD";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform";"PIK3CD";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform";"PIK3CA";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform";"PIK3CA";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform";"PIK3CA";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform";"PIK3CB";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform";"PIK3CB";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform";"PIK3CB";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Inositol 1,4,5-trisphosphate receptor";"ITPR1";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Inositol 1,4,5-trisphosphate receptor";"ITPR1";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Inositol 1,4,5-trisphosphate receptor";"ITPR1";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Inositol 1,4,5-trisphosphate receptor";"ITPR2";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Inositol 1,4,5-trisphosphate receptor";"ITPR2";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Inositol 1,4,5-trisphosphate receptor";"ITPR2";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Inositol 1,4,5-trisphosphate receptor";"ITPR3";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Inositol 1,4,5-trisphosphate receptor";"ITPR3";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Inositol 1,4,5-trisphosphate receptor";"ITPR3";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"V04CG30";"Serine-protein kinase ATM";"ATM";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"R03DA20";"Serine-protein kinase ATM";"ATM";"unknown";""
"Caffeine";"CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"3 to 7 hours in adults, 65 to 130 hours in neonates";"N06BC01";"Serine-protein kinase ATM";"ATM";"unknown";""
"Succinylcholine";"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C";"";"M03AB01";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"yes";"agonist"
"Succinylcholine";"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C";"";"M03AB01";"Alpha-7 nicotinic cholinergic receptor subunit";"CHRNA7";"yes";"agonist"
"Succinylcholine";"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C";"";"M03AB01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Succinylcholine";"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C";"";"M03AB01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"agonist"
"Succinylcholine";"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C";"";"M03AB01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"agonist"
"Sildenafil";"CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1";"4 hours";"G04BE03";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Sildenafil";"CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1";"4 hours";"G01AE10";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Sildenafil";"CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1";"4 hours";"G04BE03";"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma";"PDE6G";"no";"inhibitor"
"Sildenafil";"CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1";"4 hours";"G01AE10";"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma";"PDE6G";"no";"inhibitor"
"Sildenafil";"CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1";"4 hours";"G04BE03";"Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma";"PDE6H";"no";"inhibitor"
"Sildenafil";"CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1";"4 hours";"G01AE10";"Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma";"PDE6H";"no";"inhibitor"
"Dofetilide";"CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1";"10 hours";"C01BD04";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Dofetilide";"CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1";"10 hours";"C01BD04";"Potassium channel subfamily K member 2";"KCNK2";"yes";"inhibitor"
"Dofetilide";"CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1";"10 hours";"C01BD04";"ATP-sensitive inward rectifier potassium channel 12";"KCNJ12";"yes";"inhibitor"
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BF04";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BD01";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BD51";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BF04";"Bifunctional dihydrofolate reductase-thymidylate synthase";"";"yes";"inhibitor"
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BD01";"Bifunctional dihydrofolate reductase-thymidylate synthase";"";"yes";"inhibitor"
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BD51";"Bifunctional dihydrofolate reductase-thymidylate synthase";"";"yes";"inhibitor"
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BF04";"Beta-hexosaminidase subunit beta";"HEXB";"unknown";""
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BD01";"Beta-hexosaminidase subunit beta";"HEXB";"unknown";""
"Pyrimethamine";"CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1";"96 hours";"P01BD51";"Beta-hexosaminidase subunit beta";"HEXB";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA51";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02AA52";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA71";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA01";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02AA02";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA51";"Chromaffin granule amine transporter";"SLC18A1";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02AA52";"Chromaffin granule amine transporter";"SLC18A1";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA71";"Chromaffin granule amine transporter";"SLC18A1";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA01";"Chromaffin granule amine transporter";"SLC18A1";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02AA02";"Chromaffin granule amine transporter";"SLC18A1";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA51";"Baculoviral IAP repeat-containing protein 5";"BIRC5";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02AA52";"Baculoviral IAP repeat-containing protein 5";"BIRC5";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA71";"Baculoviral IAP repeat-containing protein 5";"BIRC5";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA01";"Baculoviral IAP repeat-containing protein 5";"BIRC5";"unknown";""
"Reserpine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02AA02";"Baculoviral IAP repeat-containing protein 5";"BIRC5";"unknown";""
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"J01FA10";"50S ribosomal protein L4";"rplD";"yes";"inhibitor"
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"S01AA26";"50S ribosomal protein L4";"rplD";"yes";"inhibitor"
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"J01RA07";"50S ribosomal protein L4";"rplD";"yes";"inhibitor"
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"J01FA10";"50S ribosomal protein L22";"rplV";"yes";"inhibitor"
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"S01AA26";"50S ribosomal protein L22";"rplV";"yes";"inhibitor"
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"J01RA07";"50S ribosomal protein L22";"rplV";"yes";"inhibitor"
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"J01FA10";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"S01AA26";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Azithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"68 hours";"J01RA07";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Ticlopidine";"ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2";"Half-life following a single 250-mg dose is approximately 7.9 hours in subjects 20 to 43 years of age and 12.6 hours in subjects 65 to 76 years of age. With repeated dosing (250 mg twice a day), half-life is about 4 days in subjects 20 to 43 years of age and about 5 days in subjects 65 to 76 years of age.";"B01AC05";"P2Y purinoceptor 12";"P2RY12";"yes";"antagonist"
"Trospium";"[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1";"20 hours";"A03DA06";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Trospium";"[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1";"20 hours";"G04BD09";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD53";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD03";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD53";"Retinoic acid receptor beta";"RARB";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD03";"Retinoic acid receptor beta";"RARB";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD53";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD03";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD53";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD03";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD53";"Retinoic acid receptor alpha";"RARA";"unknown";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD03";"Retinoic acid receptor alpha";"RARA";"unknown";"agonist"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD53";"Retinoic acid receptor RXR-alpha";"RXRA";"no";"other/unknown"
"Adapalene";"COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2";"";"D10AD03";"Retinoic acid receptor RXR-alpha";"RXRA";"no";"other/unknown"
"Midodrine";"COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1";"The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.";"C01CA17";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Midodrine";"COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1";"The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.";"C01CA17";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Midodrine";"COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1";"The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.";"C01CA17";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Remikiren";"[H][C@@](CC1=CC=CC=C1)(CS(=O)(=O)C(C)(C)C)C(O)=N[C@@]([H])(CC1=CN=CN1)C(O)=N[C@@]([H])(CC1CCCCC1)[C@@]([H])(O)[C@@]([H])(O)C1CC1";"";"C09XA01";"Renin";"REN";"yes";"inhibitor"
"Pantoprazole";"COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1";"1 hour";"A02BC02";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Pantoprazole";"COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1";"1 hour";"A02BD04";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Pantoprazole";"COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1";"1 hour";"A02BD11";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Torasemide";"CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1";"3.5 hours";"C03CA04";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Citalopram";"CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"35 hours [FDA label].";"N06AB04";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Citalopram";"CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"35 hours [FDA label].";"N06AB04";"Histamine H1 receptor";"HRH1";"unknown";"binder"
"Citalopram";"CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"35 hours [FDA label].";"N06AB04";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"binder"
"Citalopram";"CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"35 hours [FDA label].";"N06AB04";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"binder"
"Citalopram";"CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"35 hours [FDA label].";"N06AB04";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Eletriptan";"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2";"The terminal elimination half-life of eletriptan is approximately 4 hours.";"N02CC06";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Eletriptan";"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2";"The terminal elimination half-life of eletriptan is approximately 4 hours.";"N02CC06";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Eletriptan";"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2";"The terminal elimination half-life of eletriptan is approximately 4 hours.";"N02CC06";"5-hydroxytryptamine receptor 1F";"HTR1F";"yes";"agonist"
"Eletriptan";"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2";"The terminal elimination half-life of eletriptan is approximately 4 hours.";"N02CC06";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Eletriptan";"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2";"The terminal elimination half-life of eletriptan is approximately 4 hours.";"N02CC06";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"agonist"
"Eletriptan";"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2";"The terminal elimination half-life of eletriptan is approximately 4 hours.";"N02CC06";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Eletriptan";"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2";"The terminal elimination half-life of eletriptan is approximately 4 hours.";"N02CC06";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"agonist"
"Bethanidine";"CN\C(NCC1=CC=CC=C1)=N/C";"9 hours (range 7 to 11 hours)";"C02CC01";"Alpha-2 adrenergic receptors";"ADRA2A";"yes";"agonist"
"Bethanidine";"CN\C(NCC1=CC=CC=C1)=N/C";"9 hours (range 7 to 11 hours)";"C02CC01";"Alpha-2 adrenergic receptors";"ADRA2B";"yes";"agonist"
"Bethanidine";"CN\C(NCC1=CC=CC=C1)=N/C";"9 hours (range 7 to 11 hours)";"C02CC01";"Alpha-2 adrenergic receptors";"ADRA2C";"yes";"agonist"
"Bethanidine";"CN\C(NCC1=CC=CC=C1)=N/C";"9 hours (range 7 to 11 hours)";"C02CC01";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"inhibitor"
"Bethanidine";"CN\C(NCC1=CC=CC=C1)=N/C";"9 hours (range 7 to 11 hours)";"C02CC01";"Beta adrenergic receptor";"ADRB1";"unknown";"antagonist"
"Bethanidine";"CN\C(NCC1=CC=CC=C1)=N/C";"9 hours (range 7 to 11 hours)";"C02CC01";"Beta adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Bethanidine";"CN\C(NCC1=CC=CC=C1)=N/C";"9 hours (range 7 to 11 hours)";"C02CC01";"Beta adrenergic receptor";"ADRB3";"unknown";"antagonist"
"Moxifloxacin";"[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O";"11.5-15.6 hours (single dose, oral)";"J01MA14";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Moxifloxacin";"[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O";"11.5-15.6 hours (single dose, oral)";"S01AE07";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Moxifloxacin";"[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O";"11.5-15.6 hours (single dose, oral)";"J01MA14";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Moxifloxacin";"[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O";"11.5-15.6 hours (single dose, oral)";"S01AE07";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Moxifloxacin";"[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O";"11.5-15.6 hours (single dose, oral)";"J01MA14";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Moxifloxacin";"[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O";"11.5-15.6 hours (single dose, oral)";"S01AE07";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Oxyphenonium";"CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AB53";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Oxyphenonium";"CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AB03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Nelfinavir";"[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C";"3.5 - 5 hours";"J05AE04";"HIV-1 protease";"HIV-1 protease";"yes";"inhibitor"
"Isoetarine";"CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1";"";"R03AC07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Isoetarine";"CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1";"";"R03CC06";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Isoetarine";"CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1";"";"R03AC07";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"agonist"
"Isoetarine";"CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1";"";"R03CC06";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"agonist"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BB12";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inhibitor"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BD06";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inhibitor"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BD04";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inhibitor"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BB12";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"inhibitor"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BD06";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"inhibitor"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BD04";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"inhibitor"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BB12";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inducer"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BD06";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inducer"
"Glimepiride";"[H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1";"Approximately 5 hours following single dose.";"A10BD04";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inducer"
"Diflorasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07AC10";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Indinavir";"CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12";"1.8 (&plusmn; 0.4) hours";"J05AE02";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Lovastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC";"5.3 hours";"C10BA01";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Lovastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC";"5.3 hours";"C10AA02";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Lovastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC";"5.3 hours";"C10BA01";"Integrin alpha-L";"ITGAL";"no";"other/unknown"
"Lovastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC";"5.3 hours";"C10AA02";"Integrin alpha-L";"ITGAL";"no";"other/unknown"
"Lovastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC";"5.3 hours";"C10BA01";"Histone deacetylase 2";"HDAC2";"no";"other"
"Lovastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC";"5.3 hours";"C10AA02";"Histone deacetylase 2";"HDAC2";"no";"other"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"Glycine receptor (alpha-1/beta)";"GLRA1";"yes";"agonist"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"Glycine receptor (alpha-1/beta)";"GLRB";"yes";"agonist"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"yes";"inducer"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"inhibitor"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"Glutamate receptor 1";"GRIA1";"yes";"antagonist"
"Enflurane";"FC(F)OC(F)(F)C(F)Cl";"";"N01AB04";"ATP synthase subunit delta, mitochondrial";"ATP5D";"unknown";"other/unknown"
"Cefotiam";"[H][C@]12SCC(CSC3=NN=NN3CCN(C)C)=C(N1C(=O)[C@H]2NC(=O)CC1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DC07";"Penicillin-binding protein 1A";"pbpA";"yes";"inducer"
"Pregabalin";"CC(C)C[C@H](CN)CC(O)=O";"Mean elimination half-life is 6.3 hours in subjects with normal renal function.[A31169]";"N03AX16";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"yes";"inhibitor"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"Translocator protein";"TSPO";"unknown";"other"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Temazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1";"10-20 hours";"N05CD07";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AA08";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AB08";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"G01AE10";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AA08";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AB08";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AA08";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AB08";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AA08";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AB08";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Methyclothiazide";"CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA02";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA01";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA03";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA02";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA01";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA03";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA02";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA01";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA03";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"inhibitor"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA02";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";"unknown"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA01";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";"unknown"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA03";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";"unknown"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA02";"2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase";"folK";"unknown";"unknown"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA01";"2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase";"folK";"unknown";"unknown"
"Aminosalicylic Acid";"NC1=CC(O)=C(C=C1)C(O)=O";"";"J04AA03";"2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase";"folK";"unknown";"unknown"
"Reboxetine";"[H][C@@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@@]1([H])CNCCO1";"12.5 hours";"N06AX18";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Milrinone";"CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1";"2.3 hours";"C01CE02";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Nevirapine";"CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1";"45 hours";"J05AG01";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Nevirapine";"CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1";"45 hours";"J05AR05";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Nevirapine";"CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1";"45 hours";"J05AR07";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"D01AC11";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"G01AF17";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"G01AF20";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"D01AC11";"Lanosterol synthase";"ERG7";"yes";"inhibitor"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"G01AF17";"Lanosterol synthase";"ERG7";"yes";"inhibitor"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"G01AF20";"Lanosterol synthase";"ERG7";"yes";"inhibitor"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"D01AC11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"G01AF17";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Oxiconazole";"ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1";"";"G01AF20";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Alclometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C";"";"S01BA10";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Alclometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C";"";"D07AB10";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"Ribonucleoside-diphosphate reductase large subunit";"RRM1";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"Ribonucleoside-diphosphate reductase subunit M2";"RRM2";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"Ribonucleoside-diphosphate reductase subunit M2 B";"RRM2B";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"DNA polymerase alpha catalytic subunit";"POLA1";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"DNA polymerase epsilon catalytic subunit A";"POLE";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"DNA polymerase epsilon subunit 2";"POLE2";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"DNA polymerase epsilon subunit 3";"POLE3";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"DNA polymerase epsilon subunit 4";"POLE4";"yes";"inhibitor"
"Cladribine";"NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1";"5.4 hours";"L01BB04";"Purine nucleoside phosphorylase";"PNP";"yes";"inducer"
"Ranolazine";"COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1";"7 hours";"C01EB18";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Ranolazine";"COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1";"7 hours";"C01EB18";"Sodium channel protein type 9 subunit alpha";"SCN9A";"unknown";"inhibitor"
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";"inhibitor"
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Myeloperoxidase";"MPO";"unknown";""
"Mesalazine";"NC1=CC(C(O)=O)=C(O)C=C1";"The mean elimination half-life was 5 hours for 5-ASA and six hours for N-acetyl-5-ASA following the initial dose. At steady state, the mean elimination half-life was seven hours for both 5-ASA and N-acetyl-5-ASA.";"A07EC02";"Arylamine N-acetyltransferase";"nat";"unknown";""
"Benzatropine";"[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C";"";"N04AC01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Benzatropine";"[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C";"";"N04AC01";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Benzatropine";"[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C";"";"N04AC01";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"D(1B) dopamine receptor";"DRD5";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Alpha-1B adrenergic receptor";"ADRA1B";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Alpha-2A adrenergic receptor";"ADRA2A";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Alpha-2B adrenergic receptor";"ADRA2B";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Alpha-2C adrenergic receptor";"ADRA2C";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Ziprasidone";"ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1";"7 hours";"N05AE04";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"antagonist"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonist"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 7";"HTR7";"yes";"antagonist"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"binder"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 1F";"HTR1F";"unknown";"binder"
"Methysergide";"[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO";"";"N02CA04";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"D(3) dopamine receptor";"DRD3";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"D(3) dopamine receptor";"DRD3";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"D(4) dopamine receptor";"DRD4";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"D(4) dopamine receptor";"DRD4";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"binder"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"D(1) dopamine receptor";"DRD1";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"D(1) dopamine receptor";"DRD1";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"N04BC06";"D(1) dopamine receptor";"DRD5";"unknown";"agonist"
"Cabergoline";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC";"The elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.";"G02CB03";"D(1) dopamine receptor";"DRD5";"unknown";"agonist"
"Idoxuridine";"OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O";"";"J05AB02";"Thymidine kinase";"TK";"unknown";"unknown"
"Idoxuridine";"OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O";"";"S01AD01";"Thymidine kinase";"TK";"unknown";"unknown"
"Idoxuridine";"OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O";"";"D06BB01";"Thymidine kinase";"TK";"unknown";"unknown"
"Dapsone";"NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1";"28 hours (range 10-50 hours)";"D10AX05";"Inactive dihydropteroate synthase 2";"folP2";"yes";"inhibitor"
"Dapsone";"NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1";"28 hours (range 10-50 hours)";"J04BA02";"Inactive dihydropteroate synthase 2";"folP2";"yes";"inhibitor"
"Dapsone";"NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1";"28 hours (range 10-50 hours)";"D10AX05";"Dihydropteroate synthase 1";"folP1";"yes";"inhibitor"
"Dapsone";"NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1";"28 hours (range 10-50 hours)";"J04BA02";"Dihydropteroate synthase 1";"folP1";"yes";"inhibitor"
"Terconazole";"CC(C)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"6.9 hours (range 4.0-11.3)";"G01AG02";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonist"
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB52";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB02";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB52";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB52";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB02";"Sodium channel subunit beta-1";"SCN1B";"unknown";""
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB52";"Sodium channel subunit beta-1";"SCN1B";"unknown";""
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB02";"Sodium channel protein type 3 subunit alpha";"SCN3A";"unknown";""
"Phenytoin";"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1";"22 hours (range of 7 to 42 hours)";"N03AB52";"Sodium channel protein type 3 subunit alpha";"SCN3A";"unknown";""
"Medrysone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"";"S01BA08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"A01AB22";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA20";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA02";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"A01AB22";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA20";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA02";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"A01AB22";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA20";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA02";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"A01AB22";"Beta-2-microglobulin";"B2M";"unknown";""
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA20";"Beta-2-microglobulin";"B2M";"unknown";""
"Doxycycline";"[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O";"18-22 hours";"J01AA02";"Beta-2-microglobulin";"B2M";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Estrogen-related receptor gamma";"ESRRG";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Estrogen-related receptor gamma";"ESRRG";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Estrogen-related receptor gamma";"ESRRG";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Estrogen-related receptor gamma";"ESRRG";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Steroid hormone receptor ERR1";"ESRRA";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Steroid hormone receptor ERR1";"ESRRA";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Steroid hormone receptor ERR1";"ESRRA";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Steroid hormone receptor ERR1";"ESRRA";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Steroid hormone receptor ERR2";"ESRRB";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Steroid hormone receptor ERR2";"ESRRB";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Steroid hormone receptor ERR2";"ESRRB";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Steroid hormone receptor ERR2";"ESRRB";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Androgen receptor";"AR";"unknown";"antagonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Androgen receptor";"AR";"unknown";"antagonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Androgen receptor";"AR";"unknown";"antagonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Androgen receptor";"AR";"unknown";"antagonist"
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA01";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC05";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB02";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Diethylstilbestrol";"CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"L02AA04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Lymecycline";"[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C";"";"J01AA04";"30S ribosomal protein S9";"rpsI";"unknown";"inhibitor"
"Lymecycline";"[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C";"";"J01AA20";"30S ribosomal protein S9";"rpsI";"unknown";"inhibitor"
"Lymecycline";"[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C";"";"J01AA04";"30S ribosomal protein S4";"rpsD";"unknown";"inhibitor"
"Lymecycline";"[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C";"";"J01AA20";"30S ribosomal protein S4";"rpsD";"unknown";"inhibitor"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"D01AC01";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonistinhibitor"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"G01AF02";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonistinhibitor"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"A01AB18";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonistinhibitor"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"D01AC01";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"yes";"inhibitor"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"G01AF02";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"yes";"inhibitor"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"A01AB18";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"yes";"inhibitor"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"D01AC01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"G01AF02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"A01AB18";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"D01AC01";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"partial agonist"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"G01AF02";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"partial agonist"
"Clotrimazole";"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"2 hours";"A01AB18";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"partial agonist"
"Sulfanilamide";"NC1=CC=C(C=C1)S(N)(=O)=O";"";"J01EB06";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfanilamide";"NC1=CC=C(C=C1)S(N)(=O)=O";"";"D06BA05";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfanilamide";"NC1=CC=C(C=C1)S(N)(=O)=O";"";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Cycloserine";"N[C@@H]1CONC1=O";"Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.";"J04AB01";"D-alanine--D-alanine ligase A";"ddlA";"yes";"inhibitor"
"Cycloserine";"N[C@@H]1CONC1=O";"Half-life in patients with normal renal function is 10 hours, and is prolonged in patients with impaired renal function.";"J04AB01";"Alanine racemase";"alr";"yes";"inhibitor"
"Anagrelide";"ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl";"At fasting and at a dose of 0.5 mg of anagrelide, the plasma half-life is 1.3 hours.";"L01XX35";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Carmustine";"ClCCNC(=O)N(CCCl)N=O";"15-30 minutes";"L01AD01";"Glutathione reductase, mitochondrial";"GSR";"yes";"inhibitor"
"Sulfisoxazole";"CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C";"";"J01EB05";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfisoxazole";"CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C";"";"S01AB02";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfisoxazole";"CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C";"";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07BB02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07AB02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07BB52";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07AB52";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07CB02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07FB02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07BB02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07AB02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07BB52";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07AB52";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07CB02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Metoprolol";"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1";"3-7 hours";"C07FB02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Dicoumarol";"OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2";"";"B01AA01";"Vitamin K epoxide reductase complex subunit 1";"VKORC1";"yes";"inhibitor"
"Dicoumarol";"OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2";"";"B01AA01";"NAD(P)H dehydrogenase [quinone] 1";"NQO1";"unknown";"inhibitor"
"Dicoumarol";"OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2";"";"B01AA01";"Quinone oxidoreductase";"CRYZ";"unknown";"inhibitor"
"Cefmenoxime";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"1 hour";"J01DD05";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefmenoxime";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"1 hour";"J01DD05";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"D(4) dopamine receptor";"DRD4";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Ropinirole";"CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1";"6 hours";"N04BC04";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Chlorotrianisene";"COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1";"";"G03CA06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Isradipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C";"8 hours";"C08CA03";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Isradipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C";"8 hours";"C08CA03";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Isradipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C";"8 hours";"C08CA03";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Isradipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C";"8 hours";"C08CA03";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"yes";"inhibitor"
"Isradipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C";"8 hours";"C08CA03";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"yes";"inhibitor"
"Isradipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C";"8 hours";"C08CA03";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Isradipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C";"8 hours";"C08CA03";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Betazole";"NCCC1=CC=NN1";"";"V04CG02";"Histamine H2 receptor";"HRH2";"yes";"agonist"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"Glutamate receptor ionotropic, kainate 1";"GRIK1";"yes";"antagonist"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Topiramate";"[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2";"19 to 23 hours. The mean elimination half-life was 31 hours following repeat administration of the extended-release formulation.";"N03AX11";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Cefmetazole";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O";"1.50 &plusmn;0.14 hours";"J01DC09";"Penicillin binding protein 2a";"mecA";"yes";"inhibitor"
"Cefmetazole";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O";"1.50 &plusmn;0.14 hours";"J01DC09";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefmetazole";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O";"1.50 &plusmn;0.14 hours";"J01DC09";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Cefmetazole";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O";"1.50 &plusmn;0.14 hours";"J01DC09";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefmetazole";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O";"1.50 &plusmn;0.14 hours";"J01DC09";"D-alanyl-D-alanine carboxypeptidase DacA";"dacA";"yes";"inhibitor"
"Cefmetazole";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O";"1.50 &plusmn;0.14 hours";"J01DC09";"D-alanyl-D-alanine carboxypeptidase DacC";"dacC";"yes";"inhibitor"
"Olmesartan";"CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O";"The half life is approximately 13 hours.";"C09DA08";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Olmesartan";"CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O";"The half life is approximately 13 hours.";"C09CA08";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Olmesartan";"CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O";"The half life is approximately 13 hours.";"C09DX03";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Olmesartan";"CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O";"The half life is approximately 13 hours.";"C09DB02";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Amsacrine";"COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1";"8-9 hours";"L01XX01";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Amsacrine";"COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1";"8-9 hours";"L01XX01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Amsacrine";"COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1";"8-9 hours";"L01XX01";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Amsacrine";"COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1";"8-9 hours";"L01XX01";"Serum albumin";"ALB";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Adenosine receptor A2b";"ADORA2B";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Adenosine receptor A2b";"ADORA2B";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Adenosine receptor A2b";"ADORA2B";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Adenosine receptor A2b";"ADORA2B";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Adenosine receptor A2b";"ADORA2B";"yes";"antagonist"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Copine-1";"CPNE1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Copine-1";"CPNE1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Copine-1";"CPNE1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Copine-1";"CPNE1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Copine-1";"CPNE1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Minor histocompatibility antigen H13";"HM13";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Minor histocompatibility antigen H13";"HM13";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Minor histocompatibility antigen H13";"HM13";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Minor histocompatibility antigen H13";"HM13";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Minor histocompatibility antigen H13";"HM13";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Nodal modulator 1";"NOMO1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Nodal modulator 1";"NOMO1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Nodal modulator 1";"NOMO1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Nodal modulator 1";"NOMO1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Nodal modulator 1";"NOMO1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Protein RIC-3";"RIC3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Protein RIC-3";"RIC3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Protein RIC-3";"RIC3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Protein RIC-3";"RIC3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Protein RIC-3";"RIC3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA54";"Tubulin monoglycylase TTLL3";"TTLL3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA74";"Tubulin monoglycylase TTLL3";"TTLL3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA20";"Tubulin monoglycylase TTLL3";"TTLL3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DA04";"Tubulin monoglycylase TTLL3";"TTLL3";"unknown";""
"Theophylline";"CN1C2=C(NC=N2)C(=O)N(C)C1=O";"8 hours";"R03DB04";"Tubulin monoglycylase TTLL3";"TTLL3";"unknown";""
"Argatroban";"C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2";"39 and 51 minutes";"B01AE03";"Prothrombin";"F2";"yes";"inhibitor"
"Liothyronine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O";"2.5 days";"H03AA03";"Thyroid hormone receptor alpha";"THRA";"yes";"agonist"
"Liothyronine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O";"2.5 days";"H03AA02";"Thyroid hormone receptor alpha";"THRA";"yes";"agonist"
"Liothyronine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O";"2.5 days";"H03AA03";"Thyroid hormone receptor beta";"THRB";"yes";"agonist"
"Liothyronine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O";"2.5 days";"H03AA02";"Thyroid hormone receptor beta";"THRB";"yes";"agonist"
"Liothyronine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O";"2.5 days";"H03AA03";"Proliferating cell nuclear antigen";"PCNA";"unknown";""
"Liothyronine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O";"2.5 days";"H03AA02";"Proliferating cell nuclear antigen";"PCNA";"unknown";""
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Potassium voltage-gated channel subfamily D member 2";"KCND2";"unknown";"inhibitor"
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Potassium voltage-gated channel subfamily D member 3";"KCND3";"unknown";"inhibitor"
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Disopyramide";"CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C";"6.7 hours (range 4-10 hours)";"C01BA03";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C01BB01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"D04AB01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S02DA01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"R02AD02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C05AD01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S01HA07";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB52";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C01BB01";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB02";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"D04AB01";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S02DA01";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"R02AD02";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C05AD01";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S01HA07";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB52";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C01BB01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"D04AB01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S02DA01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"R02AD02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C05AD01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S01HA07";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB52";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C01BB01";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB02";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"D04AB01";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S02DA01";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"R02AD02";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C05AD01";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S01HA07";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB52";"Epidermal growth factor receptor";"EGFR";"unknown";"antagonist"
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C01BB01";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB02";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"D04AB01";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S02DA01";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"R02AD02";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C05AD01";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S01HA07";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB52";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C01BB01";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB02";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"D04AB01";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S02DA01";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"R02AD02";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C05AD01";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S01HA07";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB52";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C01BB01";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB02";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"D04AB01";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S02DA01";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"R02AD02";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"C05AD01";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"S01HA07";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Lidocaine";"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C";"109 minutes";"N01BB52";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Pamidronate";"NCCC(O)(P(O)(O)=O)P(O)(O)=O";"The mean &plusmn; SD elimination half-life is 28 &plusmn; 7 hours";"M05BA03";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Clemastine";"CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"";"D04AA14";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Clemastine";"CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"";"R06AA04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Clemastine";"CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"";"R06AA54";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BF01";"Maltase-glucoamylase, intestinal";"MGAM";"yes";"inhibitor"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BD17";"Maltase-glucoamylase, intestinal";"MGAM";"yes";"inhibitor"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BF01";"Pancreatic alpha-amylase";"AMY2A";"yes";"inhibitor"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BD17";"Pancreatic alpha-amylase";"AMY2A";"yes";"inhibitor"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BF01";"Lysosomal alpha-glucosidase";"GAA";"yes";"inhibitor"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BD17";"Lysosomal alpha-glucosidase";"GAA";"yes";"inhibitor"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BF01";"Sucrase-isomaltase, intestinal";"SI";"yes";"inhibitor"
"Acarbose";"[H][C@@](O)(CO)[C@@]([H])(O[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O[C@@]2([H])O[C@]([H])(C)[C@@]([H])(N[C@@]3([H])C=C(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]3([H])O)[C@]([H])(O)[C@@]2([H])O)[C@]([H])(O)[C@@]1([H])O)[C@]([H])(O)[C@@]([H])(O)C=O";"Healthy volunteers = 2 hours";"A10BD17";"Sucrase-isomaltase, intestinal";"SI";"yes";"inhibitor"
"Venlafaxine";"COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1";"5 hours";"N06AX16";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Venlafaxine";"COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1";"5 hours";"N06AX16";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Venlafaxine";"COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1";"5 hours";"N06AX16";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Travoprost";"CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F";"Terminal elimination half-life of travoprost free acid is 45 minutes.";"S01EE04";"Prostaglandin F2-alpha receptor";"PTGFR";"yes";"agonist"
"Amcinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC1(CCCC1)O2)C(=O)COC(C)=O";"";"D07AC11";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Amcinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC1(CCCC1)O2)C(=O)COC(C)=O";"";"D07AC11";"Annexin A1";"ANXA1";"unknown";"agonist"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";""
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";""
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"binder"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"NMDA receptor";"GRIN1";"unknown";"blocker"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"NMDA receptor";"GRIN2A";"unknown";"blocker"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"NMDA receptor";"GRIN2B";"unknown";"blocker"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"NMDA receptor";"GRIN2C";"unknown";"blocker"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"NMDA receptor";"GRIN2D";"unknown";"blocker"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"NMDA receptor";"GRIN3A";"unknown";"blocker"
"Atomoxetine";"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1";"5 hours";"N06BA09";"NMDA receptor";"GRIN3B";"unknown";"blocker"
"Bleomycin";"C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C";"115 minutes";"L01DC01";"DNA ligase 1";"LIG1";"unknown";"inhibitor"
"Bleomycin";"C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C";"115 minutes";"L01DC01";"DNA ligase 3";"LIG3";"unknown";"inhibitor"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Etomidate";"CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1";"75 minutes.";"N01AX07";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Raltitrexed";"CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O";"198 hours";"L01BA03";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Raltitrexed";"CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O";"198 hours";"L01BA03";"Folylpolyglutamate synthase, mitochondrial";"FPGS";"unknown";"antagonist"
"Etonogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"25 hours";"G03AC08";"Progesterone receptor";"PGR";"yes";"agonist"
"Etonogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"25 hours";"G03AC08";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA01";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"A07DA52";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA51";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AG01";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA01";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"A07DA52";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA51";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AG01";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA01";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"A07DA52";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA51";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AG01";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA01";"Lymphocyte antigen 96";"LY96";"unknown";""
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"A07DA52";"Lymphocyte antigen 96";"LY96";"unknown";""
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AA51";"Lymphocyte antigen 96";"LY96";"unknown";""
"Morphine";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"2-4 hours";"N02AG01";"Lymphocyte antigen 96";"LY96";"unknown";""
"Ropivacaine";"CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C";"Approximately 4.2 hours.";"N01BB09";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Bupivacaine";"CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C";"2.7 hours in adults and 8.1 hours in neonates";"N01BB51";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Bupivacaine";"CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C";"2.7 hours in adults and 8.1 hours in neonates";"N01BB01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Bupivacaine";"CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C";"2.7 hours in adults and 8.1 hours in neonates";"N01BB51";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"unknown";"other/unknown"
"Bupivacaine";"CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C";"2.7 hours in adults and 8.1 hours in neonates";"N01BB01";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"unknown";"other/unknown"
"Dapiprazole";"CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1";"";"S01EX02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Dapiprazole";"CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1";"";"S01EX02";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Dapiprazole";"CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1";"";"S01EX02";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Penciclovir";"NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2";"2 hours";"D06BB06";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Penciclovir";"NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2";"2 hours";"J05AB13";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Penciclovir";"NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2";"2 hours";"D06BB06";"Thymidine kinase";"TK";"yes";"inducer"
"Penciclovir";"NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2";"2 hours";"J05AB13";"Thymidine kinase";"TK";"yes";"inducer"
"Tenofovir disoproxil";"[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C";"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.";"J05AR12";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir disoproxil";"[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C";"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.";"J05AR03";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir disoproxil";"[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C";"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.";"J05AR06";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir disoproxil";"[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C";"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.";"J05AR09";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir disoproxil";"[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C";"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.";"J05AF07";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir disoproxil";"[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C";"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.";"J05AR08";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir disoproxil";"[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C";"When a single oral dose is given, the terminal elimination half-life is approximately 17 hours.";"J05AR11";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Flucloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O";"0.75–1 hour";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Flucloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl)C(O)=O";"0.75–1 hour";"J01CF05";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Tranexamic Acid";"NC[C@H]1CC[C@@H](CC1)C(O)=O";"Biological half-life in the joint fluid is about 3 hours.";"B02AA02";"Plasminogen";"PLG";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Ertapenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"The mean plasma half-life is approximately 4 hours.";"J01DH03";"D-alanyl-D-alanine carboxypeptidase DacC";"dacC";"yes";"inhibitor"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03AC09";"Progesterone receptor";"PGR";"yes";"agonist"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03AB05";"Progesterone receptor";"PGR";"yes";"agonist"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03AA09";"Progesterone receptor";"PGR";"yes";"agonist"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03FB10";"Progesterone receptor";"PGR";"yes";"agonist"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03AC09";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03AB05";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03AA09";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Desogestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"27.8&plusmn;7.2 hours";"G03FB10";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Talbutal";"CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA07";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Bexarotene";"CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C";"7 hours";"L01XX25";"Retinoic acid receptor RXR-alpha";"RXRA";"yes";"agonist"
"Bexarotene";"CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C";"7 hours";"L01XX25";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Bexarotene";"CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C";"7 hours";"L01XX25";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"activator"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"yes";"activator"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"unknown";"activator"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";"activator"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Potassium channel subfamily K member 1";"KCNK1";"unknown";"inhibitor"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Potassium channel subfamily K member 6";"KCNK6";"unknown";"inhibitor"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Ibutilide";"CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"6 hours (ranges from 2-12 hours)";"C01BD05";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"unknown";"inhibitor"
"Vindesine";"[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"24 hours.";"L01CA03";"Tubulin beta-1 chain";"TUBB1";"yes";"inhibitor"
"Chlorthalidone";"NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12";"40 hours";"C03BA04";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Chlorthalidone";"NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12";"40 hours";"C03BB04";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Chlorthalidone";"NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12";"40 hours";"C03EA06";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Chlorthalidone";"NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12";"40 hours";"G01AE10";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Pentobarbital";"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O";"5 to 50 hours (dose dependent)";"N05CB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Histone deacetylase 9";"HDAC9";"yes";"inhibitor"
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"4-aminobutyrate aminotransferase, mitochondrial";"ABAT";"yes";"inhibitor"
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial";"ACADSB";"unknown";"inhibitor"
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"2-oxoglutarate dehydrogenase, mitochondrial";"OGDH";"unknown";"inhibitor"
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Succinate-semialdehyde dehydrogenase, mitochondrial";"ALDH5A1";"unknown";"inhibitor"
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN1A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN10A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN11A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN2A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN3A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN4A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN5A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN7A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN8A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN9A";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN1B";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN2B";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN3B";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Sodium channel protein";"SCN4B";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Histone deacetylase 2";"HDAC2";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Valproic Acid";"CCCC(CCC)C(O)=O";"9-16 hours (following oral administration of 250 mg to 1000 mg)";"N03AG01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Zolmitriptan";"CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12";"The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.";"N02CC03";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Zolmitriptan";"CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12";"The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.";"N02CC03";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Zolmitriptan";"CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12";"The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.";"N02CC03";"5-hydroxytryptamine receptor 1F";"HTR1F";"yes";"agonist"
"Zolmitriptan";"CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12";"The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.";"N02CC03";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonist"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE51";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE71";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE51";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE71";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE01";"Fatty-acid amide hydrolase 1";"FAAH";"unknown";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE51";"Fatty-acid amide hydrolase 1";"FAAH";"unknown";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE71";"Fatty-acid amide hydrolase 1";"FAAH";"unknown";"inhibitor"
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE01";"Transient receptor potential cation channel subfamily V member 1";"TRPV1";"unknown";""
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE51";"Transient receptor potential cation channel subfamily V member 1";"TRPV1";"unknown";""
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE71";"Transient receptor potential cation channel subfamily V member 1";"TRPV1";"unknown";""
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE01";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE51";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Acetaminophen";"CC(=O)NC1=CC=C(O)C=C1";"1 to 4 hours";"N02BE71";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Gefitinib";"COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1";"48 hours [IV administration]";"L01XE02";"Epidermal growth factor receptor";"EGFR";"yes";"antagonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"N02AA59";"Mu-type opioid receptor";"OPRM1";"yes";"partial agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"N02AA79";"Mu-type opioid receptor";"OPRM1";"yes";"partial agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"R05DA04";"Mu-type opioid receptor";"OPRM1";"yes";"partial agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"N02AA59";"Kappa-type opioid receptor";"OPRK1";"yes";"partial agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"N02AA79";"Kappa-type opioid receptor";"OPRK1";"yes";"partial agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"R05DA04";"Kappa-type opioid receptor";"OPRK1";"yes";"partial agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"N02AA59";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"N02AA79";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Codeine";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.";"R05DA04";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CA12";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR05";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CA12";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR05";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CA12";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR05";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CA12";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR50";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Piperacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O";"36-72 minutes";"J01CR05";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA01";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA51";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA01";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA51";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA01";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA51";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA01";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Dihydroergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O";"9 hours";"N02CA51";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"High affinity nerve growth factor receptor";"NTRK1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"High affinity nerve growth factor receptor";"NTRK1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"BDNF/NT-3 growth factors receptor";"NTRK2";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"BDNF/NT-3 growth factors receptor";"NTRK2";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Alpha-1D adrenergic receptor";"ADRA1D";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Alpha-1D adrenergic receptor";"ADRA1D";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Alpha-2A adrenergic receptor";"ADRA2A";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Alpha-2A adrenergic receptor";"ADRA2A";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Potassium voltage-gated channel subfamily D member 2";"KCND2";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Potassium voltage-gated channel subfamily D member 2";"KCND2";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Potassium voltage-gated channel subfamily D member 3";"KCND3";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Potassium voltage-gated channel subfamily D member 3";"KCND3";"no";"inhibitor"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Histamine H2 receptor";"HRH2";"unknown";"blocker"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Histamine H2 receptor";"HRH2";"unknown";"blocker"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Histamine H4 receptor";"HRH4";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Histamine H4 receptor";"HRH4";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";"agonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Mu-type opioid receptor";"OPRM1";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Mu-type opioid receptor";"OPRM1";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"unknown";""
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"unknown";""
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Beta adrenergic receptor";"ADRB1";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Beta adrenergic receptor";"ADRB1";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Beta adrenergic receptor";"ADRB2";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Beta adrenergic receptor";"ADRB2";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06CA01";"Beta adrenergic receptor";"ADRB3";"unknown";"binder"
"Amitriptyline";"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t1⁄2 β) amitriptyline after peroral administration is about 25 hours (24.65 ± 6.31 hours; range 16.49-40.36 hours) [FDA Label].";"N06AA09";"Beta adrenergic receptor";"ADRB3";"unknown";"binder"
"Tolcapone";"CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O";"2-3.5 hours";"N04BX01";"Catechol O-methyltransferase";"COMT";"yes";"inhibitor"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"S01BA07";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"C05AA06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"D07XB04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"D10AA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"D07AB06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"S01CB05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"S01BB03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"D07CB03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluorometholone";"[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"";"S01CA07";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Nitroprusside";"O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N";"Approximately 2 minutes";"C02DD01";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Hydromorphone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"2.6 hours (oral); 18.6 hours for sustained release Palladone";"N02AG04";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Hydromorphone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"2.6 hours (oral); 18.6 hours for sustained release Palladone";"N02AA03";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Hydromorphone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"2.6 hours (oral); 18.6 hours for sustained release Palladone";"N02AG04";"Delta-type opioid receptor";"OPRD1";"yes";"partial agonist"
"Hydromorphone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"2.6 hours (oral); 18.6 hours for sustained release Palladone";"N02AA03";"Delta-type opioid receptor";"OPRD1";"yes";"partial agonist"
"Hydromorphone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"2.6 hours (oral); 18.6 hours for sustained release Palladone";"N02AG04";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Hydromorphone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"2.6 hours (oral); 18.6 hours for sustained release Palladone";"N02AA03";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Phospholipase A2, membrane associated";"PLA2G2A";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Phospholipase A2, membrane associated";"PLA2G2A";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Phospholipase A2, membrane associated";"PLA2G2A";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Phospholipase A2, membrane associated";"PLA2G2A";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Phospholipase A2, membrane associated";"PLA2G2A";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Phospholipase A2, membrane associated";"PLA2G2A";"yes";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Prostaglandin reductase 2";"PTGR2";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Prostaglandin reductase 2";"PTGR2";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Prostaglandin reductase 2";"PTGR2";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Prostaglandin reductase 2";"PTGR2";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Prostaglandin reductase 2";"PTGR2";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Prostaglandin reductase 2";"PTGR2";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Lactoylglutathione lyase";"GLO1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Lactoylglutathione lyase";"GLO1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Lactoylglutathione lyase";"GLO1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Lactoylglutathione lyase";"GLO1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Lactoylglutathione lyase";"GLO1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Lactoylglutathione lyase";"GLO1";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"other/unknown"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"other/unknown"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"other/unknown"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"other/unknown"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"other/unknown"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"other/unknown"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"agonist"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"agonist"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"agonist"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"agonist"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"agonist"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"agonist"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01CC02";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M02AA23";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB01";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"M01AB51";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"S01BC01";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";"inhibitor"
"Indomethacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O";"4.5 hours";"C01EB03";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AM06";"Probable arabinosyltransferase C";"embC";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AK02";"Probable arabinosyltransferase C";"embC";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AM03";"Probable arabinosyltransferase C";"embC";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AM06";"Probable arabinosyltransferase B";"embB";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AK02";"Probable arabinosyltransferase B";"embB";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AM03";"Probable arabinosyltransferase B";"embB";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AM06";"Probable arabinosyltransferase A";"embA";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AK02";"Probable arabinosyltransferase A";"embA";"yes";"inhibitor"
"Ethambutol";"CC[C@@H](CO)NCCN[C@@H](CC)CO";"In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.";"J04AM03";"Probable arabinosyltransferase A";"embA";"yes";"inhibitor"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD13";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BA02";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD18";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD10";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD16";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD02";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD03";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD14";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD15";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD05";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD08";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD20";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD17";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD07";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Metformin";"CN(C)C(=N)NC(N)=N";"6.2 hours. Duration of action is 8-12 hours.";"A10BD11";"5'-AMP-activated protein kinase subunit beta-1";"PRKAB1";"yes";"inducer"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03BB01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03AL01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03AL02";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R01AX03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03BB01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03AL01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03AL02";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R01AX03";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03BB01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03AL01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R03AL02";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Ipratropium bromide";"[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C";"2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t<sub>1/2 &alpha;</sub>) and terminal elimination-phase half-life (t<sub>1/2 &beta;</sub>) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.";"R01AX03";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N07BC02";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N02AC52";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N07BC02";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N02AC52";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N07BC02";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"yes";"antagonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N02AC52";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"yes";"antagonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N07BC02";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N02AC52";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N07BC02";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N02AC52";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N07BC02";"Lymphocyte antigen 96";"LY96";"unknown";""
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N02AC52";"Lymphocyte antigen 96";"LY96";"unknown";""
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N07BC02";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Methadone";"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"24-36 hours";"N02AC52";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"D(2) dopamine receptor";"DRD2";"yes";"antagonistagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"D(1B) dopamine receptor";"DRD5";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"5-hydroxytryptamine receptor 5A";"HTR5A";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"D(1) dopamine receptor";"DRD1";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"D(1) dopamine receptor";"DRD5";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Histamine H2 receptor";"HRH2";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Histamine H4 receptor";"HRH4";"unknown";"antagonist"
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRA1";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRA2";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRA3";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRA4";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRA5";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRA6";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRB1";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRB2";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRB3";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRD";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRE";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRG1";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRG2";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRG3";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRP";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"GABA-A receptor (anion channel)";"GABRQ";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Beta adrenergic receptor";"ADRB1";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Beta adrenergic receptor";"ADRB2";"unknown";""
"Olanzapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2";"21 to 54 hours";"N05AH03";"Beta adrenergic receptor";"ADRB3";"unknown";""
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07CB03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07DB01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07FB03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07BB03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07CB53";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07AB03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07CB03";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07DB01";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07FB03";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07BB03";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07CB53";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Atenolol";"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1";"6-7 hours";"C07AB03";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D08AF01";"Pyruvate dehydrogenase [ubiquinone]";"poxB";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S02AA02";"Pyruvate dehydrogenase [ubiquinone]";"poxB";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S01AX04";"Pyruvate dehydrogenase [ubiquinone]";"poxB";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"B05CA03";"Pyruvate dehydrogenase [ubiquinone]";"poxB";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D09AA03";"Pyruvate dehydrogenase [ubiquinone]";"poxB";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"P01CC02";"Pyruvate dehydrogenase [ubiquinone]";"poxB";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D08AF01";"Glutathione reductase";"gor";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S02AA02";"Glutathione reductase";"gor";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S01AX04";"Glutathione reductase";"gor";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"B05CA03";"Glutathione reductase";"gor";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D09AA03";"Glutathione reductase";"gor";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"P01CC02";"Glutathione reductase";"gor";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D08AF01";"Malate dehydrogenase";"mdh";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S02AA02";"Malate dehydrogenase";"mdh";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S01AX04";"Malate dehydrogenase";"mdh";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"B05CA03";"Malate dehydrogenase";"mdh";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D09AA03";"Malate dehydrogenase";"mdh";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"P01CC02";"Malate dehydrogenase";"mdh";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D08AF01";"[Citrate [pro-3S]-lyase] ligase";"citC";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S02AA02";"[Citrate [pro-3S]-lyase] ligase";"citC";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"S01AX04";"[Citrate [pro-3S]-lyase] ligase";"citC";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"B05CA03";"[Citrate [pro-3S]-lyase] ligase";"citC";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"D09AA03";"[Citrate [pro-3S]-lyase] ligase";"citC";"yes";"inhibitor"
"Nitrofural";"NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O";"5 hours";"P01CC02";"[Citrate [pro-3S]-lyase] ligase";"citC";"yes";"inhibitor"
"Pimecrolimus";"[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC";"";"D11AH02";"Serine/threonine-protein kinase mTOR";"MTOR";"yes";"potentiator"
"Pimecrolimus";"[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC";"";"D11AH02";"Peptidyl-prolyl cis-trans isomerase FKBP1A";"FKBP1A";"unknown";"potentiator"
"Omeprazole";"COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C";"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)";"A02BD01";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Omeprazole";"COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C";"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)";"A02BD05";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Omeprazole";"COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C";"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)";"A02BC01";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Omeprazole";"COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C";"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)";"A02BD01";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Omeprazole";"COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C";"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)";"A02BD05";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Omeprazole";"COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C";"0.5-1 hour (healthy subjects, delayed-release capsule); 
3 hours (hepatic impairment)";"A02BC01";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Metixene";"CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1";"";"N04AA03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Metixene";"CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1";"";"N04AA03";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Metixene";"CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1";"";"N04AA03";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Metixene";"CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1";"";"N04AA03";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Metixene";"CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1";"";"N04AA03";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Cetirizine";"OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"8.3 hours";"R06AE07";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Terfenadine";"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"3.5 hours";"R06AX12";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Terfenadine";"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"3.5 hours";"R06AX12";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Terfenadine";"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"3.5 hours";"R06AX12";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Terfenadine";"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"3.5 hours";"R06AX12";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"binder"
"Terfenadine";"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"3.5 hours";"R06AX12";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"binder"
"Terfenadine";"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"3.5 hours";"R06AX12";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"binder"
"Terfenadine";"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"3.5 hours";"R06AX12";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"binder"
"Diltiazem";"COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O";"3.0 - 4.5 hours";"C05AE03";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"yes";"inhibitor"
"Diltiazem";"COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O";"3.0 - 4.5 hours";"C08DB01";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"yes";"inhibitor"
"Protriptyline";"CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"N06AA11";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Protriptyline";"CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"N06AA11";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA51";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA51";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA51";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA01";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA51";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Alfuzosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1";"10 hours";"G04CA01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Trimethadione";"CN1C(=O)OC(C)(C)C1=O";"";"N03AC02";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Nitisinone";"[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O";"~54 hours";"A16AX04";"4-hydroxyphenylpyruvate dioxygenase";"HPD";"yes";"inhibitor"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Clobazam";"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O";"The mean elimination half life of an oral dose of clobazam 40 mg is 32 hours. It's main metabolite, norclobazam, as a half life of 57 hours. The half life in adult patients with epilepsy are higher than those that are healthy.";"N05BA09";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Minoxidil";"NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1";"4.2 hours";"D11AX01";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"inducer"
"Minoxidil";"NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1";"4.2 hours";"C02DC01";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"inducer"
"Minoxidil";"NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1";"4.2 hours";"D11AX01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inducer"
"Minoxidil";"NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1";"4.2 hours";"C02DC01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inducer"
"Minoxidil";"NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1";"4.2 hours";"D11AX01";"Renin";"REN";"unknown";""
"Minoxidil";"NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1";"4.2 hours";"C02DC01";"Renin";"REN";"unknown";""
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"L02AB01";"Progesterone receptor";"PGR";"yes";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03DB02";"Progesterone receptor";"PGR";"yes";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03AA04";"Progesterone receptor";"PGR";"yes";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03FA08";"Progesterone receptor";"PGR";"yes";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03AC05";"Progesterone receptor";"PGR";"yes";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03FB04";"Progesterone receptor";"PGR";"yes";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03AB01";"Progesterone receptor";"PGR";"yes";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"L02AB01";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03DB02";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03AA04";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03FA08";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03AC05";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03FB04";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Megestrol acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"34 hours";"G03AB01";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Methylergometrine";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO";"3.39 hours";"G02AC01";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Methylergometrine";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO";"3.39 hours";"G02AB01";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Methylergometrine";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO";"3.39 hours";"G02AC01";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";""
"Methylergometrine";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO";"3.39 hours";"G02AB01";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";""
"Buclizine";"CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1";"";"R06AE51";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Buclizine";"CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1";"";"R06AE01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Buclizine";"CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1";"";"R06AE51";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Buclizine";"CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1";"";"R06AE01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Aztreonam";"C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O";"The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively).";"J01DF01";"Penicillin-binding protein 3";"pbpC";"yes";"inhibitor"
"Aztreonam";"C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O";"The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively).";"J01DF01";"Beta-lactamase";"ampC";"yes";"potentiator"
"Chlorzoxazone";"ClC1=CC2=C(OC(=O)N2)C=C1";"";"M03BB73";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";""
"Chlorzoxazone";"ClC1=CC2=C(OC(=O)N2)C=C1";"";"M03BB03";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";""
"Chlorzoxazone";"ClC1=CC2=C(OC(=O)N2)C=C1";"";"M03BB53";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";""
"Aminoglutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1";"12.5 &plusmn; 1.6 hours";"L02BG01";"Cytochrome P450 19A1";"CYP19A1";"yes";"inhibitor"
"Aminoglutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1";"12.5 &plusmn; 1.6 hours";"L02BG01";"Cholesterol side-chain cleavage enzyme, mitochondrial";"CYP11A1";"yes";"inhibitor"
"Mefloquine";"OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F";"2 to 4 weeks";"P01BC02";"Hemoglobin subunit alpha";"HBA1";"yes";"antagonist"
"Mefloquine";"OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F";"2 to 4 weeks";"P01BF02";"Hemoglobin subunit alpha";"HBA1";"yes";"antagonist"
"Mefloquine";"OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F";"2 to 4 weeks";"P01BC02";"Adenosine receptor A2a";"ADORA2A";"unknown";"antagonist"
"Mefloquine";"OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F";"2 to 4 weeks";"P01BF02";"Adenosine receptor A2a";"ADORA2A";"unknown";"antagonist"
"Sulfadiazine";"NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1";"";"J01EE06";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfadiazine";"NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1";"";"J01EE02";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfadiazine";"NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1";"";"G01AE10";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfadiazine";"NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1";"";"J01EC02";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sapropterin";"[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O";"";"A16AX07";"Phenylalanine-4-hydroxylase";"PAH";"yes";"cofactor"
"Sapropterin";"[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O";"";"A16AX07";"Nitric oxide synthase, endothelial";"NOS3";"yes";"cofactor"
"Sapropterin";"[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O";"";"A16AX07";"Tyrosine 3-monooxygenase";"TH";"yes";"cofactor"
"Sapropterin";"[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O";"";"A16AX07";"Tryptophan 5-hydroxylase 1";"TPH1";"yes";"cofactor"
"Vinorelbine";"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC";"The terminal phase half-life averaged 27.7 to 43.6 hours; the mean plasma clearances ranged from 0.97 to 1.26 L/hr/kg [A32354].";"L01CA04";"Tubulin beta chain";"TUBB";"yes";"inhibitor"
"Anidulafungin";"[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O";"40-50 hours";"J02AX06";"1,3-beta-glucan synthase component FKS1";"fksA";"yes";"inhibitor"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Histamine H4 receptor";"HRH4";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Alpha-1B adrenergic receptor";"ADRA1B";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Alpha-2A adrenergic receptor";"ADRA2A";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Alpha-2B adrenergic receptor";"ADRA2B";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Alpha-2C adrenergic receptor";"ADRA2C";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Neuron-specific vesicular protein calcyon";"CALY";"unknown";"unknown"
"Clozapine";"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12";"8 hours (range 4-12 hours)";"N05AH02";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Sucralfate";"O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O";"Not known.";"A02BX02";"Fibroblast growth factor 2";"FGF2";"yes";"agonist"
"Sucralfate";"O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O";"Not known.";"A02BX02";"Pro-epidermal growth factor";"EGF";"yes";"inducer"
"Sucralfate";"O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O";"Not known.";"A02BX02";"Fibrinogen alpha chain";"FGA";"unknown";"antagonist"
"Sucralfate";"O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O";"Not known.";"A02BX02";"Fibrinogen beta chain";"FGB";"unknown";"antagonist"
"Sucralfate";"O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O";"Not known.";"A02BX02";"Fibrinogen gamma chain";"FGG";"unknown";"antagonist"
"Grepafloxacin";"CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O";"15 &plusmn; 3 hours";"J01MA11";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Grepafloxacin";"CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O";"15 &plusmn; 3 hours";"J01MA11";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Doxylamine";"CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1";"10 hours";"R06AA59";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Doxylamine";"CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1";"10 hours";"R06AA09";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Doxylamine";"CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1";"10 hours";"R06AA59";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Doxylamine";"CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1";"10 hours";"R06AA09";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Doxylamine";"CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1";"10 hours";"R06AA59";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Doxylamine";"CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1";"10 hours";"R06AA09";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FA11";"Progesterone receptor";"PGR";"yes";"binder"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FB09";"Progesterone receptor";"PGR";"yes";"binder"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AC03";"Progesterone receptor";"PGR";"yes";"binder"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AB03";"Progesterone receptor";"PGR";"yes";"binder"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AD01";"Progesterone receptor";"PGR";"yes";"binder"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AA07";"Progesterone receptor";"PGR";"yes";"binder"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FA11";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FB09";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AC03";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AB03";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AD01";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AA07";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FA11";"Estrogen receptor alpha";"ESR1";"yes";"other"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FB09";"Estrogen receptor alpha";"ESR1";"yes";"other"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AC03";"Estrogen receptor alpha";"ESR1";"yes";"other"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AB03";"Estrogen receptor alpha";"ESR1";"yes";"other"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AD01";"Estrogen receptor alpha";"ESR1";"yes";"other"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AA07";"Estrogen receptor alpha";"ESR1";"yes";"other"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FA11";"Androgen receptor";"AR";"unknown";"agonist"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FB09";"Androgen receptor";"AR";"unknown";"agonist"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AC03";"Androgen receptor";"AR";"unknown";"agonist"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AB03";"Androgen receptor";"AR";"unknown";"agonist"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AD01";"Androgen receptor";"AR";"unknown";"agonist"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AA07";"Androgen receptor";"AR";"unknown";"agonist"
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FA11";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03FB09";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AC03";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AB03";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AD01";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Levonorgestrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"";"G03AA07";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Phenylalanine-4-hydroxylase";"PAH";"no";"inhibitor"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";"binder"
"Norepinephrine";"NC[C@H](O)C1=CC(O)=C(O)C=C1";"";"C01CA03";"Chromaffin granule amine transporter";"SLC18A1";"unknown";"binder"
"Cidofovir";"NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1";"2.4 to 3.2 hours";"J05AB12";"DNA polymerase catalytic subunit";"UL54";"yes";"inhibitor"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"binding"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"D(2) dopamine receptor";"DRD2";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"D(3) dopamine receptor";"DRD3";"unknown";""
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"D(1) dopamine receptor";"DRD1";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"D(1) dopamine receptor";"DRD5";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Histamine H3 receptor";"HRH3";"unknown";"antagonist"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"binder"
"Mirtazapine";"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1";"20-40 hours";"N06AX11";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"binder"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"agonist"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05CX01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC51";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Meprobamate";"CCCC(C)(COC(N)=O)COC(N)=O";"Plasma half-life is about 10 hours.";"N05BC01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Thiethylperazine";"CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"R06AD03";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Thiethylperazine";"CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"R06AD03";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Thiethylperazine";"CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"R06AD03";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"S01ED51";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"S01ED01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07DA06";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07AA06";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07BA06";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"S01ED51";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"S01ED01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07DA06";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07AA06";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07BA06";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"S01ED51";"Lysozyme";"E";"unknown";""
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"S01ED01";"Lysozyme";"E";"unknown";""
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07DA06";"Lysozyme";"E";"unknown";""
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07AA06";"Lysozyme";"E";"unknown";""
"Timolol";"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1";"2.5-5 hours";"C07BA06";"Lysozyme";"E";"unknown";""
"Treprostinil";"[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1";"Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.";"B01AC21";"Prostacyclin receptor";"PTGIR";"yes";"agonist"
"Treprostinil";"[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1";"Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.";"B01AC21";"Peroxisome proliferator-activated receptor delta";"PPARD";"yes";"agonist"
"Treprostinil";"[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1";"Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively.";"B01AC21";"P2Y purinoceptor 12";"P2RY12";"yes";"agonist"
"Trihexyphenidyl";"OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1";"3.3-4.1 hours";"N04AA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Trihexyphenidyl";"OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1";"3.3-4.1 hours";"N04AA01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Trihexyphenidyl";"OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1";"3.3-4.1 hours";"N04AA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Trihexyphenidyl";"OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1";"3.3-4.1 hours";"N04AA01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Trihexyphenidyl";"OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1";"3.3-4.1 hours";"N04AA01";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Palonosetron";"[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2";"Approximately 40 hours";"A04AA55";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Palonosetron";"[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2";"Approximately 40 hours";"A04AA05";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Dydrogesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C";"Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours";"G03FA14";"Progesterone receptor";"PGR";"yes";"agonist"
"Dydrogesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C";"Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours";"G03DB01";"Progesterone receptor";"PGR";"yes";"agonist"
"Dydrogesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C";"Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours";"G03FB08";"Progesterone receptor";"PGR";"yes";"agonist"
"Mexiletine";"CC(N)COC1=C(C)C=CC=C1C";"10-12 hours";"C01BB02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Mexiletine";"CC(N)COC1=C(C)C=CC=C1C";"10-12 hours";"C01BB02";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Dexrazoxane";"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1";"2.5 hours";"V03AF02";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Dexrazoxane";"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1";"2.5 hours";"V03AF02";"DNA topoisomerase 2-beta";"TOP2B";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Voltage-gated calcium channel beta 1 subunit splice variant CavB1d";"CACNB1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB05";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX01";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB01";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB04";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DX03";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX03";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB06";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08GA02";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX11";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB07";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09DB02";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB03";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C08CA01";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB07";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX07";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BX01";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA53";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09XA54";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C09BB04";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Amlodipine";"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC";"30-50 hours";"C10BX09";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Tacrine";"NC1=C2CCCCC2=NC2=CC=CC=C12";"2 to 4 hours";"N06DA01";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Tacrine";"NC1=C2CCCCC2=NC2=CC=CC=C12";"2 to 4 hours";"N06DA01";"Cholinesterase";"BCHE";"yes";"inhibitor"
"Tacrine";"NC1=C2CCCCC2=NC2=CC=CC=C12";"2 to 4 hours";"N06DA01";"Liver carboxylesterase 1";"CES1";"unknown";""
"Oxyphencyclimine";"CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03CA03";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Oxyphencyclimine";"CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Oxyphencyclimine";"CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03CA03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Oxyphencyclimine";"CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Oxyphencyclimine";"CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03CA03";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Oxyphencyclimine";"CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AA01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Triamterene";"NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1";"255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.";"C03DB02";"Amiloride-sensitive sodium channel subunit gamma";"SCNN1G";"yes";"inhibitor"
"Triamterene";"NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1";"255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.";"C03DB02";"Amiloride-sensitive sodium channel subunit alpha";"SCNN1A";"yes";"inhibitor"
"Triamterene";"NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1";"255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.";"C03DB02";"Amiloride-sensitive sodium channel subunit beta";"SCNN1B";"yes";"inhibitor"
"Triamterene";"NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1";"255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.";"C03DB02";"Amiloride-sensitive sodium channel subunit delta";"SCNN1D";"unknown";"inhibitor"
"Valrubicin";"[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1";"";"L01DB09";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Procyclidine";"OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1";"";"N04AA04";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Procyclidine";"OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1";"";"N04AA04";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Procyclidine";"OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1";"";"N04AA04";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Procyclidine";"OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1";"";"N04AA04";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01AA04";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01FB01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01GA05";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01GA55";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01BA03";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01BA53";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"C01CA06";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01AB01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01AA04";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01FB01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01GA05";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01GA55";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01BA03";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01BA53";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"C01CA06";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01AB01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01AA04";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01FB01";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01GA05";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"S01GA55";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01BA03";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01BA53";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"C01CA06";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Phenylephrine";"CNC[C@H](O)C1=CC(O)=CC=C1";"2.1 to 3.4 hours";"R01AB01";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";""
"Carbimazole";"CCOC(=O)N1C=CN(C)C1=S";"";"H03BB01";"Thyroid peroxidase";"TPO";"yes";"inhibitor"
"Digoxin";"[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1";"3.5 to 5 days";"C01AA05";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";""
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL07";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL01";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL07";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL01";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL07";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL01";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Sulpiride";"CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O";"6 to 8 hours";"N05AL07";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Ethopropazine";"CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12";"1 to 2 hours";"N04AA05";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Ethopropazine";"CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12";"1 to 2 hours";"N04AA05";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Ethopropazine";"CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12";"1 to 2 hours";"N04AA05";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit beta-3";"CACNB3";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Voltage-dependent L-type calcium channel subunit beta-4";"CACNB4";"yes";"inhibitor"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Mineralocorticoid receptor";"NR3C2";"unknown";"antagonist"
"Nimodipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C";"1.7-9 hours";"C08CA06";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Beclomethasone dipropionate";"[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2.8 hours";"R03BA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Beclomethasone dipropionate";"[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2.8 hours";"R03AK08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Beclomethasone dipropionate";"[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2.8 hours";"A07EA07";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Beclomethasone dipropionate";"[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2.8 hours";"D07CC04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Beclomethasone dipropionate";"[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2.8 hours";"R01AD01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Beclomethasone dipropionate";"[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2.8 hours";"D07AC15";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA52";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA72";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA52";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA02";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA72";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA52";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA02";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"unknown";""
"Carisoprodol";"CCCC(C)(COC(N)=O)COC(=O)NC(C)C";"8 hours";"M03BA72";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Progesterone receptor";"PGR";"yes";"agonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Progesterone receptor";"PGR";"yes";"agonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Mineralocorticoid receptor";"NR3C2";"yes";"antagonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Mineralocorticoid receptor";"NR3C2";"yes";"antagonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Steroid 17-alpha-hydroxylase/17,20 lyase";"CYP17A1";"unknown";"inhibitor"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Steroid 17-alpha-hydroxylase/17,20 lyase";"CYP17A1";"unknown";"inhibitor"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Kappa-type opioid receptor";"OPRK1";"unknown";"activator"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Kappa-type opioid receptor";"OPRK1";"unknown";"activator"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Glucocorticoid receptor";"NR3C1";"unknown";"partial agonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Glucocorticoid receptor";"NR3C1";"unknown";"partial agonist"
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Androgen receptor";"AR";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Androgen receptor";"AR";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03DA04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Progesterone";"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"34.8-55.13 hours";"G03FA04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA51";"D(1A) dopamine receptor";"DRD1";"unknown";"partial agonist"
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA01";"D(1A) dopamine receptor";"DRD1";"unknown";"partial agonist"
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA51";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA01";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA51";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"agonist"
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA01";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"agonist"
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA51";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";""
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA01";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";""
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA51";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";""
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA01";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";""
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA51";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";""
"Phenylpropanolamine";"C[C@@H](N)[C@@H](O)C1=CC=CC=C1";"2.1 to 3.4 hours.";"R01BA01";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";""
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Serine/threonine-protein kinase B-raf";"BRAF";"yes";"inhibitor"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"RAF proto-oncogene serine/threonine-protein kinase";"RAF1";"yes";"inhibitor"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Vascular endothelial growth factor receptor 3";"FLT4";"yes";"antagonist"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"antagonist"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Receptor-type tyrosine-protein kinase FLT3";"FLT3";"yes";"antagonist"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Platelet-derived growth factor receptor beta";"PDGFRB";"yes";"antagonist"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Mast/stem cell growth factor receptor Kit";"KIT";"yes";"antagonist"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Fibroblast growth factor receptor 1";"FGFR1";"yes";"inhibitor"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Proto-oncogene tyrosine-protein kinase receptor Ret";"RET";"yes";"inhibitor"
"Sorafenib";"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1";"25-48 hours";"L01XE05";"Vascular endothelial growth factor receptor 1";"FLT1";"yes";"inhibitor"
"Zoledronic acid";"OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O";"146 hours";"M05BB08";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Zoledronic acid";"OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O";"146 hours";"M05BA08";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Zoledronic acid";"OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O";"146 hours";"M05BB08";"Geranylgeranyl pyrophosphate synthase";"GGPS1";"yes";"inhibitor"
"Zoledronic acid";"OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O";"146 hours";"M05BA08";"Geranylgeranyl pyrophosphate synthase";"GGPS1";"yes";"inhibitor"
"Griseofulvin";"COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC";"9-21 hours";"D01AA08";"Tubulin beta chain";"TUB2";"yes";"inhibitor"
"Griseofulvin";"COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC";"9-21 hours";"D01BA01";"Tubulin beta chain";"TUB2";"yes";"inhibitor"
"Griseofulvin";"COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC";"9-21 hours";"D01AA08";"Tubulin alpha chain";"TUB1";"yes";"inhibitor"
"Griseofulvin";"COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC";"9-21 hours";"D01BA01";"Tubulin alpha chain";"TUB1";"yes";"inhibitor"
"Griseofulvin";"COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC";"9-21 hours";"D01AA08";"Keratin, type I cytoskeletal 12";"KRT12";"unknown";"other/unknown"
"Griseofulvin";"COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC";"9-21 hours";"D01BA01";"Keratin, type I cytoskeletal 12";"KRT12";"unknown";"other/unknown"
"Nisoldipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C";"7-12 hours";"C08CA07";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nisoldipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C";"7-12 hours";"C08CA07";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nisoldipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C";"7-12 hours";"C08CA07";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nisoldipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C";"7-12 hours";"C08CA07";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nisoldipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C";"7-12 hours";"C08CA07";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"unknown";"agonist"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"unknown";"agonist"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"unknown";"agonist"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"Translocator protein";"TSPO";"yes";"agonist"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Eszopiclone";"CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"6 hours";"N05CF04";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Ceruletide";"[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O";"";"V04CC04";"Cholecystokinin receptor type A";"CCKAR";"yes";"inducer"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Alprazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"6.3-26.9 hours";"N05BA12";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Dexbrompheniramine";"CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1";"25 hours";"R06AB56";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Dexbrompheniramine";"CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1";"25 hours";"R06AB06";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 5A";"HTR5A";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"D(1) dopamine receptor";"DRD1";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"D(1) dopamine receptor";"DRD5";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"D(3) dopamine receptor";"DRD3";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"D(4) dopamine receptor";"DRD4";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"D(1B) dopamine receptor";"DRD5";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Histamine H1 receptor";"HRH1";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Histamine H2 receptor";"HRH2";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Histamine H4 receptor";"HRH4";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"binder"
"Loxapine";"CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2";"Oral-4 hours";"N05AH01";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"binder"
"Remoxipride";"CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC";"4-7 hours";"N05AL04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Remoxipride";"CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC";"4-7 hours";"N05AL04";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Remoxipride";"CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC";"4-7 hours";"N05AL04";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Remoxipride";"CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC";"4-7 hours";"N05AL04";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"other/unknown"
"Remoxipride";"CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC";"4-7 hours";"N05AL04";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";"antagonist"
"Mupirocin";"C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O";"20 to 40 minutes";"R01AX06";"Isoleucine--tRNA ligase";"ileS";"yes";"inhibitor"
"Mupirocin";"C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O";"20 to 40 minutes";"D06AX09";"Isoleucine--tRNA ligase";"ileS";"yes";"inhibitor"
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"N07AB01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"S01EB02";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"N07AB01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"agonist"
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"S01EB02";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"agonist"
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"N07AB01";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"agonist"
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"S01EB02";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"agonist"
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"N07AB01";"Acetylcholinesterase";"ACHE";"unknown";""
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"S01EB02";"Acetylcholinesterase";"ACHE";"unknown";""
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"N07AB01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"S01EB02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"N07AB01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";""
"Carbachol";"[Cl-].C[N+](C)(C)CCOC(N)=O";"";"S01EB02";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD03";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BG02";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD04";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD03";"Long-chain-fatty-acid--CoA ligase 4";"ACSL4";"unknown";"inhibitor"
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BG02";"Long-chain-fatty-acid--CoA ligase 4";"ACSL4";"unknown";"inhibitor"
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD04";"Long-chain-fatty-acid--CoA ligase 4";"ACSL4";"unknown";"inhibitor"
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD03";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BG02";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD04";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD03";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BG02";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD04";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD03";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BG02";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD04";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD03";"Retinoic acid receptor RXR-beta";"RXRB";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BG02";"Retinoic acid receptor RXR-beta";"RXRB";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD04";"Retinoic acid receptor RXR-beta";"RXRB";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD03";"Retinoic acid receptor RXR-gamma";"RXRG";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BG02";"Retinoic acid receptor RXR-gamma";"RXRG";"unknown";""
"Rosiglitazone";"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1";"3-4 hours (single oral dose, independent of dose)";"A10BD04";"Retinoic acid receptor RXR-gamma";"RXRG";"unknown";""
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"partial agonist"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"D(1A) dopamine receptor";"DRD1";"unknown";"unknown"
"Pramipexole";"CCCN[C@H]1CCC2=C(C1)SC(N)=N2";"8 hours";"N04BC05";"D(1B) dopamine receptor";"DRD5";"unknown";"unknown"
"Acetohexamide";"CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"Elimination half-life of the parent compound is 1.3 hours and the elimination half-life of the active metabolite is approximately 5-6 hours.";"A10BB31";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Angiopoietin-1 receptor";"TEK";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"S01AA19";"Angiopoietin-1 receptor";"TEK";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA51";"Angiopoietin-1 receptor";"TEK";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CA01";"Angiopoietin-1 receptor";"TEK";"unknown";""
"Ampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"";"J01CR01";"Angiopoietin-1 receptor";"TEK";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE02";"Penicillin-binding protein 1A";"pbpA";"yes";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE10";"Penicillin-binding protein 1A";"pbpA";"yes";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CR50";"MecA PBP2' (penicillin binding protein 2')";"mecA";"yes";"inhibitor"
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE02";"MecA PBP2' (penicillin binding protein 2')";"mecA";"yes";"inhibitor"
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE10";"MecA PBP2' (penicillin binding protein 2')";"mecA";"yes";"inhibitor"
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CR50";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE02";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE10";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CR50";"Penicillin acylase";"";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE02";"Penicillin acylase";"";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE10";"Penicillin acylase";"";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CR50";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE02";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Phenoxymethylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O";"30 to 40 minutes";"J01CE10";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA06";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Secobarbital";"CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CB01";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Miglustat";"CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO";"The effective half-life of miglustat is approximately 6 to 7 hours.";"A16AX06";"Ceramide glucosyltransferase";"UGCG";"yes";"inhibitor"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Promazine";"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12";"";"N05AA03";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Mineralocorticoid receptor";"NR3C2";"yes";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Androgen receptor";"AR";"unknown";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Progesterone receptor";"PGR";"unknown";"agonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Glucocorticoid receptor";"NR3C1";"unknown";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Cytochrome P450 11B2, mitochondrial";"CYP11B2";"unknown";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"3-oxo-5-alpha-steroid 4-dehydrogenase";"SRD5A1";"unknown";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"3-oxo-5-alpha-steroid 4-dehydrogenase";"SRD5A2";"unknown";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"3-oxo-5-alpha-steroid 4-dehydrogenase";"SRD5A3";"unknown";"antagonist"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Sex hormone-binding globulin";"SHBG";"unknown";"binder"
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNG1";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA2D1";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA2D2";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA2D3";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1C";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1D";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1F";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1S";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNB1";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNB1";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNB2";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNB3";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNB4";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1B";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1A";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1G";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1H";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Voltage-dependent calcium channel";"CACNA1I";"unknown";""
"Spironolactone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O";"10 minutes";"C03DA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Methylphenidate";"COC(=O)C(C1CCCCN1)C1=CC=CC=C1";"d-methylphenidate = 3-4 hours;
l-methylphenidate = 1-3 hours; 
Ritalinic acid = 3-4 hours;";"N06BA04";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Methylphenidate";"COC(=O)C(C1CCCCN1)C1=CC=CC=C1";"d-methylphenidate = 3-4 hours;
l-methylphenidate = 1-3 hours; 
Ritalinic acid = 3-4 hours;";"N06BA04";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Methylphenidate";"COC(=O)C(C1CCCCN1)C1=CC=CC=C1";"d-methylphenidate = 3-4 hours;
l-methylphenidate = 1-3 hours; 
Ritalinic acid = 3-4 hours;";"N06BA04";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Methocarbamol";"COC1=CC=CC=C1OCC(O)COC(N)=O";"1.14-1.24 hours";"M03BA53";"Carbonic anhydrase 1";"CA1";"no";"inhibitor"
"Methocarbamol";"COC1=CC=CC=C1OCC(O)COC(N)=O";"1.14-1.24 hours";"M03BA03";"Carbonic anhydrase 1";"CA1";"no";"inhibitor"
"Methocarbamol";"COC1=CC=CC=C1OCC(O)COC(N)=O";"1.14-1.24 hours";"M03BA73";"Carbonic anhydrase 1";"CA1";"no";"inhibitor"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03CB31";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03BA03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03CB31";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03BA03";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03CB31";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03BA03";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03CB31";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Hyoscyamine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1";"2-3.5 hours";"A03BA03";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Zolpidem";"CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1";"2.6 hours";"N05CF02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Zolpidem";"CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1";"2.6 hours";"N05CF02";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"unknown";"agonist"
"Zolpidem";"CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1";"2.6 hours";"N05CF02";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"unknown";"agonist"
"Zolpidem";"CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1";"2.6 hours";"N05CF02";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";"agonist"
"Zolpidem";"CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1";"2.6 hours";"N05CF02";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"unknown";"agonist"
"Famciclovir";"CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O";"10 hours";"S01AD07";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Famciclovir";"CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O";"10 hours";"J05AB09";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Famciclovir";"CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O";"10 hours";"S01AD07";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Famciclovir";"CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O";"10 hours";"J05AB09";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Triprolidine";"CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1";"4 to 6 hours.";"R06AX07";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Streptozocin";"CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O";"5-15 minutes";"L01AD04";"Solute carrier family 2, facilitated glucose transporter member 2";"SLC2A2";"unknown";"ligand"
"Streptozocin";"CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O";"5-15 minutes";"L01AD04";"O-GlcNAcase BT_4395";"";"yes";"antagonist"
"Streptozocin";"CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O";"5-15 minutes";"L01AD04";"Bifunctional protein NCOAT";"MGEA5";"unknown";""
"Carboprost Tromethamine";"OCC([NH3+])(CO)CO.CCCCC[C@@](O)(C)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)[O-]";"";"G02AD04";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"yes";"agonist"
"Cefpiramide";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O";"4.44 hours";"J01DD11";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefpiramide";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O";"4.44 hours";"J01DD11";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Cefpiramide";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O";"4.44 hours";"J01DD11";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefpiramide";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O";"4.44 hours";"J01DD11";"Penicillin-binding protein 1B";"ponB";"yes";"inhibitor"
"Cefpiramide";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O";"4.44 hours";"J01DD11";"D-alanyl-D-alanine carboxypeptidase DacC";"dacC";"yes";"inhibitor"
"Cefpiramide";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O";"4.44 hours";"J01DD11";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefpiramide";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O";"4.44 hours";"J01DD11";"Penicillin binding protein 2a";"mecA";"no";"inhibitor"
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"antagonist"
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";"antagonist"
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Glycine receptor subunit alpha-2";"GLRA2";"unknown";"antagonist"
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Glycine receptor subunit alpha-3";"GLRA3";"unknown";"antagonist"
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Glycine receptor subunit beta";"GLRB";"unknown";"antagonist"
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";""
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"unknown";""
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Progesterone receptor";"PGR";"unknown";""
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Estrogen receptor alpha";"ESR1";"unknown";""
"Lindane";"Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl";"18 hours";"P03AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Trifluridine";"OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F";"Approximately 12 to 18 minutes following ophthalmic administration.";"S01AD02";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trifluridine";"OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F";"Approximately 12 to 18 minutes following ophthalmic administration.";"L01BC59";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Prochlorperazine";"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"6 to 8 hours";"N05AB04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Cyproheptadine";"CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"R06AX02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Cyproheptadine";"CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"R06AX02";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Cyproheptadine";"CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"R06AX02";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Cyproheptadine";"CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"R06AX02";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Cyproheptadine";"CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"R06AX02";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Cyproheptadine";"CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"R06AX02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Cyproheptadine";"CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"";"R06AX02";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";""
"Nitric Oxide";"[N]=O";"2&ndash;6 seconds";"R07AX01";"Guanylate cyclase soluble subunit alpha-2";"GUCY1A2";"yes";"inducer"
"Nitric Oxide";"[N]=O";"2&ndash;6 seconds";"R07AX01";"Metallothionein-1A";"MT1A";"unknown";""
"Nitric Oxide";"[N]=O";"2&ndash;6 seconds";"R07AX01";"Indoleamine 2,3-dioxygenase 1";"IDO1";"unknown";""
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AA01";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03EA13";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AB01";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"G01AE10";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AA01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inducer"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03EA13";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inducer"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AB01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inducer"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"G01AE10";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inducer"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AA01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03EA13";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AB01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"G01AE10";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AA01";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03EA13";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AB01";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AA01";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03EA13";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"C03AB01";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Bendroflumethiazide";"NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F";"8.5 hours";"G01AE10";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Allopurinol";"O=C1N=CN=C2NNC=C12";"1-3 hours";"M04AA01";"Xanthine dehydrogenase/oxidase";"XDH";"yes";"inhibitor"
"Allopurinol";"O=C1N=CN=C2NNC=C12";"1-3 hours";"M04AA51";"Xanthine dehydrogenase/oxidase";"XDH";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Penicillin-binding protein 1B";"ponB";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Penicillin-binding protein 1B";"ponB";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Penicillin-binding protein 2";"pbpA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Penicillin-binding protein 2";"pbpA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD52";"D-alanyl-D-alanine endopeptidase";"pbpG";"no";"inhibitor"
"Ceftazidime";"[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1";"Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.";"J01DD02";"D-alanyl-D-alanine endopeptidase";"pbpG";"no";"inhibitor"
"Cerivastatin";"COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C";"2-3 hours";"C10AA06";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE07";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE01";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE05";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EA01";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE04";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE02";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE03";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE07";"Dihydrofolate reductase";"DHFR";"no";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE01";"Dihydrofolate reductase";"DHFR";"no";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE05";"Dihydrofolate reductase";"DHFR";"no";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EA01";"Dihydrofolate reductase";"DHFR";"no";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE04";"Dihydrofolate reductase";"DHFR";"no";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE02";"Dihydrofolate reductase";"DHFR";"no";"inhibitor"
"Trimethoprim";"COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC";"8-11 hours in adults with normal renal function";"J01EE03";"Dihydrofolate reductase";"DHFR";"no";"inhibitor"
"Gemcitabine";"NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F";"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.";"L01BC05";"Ribonucleoside-diphosphate reductase large subunit";"RRM1";"yes";"inhibitor"
"Gemcitabine";"NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F";"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.";"L01BC05";"Thymidylate synthase";"TYMS";"unknown";"inhibitor"
"Gemcitabine";"NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F";"Gemcitabine half-life for short infusions ranged from 42 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions.";"L01BC05";"UMP-CMP kinase";"CMPK1";"unknown";"inhibitor"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"S01BB04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"R03BA04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"S01CA05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"H02AB01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"D07CC01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"R01AD06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"D07BC01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"C05AA05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"D07XC01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"S01CB04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"A07EA04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"S02BA07";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"S03BA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"D07AC01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"S03CA06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Betamethasone";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.6 hours";"S01BA06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Teniposide";"[H][C@]12COC(=O)[C@]1([H])[C@]([H])(C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@]2([H])O[C@]1([H])O[C@]2([H])CO[C@]([H])(O[C@@]2([H])[C@]([H])(O)[C@@]1([H])O)C1=CC=CS1";"5 hours";"L01CB02";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Epirubicin";"COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O";"Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively";"L01DB03";"Chromodomain-helicase-DNA-binding protein 1";"CHD1";"yes";"antagonist"
"Epirubicin";"COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O";"Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively";"L01DB03";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"G01AA05";"50S ribosomal protein L16";"rplP";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"J01BA01";"50S ribosomal protein L16";"rplP";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"D10AF03";"50S ribosomal protein L16";"rplP";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S01AA01";"50S ribosomal protein L16";"rplP";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S02AA01";"50S ribosomal protein L16";"rplP";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S03AA08";"50S ribosomal protein L16";"rplP";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"D06AX02";"50S ribosomal protein L16";"rplP";"unknown";"inhibitor"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"G01AA05";"Dr hemagglutinin structural subunit";"draA";"unknown";"antagonist"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"J01BA01";"Dr hemagglutinin structural subunit";"draA";"unknown";"antagonist"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"D10AF03";"Dr hemagglutinin structural subunit";"draA";"unknown";"antagonist"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S01AA01";"Dr hemagglutinin structural subunit";"draA";"unknown";"antagonist"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S02AA01";"Dr hemagglutinin structural subunit";"draA";"unknown";"antagonist"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S03AA08";"Dr hemagglutinin structural subunit";"draA";"unknown";"antagonist"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"D06AX02";"Dr hemagglutinin structural subunit";"draA";"unknown";"antagonist"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"G01AA05";"Complement decay-accelerating factor";"CD55";"unknown";"other"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"J01BA01";"Complement decay-accelerating factor";"CD55";"unknown";"other"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"D10AF03";"Complement decay-accelerating factor";"CD55";"unknown";"other"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S01AA01";"Complement decay-accelerating factor";"CD55";"unknown";"other"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S02AA01";"Complement decay-accelerating factor";"CD55";"unknown";"other"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"S03AA08";"Complement decay-accelerating factor";"CD55";"unknown";"other"
"Chloramphenicol";"OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O";"Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.";"D06AX02";"Complement decay-accelerating factor";"CD55";"unknown";"other"
"Loracarbef";"N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1";"1 hour. In subjects with moderate impairment of renal function the plasma half-life was prolonged to approximately 5.6 hours.";"J01DC08";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Loracarbef";"N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1";"1 hour. In subjects with moderate impairment of renal function the plasma half-life was prolonged to approximately 5.6 hours.";"J01DC08";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD10";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BC53";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BC03";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD03";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD02";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD09";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD07";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD10";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BC53";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BC03";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD03";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD02";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD09";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Lansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1";"1.5 (&plusmn; 1.0) hours";"A02BD07";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Dipivefrin";"CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1";"";"S01EA02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Dipivefrin";"CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1";"";"S01EA02";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Dipivefrin";"CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1";"";"S01EA02";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Dipivefrin";"CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1";"";"S01EA02";"Cholinesterase";"BCHE";"yes";"potentiator"
"Dipivefrin";"CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1";"";"S01EA02";"Acetylcholinesterase";"ACHE";"unknown";""
"Droperidol";"FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12";"Biphasic distribution. The rapid distribution phase is 1.4 &plusmn; 0.5 minutes and the slower distribution phase is 14.3 &plusmn; 6.5 minutes. Elimination half-life in adults is 134 &plusmn; 13 minutes and may be increased in geriatric patients. In children, it is 101.5 &plusmn; 26.4 minutes.";"N05AD08";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Droperidol";"FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12";"Biphasic distribution. The rapid distribution phase is 1.4 &plusmn; 0.5 minutes and the slower distribution phase is 14.3 &plusmn; 6.5 minutes. Elimination half-life in adults is 134 &plusmn; 13 minutes and may be increased in geriatric patients. In children, it is 101.5 &plusmn; 26.4 minutes.";"N05AD08";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Levothyroxine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O";"T<sub>4</sub>, 6 to 7 days. T<sub>3</sub>, 1 to 2 days.";"H03AA01";"Thyroid hormone receptor alpha";"THRA";"yes";"agonist"
"Levothyroxine";"N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O";"T<sub>4</sub>, 6 to 7 days. T<sub>3</sub>, 1 to 2 days.";"H03AA01";"Thyroid hormone receptor beta";"THRB";"yes";"agonist"
"Framycetin";"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O";"";"D09AA01";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Framycetin";"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O";"";"R01AX08";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Framycetin";"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O";"";"S01AA07";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Framycetin";"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O";"";"D09AA01";"C-X-C chemokine receptor type 4";"CXCR4";"unknown";"antagonist"
"Framycetin";"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O";"";"R01AX08";"C-X-C chemokine receptor type 4";"CXCR4";"unknown";"antagonist"
"Framycetin";"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O";"";"S01AA07";"C-X-C chemokine receptor type 4";"CXCR4";"unknown";"antagonist"
"Clomocycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(=O)NCO)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O";"";"J01AA11";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Clomocycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(=O)NCO)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O";"";"J01AA20";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Clomocycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(=O)NCO)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O";"";"J01AA11";"30S ribosomal protein S9";"rpsI";"unknown";"inhibitor"
"Clomocycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(=O)NCO)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O";"";"J01AA20";"30S ribosomal protein S9";"rpsI";"unknown";"inhibitor"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Kappa-type opioid receptor";"OPRK1";"yes";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Kappa-type opioid receptor";"OPRK1";"yes";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Kappa-type opioid receptor";"OPRK1";"yes";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Kappa-type opioid receptor";"OPRK1";"yes";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Glutamate receptor ionotropic, NMDA 2C";"GRIN2C";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Glutamate receptor ionotropic, NMDA 2C";"GRIN2C";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Glutamate receptor ionotropic, NMDA 2C";"GRIN2C";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Glutamate receptor ionotropic, NMDA 2C";"GRIN2C";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";"antagonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Mu-type opioid receptor";"OPRM1";"unknown";"agonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Mu-type opioid receptor";"OPRM1";"unknown";"agonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Mu-type opioid receptor";"OPRM1";"unknown";"agonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Mu-type opioid receptor";"OPRM1";"unknown";"agonist"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"binding"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"binding"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"binding"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"binding"
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB72";"Liver carboxylesterase 1";"CES1";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB52";"Liver carboxylesterase 1";"CES1";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AG03";"Liver carboxylesterase 1";"CES1";"unknown";""
"Pethidine";"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1";"Initial distribution phase (t<sub>1/2 &alpha;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &beta;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &beta;</sub> is prolonged to 7-11 hours.";"N02AB02";"Liver carboxylesterase 1";"CES1";"unknown";""
"Loratadine";"CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2";"8.4 hours";"R06AX13";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Loratadine";"CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2";"8.4 hours";"R06AX13";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"D-alanyl-D-alanine carboxypeptidase";"";"yes";"inhibitor"
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefalotin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O";"30 minutes";"J01DB03";"Beta-lactamase";"ampC";"yes";"potentiator"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"binder"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"binder"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02LE01";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Prazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1";"2-3 hours";"C02CA01";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Alpha-1D adrenergic receptor";"ADRA1D";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Potassium voltage-gated channel subfamily D member 2";"KCND2";"no";"inhibitor"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Potassium voltage-gated channel subfamily D member 3";"KCND3";"no";"inhibitor"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonistbinder"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"D(1) dopamine receptor";"DRD1";"unknown";"binder"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"D(1) dopamine receptor";"DRD5";"unknown";"binder"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"D(2) dopamine receptor";"DRD2";"unknown";"binder"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";""
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"activator"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"binder"
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Potassium voltage-gated channel subfamily H member 1";"KCNH1";"unknown";""
"Imipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"Imipramine has a mean half life of 12 h. Its active metabolite, desipramine has a mean half life of 22.5 h [A31907].";"N06AA02";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Acitretin";"COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1";"49 hours (range 33 to 96 hours)";"D05BB02";"Retinoic acid receptor RXR-alpha";"RXRA";"yes";"agonist"
"Acitretin";"COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1";"49 hours (range 33 to 96 hours)";"D05BB02";"Retinoic acid receptor alpha";"RARA";"yes";"agonist"
"Acitretin";"COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1";"49 hours (range 33 to 96 hours)";"D05BB02";"Retinoic acid receptor beta";"RARB";"yes";"agonist"
"Acitretin";"COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1";"49 hours (range 33 to 96 hours)";"D05BB02";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Acitretin";"COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1";"49 hours (range 33 to 96 hours)";"D05BB02";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Acitretin";"COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1";"49 hours (range 33 to 96 hours)";"D05BB02";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Acitretin";"COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1";"49 hours (range 33 to 96 hours)";"D05BB02";"Retinol-binding protein 1";"RBP1";"unknown";"agonist"
"Nabumetone";"COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2";"Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.";"M01AX01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Nabumetone";"COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2";"Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.";"M01AX01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Metharbital";"CCC1(CC)C(=O)NC(=O)N(C)C1=O";"";"N03AA30";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Sodium Tetradecyl Sulfate";"[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O";"";"C05BB04";"Vitamin K-dependent protein C";"PROC";"yes";"inhibitor"
"Sodium Tetradecyl Sulfate";"[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O";"";"C05BB04";"Vitamin K-dependent protein S";"PROS1";"yes";"inhibitor"
"Ketorolac";"OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1";"2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer";"M01AB15";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ketorolac";"OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1";"2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer";"S01BC05";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ketorolac";"OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1";"2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer";"M01AB15";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Ketorolac";"OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1";"2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer";"S01BC05";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Enoxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1";"Plasma half-life is 3 to 6 hours.";"J01MA04";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Enoxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1";"Plasma half-life is 3 to 6 hours.";"J01MA04";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Enoxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1";"Plasma half-life is 3 to 6 hours.";"J01MA04";"DNA topoisomerase 2-alpha";"TOP2A";"no";"inhibitor"
"Quinine";"[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12";"Approximately 18 hours";"M09AA72";"Platelet glycoprotein IX";"GP9";"unknown";"other"
"Quinine";"[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12";"Approximately 18 hours";"P01BC01";"Platelet glycoprotein IX";"GP9";"unknown";"other"
"Quinine";"[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12";"Approximately 18 hours";"M09AA72";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Quinine";"[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12";"Approximately 18 hours";"P01BC01";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Tenoxicam";"CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O";"72 hours (range 59 to 74 hours)";"M01AC02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Tenoxicam";"CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O";"72 hours (range 59 to 74 hours)";"M01AC02";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Dronabinol";"[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1";"Alpha phase: approximately 4 hours; Beta phase: 25-36 hours";"A04AD10";"Cannabinoid receptor 1";"CNR1";"yes";"agonist"
"Dronabinol";"[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1";"Alpha phase: approximately 4 hours; Beta phase: 25-36 hours";"A04AD10";"Cannabinoid receptor 2";"CNR2";"unknown";"agonist"
"Montelukast";"OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1";"2.7-5.5 hours";"R03DC53";"Cysteinyl leukotriene receptor 1";"CYSLTR1";"yes";"antagonist"
"Montelukast";"OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1";"2.7-5.5 hours";"R03DC03";"Cysteinyl leukotriene receptor 1";"CYSLTR1";"yes";"antagonist"
"Montelukast";"OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1";"2.7-5.5 hours";"R03DC53";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"other/unknown"
"Montelukast";"OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1";"2.7-5.5 hours";"R03DC03";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"other/unknown"
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06CA03";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06AB03";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06CA03";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06AB03";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06CA03";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06AB03";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06CA03";"Cyclin-dependent kinases regulatory subunit 1";"CKS1B";"unknown";""
"Fluoxetine";"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1";"1-3 days [acute administration];
4-6 days [chronic administration];
4-16 days [norfluoxetine, acute and chronic administration].";"N06AB03";"Cyclin-dependent kinases regulatory subunit 1";"CKS1B";"unknown";""
"Methohexital";"CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O";"5.6 &plusmn; 2.7 minutes";"N01AF01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"antagonist"
"Methohexital";"CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O";"5.6 &plusmn; 2.7 minutes";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"antagonist"
"Methohexital";"CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O";"5.6 &plusmn; 2.7 minutes";"N05CA15";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"antagonist"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Chlordiazepoxide";"CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1";"24-48 hours";"N05BA02";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Duloxetine";"CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1";"12 hours (range 8-17 hours)";"N06AX21";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Duloxetine";"CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1";"12 hours (range 8-17 hours)";"N06AX21";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Duloxetine";"CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1";"12 hours (range 8-17 hours)";"N06AX21";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"D(1) dopamine receptor";"DRD1";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"D(1) dopamine receptor";"DRD5";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"D(3) dopamine receptor";"DRD3";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"D(4) dopamine receptor";"DRD4";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"D(1B) dopamine receptor";"DRD5";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine 2 receptor";"HTR2A";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine 2 receptor";"HTR2B";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine 2 receptor";"HTR2C";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Calmodulin";"CALM1";"unknown";""
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"alpha1-acid glycoprotein";"ORM1";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"alpha1-acid glycoprotein";"ORM2";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"binder"
"Chlorpromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2";"~ 30 hours";"N05AA01";"Histamine H4 receptor";"HRH4";"unknown";"binder"
"Rimantadine";"CC(N)C12CC3CC(CC(C3)C1)C2";"25 to 30 hours in young adults (22 to 44 years old). Approximately 32 hours in elderly (71 to 79 years old) and in patients with chronic liver disease. Approximately 13 to 38 hours in children (4 to 8 years old).";"J05AC02";"Matrix protein 2";"M";"yes";"other/unknown"
"Amikacin";"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O";"2-3 hours";"J01RA06";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Amikacin";"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O";"2-3 hours";"S01AA21";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Amikacin";"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O";"2-3 hours";"D06AX12";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Amikacin";"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O";"2-3 hours";"J01GB06";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Lenalidomide";"NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O";"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.";"L04AX04";"Protein cereblon";"CRBN";"yes";"inhibitor"
"Lenalidomide";"NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O";"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.";"L04AX04";"Tumor necrosis factor ligand superfamily member 11";"TNFSF11";"yes";"inhibitor"
"Lenalidomide";"NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O";"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.";"L04AX04";"Cadherin-5";"CDH5";"unknown";"antagonist"
"Lenalidomide";"NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O";"Healthy subjects = 3 hours;
Multiple myeloma or MDS patients = 3 - 5 hours.";"L04AX04";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"negative modulator"
"Raloxifene";"OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2";"27.7";"G03XC01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Raloxifene";"OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2";"27.7";"G03XC01";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Raloxifene";"OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2";"27.7";"G03XC01";"Serpin B9";"SERPINB9";"unknown";""
"Raloxifene";"OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2";"27.7";"G03XC01";"Trefoil factor 1";"TFF1";"unknown";""
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"L01XX33";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"G01AE10";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"M01AH01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"L01XX33";"3-phosphoinositide-dependent protein kinase 1";"PDPK1";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"G01AE10";"3-phosphoinositide-dependent protein kinase 1";"PDPK1";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"M01AH01";"3-phosphoinositide-dependent protein kinase 1";"PDPK1";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"L01XX33";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"M01AH01";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"L01XX33";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"G01AE10";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Celecoxib";"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F";"The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.";"M01AH01";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Brimonidine";"BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12";"2 hours [ophthalmic solution]";"S01EA05";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Brimonidine";"BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12";"2 hours [ophthalmic solution]";"D11AX21";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Brimonidine";"BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12";"2 hours [ophthalmic solution]";"S01EA05";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Brimonidine";"BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12";"2 hours [ophthalmic solution]";"D11AX21";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Brimonidine";"BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12";"2 hours [ophthalmic solution]";"S01EA05";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Brimonidine";"BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12";"2 hours [ophthalmic solution]";"D11AX21";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CR50";"Penicillin-binding protein 3";"pbpC";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CF01";"Penicillin-binding protein 3";"pbpC";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CR50";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CF01";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CF01";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CF01";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CF01";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Dicloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O";"The elimination half-life for dicloxacillin is about 0.7 hour.";"J01CF01";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Nabilone";"[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC";"2 hours, with metabolites around 35 hours.";"A04AD11";"Cannabinoid receptor 2";"CNR2";"yes";"partial agonist"
"Nabilone";"[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC";"2 hours, with metabolites around 35 hours.";"A04AD11";"Cannabinoid receptor 1";"CNR1";"yes";"partial agonist"
"Pefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1";"8.6 hours";"J01MA03";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Pefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1";"8.6 hours";"J01MA03";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Pefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1";"8.6 hours";"J01MA03";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Pefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1";"8.6 hours";"J01MA03";"DNA topoisomerase 1";"topA";"unknown";""
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07AA57";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07BA07";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07AA07";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07AA57";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07BA07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07AA07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07AA57";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07BA07";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Sotalol";"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1";"Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.";"C07AA07";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Buspirone";"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1";"2-3 hours (although the action of a single dose is much longer than the short halflife indicates).";"N05BE01";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"partial agonist"
"Buspirone";"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1";"2-3 hours (although the action of a single dose is much longer than the short halflife indicates).";"N05BE01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Miglitol";"OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO";"The elimination half-life of miglitol from plasma is approximately 2 hours.";"A10BF02";"Maltase-glucoamylase, intestinal";"MGAM";"yes";"antagonistinhibitor"
"Miglitol";"OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO";"The elimination half-life of miglitol from plasma is approximately 2 hours.";"A10BF02";"Lysosomal alpha-glucosidase";"GAA";"yes";"antagonist"
"Miglitol";"OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO";"The elimination half-life of miglitol from plasma is approximately 2 hours.";"A10BF02";"Neutral alpha-glucosidase AB";"GANAB";"yes";"antagonist"
"Miglitol";"OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO";"The elimination half-life of miglitol from plasma is approximately 2 hours.";"A10BF02";"Neutral alpha-glucosidase C";"GANC";"yes";"antagonist"
"Fosinopril";"CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C";"12 hours";"C09AA09";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Fosinopril";"CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C";"12 hours";"C09BA09";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Penicillin-binding protein 3";"pbpC";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Penicillin-binding protein 3";"pbpC";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Solute carrier family 22 member 6";"SLC22A6";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Solute carrier family 22 member 6";"SLC22A6";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Solute carrier family 22 member 8";"SLC22A8";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Solute carrier family 22 member 8";"SLC22A8";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Solute carrier family 22 member 11";"SLC22A11";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Solute carrier family 22 member 11";"SLC22A11";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Solute carrier family 22 member 7";"SLC22A7";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Solute carrier family 22 member 7";"SLC22A7";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Serum albumin";"ALB";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Serum albumin";"ALB";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Beta-lactamase";"";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Beta-lactamase";"";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD51";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Cefotaxime";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Approximately 1 hour.";"J01DD01";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Entacapone";"CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N";"0.4-0.7 hour";"N04BX02";"Catechol O-methyltransferase";"COMT";"yes";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AR01";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AR05";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AR04";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AF01";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AR01";"Telomerase reverse transcriptase";"TERT";"unknown";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AR05";"Telomerase reverse transcriptase";"TERT";"unknown";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AR04";"Telomerase reverse transcriptase";"TERT";"unknown";"inhibitor"
"Zidovudine";"CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O";"Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)";"J05AF01";"Telomerase reverse transcriptase";"TERT";"unknown";"inhibitor"
"Darifenacin";"NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1";"The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.";"G04BD10";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Darifenacin";"NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1";"The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.";"G04BD10";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Darifenacin";"NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1";"The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.";"G04BD10";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Darifenacin";"NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1";"The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.";"G04BD10";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Darifenacin";"NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1";"The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.";"G04BD10";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA55";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA05";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA55";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA05";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA55";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA05";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA55";"alpha1-acid glycoprotein";"ORM1";"unknown";"binder"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA05";"alpha1-acid glycoprotein";"ORM1";"unknown";"binder"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA55";"alpha1-acid glycoprotein";"ORM2";"unknown";"binder"
"Oxycodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O";"4.5 hours";"N02AA05";"alpha1-acid glycoprotein";"ORM2";"unknown";"binder"
"Phenindione";"O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1";"5-10 hours";"B01AA02";"Vitamin K epoxide reductase complex subunit 1";"VKORC1";"yes";"inhibitor"
"Flutamide";"CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F";"The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.";"L02BB01";"Androgen receptor";"AR";"yes";"antagonist"
"Flutamide";"CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F";"The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.";"L02BB01";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Flutamide";"CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F";"The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.";"L02BB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Tolmetin";"CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1";"Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.";"M01AB03";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Tolmetin";"CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1";"Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.";"M02AA21";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Tolmetin";"CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1";"Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.";"M01AB03";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Tolmetin";"CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1";"Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.";"M02AA21";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Cimetidine";"C\N=C(\NCCSCC1=C(C)NC=N1)NC#N";"2 hours";"A02BA01";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Cimetidine";"C\N=C(\NCCSCC1=C(C)NC=N1)NC#N";"2 hours";"A02BA51";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Haloperidol";"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1";"Half-life: 21-24h [L1997]";"N05AD01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Haloperidol";"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1";"Half-life: 21-24h [L1997]";"N05AD01";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Haloperidol";"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1";"Half-life: 21-24h [L1997]";"N05AD01";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"antagonist"
"Haloperidol";"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1";"Half-life: 21-24h [L1997]";"N05AD01";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"other/unknown"
"Haloperidol";"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1";"Half-life: 21-24h [L1997]";"N05AD01";"D(3) dopamine receptor";"DRD3";"unknown";"inverse agonist"
"Haloperidol";"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1";"Half-life: 21-24h [L1997]";"N05AD01";"Melanin-concentrating hormone receptor 1";"MCHR1";"unknown";""
"Haloperidol";"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1";"Half-life: 21-24h [L1997]";"N05AD01";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";""
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AX67";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AR10";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AE03";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AX66";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AX67";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AR10";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AE03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Ritonavir";"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1";"3-5 hours [A19647].";"J05AX66";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Tridihexethyl";"CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AB08";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Tridihexethyl";"CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AB08";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Tridihexethyl";"CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1";"";"A03AB08";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Nitazoxanide";"CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O";"7.3h [L1422]";"P01AX11";"Pyruvate-flavodoxin oxidoreductase";"por";"yes";"antagonistinhibitor"
"Triflupromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"";"N05AA05";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Triflupromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"";"N05AA05";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Triflupromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"";"N05AA05";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"antagonist"
"Triflupromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"";"N05AA05";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Triflupromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"";"N05AA05";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Dextrothyroxine";"N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O";"";"C10AX01";"Thyroid hormone receptor alpha";"THRA";"yes";"agonist"
"Dextrothyroxine";"N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O";"";"C10AX01";"Thyroid hormone receptor beta";"THRB";"yes";"agonist"
"Dextrothyroxine";"N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O";"";"C10AX01";"Thyroid peroxidase";"TPO";"unknown";""
"Acetyldigitoxin";"[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1";"";"C01AA01";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Aminocaproic Acid";"NCCCCCC(O)=O";"The terminal elimination half-life is approximately 2 hours.";"B02AA01";"Plasminogen";"PLG";"yes";"inhibitor"
"Aminocaproic Acid";"NCCCCCC(O)=O";"The terminal elimination half-life is approximately 2 hours.";"B02AA01";"Tissue-type plasminogen activator";"PLAT";"yes";"antagonist"
"Aminocaproic Acid";"NCCCCCC(O)=O";"The terminal elimination half-life is approximately 2 hours.";"B02AA01";"Apolipoprotein(a)";"LPA";"unknown";"other"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"yes";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"yes";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"HCG20471, isoform CRA_c";"SIGMAR1";"yes";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"HCG20471, isoform CRA_c";"SIGMAR1";"yes";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Membrane-associated progesterone receptor component 1";"PGRMC1";"unknown";"binder"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Membrane-associated progesterone receptor component 1";"PGRMC1";"unknown";"binder"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Mu-type opioid receptor";"OPRM1";"unknown";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Mu-type opioid receptor";"OPRM1";"unknown";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"NADPH oxidase";"CYBB";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"NADPH oxidase";"CYBB";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"NADPH oxidase";"CYBA";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"NADPH oxidase";"CYBA";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"NADPH oxidase";"NCF1";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"NADPH oxidase";"NCF1";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"NADPH oxidase";"NCF2";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"NADPH oxidase";"NCF2";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"NADPH oxidase";"NCF4";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"NADPH oxidase";"NCF4";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"NADPH oxidase";"RAC1";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"NADPH oxidase";"RAC1";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"NADPH oxidase";"RAC2";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"NADPH oxidase";"RAC2";"unknown";"inhibitor"
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"R05DA09";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Dextromethorphan";"[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C";"3-6 hours";"N07XX59";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Cisplatin";"N[Pt](N)(Cl)Cl";"Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.";"L01XA01";"DNA-3-methyladenine glycosylase";"MPG";"unknown";""
"Cisplatin";"N[Pt](N)(Cl)Cl";"Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.";"L01XA01";"Alpha-2-macroglobulin";"A2M";"unknown";""
"Cisplatin";"N[Pt](N)(Cl)Cl";"Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.";"L01XA01";"Serotransferrin";"TF";"unknown";""
"Cisplatin";"N[Pt](N)(Cl)Cl";"Cisplatin decays monoexponentially with a half life of 20 to 30 minutes following administrations of 50 or 100 mg/m^2.  Cisplatin has a plasma half-life of 30 minutes. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more.";"L01XA01";"Copper transport protein ATOX1";"ATOX1";"unknown";""
"Albendazole";"CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2";"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).";"P02CA03";"Tubulin beta-2 chain";"";"yes";"inhibitor"
"Albendazole";"CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2";"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).";"P02CA03";"Tubulin alpha-1A chain";"TUBA1A";"no";"inhibitor"
"Albendazole";"CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2";"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).";"P02CA03";"Tubulin beta-4B chain";"TUBB4B";"no";"inhibitor"
"Albendazole";"CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2";"Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).";"P02CA03";"Fumarate reductase flavoprotein subunit";"";"unknown";"inhibitor"
"Trandolapril";"[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours.";"C09AA10";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Trandolapril";"[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours.";"C09BB10";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Caspofungin";"CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN";"9-11 hours";"J02AX04";"1,3-beta-glucan synthase component FKS1";"fksA";"yes";"inhibitor"
"Carteolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2";"";"S01ED05";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Carteolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2";"";"S01ED55";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Carteolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2";"";"C07AA15";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Carteolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2";"";"S01ED05";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Carteolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2";"";"S01ED55";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Carteolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2";"";"C07AA15";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Bentiromide";"OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1";"";"V04CK03";"Serine protease hepsin";"HPN";"yes";"ligand"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Retinoic acid receptor alpha";"RARA";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Retinoic acid receptor alpha";"RARA";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Retinoic acid receptor RXR-alpha";"RXRA";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Retinoic acid receptor RXR-alpha";"RXRA";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Retinoic acid receptor beta";"RARB";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Retinoic acid receptor beta";"RARB";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Insulin-like growth factor-binding protein 3";"IGFBP3";"unknown";""
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Insulin-like growth factor-binding protein 3";"IGFBP3";"unknown";""
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Pregnancy-specific beta-1-glycoprotein 5";"PSG5";"unknown";""
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Pregnancy-specific beta-1-glycoprotein 5";"PSG5";"unknown";""
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"D11AH04";"Cytochrome P450 26C1";"CYP26C1";"unknown";""
"Alitretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O";"";"L01XX22";"Cytochrome P450 26C1";"CYP26C1";"unknown";""
"Metolazone";"CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O";"Approximately 14 hours.";"C03BA08";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Metolazone";"CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O";"Approximately 14 hours.";"C03EA12";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Metolazone";"CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O";"Approximately 14 hours.";"G01AE10";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Tolnaftate";"CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1";"";"D01AE18";"Squalene monooxygenase";"ERG1";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"S02DA04";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"S01HA06";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"N01BB06";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"D04AB02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"C05AD04";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"S02DA04";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"S01HA06";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"N01BB06";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"D04AB02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"C05AD04";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"S02DA04";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"S01HA06";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"N01BB06";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"D04AB02";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Cinchocaine";"CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC";"";"C05AD04";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Lercanidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1";"";"C09DB08";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"yes";"inhibitor"
"Lercanidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1";"";"C08CA13";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"yes";"inhibitor"
"Lercanidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1";"";"C09BB02";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"yes";"inhibitor"
"Foscarnet";"OC(=O)P(O)(O)=O";"3.3-6.8 hours";"J05AD01";"DNA polymerase catalytic subunit";"UL54";"yes";"inhibitor"
"Foscarnet";"OC(=O)P(O)(O)=O";"3.3-6.8 hours";"J05AD01";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Erlotinib";"COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1";"Median half-life of 36.2 hours.";"L01XE03";"Epidermal growth factor receptor";"EGFR";"yes";"antagonist"
"Erlotinib";"COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1";"Median half-life of 36.2 hours.";"L01XE03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"yes";"agonist"
"Cyclophosphamide";"ClCCN(CCCl)P1(=O)NCCCO1";"3-12 hours";"L01AA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Mephenytoin";"CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1";"Approximately 7 hours";"N03AB54";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Mephenytoin";"CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1";"Approximately 7 hours";"N03AB04";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Mephenytoin";"CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1";"Approximately 7 hours";"N03AB54";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Mephenytoin";"CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1";"Approximately 7 hours";"N03AB04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Rofecoxib";"CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1";"17 hours";"M01AH02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Rofecoxib";"CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1";"17 hours";"M01AH02";"Elastin";"ELN";"unknown";"other/unknown"
"Cefdinir";"[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O";"1.7 &plusmn; 0.6 hours";"J01DD15";"Penicillin-binding protein 2";"penA";"yes";"inhibitor"
"Cefdinir";"[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O";"1.7 &plusmn; 0.6 hours";"J01DD15";"PBP3";"pbp3";"yes";"inhibitor"
"Cefdinir";"[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O";"1.7 &plusmn; 0.6 hours";"J01DD15";"Myeloperoxidase";"MPO";"no";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA topoisomerase 4 subunit A";"parC";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA topoisomerase 4 subunit A";"parC";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA topoisomerase 4 subunit A";"parC";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA topoisomerase 4 subunit A";"parC";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA topoisomerase 4 subunit A";"parC";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA topoisomerase 4 subunit A";"parC";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA topoisomerase 4 subunit A";"parC";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA topoisomerase 4 subunit B";"parE";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA topoisomerase 4 subunit B";"parE";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA topoisomerase 4 subunit B";"parE";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA topoisomerase 4 subunit B";"parE";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA topoisomerase 4 subunit B";"parE";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA topoisomerase 4 subunit B";"parE";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA topoisomerase 4 subunit B";"parE";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"Multidrug resistance protein MdtK";"mdtK";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"Multidrug resistance protein MdtK";"mdtK";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"Multidrug resistance protein MdtK";"mdtK";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"Multidrug resistance protein MdtK";"mdtK";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"Multidrug resistance protein MdtK";"mdtK";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"Multidrug resistance protein MdtK";"mdtK";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"Multidrug resistance protein MdtK";"mdtK";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"Gyrase A";"";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"Gyrase A";"";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"Gyrase A";"";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"Gyrase A";"";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"Gyrase A";"";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"Gyrase A";"";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"Gyrase A";"";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01MA02";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA11";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA12";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S02AA15";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S03AA07";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"S01AE03";"DNA gyrase subunit A";"gyrA";"unknown";""
"Ciprofloxacin";"OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O";"4 hours";"J01RA10";"DNA gyrase subunit A";"gyrA";"unknown";""
"Toremifene";"CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1";"5 days";"L02BA02";"Estrogen receptor alpha";"ESR1";"yes";"modulator"
"Toremifene";"CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1";"5 days";"L02BA02";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Alpha-1D adrenergic receptor";"ADRA1D";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"binder"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Beta adrenergic receptor";"ADRB1";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Beta adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Beta adrenergic receptor";"ADRB3";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Sigma receptor";"PGRMC1";"unknown";"binder"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"Sigma receptor";"SIGMAR1";"unknown";"binder"
"Nortriptyline";"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12";"The elimination half-life (t 1⁄2β) after oral nortriptyline administration is approximately 26 hours (25.5 ± 7.9 hours; range 16-38 hours) [L1354].";"N06AA10";"5-hydroxytryptamine receptor 1C";"Htr2c";"unknown";"antagonist"
"Vincristine";"[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.";"L01CA02";"Tubulin beta chain";"TUBB";"yes";"inhibitor"
"Vincristine";"[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.";"L01CA02";"Tubulin alpha-4A chain";"TUBA4A";"unknown";"inhibitor"
"Benazepril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O";"10-11 hours";"C09AA07";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Benazepril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O";"10-11 hours";"C09BA07";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";"antagonist"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Histamine H4 receptor";"HRH4";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRA1";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRA2";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRA3";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRA4";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRA5";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRA6";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRB1";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRB2";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRB3";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRD";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRE";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRG1";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRG2";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRG3";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRP";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"GABA-A receptor (anion channel)";"GABRQ";"unknown";"binder"
"Amoxapine";"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1";"8 hours";"N06AA17";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"binder"
"Fluorouracil";"FC1=CNC(=O)NC1=O";"10-20 minutes";"L01BC02";"Thymidylate synthase";"TYMS";"yes";"other/unknown"
"Fluorouracil";"FC1=CNC(=O)NC1=O";"10-20 minutes";"L01BC52";"Thymidylate synthase";"TYMS";"yes";"other/unknown"
"Pyridostigmine";"CN(C)C(=O)OC1=C[N+](C)=CC=C1";"3 hours following oral administration.";"N07AA02";"Acetylcholinesterase";"ACHE";"yes";"antagonistinhibitor"
"Pyridostigmine";"CN(C)C(=O)OC1=C[N+](C)=CC=C1";"3 hours following oral administration.";"N07AA02";"Cholinesterase";"BCHE";"yes";"antagonist"
"Pyridostigmine";"CN(C)C(=O)OC1=C[N+](C)=CC=C1";"3 hours following oral administration.";"N07AA02";"Serum albumin";"ALB";"unknown";""
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Adinazolam";"CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12";"Less than 3 hours.";"N05BA07";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Desoximetasone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"The half-life of the material was 15 &plusmn; 2 hours (for urine) and 17 &plusmn; 2 hours (for feces) between the third and fifth trial day.";"D07XC02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Desoximetasone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"The half-life of the material was 15 &plusmn; 2 hours (for urine) and 17 &plusmn; 2 hours (for feces) between the third and fifth trial day.";"D07AC03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Azelaic Acid";"OC(=O)CCCCCCCC(O)=O";"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.";"D10AX03";"Thioredoxin reductase";"trxB";"yes";"inhibitor"
"Azelaic Acid";"OC(=O)CCCCCCCC(O)=O";"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.";"D10AX03";"3-oxo-5-beta-steroid 4-dehydrogenase";"AKR1D1";"yes";"inhibitor"
"Azelaic Acid";"OC(=O)CCCCCCCC(O)=O";"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.";"D10AX03";"3-oxo-5-alpha-steroid 4-dehydrogenase 2";"SRD5A2";"yes";"inhibitor"
"Azelaic Acid";"OC(=O)CCCCCCCC(O)=O";"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.";"D10AX03";"Tyrosinase";"TYR";"yes";"inhibitor"
"Azelaic Acid";"OC(=O)CCCCCCCC(O)=O";"The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.";"D10AX03";"DNA polymerase I";"polA";"yes";"inhibitor"
"Zafirlukast";"COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=CC=CC=C1C";"10 hours";"R03DC01";"Cysteinyl leukotriene receptor 1";"CYSLTR1";"yes";"antagonist"
"Propylthiouracil";"CCCC1=CC(=O)NC(=S)N1";"2 hours";"H03BA02";"Thyroid peroxidase";"TPO";"yes";"inhibitor"
"Acetohydroxamic Acid";"CC(=O)NO";"5-10 hours in patients with normal renal function";"G04BX03";"Urease subunit alpha";"ureC";"yes";"inhibitor"
"Acetohydroxamic Acid";"CC(=O)NO";"5-10 hours in patients with normal renal function";"G04BX03";"Macrophage metalloelastase";"MMP12";"unknown";"inhibitor"
"Pentostatin";"OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O";"5.7 hours (with a range between 2.6 and 16 hrs)";"L01XX08";"Adenosine deaminase";"ADA";"yes";"inhibitor"
"Piroxicam";"CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"30 to 86 hours";"S01BC06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Piroxicam";"CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"30 to 86 hours";"M02AA07";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Piroxicam";"CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"30 to 86 hours";"M01AC01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Piroxicam";"CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"30 to 86 hours";"S01BC06";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Piroxicam";"CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"30 to 86 hours";"M02AA07";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Piroxicam";"CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"30 to 86 hours";"M01AC01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Voltage-dependent R-type calcium channel subunit alpha-1E";"CACNA1E";"yes";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Sodium channel protein type 2 subunit alpha";"SCN2A";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Adenosine receptor A1";"ADORA1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Adenosine receptor A2a";"ADORA2A";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"D(1) dopamine receptor";"DRD1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"D(1) dopamine receptor";"DRD5";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"D(2) dopamine receptor";"DRD2";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRA1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRA2";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRA3";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRA4";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRA5";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRA6";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRB1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRB2";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRB3";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRD";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRE";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRG1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRG2";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRG3";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRP";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (anion channel)";"GABRQ";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRA1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRA2";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRA3";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRA4";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRA5";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRA6";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRG1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRG2";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"GABA-A receptor (benzodiazepine site)";"GABRG3";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Histamine H1 receptor";"HRH1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Kappa-type opioid receptor";"OPRK1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"inhibitor"
"Lamotrigine";"NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1";"The mean elimination half life ranges from 12-59 hours. The value is dependent on dosing regimen, concomitant antiepileptic medications, and disease state of the individual.";"N03AX09";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"inhibitor"
"Hydroxyzine";"OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"20 to 25 hours";"N05BB51";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Hydroxyzine";"OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"20 to 25 hours";"N05BB01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Zanamivir";"[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO";"2.5-5.1 hours";"J05AH01";"Neuraminidase";"NA";"yes";"inhibitor"
"Zanamivir";"[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO";"2.5-5.1 hours";"J05AH01";"Neuraminidase";"NA";"yes";"inhibitor"
"Zanamivir";"[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO";"2.5-5.1 hours";"J05AH01";"Sialidase-2";"NEU2";"unknown";"inhibitor"
"Bosentan";"COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1";"Terminal elimination half-life is about 5 hours in healthy adult subjects.";"C02KX01";"Endothelin-1 receptor";"EDNRA";"yes";"antagonist"
"Bosentan";"COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1";"Terminal elimination half-life is about 5 hours in healthy adult subjects.";"C02KX01";"Endothelin B receptor";"EDNRB";"yes";"antagonist"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA20";"30S ribosomal protein S9";"rpsI";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA12";"30S ribosomal protein S9";"rpsI";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA20";"30S ribosomal protein S12";"rpsL";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA12";"30S ribosomal protein S12";"rpsL";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA20";"30S ribosomal protein S13";"rpsM";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA12";"30S ribosomal protein S13";"rpsM";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA20";"30S ribosomal protein S14";"rpsN";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA12";"30S ribosomal protein S14";"rpsN";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA20";"30S ribosomal protein S19";"rpsS";"yes";"adduct"
"Tigecycline";"[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C";"27-43 hours";"J01AA12";"30S ribosomal protein S19";"rpsS";"yes";"adduct"
"Doxapram";"CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1";"";"R07AB01";"Potassium channel subfamily K member 3";"KCNK3";"yes";"inhibitor"
"Doxapram";"CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1";"";"R07AB01";"Potassium channel subfamily K member 9";"KCNK9";"yes";"inhibitor"
"Benzthiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(CSCC3=CC=CC=C3)=NS(=O)(=O)C2=C1";"";"G01AE10";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Benzthiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(CSCC3=CC=CC=C3)=NS(=O)(=O)C2=C1";"";"G01AE10";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Benzthiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(CSCC3=CC=CC=C3)=NS(=O)(=O)C2=C1";"";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Benzthiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(CSCC3=CC=CC=C3)=NS(=O)(=O)C2=C1";"";"G01AE10";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Benzthiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(CSCC3=CC=CC=C3)=NS(=O)(=O)C2=C1";"";"G01AE10";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Benzthiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(CSCC3=CC=CC=C3)=NS(=O)(=O)C2=C1";"";"G01AE10";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Methotrexate";"CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O";"Low doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.";"L04AX03";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Methotrexate";"CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O";"Low doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.";"L01BA01";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Carbamazepine";"NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12";"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.";"N03AF01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Carbamazepine";"NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12";"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.";"N03AF01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Carbamazepine";"NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12";"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.";"N03AF01";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Carbamazepine";"NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12";"Initial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.";"N03AF01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Cephalexin";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"1 hour";"J01DB01";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Cephalexin";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"1 hour";"J01DB01";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Cephalexin";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"1 hour";"J01DB01";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Cephalexin";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"1 hour";"J01DB01";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Cephalexin";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"1 hour";"J01DB01";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"yes";"inhibitor"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"D(2) dopamine receptor";"DRD2";"no";"other/unknown"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"D(2) dopamine receptor";"DRD2";"no";"other/unknown"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"D(1) dopamine receptor";"DRD1";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"D(1) dopamine receptor";"DRD1";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"D(1) dopamine receptor";"DRD5";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"D(1) dopamine receptor";"DRD5";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA52";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Cinnarizine";"C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"";"N07CA02";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Vinblastine";"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"Triphasic: 35 min, 53 min, and 19 hours";"L01CA01";"Tubulin alpha-1A chain";"TUBA1A";"yes";"adduct"
"Vinblastine";"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"Triphasic: 35 min, 53 min, and 19 hours";"L01CA01";"Tubulin beta chain";"TUBB";"yes";"adduct"
"Vinblastine";"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"Triphasic: 35 min, 53 min, and 19 hours";"L01CA01";"Tubulin delta chain";"TUBD1";"yes";"adduct"
"Vinblastine";"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"Triphasic: 35 min, 53 min, and 19 hours";"L01CA01";"Tubulin gamma-1 chain";"TUBG1";"yes";"adduct"
"Vinblastine";"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"Triphasic: 35 min, 53 min, and 19 hours";"L01CA01";"Tubulin epsilon chain";"TUBE1";"yes";"adduct"
"Vinblastine";"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"Triphasic: 35 min, 53 min, and 19 hours";"L01CA01";"Transcription factor AP-1";"JUN";"no";"other/unknown"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07BA05";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07AA05";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07FA05";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07BA05";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07AA05";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07FA05";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07BA05";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07AA05";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07FA05";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"antagonist"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07BA05";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"other/unknown"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07AA05";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"other/unknown"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07FA05";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"other/unknown"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07BA05";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"other/unknown"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07AA05";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"other/unknown"
"Propranolol";"CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12";"4 hours";"C07FA05";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"other/unknown"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";"antagonist"
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"S01FA01";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03BA01";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Atropine";"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1";"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.";"A03CB03";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Fenoprofen";"CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1";"Plasma half-life is approximately 3 hours.";"M01AE04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Fenoprofen";"CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1";"Plasma half-life is approximately 3 hours.";"M01AE04";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Fenoprofen";"CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1";"Plasma half-life is approximately 3 hours.";"M01AE04";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Fenoprofen";"CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1";"Plasma half-life is approximately 3 hours.";"M01AE04";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Fenfluramine";"CCNC(C)CC1=CC(=CC=C1)C(F)(F)F";"20 hours";"A08AA02";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Fenfluramine";"CCNC(C)CC1=CC(=CC=C1)C(F)(F)F";"20 hours";"A08AA02";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"agonist"
"Fenfluramine";"CCNC(C)CC1=CC(=CC=C1)C(F)(F)F";"20 hours";"A08AA02";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"agonist"
"Fenfluramine";"CCNC(C)CC1=CC(=CC=C1)C(F)(F)F";"20 hours";"A08AA02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";""
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"S01EA04";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"N02CX02";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC51";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02AC01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"S01EA04";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"N02CX02";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC01";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC51";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02AC01";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"S01EA04";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"N02CX02";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC01";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC51";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02AC01";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"S01EA04";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"N02CX02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC01";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC51";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02AC01";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"S01EA04";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"N02CX02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC51";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02AC01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"S01EA04";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"N02CX02";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02LC51";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Clonidine";"ClC1=CC=CC(Cl)=C1NC1=NCCN1";"6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by <i>p</i>-hydroxyclonidine.";"C02AC01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Sulfamethizole";"CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1";"3-8 hours";"B05CA04";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethizole";"CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1";"3-8 hours";"J01EB02";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethizole";"CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1";"3-8 hours";"D06BA04";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethizole";"CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1";"3-8 hours";"S01AB01";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethizole";"CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1";"3-8 hours";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Valaciclovir";"CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O";"2.5-3.3 hours";"J05AB11";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Valaciclovir";"CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O";"2.5-3.3 hours";"J05AB11";"Thymidine kinase";"TK";"yes";"inducer"
"Mazindol";"OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1";"10-13 hours";"A08AA05";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Mazindol";"OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1";"10-13 hours";"A08AA05";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Mazindol";"OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1";"10-13 hours";"A08AA05";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Mazindol";"OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1";"10-13 hours";"A08AA05";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";""
"Valdecoxib";"CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O";"8-11 hours";"M01AH03";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Valdecoxib";"CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O";"8-11 hours";"M01AH03";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Valdecoxib";"CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O";"8-11 hours";"M01AH03";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Lactulose";"OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O";"1.7-2 hours";"A06AD61";"Evolved beta-galactosidase subunit alpha";"ebgA";"yes";"other"
"Lactulose";"OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O";"1.7-2 hours";"A06AD11";"Evolved beta-galactosidase subunit alpha";"ebgA";"yes";"other"
"Voriconazole";"C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1";"";"J02AC03";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonistinhibitor"
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Solute carrier family 22 member 4";"SLC22A4";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Solute carrier family 22 member 5";"SLC22A5";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Carnitine O-acetyltransferase";"CRAT";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Mitochondrial carnitine/acylcarnitine carrier protein CACL";"SLC25A29";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Mitochondrial carnitine/acylcarnitine carrier protein";"SLC25A20";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Peroxisomal carnitine O-octanoyltransferase";"CROT";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Carnitine O-palmitoyltransferase 2, mitochondrial";"CPT2";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Carnitine O-palmitoyltransferase 1, liver isoform";"CPT1A";"unknown";"activator"
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Xanthine dehydrogenase/oxidase";"XDH";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Liver carboxylesterase 1";"CES1";"unknown";""
"L-Carnitine";"C[N+](C)(C)C[C@H](O)CC([O-])=O";"17.4 hours (elimination) following a single intravenous dose.";"A16AA01";"Myeloperoxidase";"MPO";"unknown";""
"Enalapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O";"< 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.";"C09BB06";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Enalapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O";"< 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.";"C09BB02";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Enalapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O";"< 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.";"C09BA02";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Enalapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O";"< 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.";"C09AA02";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Nizatidine";"CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O";"1-2 hours";"A02BA04";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"potentiator"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"potentiator"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"potentiator"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"potentiator"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"potentiator"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"potentiator"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Acid-sensing ion channel 1";"ASIC1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Acid-sensing ion channel 1";"ASIC1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Acid-sensing ion channel 1";"ASIC1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Acid-sensing ion channel 1";"ASIC1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Acid-sensing ion channel 1";"ASIC1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Acid-sensing ion channel 1";"ASIC1";"yes";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"yes";"other"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB05";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01BC03";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M01AB55";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"M02AA15";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"D11AX18";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";"inhibitor"
"Diclofenac";"OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"2 hours";"S01CC01";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";"inhibitor"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"D(1B) dopamine receptor";"DRD5";"unknown";"antagonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"D(1B) dopamine receptor";"DRD5";"unknown";"antagonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"antagonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"antagonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"other/unknown"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"other/unknown"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"other/unknown"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"other/unknown"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"other/unknown"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"other/unknown"
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"G02CB02";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";""
"Lisuride";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC";"";"N02CA07";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";""
"Doxazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1";"22 hours";"C02CA04";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Doxazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1";"22 hours";"C02CA04";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Doxazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1";"22 hours";"C02CA04";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Doxazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1";"22 hours";"C02CA04";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Doxazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1";"22 hours";"C02CA04";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Doxazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1";"22 hours";"C02CA04";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"S02BA08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"S01BA15";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"S01CA10";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"S02CA05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"D07BC02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"D07CC02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"C05AA10";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinolone Acetonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"1.3-1.7 hours";"D07AC04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Piperazine";"C1CNCCN1";"";"P02CB01";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"agonist"
"Ethosuximide";"CCC1(C)CC(=O)NC1=O";"53 hours";"N03AD51";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Ethosuximide";"CCC1(C)CC(=O)NC1=O";"53 hours";"N03AD01";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Amiloride-sensitive sodium channel subunit alpha";"SCNN1A";"yes";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Amiloride-sensitive sodium channel subunit beta";"SCNN1B";"yes";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Amiloride-sensitive sodium channel subunit gamma";"SCNN1G";"yes";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Amiloride-sensitive sodium channel subunit delta";"SCNN1D";"yes";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Acid-sensing ion channel 2";"ASIC2";"unknown";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Acid-sensing ion channel 1";"ASIC1";"unknown";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Sodium/hydrogen exchanger 1";"SLC9A1";"unknown";"inhibitor"
"Amiloride";"NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1";"Plasma half-life varies from 6 to 9 hours.";"C03DB01";"Urokinase-type plasminogen activator";"PLAU";"unknown";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"J01AA56";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"S01AA04";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"J01AA20";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"D06AA03";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"J01AA06";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"G01AA07";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"J01AA56";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"S01AA04";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"J01AA20";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"D06AA03";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"J01AA06";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Oxytetracycline";"[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C";"";"G01AA07";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Ulobetasol";"[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07AC21";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07BG01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07CG01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07AG01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07BG01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07CG01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07AG01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07BG01";"Alpha-1 adrenergic receptors";"ADRA1A";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07CG01";"Alpha-1 adrenergic receptors";"ADRA1A";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07AG01";"Alpha-1 adrenergic receptors";"ADRA1A";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07BG01";"Alpha-1 adrenergic receptors";"ADRA1B";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07CG01";"Alpha-1 adrenergic receptors";"ADRA1B";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07AG01";"Alpha-1 adrenergic receptors";"ADRA1B";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07BG01";"Alpha-1 adrenergic receptors";"ADRA1D";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07CG01";"Alpha-1 adrenergic receptors";"ADRA1D";"yes";"antagonist"
"Labetalol";"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1";"6-8 hours";"C07AG01";"Alpha-1 adrenergic receptors";"ADRA1D";"yes";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Fatty-acid amide hydrolase 1";"FAAH";"unknown";"inhibitor"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Fatty-acid amide hydrolase 1";"FAAH";"unknown";"inhibitor"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Fatty-acid amide hydrolase 1";"FAAH";"unknown";"inhibitor"
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CA19";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N01AF03";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Thiopental";"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O";"3-8 hours";"N05CB01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Monobenzone";"OC1=CC=C(OCC2=CC=CC=C2)C=C1";"";"D11AX13";"Tyrosinase";"TYR";"unknown";"inhibitor"
"Ivermectin";"CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O";"16 hours (also reported at 22-28 hours)";"P02CF01";"Glycine receptor subunit alpha-3";"GLRA3";"yes";"agonist"
"Ivermectin";"CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O";"16 hours (also reported at 22-28 hours)";"D11AX22";"Glycine receptor subunit alpha-3";"GLRA3";"yes";"agonist"
"Ivermectin";"CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O";"16 hours (also reported at 22-28 hours)";"P02CF01";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";"agonist"
"Ivermectin";"CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O";"16 hours (also reported at 22-28 hours)";"D11AX22";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03AC06";"Progesterone receptor";"PGR";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03FA12";"Progesterone receptor";"PGR";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03AA08";"Progesterone receptor";"PGR";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03DA02";"Progesterone receptor";"PGR";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"L02AB02";"Progesterone receptor";"PGR";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03FB06";"Progesterone receptor";"PGR";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03AC06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03FA12";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03AA08";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03DA02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"L02AB02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Medroxyprogesterone acetate";"[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C";"50 days";"G03FB06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Cisapride";"CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC";"6-12 hours";"A03FA02";"5-hydroxytryptamine receptor 4";"HTR4";"yes";"agonist"
"Cisapride";"CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC";"6-12 hours";"A03FA02";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"agonist"
"Cisapride";"CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC";"6-12 hours";"A03FA02";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"agonist"
"Cisapride";"CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC";"6-12 hours";"A03FA02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Sulindac";"CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O";"The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.";"M01AB02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Sulindac";"CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O";"The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.";"M01AB02";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Sulindac";"CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O";"The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.";"M01AB02";"Aldose reductase";"AKR1B1";"unknown";"inhibitor"
"Sulindac";"CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O";"The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.";"M01AB02";"Mitogen-activated protein kinase 3";"MAPK3";"unknown";"inhibitor"
"Sulindac";"CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O";"The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.";"M01AB02";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";"negative modulator"
"Sulindac";"CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O";"The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.";"M01AB02";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"antagonist"
"Sulindac";"CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O";"The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.";"M01AB02";"Aldo-keto reductase family 1 member B10";"AKR1B10";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AA09";"Sodium/potassium-transporting ATPase subunit gamma";"FXYD2";"yes";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AB09";"Sodium/potassium-transporting ATPase subunit gamma";"FXYD2";"yes";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"G01AE10";"Sodium/potassium-transporting ATPase subunit gamma";"FXYD2";"yes";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AA09";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AB09";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"G01AE10";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AA09";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AB09";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AA09";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AB09";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"G01AE10";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AA09";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"C03AB09";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Cyclothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2";"";"G01AE10";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CR50";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CF06";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CF06";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CF06";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CF06";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Nafcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O";"The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.";"J01CF06";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Chloroquine";"CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1";"1-2 months";"P01BA01";"Glutathione S-transferase A2";"GSTA2";"unknown";""
"Chloroquine";"CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1";"1-2 months";"P01BA01";"Tumor necrosis factor";"TNF";"unknown";""
"Chloroquine";"CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1";"1-2 months";"P01BA01";"Toll-like receptor 9";"TLR9";"unknown";""
"Chloroquine";"CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1";"1-2 months";"P01BA01";"Glutathione S-transferase";"GST";"unknown";""
"Ethionamide";"CCC1=NC=CC(=C1)C(N)=S";"2 to 3 hours";"J04AD03";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Ethionamide";"CCC1=NC=CC(=C1)C(N)=S";"2 to 3 hours";"J04AD03";"Catalase-peroxidase";"katG";"unknown";"other/unknown"
"Metaraminol";"C[C@H](N)[C@H](O)C1=CC(O)=CC=C1";"";"C01CA09";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Butorphanol";"[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1";"The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances &lt;30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.";"N02AF01";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Butorphanol";"[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1";"The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances &lt;30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.";"N02AF01";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Butorphanol";"[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1";"The elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances &lt;30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.";"N02AF01";"Mu-type opioid receptor";"OPRM1";"yes";"partial antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07BB07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C09BX02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07FB07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07AB07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07AB57";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07BB07";"Beta-2 adrenergic receptor";"ADRB2";"no";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C09BX02";"Beta-2 adrenergic receptor";"ADRB2";"no";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07FB07";"Beta-2 adrenergic receptor";"ADRB2";"no";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07AB07";"Beta-2 adrenergic receptor";"ADRB2";"no";"antagonist"
"Bisoprolol";"CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1";"9-12 hours; prolonged in the elderly and those with decreased renal function";"C07AB57";"Beta-2 adrenergic receptor";"ADRB2";"no";"antagonist"
"Amodiaquine";"CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1";"5.2 &plusmn; 1.7 (range 0.4 to 5.5) minutes";"P01BF03";"Histamine N-methyltransferase";"HNMT";"unknown";"inhibitor"
"Amodiaquine";"CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1";"5.2 &plusmn; 1.7 (range 0.4 to 5.5) minutes";"P01BA06";"Histamine N-methyltransferase";"HNMT";"unknown";"inhibitor"
"Rifabutin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21";"45 (&plusmn; 17) hours";"J04AB04";"DNA-directed RNA polymerase subunit alpha";"rpoA";"yes";"inhibitor"
"Rifabutin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21";"45 (&plusmn; 17) hours";"J04AB04";"DNA-directed RNA polymerase subunit beta";"rpoB";"yes";"inhibitor"
"Rifabutin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21";"45 (&plusmn; 17) hours";"J04AB04";"DNA-directed RNA polymerase subunit beta'";"rpoC";"yes";"inhibitor"
"Rifabutin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21";"45 (&plusmn; 17) hours";"J04AB04";"Heat shock protein HSP 90-alpha";"HSP90AA1";"no";"other/unknown"
"Rifabutin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21";"45 (&plusmn; 17) hours";"J04AB04";"Endoplasmin";"HSP90B1";"no";"other/unknown"
"Paramethadione";"CCC1(C)OC(=O)N(C)C1=O";"12 to 24 hours (however the half-life for the active metabolite is not known)";"N03AC01";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"yes";"suppressor"
"Demeclocycline";"[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O";"10-17 hours";"J01AA01";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Demeclocycline";"[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O";"10-17 hours";"J01AA20";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Demeclocycline";"[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O";"10-17 hours";"D06AA01";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Demeclocycline";"[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O";"10-17 hours";"J01AA01";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Demeclocycline";"[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O";"10-17 hours";"J01AA20";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Demeclocycline";"[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O";"10-17 hours";"D06AA01";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"BCR/ABL fusion protein isoform X9";"BCR/ABL fusion";"yes";"inhibitor"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"Mast/stem cell growth factor receptor Kit";"KIT";"yes";"antagonistmultitarget"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"RET proto-oncogene";"RET";"yes";"inhibitor"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"High affinity nerve growth factor receptor";"NTRK1";"unknown";"antagonist"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"Macrophage colony-stimulating factor 1 receptor";"CSF1R";"unknown";"antagonist"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"Platelet-derived growth factor receptor alpha";"PDGFRA";"unknown";"antagonist"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"Epithelial discoidin domain-containing receptor 1";"DDR1";"unknown";"antagonist"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"Tyrosine-protein kinase ABL1";"ABL1";"unknown";"inhibitor"
"Imatinib";"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1";"Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.";"L01XE01";"Platelet-derived growth factor receptor beta";"PDGFRB";"unknown";"antagonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"R01AD11";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"C05AA12";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"S02CA04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"D07CB01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"D07BB03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"D07AB09";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"H02AB08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"S01BA05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"D07XB02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"R03BA06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triamcinolone";"[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"88 minutes";"A01AC01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Oxandrolone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C";"0.55 hours (1st phage), 9 hours (2nd phase)";"A14AA08";"Androgen receptor";"AR";"yes";"agonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A";"PDE1A";"unknown";"inhibitor"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B";"PDE1B";"unknown";"inhibitor"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Nicardipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1";"8.6 hours";"C08CA04";"Calmodulin";"CALM1";"unknown";"other/unknown"
"Fluphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"";"N05AB02";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Fluphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"";"N05AB02";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Fluphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"";"N05AB02";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Fluphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"";"N05AB02";"Androgen receptor";"AR";"unknown";""
"Fluphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"";"N05AB02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";""
"Fluphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"";"N05AB02";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";""
"Testosterone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"10-100 minutes";"G03EA02";"Androgen receptor";"AR";"yes";"agonist"
"Testosterone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"10-100 minutes";"G03BA03";"Androgen receptor";"AR";"yes";"agonist"
"Testosterone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"10-100 minutes";"G03EA02";"Estrogen receptor alpha";"ESR1";"unknown";""
"Testosterone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"10-100 minutes";"G03BA03";"Estrogen receptor alpha";"ESR1";"unknown";""
"Testosterone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"10-100 minutes";"G03EA02";"Mineralocorticoid receptor";"NR3C2";"unknown";""
"Testosterone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"10-100 minutes";"G03BA03";"Mineralocorticoid receptor";"NR3C2";"unknown";""
"Efavirenz";"FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1";"40-55 hours";"J05AR06";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Efavirenz";"FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1";"40-55 hours";"J05AG03";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Efavirenz";"FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1";"40-55 hours";"J05AR11";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Bacitracin";"CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC";"";"D06AX05";"Insulin-degrading enzyme";"IDE";"yes";"inhibitor"
"Bacitracin";"CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC";"";"J01XX10";"Insulin-degrading enzyme";"IDE";"yes";"inhibitor"
"Bacitracin";"CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC";"";"R02AB04";"Insulin-degrading enzyme";"IDE";"yes";"inhibitor"
"Bacitracin";"CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC";"";"D06AX05";"Alpha-2-macroglobulin";"A2M";"unknown";"inhibitor"
"Bacitracin";"CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC";"";"J01XX10";"Alpha-2-macroglobulin";"A2M";"unknown";"inhibitor"
"Bacitracin";"CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC";"";"R02AB04";"Alpha-2-macroglobulin";"A2M";"unknown";"inhibitor"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10BA01";"Hydroxycarboxylic acid receptor 3";"HCAR3";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD52";"Hydroxycarboxylic acid receptor 3";"HCAR3";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C04AC01";"Hydroxycarboxylic acid receptor 3";"HCAR3";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD02";"Hydroxycarboxylic acid receptor 3";"HCAR3";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10BA01";"Hydroxycarboxylic acid receptor 2";"HCAR2";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD52";"Hydroxycarboxylic acid receptor 2";"HCAR2";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C04AC01";"Hydroxycarboxylic acid receptor 2";"HCAR2";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD02";"Hydroxycarboxylic acid receptor 2";"HCAR2";"yes";"agonist"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10BA01";"Nicotinate-nucleotide pyrophosphorylase [carboxylating]";"QPRT";"yes";"binder"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD52";"Nicotinate-nucleotide pyrophosphorylase [carboxylating]";"QPRT";"yes";"binder"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C04AC01";"Nicotinate-nucleotide pyrophosphorylase [carboxylating]";"QPRT";"yes";"binder"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD02";"Nicotinate-nucleotide pyrophosphorylase [carboxylating]";"QPRT";"yes";"binder"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10BA01";"Nicotinamide N-methyltransferase";"NNMT";"yes";"binder"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD52";"Nicotinamide N-methyltransferase";"NNMT";"yes";"binder"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C04AC01";"Nicotinamide N-methyltransferase";"NNMT";"yes";"binder"
"Niacin";"OC(=O)C1=CN=CC=C1";"20-45 minutes.";"C10AD02";"Nicotinamide N-methyltransferase";"NNMT";"yes";"binder"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BA04";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB05";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB03";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB06";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BA04";"Tyrosine-protein phosphatase non-receptor type 4";"PTPN4";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB05";"Tyrosine-protein phosphatase non-receptor type 4";"PTPN4";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB03";"Tyrosine-protein phosphatase non-receptor type 4";"PTPN4";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB06";"Tyrosine-protein phosphatase non-receptor type 4";"PTPN4";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BA04";"Receptor-type tyrosine-protein phosphatase S";"PTPRS";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB05";"Receptor-type tyrosine-protein phosphatase S";"PTPRS";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB03";"Receptor-type tyrosine-protein phosphatase S";"PTPRS";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB06";"Receptor-type tyrosine-protein phosphatase S";"PTPRS";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BA04";"Receptor-type tyrosine-protein phosphatase epsilon";"PTPRE";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB05";"Receptor-type tyrosine-protein phosphatase epsilon";"PTPRE";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB03";"Receptor-type tyrosine-protein phosphatase epsilon";"PTPRE";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB06";"Receptor-type tyrosine-protein phosphatase epsilon";"PTPRE";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BA04";"V-type proton ATPase catalytic subunit A";"ATP6V1A";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB05";"V-type proton ATPase catalytic subunit A";"ATP6V1A";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB03";"V-type proton ATPase catalytic subunit A";"ATP6V1A";"unknown";"inhibitor"
"Alendronic acid";"NCCCC(O)(P(O)(O)=O)P(O)(O)=O";">10 years";"M05BB06";"V-type proton ATPase catalytic subunit A";"ATP6V1A";"unknown";"inhibitor"
"Clofarabine";"[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12";"The terminal half-life is estimated to be 5.2 hours.";"L01BB06";"DNA polymerase alpha catalytic subunit";"POLA1";"yes";"inhibitor"
"Clofarabine";"[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12";"The terminal half-life is estimated to be 5.2 hours.";"L01BB06";"Ribonucleoside-diphosphate reductase large subunit";"RRM1";"yes";"inhibitor"
"Docosanol";"CCCCCCCCCCCCCCCCCCCCCCO";"";"D06BB11";"Envelope glycoprotein GP350";"";"yes";"intercalation"
"Docosanol";"CCCCCCCCCCCCCCCCCCCCCCO";"";"D06BB11";"Envelope glycoprotein GP340";"";"unknown";"intercalation"
"Dexmedetomidine";"C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1";"2 hours";"N05CM18";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"S01AB04";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"D10AF06";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"S01AB04";"Dihydropteroate synthase type-1";"sulI";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"D10AF06";"Dihydropteroate synthase type-1";"sulI";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"G01AE10";"Dihydropteroate synthase type-1";"sulI";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"S01AB04";"Folic acid synthesis protein FOL1";"FOL1";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"D10AF06";"Folic acid synthesis protein FOL1";"FOL1";"yes";"inhibitor"
"Sulfacetamide";"CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1";"7-12.8 hours";"G01AE10";"Folic acid synthesis protein FOL1";"FOL1";"yes";"inhibitor"
"Prednisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.";"H02AB07";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.";"A07EA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.";"H02AB07";"Corticosteroid 11-beta-dehydrogenase isozyme 1";"HSD11B1";"unknown";"ligand"
"Prednisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.";"A07EA03";"Corticosteroid 11-beta-dehydrogenase isozyme 1";"HSD11B1";"unknown";"ligand"
"Clofibrate";"CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1";"Half-life in normal volunteers averages 18 to 22 hours (range 14 to 35 hours) but can vary by up to 7 hours in the same subject at different times.";"C10AB01";"Peroxisome proliferator-activated receptor alpha";"PPARA";"yes";"agonist"
"Astemizole";"COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1";"1 day";"R06AX11";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Astemizole";"COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1";"1 day";"R06AX11";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Astemizole";"COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1";"1 day";"R06AX11";"Potassium voltage-gated channel subfamily H member 1";"KCNH1";"unknown";""
"Astemizole";"COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1";"1 day";"R06AX11";"Microtubule-associated protein tau";"MAPT";"unknown";""
"Inulin";"OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(OC[C@@]%12(OC[C@@]%13(OC[C@@]%14(OC[C@@]%15(OC[C@@]%16(OC[C@@]%17(OC[C@@]%18(OC[C@@]%19(OC[C@@]%20(OC[C@@]%21(OC[C@@]%22(OC[C@@]%23(OC[C@@]%24(OC[C@@]%25(OC[C@@]%26(OC[C@@]%27(OC[C@@]%28(OC[C@@]%29(OC[C@@]%30(OC[C@@]%31(OC[C@@]%32(OC[C@@]%33(OC[C@@]%34(OC[C@@]%35(OC[C@@]%36(OC[C@@]%37(O[C@H]%38O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O";"2-4 hours";"V04CH01";"Cycloinulo-oligosaccharide fructanotransferase";"cft";"no";"binder"
"Adenosine";"NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1";"Less than 10 secs";"C01EB10";"Adenosine receptor A2a";"ADORA2A";"yes";"agonist"
"Adenosine";"NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1";"Less than 10 secs";"C01EB10";"Adenosine receptor A2b";"ADORA2B";"yes";"agonist"
"Adenosine";"NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1";"Less than 10 secs";"C01EB10";"Adenosine receptor A3";"ADORA3";"yes";"agonist"
"Adenosine";"NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1";"Less than 10 secs";"C01EB10";"Adenosine receptor A1";"ADORA1";"yes";"agonist"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BX04";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BA02";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"A10BH51";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BA04";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10AA01";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BX01";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BX04";"Integrin beta-2";"ITGB2";"no";"other"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BA02";"Integrin beta-2";"ITGB2";"no";"other"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"A10BH51";"Integrin beta-2";"ITGB2";"no";"other"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BA04";"Integrin beta-2";"ITGB2";"no";"other"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10AA01";"Integrin beta-2";"ITGB2";"no";"other"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BX01";"Integrin beta-2";"ITGB2";"no";"other"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BX04";"Integrin alpha-L";"ITGAL";"unknown";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BA02";"Integrin alpha-L";"ITGAL";"unknown";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"A10BH51";"Integrin alpha-L";"ITGAL";"unknown";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BA04";"Integrin alpha-L";"ITGAL";"unknown";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10AA01";"Integrin alpha-L";"ITGAL";"unknown";"inhibitor"
"Simvastatin";"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC";"3 hours";"C10BX01";"Integrin alpha-L";"ITGAL";"unknown";"inhibitor"
"Pemetrexed";"[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O";"3.5 hours";"L01BA04";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Pemetrexed";"[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O";"3.5 hours";"L01BA04";"Bifunctional purine biosynthesis protein PURH";"ATIC";"yes";"inhibitor"
"Pemetrexed";"[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O";"3.5 hours";"L01BA04";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Pemetrexed";"[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O";"3.5 hours";"L01BA04";"Trifunctional purine biosynthetic protein adenosine-3";"GART";"yes";"inhibitor"
"Mebendazole";"COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1";"2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).";"P02CA01";"Tubulin alpha-1A chain";"TUBA1A";"yes";"inhibitor"
"Mebendazole";"COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1";"2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).";"P02CA51";"Tubulin alpha-1A chain";"TUBA1A";"yes";"inhibitor"
"Mebendazole";"COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1";"2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).";"P02CA01";"Tubulin beta-4B chain";"TUBB4B";"yes";"inhibitor"
"Mebendazole";"COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1";"2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).";"P02CA51";"Tubulin beta-4B chain";"TUBB4B";"yes";"inhibitor"
"Gonadorelin";"CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O";"Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes";"V04CM01";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"agonist"
"Gonadorelin";"CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O";"Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes";"H01CA01";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"agonist"
"Gonadorelin";"CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O";"Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes";"V04CM01";"Putative gonadotropin-releasing hormone II receptor";"GNRHR2";"yes";"agonist"
"Gonadorelin";"CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O";"Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes";"H01CA01";"Putative gonadotropin-releasing hormone II receptor";"GNRHR2";"yes";"agonist"
"Dyclonine";"CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1";"Approximately 30 to 60 minutes.";"N01BX02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Dyclonine";"CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1";"Approximately 30 to 60 minutes.";"R02AD04";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC54";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC74";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC04";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC54";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC74";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC04";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC54";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC74";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC04";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC54";"Liver carboxylesterase 1";"CES1";"unknown";""
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC74";"Liver carboxylesterase 1";"CES1";"unknown";""
"Dextropropoxyphene";"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1";"6-12 hours";"N02AC04";"Liver carboxylesterase 1";"CES1";"unknown";""
"Mitotane";"ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl";"18-159 days";"L01XX23";"Cytochrome P450 11B1, mitochondrial";"CYP11B1";"yes";"inducer"
"Mitotane";"ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl";"18-159 days";"L01XX23";"Adrenodoxin, mitochondrial";"FDX1";"unknown";"unknown"
"Mitotane";"ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl";"18-159 days";"L01XX23";"Estrogen receptor alpha";"ESR1";"unknown";""
"Mitotane";"ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl";"18-159 days";"L01XX23";"Progesterone receptor";"PGR";"unknown";""
"Mitotane";"ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl";"18-159 days";"L01XX23";"Androgen receptor";"AR";"unknown";"antagonist"
"Stavudine";"CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O";"0.8-1.5 hours (in adults)";"J05AF04";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Stavudine";"CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O";"0.8-1.5 hours (in adults)";"J05AR07";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"cAMP-specific 3',5'-cyclic phosphodiesterase 4C";"PDE4C";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4C";"PDE4C";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4C";"PDE4C";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4C";"PDE4C";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A";"PDE7A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A";"PDE7A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A";"PDE7A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A";"PDE7A";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA51";"cAMP-specific 3',5'-cyclic phosphodiesterase 7B";"PDE7B";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 7B";"PDE7B";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DA01";"cAMP-specific 3',5'-cyclic phosphodiesterase 7B";"PDE7B";"yes";"inhibitor"
"Dyphylline";"CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O";"2 hours (range 1.8 - 2.1 hours)";"R03DB01";"cAMP-specific 3',5'-cyclic phosphodiesterase 7B";"PDE7B";"yes";"inhibitor"
"Pentazocine";"C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C";"2 to 3 hours";"N02AD01";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Pentazocine";"C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C";"2 to 3 hours";"N02AD01";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Pentazocine";"C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C";"2 to 3 hours";"N02AD01";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"yes";"agonist"
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A06AD04";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"V04CC02";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A12CC02";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"D11AX05";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"B05XA05";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A06AD04";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"V04CC02";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A12CC02";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"D11AX05";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"B05XA05";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A06AD04";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"V04CC02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A12CC02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"D11AX05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"B05XA05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A06AD04";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"V04CC02";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A12CC02";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"D11AX05";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"B05XA05";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A06AD04";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"V04CC02";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A12CC02";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"D11AX05";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"B05XA05";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A06AD04";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"V04CC02";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"A12CC02";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"D11AX05";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Magnesium sulfate";"[Mg++].[O-]S([O-])(=O)=O";"43.2 hours (for newborns)";"B05XA05";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Latanoprost";"CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1";"17 minutes";"S01EE01";"Prostaglandin F2-alpha receptor";"PTGFR";"yes";"agonist"
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CA07";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CC04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CA07";"Estrogen receptor beta";"ESR2";"unknown";""
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CC04";"Estrogen receptor beta";"ESR2";"unknown";""
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CA07";"Androgen receptor";"AR";"unknown";""
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CC04";"Androgen receptor";"AR";"unknown";""
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CA07";"Cytochrome P450 19A1";"CYP19A1";"unknown";""
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CC04";"Cytochrome P450 19A1";"CYP19A1";"unknown";""
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CA07";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Estrone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"19 hours";"G03CC04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Trazodone";"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1";"Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.";"N06AX05";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Trazodone";"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1";"Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.";"N06AX05";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"agonist"
"Trazodone";"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1";"Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.";"N06AX05";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Trazodone";"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1";"Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.";"N06AX05";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"partial agonist"
"Trazodone";"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1";"Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.";"N06AX05";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Trazodone";"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1";"Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.";"N06AX05";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Trazodone";"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1";"Undergoes biphasic elimination with an initial phase t<sub>1/2 &alpha;</sub> of 3-6 hours and a terminal phase t<sub>1/2 &beta;</sub> of 5-9 hours.";"N06AX05";"Alpha-2A adrenergic receptor";"ADRA2A";"no";"antagonist"
"Mecamylamine";"CNC1(C)C2CCC(C2)C1(C)C";"";"C02BB01";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"inhibitor"
"Mecamylamine";"CNC1(C)C2CCC(C2)C1(C)C";"";"C02BB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";""
"Mecamylamine";"CNC1(C)C2CCC(C2)C1(C)C";"";"C02BB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Mecamylamine";"CNC1(C)C2CCC(C2)C1(C)C";"";"C02BB01";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive modulator"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Glutamate (NMDA) receptor";"GRIN1";"yes";"antagonist"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Glutamate (NMDA) receptor";"GRIN2A";"yes";"antagonist"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Glutamate (NMDA) receptor";"GRIN2B";"yes";"antagonist"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Glutamate (NMDA) receptor";"GRIN2C";"yes";"antagonist"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Glutamate (NMDA) receptor";"GRIN2D";"yes";"antagonist"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Glutamate (NMDA) receptor";"GRIN3A";"yes";"antagonist"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Glutamate (NMDA) receptor";"GRIN3B";"yes";"antagonist"
"Acamprosate";"CC(=O)NCCCS(O)(=O)=O";"20 - 33 hours";"N07BB03";"Metabotropic glutamate receptor 5";"GRM5";"yes";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit beta-3";"CACNB3";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit beta-3";"CACNB3";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit beta-3";"CACNB3";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent L-type calcium channel subunit beta-4";"CACNB4";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent L-type calcium channel subunit beta-4";"CACNB4";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent L-type calcium channel subunit beta-4";"CACNB4";"yes";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Sodium channel protein type 5 subunit alpha";"SCN5A";"unknown";"other"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"unknown";"other"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Sodium channel protein type 5 subunit alpha";"SCN5A";"unknown";"other"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"unknown";"inhibitor"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"other/unknown"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"other/unknown"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"other/unknown"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA51";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C08DA01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Verapamil";"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1";"2.8-7.4 hours";"C09BB10";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Flumethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07AB03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Flumethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07XB01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Flumethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07BB01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Flumethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"S02CA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Flumethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07CB05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Sulfametopyrazine";"COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1";"";"J01ED02";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfametopyrazine";"COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1";"";"G01AE10";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Nilutamide";"CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F";"38.0-59.1 hours";"L02BB02";"Androgen receptor";"AR";"yes";"antagonist"
"Nafarelin";"CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O";"3 hours";"H01CA02";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"agonist"
"Nafarelin";"CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O";"3 hours";"H01CA02";"Putative gonadotropin-releasing hormone II receptor";"GNRHR2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Phenylalanine-4-hydroxylase";"PAH";"no";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Tumor necrosis factor";"TNF";"unknown";"antagonist"
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R01AA14";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AK01";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"C01CA24";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA51";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"B02BC09";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"A01AD01";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"R03AA01";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Epinephrine";"CNC[C@H](O)C1=CC(O)=C(O)C=C1";"2 minutes";"S01EA01";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"N02CC01";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"G01AE10";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"N02CC01";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"G01AE10";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"N02CC01";"5-hydroxytryptamine receptor 1F";"HTR1F";"yes";"agonist"
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"G01AE10";"5-hydroxytryptamine receptor 1F";"HTR1F";"yes";"agonist"
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"N02CC01";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonist"
"Sumatriptan";"CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1";"2.5 hours";"G01AE10";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonist"
"Pirenzepine";"CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1";"";"A02BX03";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Cefixime";"[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O";"3-4 hours (may range up to 9 hours). In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours.";"J01DD08";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Chlorpropamide";"CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1";"Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.";"A10BB02";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Aprepitant";"C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F";"9-13 hours";"A04AD12";"Substance-P receptor";"TACR1";"yes";"antagonist"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Acetylcholine receptor subunit alpha";"CHRNA1";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Acetylcholine receptor subunit beta";"CHRNB1";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Acetylcholine receptor subunit delta";"CHRND";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Acetylcholine receptor subunit gamma";"CHRNG";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Acetylcholine receptor subunit epsilon";"CHRNE";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-5";"CHRNA5";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-6";"CHRNA6";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-9";"CHRNA9";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit beta-3";"CHRNB3";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";"allosteric modulator"
"Galantamine";"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3";"7 hours";"N06DA04";"Cholinesterase";"BCHE";"unknown";"inhibitor"
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Estrogen receptor alpha";"ESR1";"yes";"antagonistagonist"
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Estrogen receptor beta";"ESR2";"yes";"antagonistagonist"
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase";"EBP";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCA";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCB";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCD";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCE";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCG";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCI";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCQ";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Protein kinase C";"PRKCZ";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Androgen receptor";"AR";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Estrogen-related receptor gamma";"ESRRG";"unknown";""
"Tamoxifen";"CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1";"The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.";"L02BA01";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Losartan";"CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"The terminal t<sub>1/2</sub> of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.";"C09DA01";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Losartan";"CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"The terminal t<sub>1/2</sub> of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.";"C09DB06";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Losartan";"CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"The terminal t<sub>1/2</sub> of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.";"C09CA01";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Thioridazine";"CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1";"21-25 hours";"N05AC02";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Thioridazine";"CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1";"21-25 hours";"N05AC02";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Thioridazine";"CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1";"21-25 hours";"N05AC02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Thioridazine";"CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1";"21-25 hours";"N05AC02";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Thioridazine";"CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1";"21-25 hours";"N05AC02";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Thioridazine";"CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1";"21-25 hours";"N05AC02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Moricizine";"CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1";"2 hours (range 1.5-3.5 hours).";"C01BG01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Warfarin";"CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2";"R-warfarin t<sub>1/2</sub>=37-89 hours; S-warfarin t<sub>1/2</sub>=21-43 hours.";"B01AA03";"Vitamin K epoxide reductase complex subunit 1";"VKORC1";"yes";"inhibitor"
"Warfarin";"CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2";"R-warfarin t<sub>1/2</sub>=37-89 hours; S-warfarin t<sub>1/2</sub>=21-43 hours.";"B01AA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Midazolam";"CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12";"Intravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)";"N05CD08";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Tobramycin";"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O";"The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.";"S01AA12";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Tobramycin";"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O";"The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.";"J01GB01";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Trovafloxacin";"[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O";"Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.";"J01MA13";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Trovafloxacin";"[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O";"Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.";"J01MA13";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Trovafloxacin";"[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O";"Following oral administration, half-life ranged from 9.1 hours to 12.2 hours over the dosage range of 100 to 200 mg tablets. Following intravenous infusion, half-life ranged from 9.4 to 12.7 hours over a dosage range of 100 to 300 mg.";"J01MA13";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Pentosan Polysulfate";"O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O";"4.8 hours";"C05BA04";"Fibroblast growth factor 2";"FGF2";"yes";"antagonist"
"Pentosan Polysulfate";"O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O";"4.8 hours";"G04BX15";"Fibroblast growth factor 2";"FGF2";"yes";"antagonist"
"Pentosan Polysulfate";"O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O";"4.8 hours";"C05BA04";"Fibroblast growth factor 1";"FGF1";"yes";"antagonist"
"Pentosan Polysulfate";"O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O";"4.8 hours";"G04BX15";"Fibroblast growth factor 1";"FGF1";"yes";"antagonist"
"Pentosan Polysulfate";"O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O";"4.8 hours";"C05BA04";"Fibroblast growth factor 4";"FGF4";"unknown";"inhibitor"
"Pentosan Polysulfate";"O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O";"4.8 hours";"G04BX15";"Fibroblast growth factor 4";"FGF4";"unknown";"inhibitor"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S01CA06";"Mineralocorticoid receptor";"NR3C2";"yes";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S02CA07";"Mineralocorticoid receptor";"NR3C2";"yes";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S03CA05";"Mineralocorticoid receptor";"NR3C2";"yes";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"H02AA02";"Mineralocorticoid receptor";"NR3C2";"yes";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S01CA06";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S02CA07";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S03CA05";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"H02AA02";"Glucocorticoid receptor";"NR3C1";"unknown";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S01CA06";"Androgen receptor";"AR";"unknown";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S02CA07";"Androgen receptor";"AR";"unknown";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"S03CA05";"Androgen receptor";"AR";"unknown";"agonist"
"Fludrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"3.5 hours";"H02AA02";"Androgen receptor";"AR";"unknown";"agonist"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Flurazepam";"CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours";"N05CD01";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Moexipril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O";"Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.";"C09BA13";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Moexipril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O";"Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.";"C09AA13";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Moexipril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O";"Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.";"C09BA13";"Angiotensin-converting enzyme 2";"ACE2";"yes";"inhibitor"
"Moexipril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O";"Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.";"C09AA13";"Angiotensin-converting enzyme 2";"ACE2";"yes";"inhibitor"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"V03AB36";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"C04AB01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"V03AB36";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"C04AB01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"V03AB36";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"C04AB01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"V03AB36";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Phentolamine";"CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1";"19 minutes";"C04AB01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Fluorescein";"OC1=CC2=C(C=C1)C1(OC(=O)C3=CC=CC=C13)C1=C(O2)C=C(O)C=C1";"";"S01JA51";"Ig kappa chain V-II region RPMI 6410";"";"no";"other"
"Fluorescein";"OC1=CC2=C(C=C1)C1(OC(=O)C3=CC=CC=C13)C1=C(O2)C=C(O)C=C1";"";"S01JA01";"Ig kappa chain V-II region RPMI 6410";"";"no";"other"
"Daunorubicin";"COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O";"18.5 hours";"L01DB02";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Daunorubicin";"COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O";"18.5 hours";"L01DB02";"DNA topoisomerase 2-beta";"TOP2B";"yes";"inhibitor"
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"C03EB01";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"C03CB01";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"C03CA01";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"G01AE10";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"C03EB01";"Carbonic anhydrase 2";"CA2";"unknown";""
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"C03CB01";"Carbonic anhydrase 2";"CA2";"unknown";""
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"C03CA01";"Carbonic anhydrase 2";"CA2";"unknown";""
"Furosemide";"NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O";"2 hours";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";""
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"partial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonistpartial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonistpartial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonistpartial agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"D(1) dopamine receptor";"DRD1";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"D(1) dopamine receptor";"DRD1";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"D(1) dopamine receptor";"DRD1";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"D(1) dopamine receptor";"DRD5";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"D(1) dopamine receptor";"DRD5";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"D(1) dopamine receptor";"DRD5";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"5-hydroxytryptamine receptor 1F";"HTR1F";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"5-hydroxytryptamine receptor 1F";"HTR1F";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"5-hydroxytryptamine receptor 1F";"HTR1F";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA52";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";""
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA72";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";""
"Ergotamine";"[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O";"2 hours";"N02CA02";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";""
"Tizanidine";"ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1";"2.5 hours";"M03BX02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Tizanidine";"ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1";"2.5 hours";"M03BX02";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Tizanidine";"ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1";"2.5 hours";"M03BX02";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Tizanidine";"ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1";"2.5 hours";"M03BX02";"Nischarin";"NISCH";"no";"agonist"
"Nitrofurantoin";"[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O";"0.3-1 hour";"J01XE51";"Probable pyruvate-flavodoxin oxidoreductase";"ydbK";"yes";"potentiator"
"Nitrofurantoin";"[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O";"0.3-1 hour";"J01XE01";"Probable pyruvate-flavodoxin oxidoreductase";"ydbK";"yes";"potentiator"
"Nitrofurantoin";"[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O";"0.3-1 hour";"J01XE51";"Oxygen-insensitive NADPH nitroreductase";"nfsA";"yes";"potentiator"
"Nitrofurantoin";"[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O";"0.3-1 hour";"J01XE01";"Oxygen-insensitive NADPH nitroreductase";"nfsA";"yes";"potentiator"
"Nitrofurantoin";"[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O";"0.3-1 hour";"J01XE51";"30S ribosomal protein S10";"rpsJ";"unknown";""
"Nitrofurantoin";"[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O";"0.3-1 hour";"J01XE01";"30S ribosomal protein S10";"rpsJ";"unknown";""
"Nicergoline";"[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CC(Br)=CN=C1)CN2C)OC";"";"C04AE02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Eplerenone";"[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC";"4-6 hours";"C03DA04";"Mineralocorticoid receptor";"NR3C2";"yes";"antagonist"
"Amprenavir";"CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1";"7.1-10.6 hours";"J05AE05";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Methazolamide";"CN1N=C(SC1=NC(C)=O)S(N)(=O)=O";"14 hours";"S01EC05";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Methazolamide";"CN1N=C(SC1=NC(C)=O)S(N)(=O)=O";"14 hours";"S01EC05";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Methazolamide";"CN1N=C(SC1=NC(C)=O)S(N)(=O)=O";"14 hours";"S01EC05";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Methazolamide";"CN1N=C(SC1=NC(C)=O)S(N)(=O)=O";"14 hours";"S01EC05";"Carbonic anhydrase 7";"CA7";"yes";"inhibitor"
"Methazolamide";"CN1N=C(SC1=NC(C)=O)S(N)(=O)=O";"14 hours";"S01EC05";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"A08AA62";"Delta-type opioid receptor";"OPRD1";"yes";"antagonist"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"N07BB04";"Delta-type opioid receptor";"OPRD1";"yes";"antagonist"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"A08AA62";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"N07BB04";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"A08AA62";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"N07BB04";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"A08AA62";"HCG20471, isoform CRA_c";"SIGMAR1";"yes";"antagonist"
"Naltrexone";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O";"4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.";"N07BB04";"HCG20471, isoform CRA_c";"SIGMAR1";"yes";"antagonist"
"Delavirdine";"CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2";"5.8 hours";"J05AG02";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA53";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA52";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA02";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA53";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA52";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA53";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Tamsulosin";"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O";"5-7 hours";"G04CA52";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Sufentanil";"CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1";"265 minutes";"N01AH03";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Sufentanil";"CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1";"265 minutes";"N01AH03";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Sufentanil";"CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1";"265 minutes";"N01AH03";"Kappa-type opioid receptor";"OPRK1";"unknown";"other"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR02";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR13";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR12";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR01";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR05";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR07";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR04";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR11";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AF05";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR16";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR02";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR13";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR12";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR01";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR05";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR07";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR04";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR11";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AF05";"Protein P";"P";"yes";"inhibitor"
"Lamivudine";"NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1";"5 to 7 hours (healthy or HBV-infected patients)";"J05AR16";"Protein P";"P";"yes";"inhibitor"
"Ibandronate";"CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O";"10-60 hours";"M05BA06";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Diethylcarbamazine";"CCN(CC)C(=O)N1CCN(C)CC1";"Approximately 8 hours.";"P02CB02";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Diethylcarbamazine";"CCN(CC)C(=O)N1CCN(C)CC1";"Approximately 8 hours.";"P02CB02";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"M02AA19";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"R02AX01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"M01AE09";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"S01BC04";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"M02AA19";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"R02AX01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"M01AE09";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Flurbiprofen";"CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1";"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours";"S01BC04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Penicillin-binding protein 2";"mecA";"unknown";""
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Penicillin-binding protein 2";"mecA";"unknown";""
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CR50";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Oxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O";"20 to 30 minutes";"J01CF04";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"G04BE07";"Neuron-specific vesicular protein calcyon";"CALY";"unknown";"agonist"
"Apomorphine";"[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23";"40 minutes (range 30 - 60 minutes)";"N04BC07";"Neuron-specific vesicular protein calcyon";"CALY";"unknown";"agonist"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"other/unknown"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Paroxetine";"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1";"21-24 hours";"N06AB05";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R03BC03";"Cysteinyl leukotriene receptor 1";"CYSLTR1";"yes";"suppressor"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"S01GX04";"Cysteinyl leukotriene receptor 1";"CYSLTR1";"yes";"suppressor"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R01AC07";"Cysteinyl leukotriene receptor 1";"CYSLTR1";"yes";"suppressor"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R03BC03";"Cysteinyl leukotriene receptor 2";"CYSLTR2";"yes";"antagonist"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"S01GX04";"Cysteinyl leukotriene receptor 2";"CYSLTR2";"yes";"antagonist"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R01AC07";"Cysteinyl leukotriene receptor 2";"CYSLTR2";"yes";"antagonist"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R03BC03";"fMet-Leu-Phe receptor";"FPR1";"unknown";"antagonist"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"S01GX04";"fMet-Leu-Phe receptor";"FPR1";"unknown";"antagonist"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R01AC07";"fMet-Leu-Phe receptor";"FPR1";"unknown";"antagonist"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R03BC03";"Prostaglandin D2 receptor";"PTGDR";"unknown";"unknown"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"S01GX04";"Prostaglandin D2 receptor";"PTGDR";"unknown";"unknown"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R01AC07";"Prostaglandin D2 receptor";"PTGDR";"unknown";"unknown"
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R03BC03";"Heat shock protein HSP 90-alpha";"HSP90AA1";"unknown";""
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"S01GX04";"Heat shock protein HSP 90-alpha";"HSP90AA1";"unknown";""
"Nedocromil";"CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O";"~3.3 hours";"R01AC07";"Heat shock protein HSP 90-alpha";"HSP90AA1";"unknown";""
"Norethisterone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"8.51 ± 2.19 (when a single dose is given to healthy women)";"G03FB05";"Progesterone receptor";"PGR";"unknown";"agonist"
"Norethisterone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"8.51 ± 2.19 (when a single dose is given to healthy women)";"G03AB04";"Progesterone receptor";"PGR";"unknown";"agonist"
"Norethisterone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"8.51 ± 2.19 (when a single dose is given to healthy women)";"G03AA05";"Progesterone receptor";"PGR";"unknown";"agonist"
"Norethisterone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"8.51 ± 2.19 (when a single dose is given to healthy women)";"G03DC02";"Progesterone receptor";"PGR";"unknown";"agonist"
"Norethisterone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"8.51 ± 2.19 (when a single dose is given to healthy women)";"G03FA01";"Progesterone receptor";"PGR";"unknown";"agonist"
"Norethisterone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]";"8.51 ± 2.19 (when a single dose is given to healthy women)";"G03AC01";"Progesterone receptor";"PGR";"unknown";"agonist"
"Adefovir Dipivoxil";"CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C";"Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 ± 1.65 hours.";"J05AF08";"DNA polymerase/reverse transcriptase";"P";"yes";"other"
"Azatadine";"CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2";"";"R06AX09";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Clodronic Acid";"OP(O)(=O)C(Cl)(Cl)P(O)(O)=O";"Approximately 13 hours.";"M05BA02";"ADP/ATP translocase 1";"SLC25A4";"yes";"inhibitor"
"Clodronic Acid";"OP(O)(=O)C(Cl)(Cl)P(O)(O)=O";"Approximately 13 hours.";"M05BA02";"ADP/ATP translocase 2";"SLC25A5";"yes";"inhibitor"
"Clodronic Acid";"OP(O)(=O)C(Cl)(Cl)P(O)(O)=O";"Approximately 13 hours.";"M05BA02";"ADP/ATP translocase 3";"SLC25A6";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";"antagonist"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNMA1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNMA1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNMA1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNMA1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNMB1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNMB1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNMB1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNMB1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNMB2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNMB2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNMB2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNMB2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNMB3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNMB3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNMB3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNMB3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNMB4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNMB4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNMB4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNMB4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNN4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNN4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNN4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNN4";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNN1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNN1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNN1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNN1";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNN2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNN2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNN2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNN2";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Calcium-activated potassium channel";"KCNN3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Calcium-activated potassium channel";"KCNN3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Calcium-activated potassium channel";"KCNN3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Calcium-activated potassium channel";"KCNN3";"unknown";"binder"
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Monoamine oxidase";"MAOA";"unknown";""
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Monoamine oxidase";"MAOA";"unknown";""
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Monoamine oxidase";"MAOA";"unknown";""
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Monoamine oxidase";"MAOA";"unknown";""
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"S01HA05";"Monoamine oxidase";"MAOB";"unknown";""
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA52";"Monoamine oxidase";"MAOB";"unknown";""
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"N01BA02";"Monoamine oxidase";"MAOB";"unknown";""
"Procaine";"CCN(CC)CCOC(=O)C1=CC=C(N)C=C1";"7.7 minutes";"C05AD05";"Monoamine oxidase";"MAOB";"unknown";""
"Lisinopril";"NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O";"Effective half life of accumulation following multiple dosing is 12 hours.";"C09AA03";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Lisinopril";"NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O";"Effective half life of accumulation following multiple dosing is 12 hours.";"C09BB03";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Lisinopril";"NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O";"Effective half life of accumulation following multiple dosing is 12 hours.";"C10BX07";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Lisinopril";"NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O";"Effective half life of accumulation following multiple dosing is 12 hours.";"C09BA03";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Methoxamine";"COC1=CC(C(O)C(C)N)=C(OC)C=C1";"";"C01CA10";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Methoxamine";"COC1=CC(C(O)C(C)N)=C(OC)C=C1";"";"C01CA10";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Methoxamine";"COC1=CC(C(O)C(C)N)=C(OC)C=C1";"";"C01CA10";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"binder"
"Imiquimod";"CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N";"20 hours (topical dose), 2 hours (subcutaneous dose)";"D06BB10";"Toll-like receptor 7";"TLR7";"yes";"agonist"
"Imiquimod";"CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N";"20 hours (topical dose), 2 hours (subcutaneous dose)";"D06BB10";"Toll-like receptor 8";"TLR8";"unknown";"agonist"
"Homatropine Methylbromide";"[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1";"";"A03CB04";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Homatropine Methylbromide";"[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1";"";"A03CB04";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Homatropine Methylbromide";"[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1";"";"A03CB04";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Homatropine Methylbromide";"[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1";"";"A03CB04";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Homatropine Methylbromide";"[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1";"";"A03CB04";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"D(2) dopamine receptor";"DRD2";"unknown";"other/unknown"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"other/unknown"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"desensitize the target"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"D(1) dopamine receptor";"DRD1";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"D(1) dopamine receptor";"DRD5";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Beta adrenergic receptor";"ADRB1";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Beta adrenergic receptor";"ADRB2";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Beta adrenergic receptor";"ADRB3";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Trimipramine";"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12";"11-18 hrs";"N06AA06";"5-hydroxytryptamine receptor 1C";"Htr2c";"unknown";"binder"
"Nitroglycerin";"[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O";"3 minutes";"C05AE01";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Nitroglycerin";"[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O";"3 minutes";"C01DA52";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Nitroglycerin";"[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O";"3 minutes";"C01DA02";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Rocuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1";"The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.";"M03AC09";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Rocuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1";"The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.";"M03AC09";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Rocuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1";"The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.";"M03AC09";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Thiabendazole";"N1C2=CC=CC=C2N=C1C1=CSC=N1";"The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).";"D01AC06";"Fumarate reductase flavoprotein subunit";"frdA";"yes";"inhibitor"
"Thiabendazole";"N1C2=CC=CC=C2N=C1C1=CSC=N1";"The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).";"P02CA02";"Fumarate reductase flavoprotein subunit";"frdA";"yes";"inhibitor"
"Nateglinide";"[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O";"1.5 hours";"A10BX03";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Nateglinide";"[H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O";"1.5 hours";"A10BX03";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"agonist"
"Pralidoxime";"C[N+]1=C(\C=N\O)C=CC=C1";"74-77 minutes";"V03AB04";"Acetylcholinesterase";"ACHE";"yes";"activator"
"Pralidoxime";"C[N+]1=C(\C=N\O)C=CC=C1";"74-77 minutes";"V03AB04";"Cholinesterase";"BCHE";"yes";"activator"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonistagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Risperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1";"3 hours in extensive metabolizers [A31772]
Up to 20 hours in poor metabolizers [A31772]";"N05AX08";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";""
"Naftifine";"CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12";"Approximately 2 to 3 days following topical administration.";"D01AE22";"Squalene monooxygenase";"SQLE";"yes";"inhibitor"
"Esomeprazole";"COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1";"1-1.5 hours";"M01AE52";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Esomeprazole";"COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1";"1-1.5 hours";"A02BC05";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Esomeprazole";"COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1";"1-1.5 hours";"A02BD06";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Meclizine";"CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1";"6 hours";"R06AE55";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Meclizine";"CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1";"6 hours";"R06AE05";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Meclizine";"CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1";"6 hours";"R06AE55";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"inverse agonist"
"Meclizine";"CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1";"6 hours";"R06AE05";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"inverse agonist"
"Pentamidine";"NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1";"9.1-13.2 hours";"P01CX01";"tRNA (cytosine(38)-C(5))-methyltransferase";"TRDMT1";"unknown";"other"
"Hetacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O";"";"J01CA18";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Hetacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O";"";"J01CA18";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Hetacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O";"";"J01CA18";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Hetacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O";"";"J01CA18";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Hetacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O";"";"J01CA18";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Riluzole";"NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2";"The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.";"N07XX02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Riluzole";"NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2";"The mean elimination half-life of riluzole is 12 hours (CV=35%) after repeated doses.";"N07XX02";"Cystine/glutamate transporter";"SLC7A11";"yes";"inducer"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S03CA04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CB03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02BA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AB02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02CA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BB04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"C05AA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AC16";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A01AC03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07CA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BB01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BA04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"R01AD60";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"H02AB09";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07XA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A07EA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S03CA04";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CB03";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CA03";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02BA01";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AB02";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02CA03";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AA02";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BB04";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"C05AA01";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AC16";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A01AC03";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BA02";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07CA01";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BB01";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BA04";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"R01AD60";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"H02AB09";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07XA01";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A07EA02";"Annexin A1";"ANXA1";"yes";"agonist"
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S03CA04";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CB03";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CA03";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02BA01";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AB02";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02CA03";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AA02";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BB04";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"C05AA01";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AC16";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A01AC03";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BA02";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07CA01";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BB01";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BA04";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"R01AD60";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"H02AB09";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07XA01";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A07EA02";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S03CA04";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CB03";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01CA03";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02BA01";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AB02";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S02CA03";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AA02";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BB04";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"C05AA01";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07AC16";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A01AC03";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BA02";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07CA01";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"S01BB01";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07BA04";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"R01AD60";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"H02AB09";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"D07XA01";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Hydrocortisone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"A07EA02";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"unknown";""
"Modafinil";"NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1";"23-215 hours";"N06BA07";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Modafinil";"NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1";"23-215 hours";"N06BA07";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"partial agonist"
"Deferoxamine";"CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN";"Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.";"V03AC01";"Amyloid beta A4 protein";"APP";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Sucrase-isomaltase, intestinal";"SI";"unknown";"inhibitor"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Sucrase-isomaltase, intestinal";"SI";"unknown";"inhibitor"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Sucrase-isomaltase, intestinal";"SI";"unknown";"inhibitor"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Sucrase-isomaltase, intestinal";"SI";"unknown";"inhibitor"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"S01FA02";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD01";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"A04AD51";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Scopolamine";"CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"4.5 hours";"N05CM05";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Carbinoxamine";"CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"10 to 20 hours";"R06AA08";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Etodolac";"CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1";"Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours";"M01AB08";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Etodolac";"CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1";"Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours";"M01AB08";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Etodolac";"CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1";"Terminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours";"M01AB08";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";"other"
"Prilocaine";"CCCNC(C)C(=O)NC1=CC=CC=C1C";"";"N01BB54";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Prilocaine";"CCCNC(C)C(=O)NC1=CC=CC=C1C";"";"N01BB04";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"R06AX24";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"S01GX10";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"R06AX24";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"S01GX10";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"R06AX24";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"unknown"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"S01GX10";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"unknown"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"R06AX24";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"unknown"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"S01GX10";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"unknown"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"R06AX24";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"S01GX10";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"R06AX24";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Epinastine";"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21";"12 hours";"S01GX10";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Tranylcypromine";"NC1CC1C1=CC=CC=C1";"1.5-3.2 hours in patients with normal renal and hepatic function";"N06AF04";"Amine oxidase [flavin-containing] A";"MAOA";"yes";"inhibitor"
"Tranylcypromine";"NC1CC1C1=CC=CC=C1";"1.5-3.2 hours in patients with normal renal and hepatic function";"N06AF04";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"inhibitor"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"inhibitor"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"Glycine receptor subunit alpha-1";"GLRA1";"yes";"agonist"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"Glutamate receptor 1";"GRIA1";"yes";"antagonist"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"yes";"inducer"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"ATP synthase subunit delta, mitochondrial";"ATP5D";"unknown";"unknown"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"Calmodulin";"CALM1";"unknown";"other/unknown"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Isoflurane";"FC(F)OC(Cl)C(F)(F)F";"";"N01AB06";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Ethotoin";"CCN1C(=O)NC(C1=O)C1=CC=CC=C1";"3 to 9 hours";"N03AB01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Ethotoin";"CCN1C(=O)NC(C1=O)C1=CC=CC=C1";"3 to 9 hours";"N03AB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinal dehydrogenase 1";"ALDH1A1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid-induced protein 3";"GPRC5A";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid-induced protein 3";"GPRC5A";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid-induced protein 3";"GPRC5A";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinal dehydrogenase 2";"ALDH1A2";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid receptor responder protein 1";"RARRES1";"unknown";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid receptor responder protein 1";"RARRES1";"unknown";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid receptor responder protein 1";"RARRES1";"unknown";"agonist"
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid receptor alpha";"RARA";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid receptor alpha";"RARA";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid receptor alpha";"RARA";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid receptor beta";"RARB";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid receptor beta";"RARB";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid receptor beta";"RARB";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Lipocalin-1";"LCN1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Lipocalin-1";"LCN1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Lipocalin-1";"LCN1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Odorant-binding protein 2a";"OBP2A";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Odorant-binding protein 2a";"OBP2A";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Odorant-binding protein 2a";"OBP2A";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinol-binding protein 4";"RBP4";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinol-binding protein 4";"RBP4";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinol-binding protein 4";"RBP4";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial";"PDK4";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial";"PDK4";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial";"PDK4";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Cytochrome P450 26A1";"CYP26A1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Cytochrome P450 26A1";"CYP26A1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Cytochrome P450 26A1";"CYP26A1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Cytochrome P450 26B1";"CYP26B1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Cytochrome P450 26B1";"CYP26B1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Cytochrome P450 26B1";"CYP26B1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Cytochrome P450 26C1";"CYP26C1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Cytochrome P450 26C1";"CYP26C1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Cytochrome P450 26C1";"CYP26C1";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"L01XX14";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD01";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Tretinoin";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O";"0.5-2 hours";"D10AD51";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Hexachlorophene";"OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl";"";"D08AE01";"D-lactate dehydrogenase";"dld";"yes";"inhibitor"
"Hexachlorophene";"OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl";"";"D08AE01";"Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial";"SDHD";"yes";"inhibitor"
"Hexachlorophene";"OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl";"";"D08AE01";"Glutamate dehydrogenase 1, mitochondrial";"GLUD1";"unknown";"inhibitor"
"Hexachlorophene";"OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl";"";"D08AE01";"Estrogen receptor alpha";"ESR1";"unknown";""
"Dolasetron";"[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2";"8.1 hours";"A04AA04";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Clopidogrel";"[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl";"Carboxylic acid derivative: 8 hours (after single and multiple doses). Covalent binding to platelets has accounted for 2% of radiolabeled clopidogrel with a half-life of 11 days.";"B01AC04";"P2Y purinoceptor 12";"P2RY12";"yes";"antagonist"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"Major prion protein";"PRNP";"unknown";"inhibitor"
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"Multidrug translocase MdfA";"mdfA";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S02AA08";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD08";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01RA08";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A01AB13";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"D06AA04";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S03AA02";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA20";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"A02BD02";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"S01AA09";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Tetracycline";"[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O";"6-12 hours";"J01AA07";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Meropenem";"[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H]";"Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.";"J01DH02";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"yes";"inhibitor"
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA51";"Solute carrier family 12 member 2";"SLC12A2";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"B05XA01";"Solute carrier family 12 member 2";"SLC12A2";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA01";"Solute carrier family 12 member 2";"SLC12A2";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA51";"Solute carrier family 12 member 1";"SLC12A1";"unknown";"binder"
"Potassium Chloride";"[Cl-].[K+]";"";"B05XA01";"Solute carrier family 12 member 1";"SLC12A1";"unknown";"binder"
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA01";"Solute carrier family 12 member 1";"SLC12A1";"unknown";"binder"
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA51";"Solute carrier family 12 member 5";"SLC12A5";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"B05XA01";"Solute carrier family 12 member 5";"SLC12A5";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA01";"Solute carrier family 12 member 5";"SLC12A5";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA51";"Solute carrier family 12 member 6";"SLC12A6";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"B05XA01";"Solute carrier family 12 member 6";"SLC12A6";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA01";"Solute carrier family 12 member 6";"SLC12A6";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA51";"Solute carrier family 12 member 7";"SLC12A7";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"B05XA01";"Solute carrier family 12 member 7";"SLC12A7";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA01";"Solute carrier family 12 member 7";"SLC12A7";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA51";"Solute carrier family 12 member 4";"SLC12A4";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"B05XA01";"Solute carrier family 12 member 4";"SLC12A4";"unknown";""
"Potassium Chloride";"[Cl-].[K+]";"";"A12BA01";"Solute carrier family 12 member 4";"SLC12A4";"unknown";""
"Irinotecan";"CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=C1C=C(OC(=O)N1CCC(CC1)N1CCCCC1)C=C2";"The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours.";"L01XX19";"DNA topoisomerase 1";"TOP1";"yes";"inhibitor"
"Irinotecan";"CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=C1C=C(OC(=O)N1CCC(CC1)N1CCCCC1)C=C2";"The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours.";"L01XX19";"DNA topoisomerase I, mitochondrial";"TOP1MT";"yes";"inhibitor"
"Methimazole";"CN1C=CNC1=S";"5-6 hours";"H03BB02";"Thyroid peroxidase";"TPO";"yes";"inhibitor"
"Methimazole";"CN1C=CNC1=S";"5-6 hours";"H03BB52";"Thyroid peroxidase";"TPO";"yes";"inhibitor"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"R03BA07";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"R01AD09";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"D07XC03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"R03AK09";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"D07AC13";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"R03BA07";"Progesterone receptor";"PGR";"unknown";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"R01AD09";"Progesterone receptor";"PGR";"unknown";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"D07XC03";"Progesterone receptor";"PGR";"unknown";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"R03AK09";"Progesterone receptor";"PGR";"unknown";"agonist"
"Mometasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"5.8 hours";"D07AC13";"Progesterone receptor";"PGR";"unknown";"agonist"
"Metyrosine";"C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O";"3.4 to 3.7 hours";"C02KB01";"Tyrosine 3-monooxygenase";"TH";"yes";"binder"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"S01GX09";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"R01AC08";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"S01GX09";"Protein S100-A1";"S100A1";"unknown";"antagonist"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"R01AC08";"Protein S100-A1";"S100A1";"unknown";"antagonist"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"S01GX09";"Protein S100-A12";"S100A12";"unknown";"antagonist"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"R01AC08";"Protein S100-A12";"S100A12";"unknown";"antagonist"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"S01GX09";"Protein S100-B";"S100B";"unknown";"other/unknown"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"R01AC08";"Protein S100-B";"S100B";"unknown";"other/unknown"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"S01GX09";"Protein S100-A13";"S100A13";"unknown";"other/unknown"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"R01AC08";"Protein S100-A13";"S100A13";"unknown";"other/unknown"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"S01GX09";"Protein S100-A2";"S100A2";"unknown";"antagonist"
"Olopatadine";"CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2";"3 hours";"R01AC08";"Protein S100-A2";"S100A2";"unknown";"antagonist"
"Alprostadil";"CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O";"5 to 10 minutes (after a single dose), in healthy adults and neonates.";"C01EA01";"Prostaglandin E2 receptor EP2 subtype";"PTGER2";"yes";"agonist"
"Alprostadil";"CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O";"5 to 10 minutes (after a single dose), in healthy adults and neonates.";"G04BE01";"Prostaglandin E2 receptor EP2 subtype";"PTGER2";"yes";"agonist"
"Alprostadil";"CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O";"5 to 10 minutes (after a single dose), in healthy adults and neonates.";"C01EA01";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"yes";"agonist"
"Alprostadil";"CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O";"5 to 10 minutes (after a single dose), in healthy adults and neonates.";"G04BE01";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"yes";"agonist"
"Alprostadil";"CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O";"5 to 10 minutes (after a single dose), in healthy adults and neonates.";"C01EA01";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"agonist"
"Alprostadil";"CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O";"5 to 10 minutes (after a single dose), in healthy adults and neonates.";"G04BE01";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"agonist"
"Clidinium";"C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"";"A03CA02";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Malathion";"CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC";"8-24 hours";"P03AX03";"Cholinesterase";"BCHE";"yes";"inhibitor"
"Etoposide";"[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O";"4-11 hours";"L01CB01";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Etoposide";"[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O";"4-11 hours";"L01CB01";"DNA topoisomerase 2-beta";"TOP2B";"no";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"other/unknown"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"other/unknown"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"other/unknown"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"other/unknown"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AB02";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AA02";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"C03AH02";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydroflumethiazide";"NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F";"It appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours";"G01AE10";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Tirofiban";"CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O";"2 hours";"B01AC17";"Integrin alpha-IIb";"ITGA2B";"yes";"antagonist"
"Tirofiban";"CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O";"2 hours";"B01AC17";"Integrin beta-3";"ITGB3";"yes";"antagonist"
"Oxcarbazepine";"NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12";"The half-life of the parent is about 2 hours, while the half-life of MHD is about 9 hours, so that MHD is responsible for most anti-epileptic activity.";"N03AF02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Propiomazine";"CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1";"";"N05CM06";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Roxithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O";"12 hours";"J01FA06";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Roxithromycin";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O";"12 hours";"J01FA06";"Multidrug resistance protein 1";"ABCB1";"unknown";""
"Phenelzine";"NNCCC1=CC=CC=C1";"After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365]";"N06AF03";"Amine oxidase [flavin-containing] A";"MAOA";"yes";"antagonist"
"Phenelzine";"NNCCC1=CC=CC=C1";"After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365]";"N06AF03";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"antagonist"
"Phenelzine";"NNCCC1=CC=CC=C1";"After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365]";"N06AF03";"Membrane primary amine oxidase";"AOC3";"unknown";"inhibitor"
"Phenelzine";"NNCCC1=CC=CC=C1";"After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365]";"N06AF03";"4-aminobutyrate aminotransferase, mitochondrial";"ABAT";"unknown";"inhibitor"
"Phenelzine";"NNCCC1=CC=CC=C1";"After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365]";"N06AF03";"Alanine aminotransferase 1";"GPT";"unknown";"inhibitor"
"Phenelzine";"NNCCC1=CC=CC=C1";"After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365]";"N06AF03";"Alanine aminotransferase 2";"GPT2";"unknown";"inhibitor"
"Phenelzine";"NNCCC1=CC=CC=C1";"After administration phenelzine presents a very short half-life of 11.6 hours in humans.[L1365]";"N06AF03";"Glutamic acid decarboxylase";"GAD65";"unknown";"inhibitor"
"Propantheline";"CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C";"";"A03AB05";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Propantheline";"CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C";"";"A03CA34";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Nuclear receptor coactivator 2";"NCOA2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"G-protein coupled estrogen receptor 1";"GPER1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"ATP synthase subunit a";"MT-ATP6";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Beclin-1";"BECN1";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Estradiol 17-beta-dehydrogenase 2";"HSD17B2";"unknown";""
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB12";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA16";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA11";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA12";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA17";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB09";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA05";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA02";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA14";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA03";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AA14";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA08";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB01";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03AB08";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB07";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB04";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA53";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA07";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB05";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03HB01";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB11";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA06";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03EA01";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03CA03";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA15";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB10";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA13";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA09";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB02";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB03";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA02";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G02BB01";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA03";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA01";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB06";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA04";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FB08";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Estradiol";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 hours";"G03FA10";"Estrogen-related receptor gamma";"ESRRG";"unknown";"ligand"
"Mefenamic acid";"CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1";"2 hours";"M01AG01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Mefenamic acid";"CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1";"2 hours";"M01AG01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"S01AD03";"Thymidine kinase";"TK";"yes";"potentiator"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"D06BB03";"Thymidine kinase";"TK";"yes";"potentiator"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"J05AB01";"Thymidine kinase";"TK";"yes";"potentiator"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"D06BB53";"Thymidine kinase";"TK";"yes";"potentiator"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"S01AD03";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"D06BB03";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"J05AB01";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"D06BB53";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"S01AD03";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"D06BB03";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"J05AB01";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Aciclovir";"NC1=NC(=O)C2=C(N1)N(COCCO)C=N2";"2.5-3.3 hours";"D06BB53";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE52";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE02";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE56";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M02AA12";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"G02CC02";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE52";"Peptostreptococcal albumin-binding protein";"pab";"unknown";""
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE02";"Peptostreptococcal albumin-binding protein";"pab";"unknown";""
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE56";"Peptostreptococcal albumin-binding protein";"pab";"unknown";""
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M02AA12";"Peptostreptococcal albumin-binding protein";"pab";"unknown";""
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"G02CC02";"Peptostreptococcal albumin-binding protein";"pab";"unknown";""
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE52";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M01AE56";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"M02AA12";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Naproxen";"COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O";"The observed terminal elimination half-life is approximately 15 hours.";"G02CC02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09AA04";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C10BX11";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BX02";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BX01";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BB04";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BA04";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09AA04";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C10BX11";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BX02";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BX01";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BB04";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Perindopril";"[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O";"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.";"C09BA04";"Secreted frizzled-related protein 4";"SFRP4";"unknown";"inhibitor"
"Tripelennamine";"CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1";"";"D04AA04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Tripelennamine";"CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1";"";"R06AC04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N03AA03";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Primidone";"CCC1(C(=O)NCNC1=O)C1=CC=CC=C1";"3-23 hours";"N05CB01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Cystine/glutamate transporter";"SLC7A11";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Cystine/glutamate transporter";"SLC7A11";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Acetyl-CoA acetyltransferase, mitochondrial";"ACAT1";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Acetyl-CoA acetyltransferase, mitochondrial";"ACAT1";"unknown";"inhibitor"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Thromboxane-A synthase";"TBXAS1";"unknown";"antagonist"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Thromboxane-A synthase";"TBXAS1";"unknown";"antagonist"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"A07EC01";"Phospholipase A2";"PLA2G1B";"unknown";"antagonist"
"Sulfasalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1";"5-10 hours";"G01AE10";"Phospholipase A2";"PLA2G1B";"unknown";"antagonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"C04AB02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"M02AX02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"C04AB02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"M02AX02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"C04AB02";"Histamine H1 receptor";"HRH1";"unknown";"agonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"M02AX02";"Histamine H1 receptor";"HRH1";"unknown";"agonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"C04AB02";"Histamine H2 receptor";"HRH2";"unknown";"agonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"M02AX02";"Histamine H2 receptor";"HRH2";"unknown";"agonist"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"C04AB02";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"binder"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"M02AX02";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"binder"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"C04AB02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Tolazoline";"C(C1=NCCN1)C1=CC=CC=C1";"";"M02AX02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S02AA14";"30S ribosomal protein S12";"rpsL";"yes";"adduct"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"D06AX07";"30S ribosomal protein S12";"rpsL";"yes";"adduct"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S01AA11";"30S ribosomal protein S12";"rpsL";"yes";"adduct"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S03AA06";"30S ribosomal protein S12";"rpsL";"yes";"adduct"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"J01GB03";"30S ribosomal protein S12";"rpsL";"yes";"adduct"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S02AA14";"Low-density lipoprotein receptor-related protein 2";"LRP2";"no";"other/unknown"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"D06AX07";"Low-density lipoprotein receptor-related protein 2";"LRP2";"no";"other/unknown"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S01AA11";"Low-density lipoprotein receptor-related protein 2";"LRP2";"no";"other/unknown"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S03AA06";"Low-density lipoprotein receptor-related protein 2";"LRP2";"no";"other/unknown"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"J01GB03";"Low-density lipoprotein receptor-related protein 2";"LRP2";"no";"other/unknown"
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S02AA14";"NH(3)-dependent NAD(+) synthetase";"nadE";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"D06AX07";"NH(3)-dependent NAD(+) synthetase";"nadE";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S01AA11";"NH(3)-dependent NAD(+) synthetase";"nadE";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S03AA06";"NH(3)-dependent NAD(+) synthetase";"nadE";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"J01GB03";"NH(3)-dependent NAD(+) synthetase";"nadE";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S02AA14";"Dihydrofolate reductase";"DHFR";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"D06AX07";"Dihydrofolate reductase";"DHFR";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S01AA11";"Dihydrofolate reductase";"DHFR";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"S03AA06";"Dihydrofolate reductase";"DHFR";"unknown";""
"Gentamicin";"CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1";"3-3&frac12; hours in infants one week to six months of age; this increases to 5&frac12; hours in full-term and large premature infants less than one week old.";"J01GB03";"Dihydrofolate reductase";"DHFR";"unknown";""
"Tazarotene";"CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1";"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.";"D05AX05";"Retinoic acid receptor alpha";"RARA";"yes";"agonist"
"Tazarotene";"CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1";"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.";"D05AX05";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Tazarotene";"CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1";"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.";"D05AX05";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Tazarotene";"CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1";"The half-life of the active form of the drug, tazarotenic acid, is approximately 18 hours in normal and psoriatic patients.";"D05AX05";"Retinoic acid receptor beta";"RARB";"yes";"agonist"
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"D(1B) dopamine receptor";"DRD5";"yes";"agonist"
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"D(1A) dopamine receptor";"DRD1";"yes";"agonist"
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";""
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";""
"Fenoldopam";"OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12";"The elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.";"C01CA19";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Halazepam";"FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"";"N05BA13";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Alfentanil";"CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O";"90-111 minutes";"N01AH02";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Dicyclomine";"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1";"";"A03AA07";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Dicyclomine";"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1";"";"A03AA07";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"Amine oxidase [flavin-containing] A";"MAOA";"yes";"inhibitor"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"antagonist"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Minaprine";"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1";"";"N06AX07";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"agonist"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"C04AD03";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"R03DA20";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"C04AD03";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"R03DA20";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"C04AD03";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"C04AD03";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"R03DA20";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"C04AD03";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"R03DA20";"5'-nucleotidase";"NT5E";"unknown";"inhibitor"
"Pentoxifylline";"CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"0.4-0.8 hours";"C04AD03";"5'-nucleotidase";"NT5E";"unknown";"inhibitor"
"Proparacaine";"CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC";"";"S01HA04";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Indapamide";"CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O";"14 hours (biphasic)";"C09BX01";"Potassium voltage-gated channel subfamily KQT member 1";"KCNQ1";"yes";"inhibitor"
"Indapamide";"CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O";"14 hours (biphasic)";"C03BA11";"Potassium voltage-gated channel subfamily KQT member 1";"KCNQ1";"yes";"inhibitor"
"Indapamide";"CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O";"14 hours (biphasic)";"G01AE10";"Potassium voltage-gated channel subfamily KQT member 1";"KCNQ1";"yes";"inhibitor"
"Indapamide";"CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O";"14 hours (biphasic)";"C09BX01";"Potassium voltage-gated channel subfamily E member 1";"KCNE1";"yes";"inhibitor"
"Indapamide";"CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O";"14 hours (biphasic)";"C03BA11";"Potassium voltage-gated channel subfamily E member 1";"KCNE1";"yes";"inhibitor"
"Indapamide";"CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O";"14 hours (biphasic)";"G01AE10";"Potassium voltage-gated channel subfamily E member 1";"KCNE1";"yes";"inhibitor"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA06";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA56";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA06";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA56";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA06";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA56";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA06";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Tropicamide";"CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1";"";"S01FA56";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Biperiden";"OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1";"";"N04AA02";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Biperiden";"OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1";"";"N04AA02";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"Inosine-5'-monophosphate dehydrogenase 1";"IMPDH1";"yes";"inhibitor"
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"Adenosine kinase";"ADK";"yes";"activator"
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"Inosine-5'-monophosphate dehydrogenase 2";"IMPDH2";"unknown";""
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"RNA-directed RNA polymerase L";"L";"yes";"antagonist"
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"RNA-directed RNA polymerase catalytic subunit";"PB1";"unknown";"inhibitor"
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"Cytosolic purine 5'-nucleotidase";"NT5C2";"unknown";"inducer"
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"Ectonucleotide pyrophosphatase/phosphodiesterase family member 1";"ENPP1";"unknown";"inhibitor"
"Ribavirin";"NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"The terminal half-life of ribavirin following administration of a single oral dose of 1200 mg is about 120 to 170 hours [FDA Label].";"J05AB04";"Genome polyprotein";"";"unknown";""
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M01AA01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M01BA01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M02AA01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M01AA01";"Prostacyclin synthase";"PTGIS";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M01BA01";"Prostacyclin synthase";"PTGIS";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M02AA01";"Prostacyclin synthase";"PTGIS";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M01AA01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M01BA01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Phenylbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1";"";"M02AA01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N01AH51";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N01AH01";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N02AB03";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N01AH51";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N01AH01";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N02AB03";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N01AH51";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N01AH01";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Fentanyl";"CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1";"7  hours (range 3-12)";"N02AB03";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Meloxicam";"CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"15-20 hours";"M01AC56";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Meloxicam";"CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"15-20 hours";"M01AC06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Meloxicam";"CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"15-20 hours";"M01AC56";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Meloxicam";"CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O";"15-20 hours";"M01AC06";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Orciprenaline";"CC(C)NCC(O)C1=CC(O)=CC(O)=C1";"6 hours";"R03CB53";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Orciprenaline";"CC(C)NCC(O)C1=CC(O)=CC(O)=C1";"6 hours";"R03AB03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Orciprenaline";"CC(C)NCC(O)C1=CC(O)=CC(O)=C1";"6 hours";"R03CB03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Rosoxacin";"CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1";"";"J01MB01";"DNA gyrase subunit B";"gyrB";"yes";"inhibitor"
"Rosoxacin";"CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1";"";"J01MB01";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"Sodium channel protein type 4 subunit alpha";"SCN4A";"unknown";"inhibitor"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"Sodium channel protein type 2 subunit alpha";"SCN2A";"unknown";"inhibitor"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Propofol";"CC(C)C1=CC=CC(C(C)C)=C1O";"Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.";"N01AX10";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Carbonic anhydrase 12";"CA12";"yes";"inhibitor"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Carbonic anhydrase 14";"CA14";"yes";"inhibitor"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Carbonic anhydrase 3";"CA3";"yes";"inhibitor"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Carbonic anhydrase 7";"CA7";"yes";"inhibitor"
"Acetazolamide";"CC(=O)NC1=NN=C(S1)S(N)(=O)=O";"3 to 9 hours";"S01EC01";"Aquaporin-1";"AQP1";"unknown";"inhibitor"
"Tadalafil";"[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1";"17.5 hours";"G04BE08";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Tadalafil";"[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1";"17.5 hours";"G04BE08";"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A";"PDE11A";"unknown";"inhibitor"
"Disulfiram";"CCN(CC)C(=S)SSC(=S)N(CC)CC";"";"P03AA54";"Aldehyde dehydrogenase, mitochondrial";"ALDH2";"yes";"inhibitor"
"Disulfiram";"CCN(CC)C(=S)SSC(=S)N(CC)CC";"";"N07BB01";"Aldehyde dehydrogenase, mitochondrial";"ALDH2";"yes";"inhibitor"
"Disulfiram";"CCN(CC)C(=S)SSC(=S)N(CC)CC";"";"P03AA04";"Aldehyde dehydrogenase, mitochondrial";"ALDH2";"yes";"inhibitor"
"Disulfiram";"CCN(CC)C(=S)SSC(=S)N(CC)CC";"";"P03AA54";"Dopamine beta-hydroxylase";"DBH";"yes";"inhibitor"
"Disulfiram";"CCN(CC)C(=S)SSC(=S)N(CC)CC";"";"N07BB01";"Dopamine beta-hydroxylase";"DBH";"yes";"inhibitor"
"Disulfiram";"CCN(CC)C(=S)SSC(=S)N(CC)CC";"";"P03AA04";"Dopamine beta-hydroxylase";"DBH";"yes";"inhibitor"
"Cinoxacin";"CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12";"The mean serum half-life is 1.5 hours. Half-life in patients with impaired renal function may exceed 10 hours.";"J01MB06";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Fosfomycin";"C[C@@H]1O[C@@H]1P(O)(O)=O";"5.7 (&plusmn; 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis.";"J01XX01";"UDP-N-acetylglucosamine 1-carboxyvinyltransferase";"murA";"yes";"inhibitor"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"Translocator protein";"TSPO";"unknown";"potentiator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Diazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1";"Biphasic 1-2 days and 2-5 days, active metabolites with long half lives.";"N05BA01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Trifluoperazine";"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"10-20 hours";"N05AB06";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Trifluoperazine";"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"10-20 hours";"N05AB06";"Neuron-specific vesicular protein calcyon";"CALY";"yes";"antagonist"
"Trifluoperazine";"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"10-20 hours";"N05AB06";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Trifluoperazine";"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"10-20 hours";"N05AB06";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Trifluoperazine";"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"10-20 hours";"N05AB06";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"unknown";""
"Trifluoperazine";"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1";"10-20 hours";"N05AB06";"Protein S100-A4";"S100A4";"unknown";"inhibitor"
"Cefaclor";"[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"0.6-0.9 hour";"J01DC04";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Cefaclor";"[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O";"0.6-0.9 hour";"J01DC04";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB01";"Progesterone receptor";"PGR";"yes";"antagonist"
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB51";"Progesterone receptor";"PGR";"yes";"antagonist"
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB01";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB51";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB01";"Prostate-specific antigen";"KLK3";"unknown";""
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB51";"Prostate-specific antigen";"KLK3";"unknown";""
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Mifepristone";"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]";"18 hours";"G03XB51";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB51";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB51";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB01";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB51";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB51";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB51";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB51";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Brompheniramine";"CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1";"";"R06AB01";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA03";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA53";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA05";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA03";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA53";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA05";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA03";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA53";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA05";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA03";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"unknown";"inhibitor"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA53";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"unknown";"inhibitor"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA05";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"unknown";"inhibitor"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA03";"Pro-opiomelanocortin";"POMC";"unknown";"modulator"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA53";"Pro-opiomelanocortin";"POMC";"unknown";"modulator"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA05";"Pro-opiomelanocortin";"POMC";"unknown";"modulator"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA03";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA53";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA05";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA03";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA53";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Loperamide";"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1";"9.1 to 14.4 hours (average 10.8 hours)";"A07DA05";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Progabide";"OC(=N)CCC\N=C(\C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1";"4 hours";"N03AG05";"Gamma-aminobutyric acid type B receptor subunit 1";"GABBR1";"yes";"agonist"
"Progabide";"OC(=N)CCC\N=C(\C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1";"4 hours";"N03AG05";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Clocortolone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07AB21";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Tolazamide";"CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1";"The average biological half-life of the drug is 7 hours.";"A10BB05";"Sulfonylurea receptor 1, Kir6.2";"ABCC8";"yes";"blocker"
"Tolazamide";"CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1";"The average biological half-life of the drug is 7 hours.";"A10BB05";"Sulfonylurea receptor 1, Kir6.2";"KCNJ11";"yes";"blocker"
"Dobutamine";"CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Dobutamine";"CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA07";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"agonist"
"Dobutamine";"CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA07";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";""
"Dobutamine";"CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA07";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";""
"Dobutamine";"CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA07";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";""
"Dobutamine";"CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA07";"Estrogen receptor alpha";"ESR1";"unknown";""
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Oxazepam";"OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2";"Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)";"N05BA04";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Donepezil";"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1";"70 hours";"N06DA02";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Donepezil";"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1";"70 hours";"N06DA53";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Donepezil";"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1";"70 hours";"N06DA52";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Donepezil";"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1";"70 hours";"N06DA02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"other/unknown"
"Donepezil";"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1";"70 hours";"N06DA53";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"other/unknown"
"Donepezil";"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1";"70 hours";"N06DA52";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"other/unknown"
"Nalbuphine";"O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5";"The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.";"N02AF02";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Nalbuphine";"O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5";"The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.";"N02AF02";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Nalbuphine";"O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5";"The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.";"N02AF02";"Delta-type opioid receptor";"OPRD1";"yes";"antagonist"
"Clofazimine";"CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1";"10 days following a single dose, 70 days after long-term, high-dose therapy.";"J04BA01";"Uncharacterized oxidoreductase CzcO-like";"";"yes";"inhibitor"
"Clofazimine";"CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1";"10 days following a single dose, 70 days after long-term, high-dose therapy.";"J04BA01";"Bile salt export pump";"ABCB11";"unknown";""
"Flurandrenolide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)CC[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"";"D07AC07";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Flurandrenolide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)CC[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"";"D07CC03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Cysteamine";"NCCS";"";"S01XA21";"Somatostatin";"SST";"unknown";"binder"
"Cysteamine";"NCCS";"";"A16AA04";"Somatostatin";"SST";"unknown";"binder"
"Cysteamine";"NCCS";"";"S01XA21";"Neuropeptide Y receptor type 2";"NPY2R";"unknown";"other/unknown"
"Cysteamine";"NCCS";"";"A16AA04";"Neuropeptide Y receptor type 2";"NPY2R";"unknown";"other/unknown"
"Levamisole";"C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1";"4.4-5.6 hours (biphasic)";"P02CE01";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"yes";"agonist"
"Levamisole";"C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1";"4.4-5.6 hours (biphasic)";"P02CE01";"Alkaline phosphatase, placental-like";"ALPPL2";"unknown";"inhibitor"
"Levamisole";"C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1";"4.4-5.6 hours (biphasic)";"P02CE01";"Acetylcholine receptor subunit alpha-type unc-38";"unc-38";"unknown";"activator"
"Levamisole";"C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1";"4.4-5.6 hours (biphasic)";"P02CE01";"Acetylcholine receptor subunit alpha-type unc-63";"unc-63";"unknown";"activator"
"Levamisole";"C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1";"4.4-5.6 hours (biphasic)";"P02CE01";"Acetylcholine receptor subunit beta-type lev-1";"lev-1";"unknown";"activator"
"Levamisole";"C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1";"4.4-5.6 hours (biphasic)";"P02CE01";"Acetylcholine receptor subunit beta-type unc-29";"unc-29";"unknown";"activator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N03AA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Methylphenobarbital";"CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1";"34 (range 11-67) hours";"N05CB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Perphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"8-12 hours, but ranges up to 20 hours.";"N05AB03";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Perphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"8-12 hours, but ranges up to 20 hours.";"N05AB03";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Perphenazine";"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"8-12 hours, but ranges up to 20 hours.";"N05AB03";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Dacarbazine";"CN(C)\N=N\C1=C(N=CN1)C(N)=O";"5 hours";"L01AX04";"DNA polymerase alpha subunit B";"POLA2";"unknown";"other/unknown"
"Dacarbazine";"CN(C)\N=N\C1=C(N=CN1)C(N)=O";"5 hours";"L01AX04";"6-phosphogluconate dehydrogenase, decarboxylating";"PGD";"unknown";"inhibitor"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"partial agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"partial agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonistpartial agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonistpartial agonist"
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Nuclear factor of activated T-cells, cytoplasmic 1";"NFATC1";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Nuclear factor of activated T-cells, cytoplasmic 1";"NFATC1";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Tumor necrosis factor";"TNF";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Tumor necrosis factor";"TNF";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"ATF1";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"ATF1";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"ATF2";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"ATF2";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"ATF3";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"ATF3";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"ATF4";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"ATF4";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"ATF5";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"ATF5";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"ATF6";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"ATF6";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"ATF7";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"ATF7";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"JDP2";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"JDP2";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"FOS";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"FOS";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"activator protein 1";"JUN";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"activator protein 1";"JUN";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA02";"Interleukin-2";"IL2";"unknown";""
"Pseudoephedrine";"CN[C@@H](C)[C@@H](O)C1=CC=CC=C1";"9-16 hours";"R01BA52";"Interleukin-2";"IL2";"unknown";""
"Aminolevulinic acid";"NCC(=O)CCC(O)=O";"Mean half-life is 0.70 &plusmn; 0.18 h after the oral dose and 0.83 &plusmn; 0.05 h after the intravenous dose.";"L01XD04";"Delta-aminolevulinic acid dehydratase";"ALAD";"yes";"inducer"
"Terbinafine";"CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12";"36 hours";"D01BA02";"Squalene monooxygenase";"SQLE";"yes";"inhibitor"
"Terbinafine";"CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12";"36 hours";"D01AE15";"Squalene monooxygenase";"SQLE";"yes";"inhibitor"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"R01AD52";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"D07AA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S02BA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"D07XA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"D07CA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S01CB02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S01CA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"C05AA04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"V03AB05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"A07EA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S02CA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S03BA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"A01AC54";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"R01AD02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S03CA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"D07BA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"H02AB06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S01BA04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Prednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"2-3 hours";"S01BB02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Diflunisal";"OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1";"8 to 12 hours";"N02BA11";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Diflunisal";"OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1";"8 to 12 hours";"N02BA11";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Vardenafil";"CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1";"4-5 hours";"G04BE09";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Vardenafil";"CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1";"4-5 hours";"G04BE09";"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma";"PDE6G";"unknown";"allosteric modulator"
"Vardenafil";"CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1";"4-5 hours";"G04BE09";"Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma";"PDE6H";"unknown";"allosteric modulator"
"Ranitidine";"CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O";"2.8-3.1 hours";"A02BA07";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Ranitidine";"CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O";"2.8-3.1 hours";"A02BA02";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Ranitidine";"CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O";"2.8-3.1 hours";"A02BA07";"Acetylcholinesterase";"ACHE";"unknown";""
"Ranitidine";"CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O";"2.8-3.1 hours";"A02BA02";"Acetylcholinesterase";"ACHE";"unknown";""
"Ranitidine";"CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O";"2.8-3.1 hours";"A02BA07";"Cholinesterase";"BCHE";"unknown";""
"Ranitidine";"CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O";"2.8-3.1 hours";"A02BA02";"Cholinesterase";"BCHE";"unknown";""
"Tacrolimus";"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC";"The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5±3.8 hours, in pediatric kidney transplant patients was 10.2±5.0 (range 3.4-25) hours.";"D11AH01";"Peptidyl-prolyl cis-trans isomerase FKBP1A";"FKBP1A";"yes";"inhibitor"
"Tacrolimus";"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC";"The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5±3.8 hours, in pediatric kidney transplant patients was 10.2±5.0 (range 3.4-25) hours.";"L04AD02";"Peptidyl-prolyl cis-trans isomerase FKBP1A";"FKBP1A";"yes";"inhibitor"
"Alprenolol";"CC(C)NCC(O)COC1=CC=CC=C1CC=C";"2-3 hours";"C07AA01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Alprenolol";"CC(C)NCC(O)COC1=CC=CC=C1CC=C";"2-3 hours";"C07AA01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Alprenolol";"CC(C)NCC(O)COC1=CC=CC=C1CC=C";"2-3 hours";"C07AA01";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Alprenolol";"CC(C)NCC(O)COC1=CC=CC=C1CC=C";"2-3 hours";"C07AA01";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"antagonist"
"Ritodrine";"C[C@H](NCCC1=CC=C(O)C=C1)[C@H](O)C1=CC=C(O)C=C1";"1.7-2.6 hours";"G02CA01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Benzonatate";"CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC";"3-8 hours";"R05DB01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"unknown";"antagonist"
"Dorzolamide";"CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"4 months";"S01EC03";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Dorzolamide";"CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"4 months";"S01EC03";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Dorzolamide";"CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"4 months";"S01EC03";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Dorzolamide";"CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"4 months";"S01EC03";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Suprofen";"CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1";"";"M01AE07";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Suprofen";"CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1";"";"M01AE07";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03CC53";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03AC03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03CC03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03CC53";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03AC03";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03CC03";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03CC53";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"antagonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03AC03";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"antagonist"
"Terbutaline";"CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1";"5.5-5.9 hours";"R03CC03";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"antagonist"
"Conivaptan";"CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1";"5 hours";"C03XA02";"Vasopressin V1a receptor";"AVPR1A";"yes";"antagonist"
"Conivaptan";"CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1";"5 hours";"C03XA02";"Vasopressin V2 receptor";"AVPR2";"yes";"antagonist"
"Loteprednol";"[H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"";"S01BA14";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Flupentixol";"[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"19 to 39 hours";"N05AF01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Flupentixol";"[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"19 to 39 hours";"N05AF01";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Flupentixol";"[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"19 to 39 hours";"N05AF01";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Flupentixol";"[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"19 to 39 hours";"N05AF01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Flupentixol";"[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F";"19 to 39 hours";"N05AF01";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Eprosartan";"CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O";"The terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.";"C09CA02";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Eprosartan";"CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O";"The terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.";"C09DA02";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Sirolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC";"57-63 hours";"S01XA23";"Serine/threonine-protein kinase mTOR";"MTOR";"yes";"inhibitor"
"Sirolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC";"57-63 hours";"L04AA10";"Serine/threonine-protein kinase mTOR";"MTOR";"yes";"inhibitor"
"Sirolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC";"57-63 hours";"S01XA23";"Peptidyl-prolyl cis-trans isomerase FKBP1A";"FKBP1A";"yes";"other"
"Sirolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC";"57-63 hours";"L04AA10";"Peptidyl-prolyl cis-trans isomerase FKBP1A";"FKBP1A";"yes";"other"
"Sirolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC";"57-63 hours";"S01XA23";"Fibroblast growth factor 2";"FGF2";"yes";"other/unknown"
"Sirolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC";"57-63 hours";"L04AA10";"Fibroblast growth factor 2";"FGF2";"yes";"other/unknown"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AR19";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AR03";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AR18";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AR17";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AR06";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AR09";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AR08";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Emtricitabine";"NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1";"10 hours";"J05AF09";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AB04";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AA04";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AH01";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"G01AE10";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AB04";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AA04";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AH01";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"G01AE10";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AB04";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AA04";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AH01";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"G01AE10";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AB04";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AA04";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"C03AH01";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Chlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1";"45-120 minutes";"G01AE10";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Quinapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O";"Elimination half life is 2 hours with a prolonged terminal phase of 25 hours.";"C09AA06";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Quinapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O";"Elimination half life is 2 hours with a prolonged terminal phase of 25 hours.";"C09BA06";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Clomifene";"CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1";"5-7 days";"G03GB02";"Estrogen receptor alpha";"ESR1";"yes";"antagonistagonist"
"Clomifene";"CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1";"5-7 days";"G03GB02";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Isosorbide Dinitrate";"[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O";"1 hour";"C05AE02";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Isosorbide Dinitrate";"[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O";"1 hour";"C01DA58";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Isosorbide Dinitrate";"[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O";"1 hour";"C01DA08";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Risedronate";"OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O";"1.5 hours";"M05BB02";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Risedronate";"OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O";"1.5 hours";"M05BA07";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Risedronate";"OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O";"1.5 hours";"M05BB04";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Risedronate";"OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O";"1.5 hours";"M05BB07";"Farnesyl pyrophosphate synthase";"FDPS";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03EB02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CB02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CA02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"G01AE10";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03EB02";"Solute carrier family 12 member 2";"SLC12A2";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CB02";"Solute carrier family 12 member 2";"SLC12A2";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CA02";"Solute carrier family 12 member 2";"SLC12A2";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"G01AE10";"Solute carrier family 12 member 2";"SLC12A2";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03EB02";"Solute carrier family 12 member 4";"SLC12A4";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CB02";"Solute carrier family 12 member 4";"SLC12A4";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CA02";"Solute carrier family 12 member 4";"SLC12A4";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"G01AE10";"Solute carrier family 12 member 4";"SLC12A4";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03EB02";"Solute carrier family 12 member 5";"SLC12A5";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CB02";"Solute carrier family 12 member 5";"SLC12A5";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CA02";"Solute carrier family 12 member 5";"SLC12A5";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"G01AE10";"Solute carrier family 12 member 5";"SLC12A5";"yes";"inhibitor"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03EB02";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"antagonist"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CB02";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"antagonist"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"C03CA02";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"antagonist"
"Bumetanide";"CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O";"60-90 minutes";"G01AE10";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"antagonist"
"Granisetron";"CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2";"4-6 hours in healthy patients, 9-12 hours in cancer patients";"A04AA02";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Dienestrol";"CC=C(C(=CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Dienestrol";"CC=C(C(=CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Dienestrol";"CC=C(C(=CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CB01";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Dienestrol";"CC=C(C(=CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1";"";"G03CC02";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Sulfapyridine";"NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1";"6-14 hours.";"J01EB04";"Dihydropteroate synthase type-1";"sulI";"unknown";"inhibitor"
"Sulfapyridine";"NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1";"6-14 hours.";"G01AE10";"Dihydropteroate synthase type-1";"sulI";"unknown";"inhibitor"
"Oxybuprocaine";"CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC";"";"S01HA02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Oxybuprocaine";"CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC";"";"D04AB03";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Rimexolone";"[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).";"H02AB12";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Rimexolone";"[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).";"S01BA13";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"Translocator protein";"TSPO";"unknown";"other"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Triazolam";"CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12";"1.5-5.5 hours";"N05CD05";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Ethanol";"CCO";"";"V03AB16";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Ethanol";"CCO";"";"D08AX08";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Ethanol";"CCO";"";"V03AZ01";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Ethanol";"CCO";"";"V03AB16";"Glycine receptor subunit alpha-1";"GLRA1";"yes";"agonist"
"Ethanol";"CCO";"";"D08AX08";"Glycine receptor subunit alpha-1";"GLRA1";"yes";"agonist"
"Ethanol";"CCO";"";"V03AZ01";"Glycine receptor subunit alpha-1";"GLRA1";"yes";"agonist"
"Ethanol";"CCO";"";"V03AB16";"Glycine receptor subunit alpha-2";"GLRA2";"yes";"agonist"
"Ethanol";"CCO";"";"D08AX08";"Glycine receptor subunit alpha-2";"GLRA2";"yes";"agonist"
"Ethanol";"CCO";"";"V03AZ01";"Glycine receptor subunit alpha-2";"GLRA2";"yes";"agonist"
"Ethanol";"CCO";"";"V03AB16";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Glutamate receptor 1";"GRIA1";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Glutamate receptor 1";"GRIA1";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Glutamate receptor 1";"GRIA1";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Glutamate receptor 2";"GRIA2";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Glutamate receptor 2";"GRIA2";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Glutamate receptor 2";"GRIA2";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Glutamate receptor 4";"GRIA4";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Glutamate receptor 4";"GRIA4";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Glutamate receptor 4";"GRIA4";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Glutamate receptor 3";"GRIA3";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Glutamate receptor 3";"GRIA3";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Glutamate receptor 3";"GRIA3";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"G protein-activated inward rectifier potassium channel 1";"KCNJ3";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"G protein-activated inward rectifier potassium channel 1";"KCNJ3";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"G protein-activated inward rectifier potassium channel 1";"KCNJ3";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"G protein-activated inward rectifier potassium channel 2";"KCNJ6";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"G protein-activated inward rectifier potassium channel 2";"KCNJ6";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"G protein-activated inward rectifier potassium channel 2";"KCNJ6";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Vascular cell adhesion protein 1";"VCAM1";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Vascular cell adhesion protein 1";"VCAM1";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Vascular cell adhesion protein 1";"VCAM1";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Equilibrative nucleoside transporter 1";"SLC29A1";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Equilibrative nucleoside transporter 1";"SLC29A1";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Equilibrative nucleoside transporter 1";"SLC29A1";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"G protein-activated inward rectifier potassium channel 4";"KCNJ5";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"G protein-activated inward rectifier potassium channel 4";"KCNJ5";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"G protein-activated inward rectifier potassium channel 4";"KCNJ5";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-9";"CHRNA9";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-9";"CHRNA9";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-9";"CHRNA9";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-5";"CHRNA5";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-5";"CHRNA5";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-5";"CHRNA5";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit alpha-6";"CHRNA6";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit alpha-6";"CHRNA6";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit alpha-6";"CHRNA6";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neuronal acetylcholine receptor subunit beta-3";"CHRNB3";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neuronal acetylcholine receptor subunit beta-3";"CHRNB3";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neuronal acetylcholine receptor subunit beta-3";"CHRNB3";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Equilibrative nucleoside transporter 2";"SLC29A2";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Equilibrative nucleoside transporter 2";"SLC29A2";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Equilibrative nucleoside transporter 2";"SLC29A2";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"5-hydroxytryptamine receptor 3E";"HTR3E";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"5-hydroxytryptamine receptor 3E";"HTR3E";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"5-hydroxytryptamine receptor 3E";"HTR3E";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"5-hydroxytryptamine receptor 3B";"HTR3B";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"5-hydroxytryptamine receptor 3B";"HTR3B";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"5-hydroxytryptamine receptor 3B";"HTR3B";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"5-hydroxytryptamine receptor 3D";"HTR3D";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"5-hydroxytryptamine receptor 3D";"HTR3D";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"5-hydroxytryptamine receptor 3D";"HTR3D";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"5-hydroxytryptamine receptor 3C";"HTR3C";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"5-hydroxytryptamine receptor 3C";"HTR3C";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"5-hydroxytryptamine receptor 3C";"HTR3C";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Voltage-dependent calcium channel gamma-2 subunit";"CACNG2";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Voltage-dependent calcium channel gamma-2 subunit";"CACNG2";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Voltage-dependent calcium channel gamma-2 subunit";"CACNG2";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"G protein-activated inward rectifier potassium channel 3";"KCNJ9";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"G protein-activated inward rectifier potassium channel 3";"KCNJ9";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"G protein-activated inward rectifier potassium channel 3";"KCNJ9";"unknown";""
"Ethanol";"CCO";"";"V03AB16";"Neural cell adhesion molecule L1";"L1CAM";"unknown";""
"Ethanol";"CCO";"";"D08AX08";"Neural cell adhesion molecule L1";"L1CAM";"unknown";""
"Ethanol";"CCO";"";"V03AZ01";"Neural cell adhesion molecule L1";"L1CAM";"unknown";""
"Remifentanil";"CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC";"1-20 minutes";"N01AH06";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Remifentanil";"CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC";"1-20 minutes";"N01AH06";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Remifentanil";"CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC";"1-20 minutes";"N01AH06";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Didanosine";"OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O";"30 minutes in plasma and more than 12 hours in intracellular environment.";"J05AF02";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Didanosine";"OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O";"30 minutes in plasma and more than 12 hours in intracellular environment.";"J05AF02";"Purine nucleoside phosphorylase";"PNP";"unknown";""
"Bitolterol";"CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C";"";"R03AC17";"Beta-2 adrenergic receptor";"ADRB2";"yes";""
"Methdilazine";"CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1";"";"R06AD04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Etacrynic acid";"CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1";"";"C03CC01";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Etacrynic acid";"CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1";"";"C03CC01";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Etacrynic acid";"CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1";"";"C03CC01";"Lymphoid enhancer-binding factor 1";"LEF1";"unknown";""
"Etacrynic acid";"CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1";"";"C03CC01";"Glutathione S-transferase P";"GSTP1";"unknown";"inhibitor"
"Ondansetron";"CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2";"5.7 hours";"A04AA01";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Ondansetron";"CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2";"5.7 hours";"A04AA01";"5-hydroxytryptamine receptor 4";"HTR4";"unknown";"agonist"
"Ondansetron";"CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2";"5.7 hours";"A04AA01";"Mu-type opioid receptor";"OPRM1";"unknown";"other/unknown"
"Ondansetron";"CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2";"5.7 hours";"A04AA01";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"other/unknown"
"Ondansetron";"CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2";"5.7 hours";"A04AA01";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"other/unknown"
"Bimatoprost";"CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1";"Elimination half-life is approximately 45 minutes.";"S01EE03";"Prostaglandin F2-alpha receptor";"PTGFR";"yes";"agonist"
"Bimatoprost";"CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1";"Elimination half-life is approximately 45 minutes.";"S01EE03";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"yes";"agonist"
"Bimatoprost";"CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1";"Elimination half-life is approximately 45 minutes.";"S01EE03";"Prostaglandin E2 receptor EP3 subtype";"PTGER3";"yes";"agonist"
"Bimatoprost";"CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1";"Elimination half-life is approximately 45 minutes.";"S01EE03";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";""
"Tiagabine";"CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1";"7-9 hours";"N03AG06";"Sodium- and chloride-dependent GABA transporter 1";"SLC6A1";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Sodium channel protein type 11 subunit alpha";"SCN11A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Sodium channel protein type 11 subunit alpha";"SCN11A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Sodium channel protein type 11 subunit alpha";"SCN11A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Sodium channel protein type 11 subunit alpha";"SCN11A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";"inhibitor"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";""
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";""
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";""
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";""
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"N01BC01";"Liver carboxylesterase 1";"CES1";"unknown";""
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S01HA01";"Liver carboxylesterase 1";"CES1";"unknown";""
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"R02AD03";"Liver carboxylesterase 1";"CES1";"unknown";""
"Cocaine";"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C";"1 hour";"S02DA02";"Liver carboxylesterase 1";"CES1";"unknown";""
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA01";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA51";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA71";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA01";"Potassium channel subfamily K member 1";"KCNK1";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA51";"Potassium channel subfamily K member 1";"KCNK1";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA71";"Potassium channel subfamily K member 1";"KCNK1";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA01";"Potassium channel subfamily K member 6";"KCNK6";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA51";"Potassium channel subfamily K member 6";"KCNK6";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA71";"Potassium channel subfamily K member 6";"KCNK6";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA51";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA71";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA01";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA51";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA71";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA51";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA71";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA51";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Quinidine";"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1";"6-8 hours";"C01BA71";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel protein type 2 subunit alpha";"SCN2A";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel protein type 3 subunit alpha";"SCN3A";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel protein type 9 subunit alpha";"SCN9A";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel protein type 11 subunit alpha";"SCN11A";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel subunit beta-1";"SCN1B";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel subunit beta-2";"SCN2B";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel subunit beta-3";"SCN3B";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Sodium channel subunit beta-4";"SCN4B";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"yes";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 5A, mitochondrial";"CA5A";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 5B, mitochondrial";"CA5B";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 6";"CA6";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 7";"CA7";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase-related protein";"CA8";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase-related protein 10";"CA10";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase-related protein 11";"CA11";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 13";"CA13";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Carbonic anhydrase 14";"CA14";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";"inhibitor"
"Zonisamide";"NS(=O)(=O)CC1=NOC2=CC=CC=C12";"63 hours";"N03AX15";"Amine oxidase [flavin-containing] A";"MAOA";"unknown";"inhibitor"
"Paricalcitol";"[H]C1CC[C@]2(C)[C@]([H])(CC[C@@]2([H])\C1=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(O)(C)C";"4 to 6 hours";"H05BX02";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Repaglinide";"CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O";"1 hour";"A10BD14";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Repaglinide";"CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O";"1 hour";"A10BX02";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Repaglinide";"CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O";"1 hour";"A10BD14";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"agonist"
"Repaglinide";"CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O";"1 hour";"A10BX02";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"agonist"
"Anileridine";"CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1";"";"N01AH05";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Phenformin";"NC(=N)NC(=N)NCCC1=CC=CC=C1";"";"A10BA01";"5'-AMP-activated protein kinase catalytic subunit alpha-1";"PRKAA1";"yes";"activator"
"Phenformin";"NC(=N)NC(=N)NCCC1=CC=CC=C1";"";"A10BD01";"5'-AMP-activated protein kinase catalytic subunit alpha-1";"PRKAA1";"yes";"activator"
"Phenformin";"NC(=N)NC(=N)NCCC1=CC=CC=C1";"";"A10BA01";"ATP-sensitive inward rectifier potassium channel 8";"KCNJ8";"unknown";"inhibitor"
"Phenformin";"NC(=N)NC(=N)NCCC1=CC=CC=C1";"";"A10BD01";"ATP-sensitive inward rectifier potassium channel 8";"KCNJ8";"unknown";"inhibitor"
"Amantadine";"NC12CC3CC(CC(C3)C1)C2";"Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.";"N04BB01";"Matrix protein 2";"M";"yes";"inhibitor"
"Amantadine";"NC12CC3CC(CC(C3)C1)C2";"Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.";"N04BB01";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Amantadine";"NC12CC3CC(CC(C3)C1)C2";"Mean half-lives ranged from 10 to 14 hours, however renal function impairment causes a severe increase in half life to 7 to 10 days.";"N04BB01";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"G01AF01";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD08";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"P01AB01";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"D06BX01";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD01";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A01AB17";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD03";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD02";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"P01AB51";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD11";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"G01AF20";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA04";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA03";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA10";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01XD01";"Oxygen-insensitive NADPH nitroreductase";"rdxA";"yes";"potentiator"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"G01AF01";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD08";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"P01AB01";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"D06BX01";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD01";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A01AB17";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD03";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD02";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"P01AB51";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD11";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"G01AF20";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA04";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA03";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA10";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01XD01";"Iron hydrogenase 1";"";"unknown";"inhibitor"
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"G01AF01";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD08";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"P01AB01";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"D06BX01";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD01";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A01AB17";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD03";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD02";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"P01AB51";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"A02BD11";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"G01AF20";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA04";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA03";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01RA10";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Metronidazole";"CC1=NC=C(N1CCO)[N+]([O-])=O";"6-8 hours";"J01XD01";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Dinoprostone";"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O";"Less than 5 minutes.";"G02AD02";"Prostaglandin E2 receptor EP2 subtype";"PTGER2";"yes";"agonist"
"Dinoprostone";"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O";"Less than 5 minutes.";"G02AD02";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"yes";"agonist"
"Dinoprostone";"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O";"Less than 5 minutes.";"G02AD02";"Prostaglandin E2 receptor EP3 subtype";"PTGER3";"yes";"agonist"
"Dinoprostone";"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O";"Less than 5 minutes.";"G02AD02";"Prostaglandin E2 receptor EP4 subtype";"PTGER4";"yes";"agonist"
"Dinoprostone";"CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O";"Less than 5 minutes.";"G02AD02";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"agonist"
"Almotriptan";"CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2";"3-4 hours";"N02CC05";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Almotriptan";"CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2";"3-4 hours";"N02CC05";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Spectinomycin";"[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2";"1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance &lt; 20 mL per minute.";"J01XX04";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Ketotifen";"CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12";"21 hours (for elimination)";"S01GX08";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Ketotifen";"CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12";"21 hours (for elimination)";"R06AX17";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Ketotifen";"CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12";"21 hours (for elimination)";"S01GX08";"6-phosphogluconate dehydrogenase, decarboxylating";"PGD";"unknown";"inhibitor"
"Ketotifen";"CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12";"21 hours (for elimination)";"R06AX17";"6-phosphogluconate dehydrogenase, decarboxylating";"PGD";"unknown";"inhibitor"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N02AE01";"Mu-type opioid receptor";"OPRM1";"yes";"partial agonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC01";"Mu-type opioid receptor";"OPRM1";"yes";"partial agonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC51";"Mu-type opioid receptor";"OPRM1";"yes";"partial agonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N02AE01";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC01";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC51";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N02AE01";"Delta-type opioid receptor";"OPRD1";"unknown";"antagonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC01";"Delta-type opioid receptor";"OPRD1";"unknown";"antagonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC51";"Delta-type opioid receptor";"OPRD1";"unknown";"antagonist"
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N02AE01";"Nociceptin receptor";"OPRL1";"unknown";""
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC01";"Nociceptin receptor";"OPRL1";"unknown";""
"Buprenorphine";"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4";"IV administration, 0.3 mg = 1.2 - 7.2 hours (mean 2.2 hours);
Sublingual administration = 37 hours.";"N07BC51";"Nociceptin receptor";"OPRL1";"unknown";""
"Levosimendan";"C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1";"Eliminination half-life is approximately 1 hour.";"C01CX08";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"potentiator"
"Levosimendan";"C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1";"Eliminination half-life is approximately 1 hour.";"C01CX08";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inducer"
"Levosimendan";"C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1";"Eliminination half-life is approximately 1 hour.";"C01CX08";"ATP-sensitive inward rectifier potassium channel 8";"KCNJ8";"yes";"inducer"
"Levosimendan";"C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1";"Eliminination half-life is approximately 1 hour.";"C01CX08";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"unknown";"inhibitor"
"Ceforanide";"[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O";"2.6 to 2.98 hours";"J01DC11";"Penicillin-binding protein 2";"pbpA";"yes";"inhibitor"
"Cyclobenzaprine";"CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12";"18 hours (range 8-37 hours)";"M03BX08";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Phenoxybenzamine";"CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1";"24 hours";"C04AX02";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Etretinate";"CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C";"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.";"D05BB01";"Retinoic acid receptor alpha";"RARA";"yes";"agonist"
"Etretinate";"CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C";"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.";"D05BB01";"Retinoic acid receptor RXR-alpha";"RXRA";"yes";"agonist"
"Etretinate";"CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C";"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.";"D05BB01";"Retinoic acid receptor beta";"RARB";"yes";"agonist"
"Etretinate";"CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C";"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.";"D05BB01";"Retinoic acid receptor RXR-gamma";"RXRG";"yes";"agonist"
"Etretinate";"CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C";"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.";"D05BB01";"Retinoic acid receptor RXR-beta";"RXRB";"yes";"agonist"
"Etretinate";"CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C";"In one study, the apparent terminal half-life of etretinate after 6 months of therapy was approximately 120 days. In another study of 47 patients who had undergone chronic therapy with etretinate, 5 patients had detectable serum drug concentrations (0.5 to 12 ng/mL) 2.1 to 2.9 years after therapy was completed.";"D05BB01";"Retinoic acid receptor gamma";"RARG";"yes";"agonist"
"Famotidine";"NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1";"2.5-3.5 hours";"A02BA53";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Famotidine";"NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1";"2.5-3.5 hours";"A02BA03";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Azacitidine";"NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"Mean elimination half-life is approximately 4 hours.";"L01BC07";"DNA (cytosine-5)-methyltransferase 1";"DNMT1";"yes";"inhibitor"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"G02AD06";"Prostaglandin E2 receptor EP3 subtype";"PTGER3";"yes";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"M01AE56";"Prostaglandin E2 receptor EP3 subtype";"PTGER3";"yes";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"A02BB01";"Prostaglandin E2 receptor EP3 subtype";"PTGER3";"yes";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"G02AD06";"Prostaglandin E2 receptor EP2 subtype";"PTGER2";"yes";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"M01AE56";"Prostaglandin E2 receptor EP2 subtype";"PTGER2";"yes";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"A02BB01";"Prostaglandin E2 receptor EP2 subtype";"PTGER2";"yes";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"G02AD06";"Prostaglandin E2 receptor EP4 subtype";"PTGER4";"unknown";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"M01AE56";"Prostaglandin E2 receptor EP4 subtype";"PTGER4";"unknown";"agonist"
"Misoprostol";"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC";"20-40 minutes";"A02BB01";"Prostaglandin E2 receptor EP4 subtype";"PTGER4";"unknown";"agonist"
"Tipranavir";"[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O";"5-6 hours";"J05AE09";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Mesoridazine";"CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O";"24 to 48 hours";"N05AC03";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Mesoridazine";"CN1CCCCC1CCN1C2=CC=CC=C2SC2=C1C=C(C=C2)S(C)=O";"24 to 48 hours";"N05AC03";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Alpha-1 adrenergic receptors";"ADRA1A";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Alpha-1 adrenergic receptors";"ADRA1B";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Alpha-1 adrenergic receptors";"ADRA1D";"no";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"binder"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"binder"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"D(2) dopamine receptor";"DRD2";"unknown";"binder"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";"antagonist"
"Maprotiline";"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21";"Average ~ 51 hours (range: 27-58 hours)";"N06AA21";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";"antagonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA05";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB07";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA04";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA05";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB07";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA04";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA05";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB07";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA04";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA05";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB07";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA04";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA05";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB07";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA04";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA05";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB07";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Oxymetazoline";"CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA04";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"D01AE12";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"N02BA04";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"S01BC08";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"N02BA12";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"D01AE12";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"N02BA04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"S01BC08";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"N02BA12";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"D01AE12";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"N02BA04";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"S01BC08";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Salicylic acid";"OC(=O)C1=CC=CC=C1O";"";"N02BA12";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Diethylpropion";"CCN(CC)C(C)C(=O)C1=CC=CC=C1";"Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.";"A08AA03";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Diethylpropion";"CCN(CC)C(C)C(=O)C1=CC=CC=C1";"Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.";"A08AA03";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AK06";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AK12";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AC12";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AK06";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AK12";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AC12";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AK06";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AK12";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Salmeterol";"OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1";"5.5 hours";"R03AC12";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M01AG04";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M02AA18";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M01AG04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M02AA18";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M01AG04";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M02AA18";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M01AG04";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"unknown";"other"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M02AA18";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"unknown";"other"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M01AG04";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"unknown";"other"
"Meclofenamic acid";"CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1";"In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.";"M02AA18";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"unknown";"other"
"Methantheline";"CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12";"";"A03AB07";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Methantheline";"CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12";"";"A03AB07";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Hexafluronium";"C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2";"";"M03AC05";"Cholinesterase";"BCHE";"yes";"inhibitor"
"Zalcitabine";"NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1";"2 hours";"J05AF03";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Demecarium";"CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C";"";"S01EB04";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Demecarium";"CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C";"";"S01EB04";"Cholinesterase";"BCHE";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Aldo-keto reductase family 1 member C1";"AKR1C1";"unknown";"inhibitor"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"5'-AMP-activated protein kinase";"PRKAA1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"5'-AMP-activated protein kinase";"PRKAA2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"5'-AMP-activated protein kinase";"PRKAB1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"5'-AMP-activated protein kinase";"PRKAB2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"5'-AMP-activated protein kinase";"PRKAG1";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"5'-AMP-activated protein kinase";"PRKAG2";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"5'-AMP-activated protein kinase";"PRKAG3";"unknown";"activator"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Endothelin-1 receptor";"EDNRA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Cellular tumor antigen p53";"TP53";"unknown";"acetylation"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"78 kDa glucose-regulated protein";"HSPA5";"unknown";"binding"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Ribosomal protein S6 kinase alpha-3";"RPS6KA3";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"NF-kappa-B inhibitor alpha";"NFKBIA";"unknown";""
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Nuclear factor NF-kappa-B";"NFKB2";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC56";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX04";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"M01BA03";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA51";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX06";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA71";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX05";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"B01AC06";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX02";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"N02BA01";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"A01AD05";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX01";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Acetylsalicylic acid";"CC(=O)OC1=CC=CC=C1C(O)=O";"The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.";"C10BX08";"Nuclear factor NF-kappa-B";"NFKB1";"unknown";"antagonist"
"Phenprocoumon";"CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2";"5-6 days";"B01AA04";"Vitamin K epoxide reductase complex subunit 1";"VKORC1";"yes";"inhibitor"
"Fulvestrant";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])C2[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=CC(O)=CC=C12";"40 days";"L02BA03";"Estrogen receptor alpha";"ESR1";"yes";"antagonist"
"Mezlocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O";"1.3 to 4.4 hours";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Mezlocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O";"1.3 to 4.4 hours";"J01CA10";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Mezlocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O";"1.3 to 4.4 hours";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Mezlocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O";"1.3 to 4.4 hours";"J01CA10";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Mezlocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O";"1.3 to 4.4 hours";"J01CR50";"Penicillin-binding protein 2";"mrdA";"unknown";"inhibitor"
"Mezlocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O";"1.3 to 4.4 hours";"J01CA10";"Penicillin-binding protein 2";"mrdA";"unknown";"inhibitor"
"Felbamate";"NC(=O)OCC(COC(N)=O)C1=CC=CC=C1";"20-23 hours";"N03AX10";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"yes";"antagonist"
"Felbamate";"NC(=O)OCC(COC(N)=O)C1=CC=CC=C1";"20-23 hours";"N03AX10";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Felbamate";"NC(=O)OCC(COC(N)=O)C1=CC=CC=C1";"20-23 hours";"N03AX10";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"yes";"antagonist"
"Fexofenadine";"CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"14.4 hours";"R06AX26";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM04";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM06";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM02";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM01";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM05";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM03";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC51";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC01";"Catalase-peroxidase";"katG";"yes";"other/unknown"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM04";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM06";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM02";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM01";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM05";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM03";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC51";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC01";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"yes";"adduct"
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM04";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM06";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM02";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM01";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM05";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM03";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC51";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC01";"Cytochrome P450 2C8";"CYP2C8";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM04";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM06";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM02";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM01";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM05";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM03";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC51";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC01";"Cytochrome P450 1A2";"CYP1A2";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM04";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM06";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM02";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM01";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM05";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM03";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC51";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC01";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM04";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM06";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM02";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM01";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM05";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM03";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC51";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC01";"Cytochrome P450 2C19";"CYP2C19";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM04";"Dihydrofolate reductase";"folA";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM06";"Dihydrofolate reductase";"folA";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM02";"Dihydrofolate reductase";"folA";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM01";"Dihydrofolate reductase";"folA";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM05";"Dihydrofolate reductase";"folA";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AM03";"Dihydrofolate reductase";"folA";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC51";"Dihydrofolate reductase";"folA";"unknown";""
"Isoniazid";"NNC(=O)C1=CC=NC=C1";"Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.";"J04AC01";"Dihydrofolate reductase";"folA";"unknown";""
"Naratriptan";"CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1";"5-8 hours";"N02CC02";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Naratriptan";"CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1";"5-8 hours";"N02CC02";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Naratriptan";"CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1";"5-8 hours";"N02CC02";"5-hydroxytryptamine receptor 1F";"HTR1F";"yes";"agonist"
"Naratriptan";"CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1";"5-8 hours";"N02CC02";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonist"
"Rizatriptan";"CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2";"2-3 hours";"N02CC04";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Rizatriptan";"CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2";"2-3 hours";"N02CC04";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Rizatriptan";"CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2";"2-3 hours";"N02CC04";"5-hydroxytryptamine receptor 1F";"HTR1F";"yes";"agonist"
"Netilmicin";"CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O";"2.5 hours";"S01AA23";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Netilmicin";"CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O";"2.5 hours";"J01GB07";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Hydrocodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"1.25-3 hours";"R05DA03";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Hydrocodone";"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O";"1.25-3 hours";"R05DA03";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Norgestimate";"[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O";"12-30 hours";"G03AA11";"Progesterone receptor";"PGR";"yes";"agonist"
"Norgestimate";"[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O";"12-30 hours";"G03FA13";"Progesterone receptor";"PGR";"yes";"agonist"
"Norgestimate";"[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O";"12-30 hours";"G03AA11";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Norgestimate";"[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O";"12-30 hours";"G03FA13";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Norgestimate";"[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O";"12-30 hours";"G03AA11";"Androgen receptor";"AR";"unknown";"partial agonist"
"Norgestimate";"[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O";"12-30 hours";"G03FA13";"Androgen receptor";"AR";"unknown";"partial agonist"
"Methylprednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"1-3 hours";"S01CA08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Methylprednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"1-3 hours";"D07CA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Methylprednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"1-3 hours";"D07AC14";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Methylprednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"1-3 hours";"D10AA02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Methylprednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"1-3 hours";"H02AB04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Methylprednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"1-3 hours";"D07AA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Methylprednisolone";"[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C";"1-3 hours";"H02BX01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07AA03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07CA03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07AA03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"partial agonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07CA03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"partial agonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07AA03";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07CA03";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07AA03";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"other/unknown"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07CA03";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"other/unknown"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07AA03";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Pindolol";"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2";"3 to 4 hours";"C07CA03";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Mepivacaine";"CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C";"The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.";"N01BB53";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Mepivacaine";"CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C";"The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.";"N01BB03";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Zaleplon";"CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N";"Approximately 1 hour";"N05CF03";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Zaleplon";"CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N";"Approximately 1 hour";"N05CF03";"Translocator protein";"TSPO";"yes";"other"
"Bromfenac";"NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1";"";"S01BC11";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Bromfenac";"NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1";"";"S01BC11";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Apraclonidine";"NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1";"8 hours";"S01EA03";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Apraclonidine";"NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1";"8 hours";"S01EA03";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Apraclonidine";"NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1";"8 hours";"S01EA03";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Telmisartan";"CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O";"Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.";"C09DB04";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Telmisartan";"CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O";"Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.";"C09DA07";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Telmisartan";"CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O";"Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.";"C09CA07";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Telmisartan";"CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O";"Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.";"C09DB04";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"partial agonist"
"Telmisartan";"CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O";"Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.";"C09DA07";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"partial agonist"
"Telmisartan";"CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O";"Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.";"C09CA07";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"partial agonist"
"Desloratadine";"ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1";"50 hours";"R06AX27";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Alosetron";"CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2";"1.5 hours";"A03AE01";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Dactinomycin";"[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C";"36 hours";"L01DA01";"DNA topoisomerase 2";"TOP2A";"unknown";""
"Dactinomycin";"[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C";"36 hours";"L01DA01";"DNA topoisomerase 2";"TOP2B";"unknown";""
"Azelastine";"CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O";"Elimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).";"R01AC03";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Azelastine";"CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O";"Elimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).";"R06AX19";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Azelastine";"CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O";"Elimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).";"S01GX07";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA02";"Sterol O-acyltransferase 1";"SOAT1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA05";"Sterol O-acyltransferase 1";"SOAT1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA06";"Sterol O-acyltransferase 1";"SOAT1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10AX09";"Sterol O-acyltransferase 1";"SOAT1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA02";"Niemann-Pick C1-like protein 1";"NPC1L1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA05";"Niemann-Pick C1-like protein 1";"NPC1L1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA06";"Niemann-Pick C1-like protein 1";"NPC1L1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10AX09";"Niemann-Pick C1-like protein 1";"NPC1L1";"yes";"inhibitor"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA02";"Aminopeptidase N";"ANPEP";"unknown";"other"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA05";"Aminopeptidase N";"ANPEP";"unknown";"other"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10BA06";"Aminopeptidase N";"ANPEP";"unknown";"other"
"Ezetimibe";"O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1";"22 hours (both ezetimibe and ezetimibe-glucuronide).";"C10AX09";"Aminopeptidase N";"ANPEP";"unknown";"other"
"Dipyridamole";"OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1";"40 minutes";"B01AC07";"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A";"PDE10A";"yes";"inhibitor"
"Dipyridamole";"OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1";"40 minutes";"B01AC07";"Adenosine deaminase";"ADA";"yes";"inhibitor"
"Dipyridamole";"OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1";"40 minutes";"B01AC07";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Dipyridamole";"OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1";"40 minutes";"B01AC07";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Dipyridamole";"OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1";"40 minutes";"B01AC07";"Calcipressin-1";"RCAN1";"unknown";""
"Dipyridamole";"OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1";"40 minutes";"B01AC07";"Alpha-1-acid glycoprotein 1";"ORM1";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA03";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA08";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA10";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB07";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB05";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA09";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA11";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"L02AA03";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB03";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03CA01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA02";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA13";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA05";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA07";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA15";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA12";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA16";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA08";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA10";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB07";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA09";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"L02AA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03CA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA13";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA07";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA15";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA12";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA16";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA03";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA08";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA10";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB07";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB05";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB01";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA09";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA11";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB02";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"L02AA03";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB03";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03CA01";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA02";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA13";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AB06";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA05";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA07";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA15";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA01";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA12";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA16";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Ethinyl Estradiol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"36 +/- 13 hours";"G03AA06";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Lomefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12";"8 hours";"J01MA07";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Lomefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12";"8 hours";"S01AE04";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Lomefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12";"8 hours";"J01MA07";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Lomefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12";"8 hours";"S01AE04";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Lomefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12";"8 hours";"J01MA07";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Lomefloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12";"8 hours";"S01AE04";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Cyclopentolate";"CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1";"";"S01FA54";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Cyclopentolate";"CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1";"";"S01FA04";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Ramelteon";"CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2";"~1-2.6 hours";"N05CH02";"Melatonin receptor type 1A";"MTNR1A";"yes";"multitarget"
"Ramelteon";"CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2";"~1-2.6 hours";"N05CH02";"Melatonin receptor type 1B";"MTNR1B";"yes";"multitarget"
"Physostigmine";"[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C";"";"S01EB05";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Physostigmine";"[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C";"";"V03AB19";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Physostigmine";"[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C";"";"S01EB05";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Physostigmine";"[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C";"";"V03AB19";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";""
"Physostigmine";"[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C";"";"S01EB05";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Physostigmine";"[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C";"";"V03AB19";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";""
"Isotretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O";"17-50 hours";"D10AD54";"Retinoic acid receptor alpha";"RARA";"unknown";"other/unknown"
"Isotretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O";"17-50 hours";"D10AD04";"Retinoic acid receptor alpha";"RARA";"unknown";"other/unknown"
"Isotretinoin";"C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O";"17-50 hours";"D10BA01";"Retinoic acid receptor alpha";"RARA";"unknown";"other/unknown"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK11";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AL05";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK07";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK08";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AC13";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK09";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK11";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AL05";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK07";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK08";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AC13";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK09";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK11";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AL05";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK07";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK08";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AC13";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Formoterol";"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1";"10 hours";"R03AK09";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Dimenhydrinate";"CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1 to 4 hours";"R03DA20";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"R03AL04";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"R03BB06";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"A03CA05";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"A03AB02";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"R03AL04";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"R03BB06";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"A03CA05";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"A03AB02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"R03AL04";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"binder"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"R03BB06";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"binder"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"A03CA05";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"binder"
"Glycopyrronium";"[H][C@@]1(CC[N+](C)(C)C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1";"0.6-1.2 hours";"A03AB02";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"binder"
"Cytarabine";"NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"10 minutes";"L01BC01";"DNA polymerase beta";"POLB";"yes";"inhibitor"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"D(1A) dopamine receptor";"DRD1";"yes";"agonist"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"D(1B) dopamine receptor";"DRD5";"yes";"agonist"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inducer"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"Dopamine beta-hydroxylase";"DBH";"yes";"ligand"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"binder"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"binder"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"D(1) dopamine receptor";"DRD1";"unknown";"agonist"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"D(1) dopamine receptor";"DRD5";"unknown";"agonist"
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";""
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";""
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"5-hydroxytryptamine receptor 3B";"HTR3B";"unknown";""
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Dopamine";"NCCC1=CC(O)=C(O)C=C1";"2 minutes";"C01CA04";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";""
"Rivastigmine";"CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C";"1.5 hours";"N06DA03";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Rivastigmine";"CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C";"1.5 hours";"N06DA03";"Cholinesterase";"BCHE";"yes";"inhibitor"
"Exemestane";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C";"24 hours";"L02BG06";"Cytochrome P450 19A1";"CYP19A1";"yes";"inhibitor"
"Oxaprozin";"OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1";"54.9 hours";"M01AE12";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Oxaprozin";"OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1";"54.9 hours";"M01AE12";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Methyl aminolevulinate";"COC(=O)CCC(=O)CN";"";"L01XD03";"High affinity immunoglobulin gamma Fc receptor I";"FCGR1A";"unknown";"antibody"
"Azathioprine";"CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O";"";"L04AX01";"Hypoxanthine-guanine phosphoribosyltransferase";"HPRT1";"yes";"inhibitor"
"Azathioprine";"CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O";"";"L04AX01";"Ras-related C3 botulinum toxin substrate 1";"RAC1";"unknown";""
"Auranofin";"CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O";"";"M01CB03";"Peroxiredoxin-5, mitochondrial";"PRDX5";"yes";"inhibitor"
"Auranofin";"CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O";"";"M01CB03";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"yes";"inhibitor"
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"yes";"inhibitor"
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"yes";"inhibitor"
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"Adenosine receptor A1";"ADORA1";"unknown";"agonist"
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"NMDA receptor";"GRIN1";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"NMDA receptor";"GRIN2A";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"NMDA receptor";"GRIN2B";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"NMDA receptor";"GRIN2C";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"NMDA receptor";"GRIN2D";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"NMDA receptor";"GRIN3A";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"NMDA receptor";"GRIN3B";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"Gamma-aminobutyric acid type B receptor subunit 1";"GABBR1";"unknown";""
"Gabapentin";"NCC1(CC(O)=O)CCCCC1";"5-7 hours";"N03AX12";"Gamma-aminobutyric acid type B receptor subunit 2";"GABBR2";"unknown";""
"Doxorubicin";"COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O";"Terminal half life = 20 - 48 hours.";"L01DB01";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Doxorubicin";"COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O";"Terminal half life = 20 - 48 hours.";"L01DB01";"Nucleolar and coiled-body phosphoprotein 1";"NOLC1";"unknown";""
"Frovatriptan";"CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O";"26 hours";"N02CC07";"5-hydroxytryptamine receptor 1D";"HTR1D";"yes";"agonist"
"Frovatriptan";"CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O";"26 hours";"N02CC07";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"agonist"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX01";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AB03";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA52";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX03";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03EA01";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AX01";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA54";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AA03";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"G01AE10";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AB03";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA52";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX03";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03EA01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AX01";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA54";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AA03";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"G01AE10";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX01";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AB03";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA52";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX03";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03EA01";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AX01";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA54";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AA03";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX01";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AB03";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA52";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX03";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03EA01";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AX01";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA54";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AA03";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"G01AE10";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX01";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AB03";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA52";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX03";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03EA01";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AX01";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA54";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AA03";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"G01AE10";"Carbonic anhydrase 9";"CA9";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX01";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AB03";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA52";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX03";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03EA01";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AX01";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA54";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AA03";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"G01AE10";"Carbonic anhydrase 12";"CA12";"unknown";"inhibitor"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AB03";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA52";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09DX03";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03EA01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AX01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C09XA54";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"C03AA03";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Hydrochlorothiazide";"NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1";"5.6 and 14.8 hours";"G01AE10";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other/unknown"
"Cyclacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cyclacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cyclacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Cyclacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O";"";"J01CR50";"Penicillin binding protein 2a";"mecA";"yes";"inhibitor"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AL02";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03CC02";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AK04";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AC02";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AL02";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03CC02";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AK04";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AC02";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AL02";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03CC02";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AK04";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Salbutamol";"CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1";"1.6 hours";"R03AC02";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Levobupivacaine";"CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C";"3.3 hours";"N01BB10";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"S01GX01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"D11AH03";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R01AC51";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R01AC01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"S01GX51";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R03BC01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R03AK04";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R03AK05";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"A07EB01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"yes";"inhibitor"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"S01GX01";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"D11AH03";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R01AC51";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R01AC01";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"S01GX51";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R03BC01";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R03AK04";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"R03AK05";"Protein S100-P";"S100P";"unknown";"antagonist"
"Cromoglicic acid";"OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O";"1.3 hours";"A07EB01";"Protein S100-P";"S100P";"unknown";"antagonist"
"Ganciclovir";"NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1";"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).";"J05AB06";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Ganciclovir";"NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1";"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).";"S01AD09";"DNA polymerase catalytic subunit";"";"yes";"inhibitor"
"Ganciclovir";"NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1";"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).";"J05AB06";"Thymidine kinase";"TK";"yes";"inducer"
"Ganciclovir";"NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1";"2.5 to 3.6 hours (mean 2.9 hours) when administered intravenously in adults. 3.1 to 5.5 hours when administered orally in adults. Renal function impairment causes a marked increase in half life (9 to 30 hours intravenously, 15.7 to 18.2 hours orally).";"S01AD09";"Thymidine kinase";"TK";"yes";"inducer"
"Hydroxyurea";"NC(=O)NO";"3-4 hours";"L01XX05";"Ribonucleoside-diphosphate reductase large subunit";"RRM1";"yes";"inhibitor"
"Letrozole";"N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N";"2 days";"L02BG04";"Cytochrome P450 19A1";"CYP19A1";"yes";"antagonist"
"Tioconazole";"ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1";"";"G01AF08";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonist"
"Tioconazole";"ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1";"";"D01AC07";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonist"
"Tioconazole";"ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1";"";"G01AF08";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";"inhibitor"
"Tioconazole";"ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1";"";"D01AC07";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";"inhibitor"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M01AE53";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M02AA10";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M01AE03";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M01AE53";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M02AA10";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M01AE03";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M01AE53";"C-X-C chemokine receptor type 1";"CXCR1";"unknown";"other"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M02AA10";"C-X-C chemokine receptor type 1";"CXCR1";"unknown";"other"
"Ketoprofen";"CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"Conventional capsules: 1.1-4 hours
<p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>";"M01AE03";"C-X-C chemokine receptor type 1";"CXCR1";"unknown";"other"
"Metyrapone";"CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1";"1.9 &plusmn;0.7 hours.";"V04CD01";"Cytochrome P450 11B1, mitochondrial";"CYP11B1";"yes";"inhibitor"
"Metyrapone";"CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1";"1.9 &plusmn;0.7 hours.";"V04CD01";"Camphor 5-monooxygenase";"camC";"unknown";"other/unknown"
"Cinacalcet";"C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12";"Terminal half-life is 30 to 40 hours. The mean half-life of cinacalcet is prolonged by 33% and 70% in patients with moderate and severe hepatic impairment, respectively.";"H05BX01";"Extracellular calcium-sensing receptor";"CASR";"yes";"agonist"
"Balsalazide";"OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O";"Half-life could not be determined.";"A07EC04";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Balsalazide";"OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O";"Half-life could not be determined.";"A07EC04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Balsalazide";"OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O";"Half-life could not be determined.";"A07EC04";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Balsalazide";"OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O";"Half-life could not be determined.";"A07EC04";"Arachidonate 5-lipoxygenase";"ALOX5";"yes";"inhibitor"
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"J01EE01";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"J01EC01";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"J01EE01";"Bifunctional protein FolC";"folC";"yes";"inhibitor"
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"J01EC01";"Bifunctional protein FolC";"folC";"yes";"inhibitor"
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"G01AE10";"Bifunctional protein FolC";"folC";"yes";"inhibitor"
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"J01EE01";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"J01EC01";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Sulfamethoxazole";"CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1";"10 hours";"G01AE10";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"Sulfonylurea receptor 1, Kir6.2";"ABCC8";"yes";"blocker"
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"Sulfonylurea receptor 1, Kir6.2";"KCNJ11";"yes";"blocker"
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"G protein-activated inward rectifier potassium channel 4";"KCNJ5";"unknown";"inhibitor"
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"ATP-binding cassette sub-family C member 9";"ABCC9";"unknown";"modulator"
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"Bile salt export pump";"ABCB11";"unknown";"inhibitor"
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"ATP-binding cassette sub-family A member 1";"ABCA1";"unknown";"inhibitor"
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"antagonist"
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"Mitochondrial ATP-sensitive potassium channel";"KCNJ11";"unknown";""
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"Mitochondrial ATP-sensitive potassium channel";"KCNJ8";"unknown";""
"Glyburide";"COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"1.4-1.8 hours (unchanged drug only); 10 hours (metabolites included). Duration of effect is 12-24 hours. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>.";"A10BB01";"Carnitine O-palmitoyltransferase 1, liver isoform";"CPT1A";"unknown";""
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"30S ribosomal protein S4";"rpsD";"yes";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"Interleukin-1 beta";"IL1B";"unknown";"modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"Interleukin-1 beta";"IL1B";"unknown";"modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"Interleukin-1 beta";"IL1B";"unknown";"modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"Matrix metalloproteinase-9";"MMP9";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"Matrix metalloproteinase-9";"MMP9";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"Matrix metalloproteinase-9";"MMP9";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"Vascular endothelial growth factor A";"VEGFA";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"Vascular endothelial growth factor A";"VEGFA";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"Vascular endothelial growth factor A";"VEGFA";"unknown";"inhibitor"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"Caspase-1";"CASP1";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"Caspase-1";"CASP1";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"Caspase-1";"CASP1";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"Caspase-3";"CASP3";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"Caspase-3";"CASP3";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"Caspase-3";"CASP3";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"A01AB23";"Cytochrome c";"CYCS";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA20";"Cytochrome c";"CYCS";"unknown";"negative modulator"
"Minocycline";"[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2";"11-22 hours";"J01AA08";"Cytochrome c";"CYCS";"unknown";"negative modulator"
"Guanfacine";"NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl";"17 hours (range 10-30 hours)";"C02AC02";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Guanfacine";"NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl";"17 hours (range 10-30 hours)";"C02AC02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"binder"
"Bethanechol";"CC(C[N+](C)(C)C)OC(N)=O";"";"N07AB02";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"agonist"
"Bethanechol";"CC(C[N+](C)(C)C)OC(N)=O";"";"N07AB02";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";""
"Bethanechol";"CC(C[N+](C)(C)C)OC(N)=O";"";"N07AB02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Bethanechol";"CC(C[N+](C)(C)C)OC(N)=O";"";"N07AB02";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";""
"Isosorbide Mononitrate";"[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O";"5 hours";"C01DA14";"Guanylate cyclase soluble subunit alpha-2";"GUCY1A2";"yes";"inducer"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AA06";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AB06";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"G01AE10";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03EA02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AA06";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AB06";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"G01AE10";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03EA02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AA06";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AB06";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"G01AE10";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03EA02";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AA06";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AB06";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"G01AE10";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03EA02";"Carbonic anhydrase 2";"CA2";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AA06";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03AB06";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"G01AE10";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Trichlormethiazide";"NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl";"";"C03EA02";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Phylloquinone";"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O";"";"B02BA01";"Vitamin K-dependent gamma-carboxylase";"GGCX";"yes";"inducer"
"Phylloquinone";"CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O";"";"B02BA01";"Osteocalcin";"BGLAP";"unknown";"agonist"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Calmodulin";"CALM1";"unknown";"other"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Calmodulin";"CALM1";"unknown";"other"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B";"PDE1B";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B";"PDE1B";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A";"PDE1A";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A";"PDE1A";"unknown";"inhibitor"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Mineralocorticoid receptor";"NR3C2";"unknown";"antagonist"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Mineralocorticoid receptor";"NR3C2";"unknown";"antagonist"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Troponin C, skeletal muscle";"TNNC2";"unknown";"other"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Troponin C, skeletal muscle";"TNNC2";"unknown";"other"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C08CA02";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"unknown";"other"
"Felodipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC";"17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.";"C09BB05";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"unknown";"other"
"Mycophenolic acid";"COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C";"The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.";"L04AA06";"Inosine-5'-monophosphate dehydrogenase 1";"IMPDH1";"yes";"inhibitor"
"Mycophenolic acid";"COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C";"The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.";"L04AA06";"Inosine-5'-monophosphate dehydrogenase 2";"IMPDH2";"yes";"inhibitor"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"A01AD07";"Protein S100-A12";"S100A12";"unknown";"antagonist"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"R03DX01";"Protein S100-A12";"S100A12";"unknown";"antagonist"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"A01AD07";"Protein S100-A13";"S100A13";"unknown";"antagonist"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"R03DX01";"Protein S100-A13";"S100A13";"unknown";"antagonist"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"A01AD07";"Interleukin-3";"IL3";"unknown";"antagonist"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"R03DX01";"Interleukin-3";"IL3";"unknown";"antagonist"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"A01AD07";"Fibroblast growth factor 1";"FGF1";"unknown";"inhibitor"
"Amlexanox";"CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1";"Elimination half-life is 3.5 &plusmn; 1.1 hours.";"R03DX01";"Fibroblast growth factor 1";"FGF1";"unknown";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"D01AC08";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF11";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF20";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"J02AB02";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"D01AC08";"Androgen receptor";"AR";"unknown";"binder"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF11";"Androgen receptor";"AR";"unknown";"binder"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF20";"Androgen receptor";"AR";"unknown";"binder"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"J02AB02";"Androgen receptor";"AR";"unknown";"binder"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"D01AC08";"Steroid 21-hydroxylase";"CYP21A2";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF11";"Steroid 21-hydroxylase";"CYP21A2";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF20";"Steroid 21-hydroxylase";"CYP21A2";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"J02AB02";"Steroid 21-hydroxylase";"CYP21A2";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"D01AC08";"Cytochrome P450 19A1";"CYP19A1";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF11";"Cytochrome P450 19A1";"CYP19A1";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF20";"Cytochrome P450 19A1";"CYP19A1";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"J02AB02";"Cytochrome P450 19A1";"CYP19A1";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"D01AC08";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF11";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF20";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"J02AB02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"D01AC08";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"antagonist"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"antagonist"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF20";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"antagonist"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"J02AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"antagonist"
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"D01AC08";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF11";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"G01AF20";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Ketoconazole";"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1";"2 hours";"J02AB02";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"Glutamate receptor 1";"GRIA1";"yes";"antagonist"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"Glycine receptor subunit alpha-1";"GLRA1";"yes";"agonist"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"unknown";"inhibitor"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"yes";"inducer"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"ATP synthase subunit delta, mitochondrial";"ATP5D";"unknown";"unknown"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"NADH-ubiquinone oxidoreductase chain 1";"MT-ND1";"unknown";"unknown"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Methoxyflurane";"COC(F)(F)C(Cl)Cl";"";"N02BG09";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Irbesartan";"CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"11-15 hours";"C09DB05";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Irbesartan";"CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"11-15 hours";"C09DA04";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Irbesartan";"CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"11-15 hours";"C09CA04";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Irbesartan";"CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"11-15 hours";"C09DB05";"Transcription factor AP-1";"JUN";"unknown";"other/unknown"
"Irbesartan";"CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"11-15 hours";"C09DA04";"Transcription factor AP-1";"JUN";"unknown";"other/unknown"
"Irbesartan";"CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1";"11-15 hours";"C09CA04";"Transcription factor AP-1";"JUN";"unknown";"other/unknown"
"Topotecan";"CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O";"2-3 hours";"L01XX17";"DNA topoisomerase 1";"TOP1";"yes";"inhibitor"
"Topotecan";"CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O";"2-3 hours";"L01XX17";"DNA topoisomerase I, mitochondrial";"TOP1MT";"unknown";"inhibitor"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"M04AB01";"Solute carrier family 22 member 6";"SLC22A6";"yes";"inhibitor"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"G01AE10";"Solute carrier family 22 member 6";"SLC22A6";"yes";"inhibitor"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"M04AB01";"Solute carrier family 22 member 11";"SLC22A11";"yes";"inhibitor"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"G01AE10";"Solute carrier family 22 member 11";"SLC22A11";"yes";"inhibitor"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"M04AB01";"Solute carrier family 22 member 8";"SLC22A8";"yes";"inhibitor"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"G01AE10";"Solute carrier family 22 member 8";"SLC22A8";"yes";"inhibitor"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"M04AB01";"Pannexin-1";"PANX1";"unknown";"antagonist"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"G01AE10";"Pannexin-1";"PANX1";"unknown";"antagonist"
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"M04AB01";"Taste receptor type 2 member 16";"TAS2R16";"unknown";""
"Probenecid";"CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O";"6-12 hours";"G01AE10";"Taste receptor type 2 member 16";"TAS2R16";"unknown";""
"Mercaptopurine";"S=C1N=CNC2=C1NC=N2";"Triphasic: 45 minutes, 2.5 hours, and 10 hours.";"L01BB02";"Hypoxanthine-guanine phosphoribosyltransferase";"HPRT1";"yes";"inhibitor"
"Mercaptopurine";"S=C1N=CNC2=C1NC=N2";"Triphasic: 45 minutes, 2.5 hours, and 10 hours.";"L01BB02";"Amidophosphoribosyltransferase";"PPAT";"unknown";""
"Mercaptopurine";"S=C1N=CNC2=C1NC=N2";"Triphasic: 45 minutes, 2.5 hours, and 10 hours.";"L01BB02";"Inosine-5'-monophosphate dehydrogenase";"IMPDH1";"unknown";"inhibitor"
"Mercaptopurine";"S=C1N=CNC2=C1NC=N2";"Triphasic: 45 minutes, 2.5 hours, and 10 hours.";"L01BB02";"Inosine-5'-monophosphate dehydrogenase";"IMPDH2";"unknown";"inhibitor"
"Procainamide";"CCN(CC)CCNC(=O)C1=CC=C(N)C=C1";"~2.5-4.5 hours";"C01BA02";"Sodium channel protein type 5 subunit alpha";"SCN5A";"unknown";"inhibitor"
"Procainamide";"CCN(CC)CCNC(=O)C1=CC=C(N)C=C1";"~2.5-4.5 hours";"C01BA02";"DNA (cytosine-5)-methyltransferase 1";"DNMT1";"unknown";"other"
"Procainamide";"CCN(CC)CCNC(=O)C1=CC=C(N)C=C1";"~2.5-4.5 hours";"C01BA02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Tolterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C";"1.9-3.7 hours";"G04BD07";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Tolterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C";"1.9-3.7 hours";"G04BD07";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Tolterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C";"1.9-3.7 hours";"G04BD07";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Tolterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C";"1.9-3.7 hours";"G04BD07";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Tolterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C";"1.9-3.7 hours";"G04BD07";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Selegiline";"C[C@H](CC1=CC=CC=C1)N(C)CC#C";"1.2-2 hours";"N04BD01";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"inhibitor"
"Selegiline";"C[C@H](CC1=CC=CC=C1)N(C)CC#C";"1.2-2 hours";"N04BD01";"Amine oxidase [flavin-containing] A";"MAOA";"no";"inhibitor"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA04";"Peroxisome proliferator-activated receptor alpha";"PPARA";"yes";"agonist"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10AB05";"Peroxisome proliferator-activated receptor alpha";"PPARA";"yes";"agonist"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA03";"Peroxisome proliferator-activated receptor alpha";"PPARA";"yes";"agonist"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA04";"Metalloproteinase";"mmp20";"unknown";"inhibitor"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10AB05";"Metalloproteinase";"mmp20";"unknown";"inhibitor"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA03";"Metalloproteinase";"mmp20";"unknown";"inhibitor"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA04";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10AB05";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA03";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA04";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10AB05";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA03";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10AB05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Fenofibrate";"CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1";"20 hours";"C10BA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Thalidomide";"O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12";"The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.";"L04AX02";"Protein cereblon";"CRBN";"yes";"inhibitor"
"Thalidomide";"O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12";"The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.";"L04AX02";"Tumor necrosis factor";"TNF";"yes";"inhibitor"
"Thalidomide";"O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12";"The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.";"L04AX02";"Nuclear factor NF-kappa-B p105 subunit";"NFKB1";"yes";"antagonist"
"Thalidomide";"O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12";"The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.";"L04AX02";"Fibroblast growth factor receptor 2";"FGFR2";"yes";"antagonist"
"Thalidomide";"O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12";"The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.";"L04AX02";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"antagonist"
"Thalidomide";"O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12";"The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.";"L04AX02";"alpha1-acid glycoprotein";"ORM1";"unknown";"binder"
"Thalidomide";"O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12";"The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.";"L04AX02";"alpha1-acid glycoprotein";"ORM2";"unknown";"binder"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DX01";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA53";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA52";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DX01";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA53";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA52";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DX01";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA53";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA52";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"yes";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DX01";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA53";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA52";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DX01";"Alpha-7 nicotinic cholinergic receptor subunit";"CHRNA7";"unknown";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA53";"Alpha-7 nicotinic cholinergic receptor subunit";"CHRNA7";"unknown";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA52";"Alpha-7 nicotinic cholinergic receptor subunit";"CHRNA7";"unknown";"antagonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DX01";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA53";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA52";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DX01";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"binder"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA53";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"binder"
"Memantine";"CC12CC3CC(C)(C1)CC(N)(C3)C2";"60-100 hours";"N06DA52";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"binder"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"S01AE06";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"J01MA16";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"S01AE06";"DNA gyrase subunit B";"gyrB";"yes";"inhibitor"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"J01MA16";"DNA gyrase subunit B";"gyrB";"yes";"inhibitor"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"S01AE06";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"J01MA16";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"S01AE06";"DNA topoisomerase 4 subunit B";"parE";"yes";"inhibitor"
"Gatifloxacin";"COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1";"7-14 hours";"J01MA16";"DNA topoisomerase 4 subunit B";"parE";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"DNA-directed RNA polymerase subunit beta";"rpoB";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"DNA-directed RNA polymerase subunit beta";"rpoB";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"DNA-directed RNA polymerase subunit beta";"rpoB";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"DNA-directed RNA polymerase subunit beta";"rpoB";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"DNA-directed RNA polymerase subunit beta'";"rpoC";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"DNA-directed RNA polymerase subunit beta'";"rpoC";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"DNA-directed RNA polymerase subunit beta'";"rpoC";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"DNA-directed RNA polymerase subunit beta'";"rpoC";"yes";"inhibitor"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"Solute carrier organic anion transporter family member 1A2";"SLCO1A2";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"Solute carrier organic anion transporter family member 1A2";"SLCO1A2";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"Solute carrier organic anion transporter family member 1A2";"SLCO1A2";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"Solute carrier organic anion transporter family member 1A2";"SLCO1A2";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"Lanosterol 14-alpha demethylase";"CYP51A1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"Serum albumin";"ALB";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"Serum albumin";"ALB";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"Serum albumin";"ALB";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"Serum albumin";"ALB";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM06";"Solute carrier organic anion transporter family member 2B1";"SLCO2B1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AB02";"Solute carrier organic anion transporter family member 2B1";"SLCO2B1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM02";"Solute carrier organic anion transporter family member 2B1";"SLCO2B1";"unknown";""
"Rifampicin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C";"3.35 (+/- 0.66) hours";"J04AM05";"Solute carrier organic anion transporter family member 2B1";"SLCO2B1";"unknown";""
"Lubiprostone";"[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC";"0.9 to 1.4 hours";"A06AX03";"Chloride channel protein 2";"CLCN2";"yes";"inducer"
"Fluocinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O";"";"D07CC05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O";"";"D07AC08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O";"";"C05AA11";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluocinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O";"";"D07CC05";"Smoothened homolog";"SMO";"unknown";"agonist"
"Fluocinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O";"";"D07AC08";"Smoothened homolog";"SMO";"unknown";"agonist"
"Fluocinonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O";"";"C05AA11";"Smoothened homolog";"SMO";"unknown";"agonist"
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AR02";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AR13";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AR04";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AF06";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AR02";"HLA class I histocompatibility antigen, B-57 alpha chain";"HLA-B";"unknown";""
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AR13";"HLA class I histocompatibility antigen, B-57 alpha chain";"HLA-B";"unknown";""
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AR04";"HLA class I histocompatibility antigen, B-57 alpha chain";"HLA-B";"unknown";""
"Abacavir";"NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1";"1.54 ± 0.63 hours";"J05AF06";"HLA class I histocompatibility antigen, B-57 alpha chain";"HLA-B";"unknown";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Prostaglandin G/H synthase 1";"PTGS1";"yes";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Prostaglandin G/H synthase 1";"PTGS1";"yes";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Prostaglandin G/H synthase 1";"PTGS1";"yes";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Prostaglandin G/H synthase 1";"PTGS1";"yes";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Prostaglandin G/H synthase 1";"PTGS1";"yes";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Apoptosis regulator Bcl-2";"BCL2";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Apoptosis regulator Bcl-2";"BCL2";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Apoptosis regulator Bcl-2";"BCL2";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Apoptosis regulator Bcl-2";"BCL2";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Apoptosis regulator Bcl-2";"BCL2";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Apoptosis regulator Bcl-2";"BCL2";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Thrombomodulin";"THBD";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Thrombomodulin";"THBD";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Thrombomodulin";"THBD";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Thrombomodulin";"THBD";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Thrombomodulin";"THBD";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Thrombomodulin";"THBD";"unknown";"modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Tissue-type plasminogen activator";"PLAT";"unknown";"negative modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Tissue-type plasminogen activator";"PLAT";"unknown";"negative modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Tissue-type plasminogen activator";"PLAT";"unknown";"negative modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Tissue-type plasminogen activator";"PLAT";"unknown";"negative modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Tissue-type plasminogen activator";"PLAT";"unknown";"negative modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Tissue-type plasminogen activator";"PLAT";"unknown";"negative modulator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Fatty acid-binding protein, intestinal";"FABP2";"unknown";"binder"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Fatty acid-binding protein, intestinal";"FABP2";"unknown";"binder"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Fatty acid-binding protein, intestinal";"FABP2";"unknown";"binder"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Fatty acid-binding protein, intestinal";"FABP2";"unknown";"binder"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Fatty acid-binding protein, intestinal";"FABP2";"unknown";"binder"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Fatty acid-binding protein, intestinal";"FABP2";"unknown";"binder"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"inhibitor"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M02AA13";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"R02AX02";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"C01EB16";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE51";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"M01AE01";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Ibuprofen";"CC(C)CC1=CC=C(C=C1)C(C)C(O)=O";"2-4 hours";"G02CC01";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CR50";"Penicillin-binding protein 3";"pbp3";"unknown";"inhibitor"
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CE01";"Penicillin-binding protein 3";"pbp3";"unknown";"inhibitor"
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"S01AA14";"Penicillin-binding protein 3";"pbp3";"unknown";"inhibitor"
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CR50";"Beta-lactamase TEM";"bla";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CE01";"Beta-lactamase TEM";"bla";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"S01AA14";"Beta-lactamase TEM";"bla";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CR50";"Solute carrier family 22 member 8";"SLC22A8";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CE01";"Solute carrier family 22 member 8";"SLC22A8";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"S01AA14";"Solute carrier family 22 member 8";"SLC22A8";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CR50";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CE01";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"S01AA14";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CR50";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"J01CE01";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Benzylpenicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O";"In adults with normal renal function is reportedly 0.4–0.9 hours";"S01AA14";"Solute carrier family 15 member 2";"SLC15A2";"unknown";""
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"unknown";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"unknown";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C08CA08";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Nitrendipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC";"";"C09BB06";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Tocainide";"CC(N)C(=O)NC1=C(C)C=CC=C1C";"The average plasma half-life in patients is approximately 15 hours. May be prolonged up to 35 hours in patients with severe renal function impairment (creatinine clearance less than 30 mL per min per 1.73 square meters of body surface area.";"C01BB03";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Echothiophate";"CCOP(=O)(OCC)SCC[N+](C)(C)C";"";"S01EB03";"Cholinesterase";"BCHE";"yes";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"S01AE02";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"J01RA13";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"J01MA06";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"S01AE02";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"J01RA13";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"J01MA06";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"S01AE02";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"J01RA13";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Norfloxacin";"CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1";"3-4 hours";"J01MA06";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD10";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD01";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD05";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD03";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD06";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"J01CA04";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD07";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD04";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"A02BD11";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amoxicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"61.3 minutes";"J01CR02";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Azlocillin";"[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1";"Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment.";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Azlocillin";"[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1";"Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment.";"J01CA09";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Oxybutynin";"CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"12.4-13.2 hours";"G04BD04";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Oxybutynin";"CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"12.4-13.2 hours";"G04BD04";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Oxybutynin";"CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1";"12.4-13.2 hours";"G04BD04";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Acetophenazine";"CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1";"";"N05AB07";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Acetophenazine";"CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1";"";"N05AB07";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Acetophenazine";"CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1";"";"N05AB07";"Androgen receptor";"AR";"unknown";""
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Mitogen-activated protein kinase 1";"MAPK1";"unknown";"inducer"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Mitogen-activated protein kinase 1";"MAPK1";"unknown";"inducer"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Mitogen-activated protein kinase 1";"MAPK1";"unknown";"inducer"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Mitogen-activated protein kinase 1";"MAPK1";"unknown";"inducer"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Mitogen-activated protein kinase 1";"MAPK1";"unknown";"inducer"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Phosphatidylinositol 3-kinase regulatory subunit alpha";"PIK3R1";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Phosphatidylinositol 3-kinase regulatory subunit alpha";"PIK3R1";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Phosphatidylinositol 3-kinase regulatory subunit alpha";"PIK3R1";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Phosphatidylinositol 3-kinase regulatory subunit alpha";"PIK3R1";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Phosphatidylinositol 3-kinase regulatory subunit alpha";"PIK3R1";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Phosphatidylinositol 3-kinase regulatory subunit beta";"PIK3R2";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Phosphatidylinositol 3-kinase regulatory subunit beta";"PIK3R2";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Phosphatidylinositol 3-kinase regulatory subunit beta";"PIK3R2";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Phosphatidylinositol 3-kinase regulatory subunit beta";"PIK3R2";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Phosphatidylinositol 3-kinase regulatory subunit beta";"PIK3R2";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Phosphatidylinositol 3-kinase regulatory subunit gamma";"PIK3R3";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Phosphatidylinositol 3-kinase regulatory subunit gamma";"PIK3R3";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Phosphatidylinositol 3-kinase regulatory subunit gamma";"PIK3R3";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Phosphatidylinositol 3-kinase regulatory subunit gamma";"PIK3R3";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Phosphatidylinositol 3-kinase regulatory subunit gamma";"PIK3R3";"unknown";"agonist"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"CAMP phosphodiesterase";"PDE4";"unknown";"activator"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"CAMP phosphodiesterase";"PDE4";"unknown";"activator"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"CAMP phosphodiesterase";"PDE4";"unknown";"activator"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"CAMP phosphodiesterase";"PDE4";"unknown";"activator"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"CAMP phosphodiesterase";"PDE4";"unknown";"activator"
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AK02";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB51";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03CB01";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"R03AB02";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Isoprenaline";"CC(C)NCC(O)C1=CC(O)=C(O)C=C1";"";"C01CA02";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Melatonin receptor type 1A";"MTNR1A";"yes";"agonist"
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Melatonin receptor type 1B";"MTNR1B";"yes";"agonist"
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Estrogen receptor alpha";"ESR1";"unknown";"antagonist"
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Nuclear receptor ROR-beta";"RORB";"unknown";"agonist"
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Calmodulin";"CALM1";"unknown";""
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Myeloperoxidase";"MPO";"unknown";"inhibitor"
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Eosinophil peroxidase";"EPX";"unknown";"inhibitor"
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Calreticulin";"CALR";"unknown";""
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Acetylserotonin O-methyltransferase";"ASMT";"unknown";""
"Melatonin";"COC1=CC2=C(NC=C2CCNC(C)=O)C=C1";"35 to 50 minutes";"N05CH01";"Ribosyldihydronicotinamide dehydrogenase [quinone]";"NQO2";"unknown";""
"Cefditoren";"[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Mean terminal elimination half-life is 1.6 &plusmn; 0.4 hours in young healthy adults.";"J01DD16";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Cefditoren";"[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"Mean terminal elimination half-life is 1.6 &plusmn; 0.4 hours in young healthy adults.";"J01DD16";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Glipizide";"CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"2-5 hours";"A10BB07";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Glipizide";"CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1";"2-5 hours";"A10BB07";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"agonist"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"Translocator protein";"TSPO";"unknown";"other/unknown"
"Clonazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1";"30-40 hours";"N03AE01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"unknown"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"unknown"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"unknown"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"unknown"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"V03AB05";"Histamine H2 receptor";"HRH2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD02";"Histamine H2 receptor";"HRH2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"R06AD52";"Histamine H2 receptor";"HRH2";"unknown";"antagonist"
"Promethazine";"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C";"16-19 hours";"D04AA10";"Histamine H2 receptor";"HRH2";"unknown";"antagonist"
"Dihydrotachysterol";"CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C";"";"A11CC02";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Mequitazine";"C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12";"";"R06AD07";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Atazanavir";"COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C";"Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).";"J05AE08";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Atazanavir";"COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C";"Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).";"J05AR15";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Fludarabine";"NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"20 hours";"L01BB05";"Ribonucleoside-diphosphate reductase large subunit";"RRM1";"yes";"inhibitor"
"Fludarabine";"NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"20 hours";"L01BB05";"DNA polymerase alpha catalytic subunit";"POLA1";"yes";"inhibitor"
"Fludarabine";"NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"20 hours";"L01BB05";"Deoxycytidine kinase";"DCK";"yes";"agonist"
"Perhexiline";"C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1";"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.";"C08EX02";"Carnitine O-palmitoyltransferase 1, liver isoform";"CPT1A";"yes";"inhibitor"
"Perhexiline";"C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1";"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.";"C08EX02";"Carnitine O-palmitoyltransferase 2, mitochondrial";"CPT2";"yes";"inhibitor"
"Perhexiline";"C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1";"Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.";"C08EX02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"D04AA32";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"D04AA33";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"R06AA02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"R06AA52";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"D04AA32";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"D04AA33";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"R06AA02";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Diphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1";"1-4 hours";"R06AA52";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10AA05";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX06";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BA05";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX03";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX11";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX08";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10AA05";"Dipeptidyl peptidase 4";"DPP4";"no";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX06";"Dipeptidyl peptidase 4";"DPP4";"no";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BA05";"Dipeptidyl peptidase 4";"DPP4";"no";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX03";"Dipeptidyl peptidase 4";"DPP4";"no";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX11";"Dipeptidyl peptidase 4";"DPP4";"no";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX08";"Dipeptidyl peptidase 4";"DPP4";"no";"inhibitor"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10AA05";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX06";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BA05";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX03";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX11";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Atorvastatin";"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1";"14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites";"C10BX08";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Etidronic acid";"CC(O)(P(O)(O)=O)P(O)(O)=O";"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.";"M05BB01";"Receptor-type tyrosine-protein phosphatase S";"PTPRS";"unknown";"inhibitor"
"Etidronic acid";"CC(O)(P(O)(O)=O)P(O)(O)=O";"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.";"M05BA01";"Receptor-type tyrosine-protein phosphatase S";"PTPRS";"unknown";"inhibitor"
"Etidronic acid";"CC(O)(P(O)(O)=O)P(O)(O)=O";"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.";"M05BB01";"V-type proton ATPase catalytic subunit A";"ATP6V1A";"unknown";"inhibitor"
"Etidronic acid";"CC(O)(P(O)(O)=O)P(O)(O)=O";"In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.";"M05BA01";"V-type proton ATPase catalytic subunit A";"ATP6V1A";"unknown";"inhibitor"
"Deslanoside";"C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1";"36 hours";"C01AA07";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Tegaserod";"CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2";"11 &plusmn; 5 hours";"A06AX06";"5-hydroxytryptamine receptor 4";"HTR4";"yes";"antagonistpartial agonist"
"Tegaserod";"CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2";"11 &plusmn; 5 hours";"A06AX06";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"antagonist"
"Tegaserod";"CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2";"11 &plusmn; 5 hours";"A06AX06";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Tegaserod";"CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2";"11 &plusmn; 5 hours";"A06AX06";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Vigabatrin";"NC(CCC(O)=O)C=C";"Neonates, 50 mg/kg = 7.5 ± 2.1 hours (due to reduced renal function); 
Infants = 5.7 hours;
Adults = 7.5 hours;
Elderly = 12 - 13 hours";"N03AG04";"Gamma-aminobutyric acid type B receptor subunit 1";"GABBR1";"yes";"agonist"
"Vigabatrin";"NC(CCC(O)=O)C=C";"Neonates, 50 mg/kg = 7.5 ± 2.1 hours (due to reduced renal function); 
Infants = 5.7 hours;
Adults = 7.5 hours;
Elderly = 12 - 13 hours";"N03AG04";"4-aminobutyrate aminotransferase, mitochondrial";"ABAT";"yes";"inhibitor"
"Diphenoxylate";"CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1";"12-14 hours";"A07DA01";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Diphenoxylate";"CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1";"12-14 hours";"A07DA01";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"J01GA01";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"J04AM01";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"A07AA04";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"A07AA54";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"J01GA01";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"J04AM01";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"A07AA04";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Streptomycin";"CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O";"5 - 6 hours in adults with normal renal function";"A07AA54";"Protein-arginine deiminase type-4";"PADI4";"unknown";""
"Orlistat";"CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O";"1 to 2 hours.";"A08AB01";"Pancreatic triacylglycerol lipase";"PNLIP";"yes";"inhibitor"
"Orlistat";"CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O";"1 to 2 hours.";"A08AB01";"Gastric triacylglycerol lipase";"LIPF";"yes";"inhibitor"
"Orlistat";"CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O";"1 to 2 hours.";"A08AB01";"Fatty acid synthase";"FASN";"yes";"inhibitor"
"Emedastine";"CCOCCN1C(=NC2=CC=CC=C12)N1CCCN(C)CC1";"The elimination half-life of oral emedastine in plasma is 3-4 hours.";"S01GX06";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB51";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"N07AX01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB51";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"N07AX01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB51";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"N07AX01";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB51";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"partial agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"S01EB01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"partial agonist"
"Pilocarpine";"CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O";"0.76 hours";"N07AX01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"partial agonist"
"Benzocaine";"CCOC(=O)C1=CC=C(N)C=C1";"";"R02AD01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Benzocaine";"CCOC(=O)C1=CC=C(N)C=C1";"";"D04AB04";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Benzocaine";"CCOC(=O)C1=CC=C(N)C=C1";"";"N01BA05";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Benzocaine";"CCOC(=O)C1=CC=C(N)C=C1";"";"C05AD03";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Primaquine";"COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1";"3.7-7.4 hours";"P01BA03";"Keratin, type II cytoskeletal 7";"KRT7";"unknown";"other/unknown"
"Primaquine";"COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1";"3.7-7.4 hours";"P01BA03";"Ribosyldihydronicotinamide dehydrogenase [quinone]";"NQO2";"unknown";"inhibitor"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"Prostacyclin receptor";"PTGIR";"yes";"agonist"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"Prostaglandin E2 receptor EP1 subtype";"PTGER1";"yes";"agonist"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"unknown";"inducer"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inducer"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"cAMP-specific 3',5'-cyclic phosphodiesterase 4C";"PDE4C";"unknown";"inducer"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"unknown";"inducer"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"Tissue-type plasminogen activator";"PLAT";"unknown";"other/unknown"
"Iloprost";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O";"20-30 minutes";"B01AC11";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"agonist"
"Deserpidine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"";"C02AA05";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Deserpidine";"[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"";"C02LA03";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Butenafine";"CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12";"Following topical application, a biphasic decline of plasma butenafine concentrations was observed with the half-lives estimated to be 35 hours initial and over 150 hours terminal.";"D01AE23";"Squalene monooxygenase";"SQLE";"yes";"inhibitor"
"Ouabain";"[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O";"";"C01AC01";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Ouabain";"[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O";"";"C01AC01";"Sodium/potassium-transporting ATPase subunit alpha-2";"ATP1A2";"unknown";"inhibitor"
"Ouabain";"[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O";"";"C01AC01";"Sodium/potassium-transporting ATPase subunit alpha-3";"ATP1A3";"unknown";"inhibitor"
"Fluvastatin";"CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12";"3 hours";"C10AA04";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Leflunomide";"CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F";"2 weeks";"L04AA13";"Dihydroorotate dehydrogenase (quinone), mitochondrial";"DHODH";"yes";"inhibitor"
"Leflunomide";"CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F";"2 weeks";"L04AA13";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Leflunomide";"CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F";"2 weeks";"L04AA13";"Protein-tyrosine kinase 2-beta";"PTK2B";"unknown";"antagonist"
"Rosuvastatin";"CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O";"19 hours";"C10BX10";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Rosuvastatin";"CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O";"19 hours";"C10BX05";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Rosuvastatin";"CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O";"19 hours";"C10BA06";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Rosuvastatin";"CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O";"19 hours";"C10AA07";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Rosuvastatin";"CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O";"19 hours";"C10BX07";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Rosuvastatin";"CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O";"19 hours";"G01AE10";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Rosuvastatin";"CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O";"19 hours";"C10BX09";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Flucytosine";"NC1=C(F)C=NC(=O)N1";"2.4 to 4.8 hours.";"D01AE21";"DNA (cytosine-5)-methyltransferase 1";"DNMT1";"unknown";"other"
"Flucytosine";"NC1=C(F)C=NC(=O)N1";"2.4 to 4.8 hours.";"J02AX01";"DNA (cytosine-5)-methyltransferase 1";"DNMT1";"unknown";"other"
"Flucytosine";"NC1=C(F)C=NC(=O)N1";"2.4 to 4.8 hours.";"D01AE21";"Thymidylate synthase";"TMP1";"unknown";"inhibitor"
"Flucytosine";"NC1=C(F)C=NC(=O)N1";"2.4 to 4.8 hours.";"J02AX01";"Thymidylate synthase";"TMP1";"unknown";"inhibitor"
"Pimozide";"FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1";"29 &plusmn; 10 hours (single-dose study of healthy volunteers).";"N05AG02";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Pimozide";"FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1";"29 &plusmn; 10 hours (single-dose study of healthy volunteers).";"N05AG02";"D(3) dopamine receptor";"DRD3";"yes";"antagonist"
"Pimozide";"FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1";"29 &plusmn; 10 hours (single-dose study of healthy volunteers).";"N05AG02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Pimozide";"FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1";"29 &plusmn; 10 hours (single-dose study of healthy volunteers).";"N05AG02";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Capecitabine";"CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O";"45-60 minutes for capecitabine and its metabolites.";"L01BC06";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Arbutamine";"O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1";"Elimination half-life is approximately 8 minutes.";"C01CA22";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Arbutamine";"O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1";"Elimination half-life is approximately 8 minutes.";"C01CA22";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"agonist"
"Arbutamine";"O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1";"Elimination half-life is approximately 8 minutes.";"C01CA22";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Quinacrine";"CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2";"5 to 14 days";"P01AX05";"85/88 kDa calcium-independent phospholipase A2";"PLA2G6";"yes";"inhibitor"
"Quinacrine";"CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2";"5 to 14 days";"P01AX05";"Cytosolic phospholipase A2";"PLA2G4A";"yes";"inhibitor"
"Quinacrine";"CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2";"5 to 14 days";"P01AX05";"Inactive phospholipase C-like protein 1";"PLCL1";"yes";"inhibitor"
"Sertraline";"CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12";"The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].";"N06AB06";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Sertraline";"CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12";"The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].";"N06AB06";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Sertraline";"CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12";"The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].";"N06AB06";"Sigma receptor";"PGRMC1";"unknown";"antagonist"
"Sertraline";"CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12";"The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours [FDA Label].";"N06AB06";"Sigma receptor";"SIGMAR1";"unknown";"antagonist"
"Sibutramine";"CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1";"1.1 hours";"A08AA10";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Sibutramine";"CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1";"1.1 hours";"A08AA10";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Sibutramine";"CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1";"1.1 hours";"A08AA10";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Levocabastine";"C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1";"36 hours (after oral administration)";"R01AC02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Levocabastine";"C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1";"36 hours (after oral administration)";"S01GX02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Levocabastine";"C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1";"36 hours (after oral administration)";"R01AC02";"Neurotensin receptor type 2";"NTSR2";"yes";"partial antagonist"
"Levocabastine";"C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1";"36 hours (after oral administration)";"S01GX02";"Neurotensin receptor type 2";"NTSR2";"yes";"partial antagonist"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Methyprylon";"CCC1(CC)C(=O)NCC(C)C1=O";"6-16 hours";"N05CE02";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Trilostane";"[H][C@]12O[C@]11CC[C@@]3([H])[C@]4([H])CC[C@H](O)[C@@]4(C)CC[C@]3([H])[C@@]1(C)CC(C#N)=C2O";"8 hours.";"H02CA01";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1";"HSD3B1";"yes";"inhibitor"
"Trilostane";"[H][C@]12O[C@]11CC[C@@]3([H])[C@]4([H])CC[C@H](O)[C@@]4(C)CC[C@]3([H])[C@@]1(C)CC(C#N)=C2O";"8 hours.";"H02CA01";"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2";"HSD3B2";"yes";"inhibitor"
"Trilostane";"[H][C@]12O[C@]11CC[C@@]3([H])[C@]4([H])CC[C@H](O)[C@@]4(C)CC[C@]3([H])[C@@]1(C)CC(C#N)=C2O";"8 hours.";"H02CA01";"Estrogen receptor alpha";"ESR1";"yes";"allosteric modulator"
"Trilostane";"[H][C@]12O[C@]11CC[C@@]3([H])[C@]4([H])CC[C@H](O)[C@@]4(C)CC[C@]3([H])[C@@]1(C)CC(C#N)=C2O";"8 hours.";"H02CA01";"Estrogen receptor beta";"ESR2";"yes";"allosteric modulator"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Nitric oxide synthase, endothelial";"NOS3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Nitric oxide synthase, endothelial";"NOS3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Nitric oxide synthase, endothelial";"NOS3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Nitric oxide synthase, endothelial";"NOS3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Nitric oxide synthase, endothelial";"NOS3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Nitric oxide synthase, endothelial";"NOS3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Nitric oxide synthase, endothelial";"NOS3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Nitric oxide synthase, inducible";"NOS2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Nitric oxide synthase, inducible";"NOS2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Nitric oxide synthase, inducible";"NOS2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Nitric oxide synthase, inducible";"NOS2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Nitric oxide synthase, inducible";"NOS2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Nitric oxide synthase, inducible";"NOS2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Nitric oxide synthase, inducible";"NOS2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Calcium-activated potassium channel subunit beta-1";"KCNMB1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Calcium-activated potassium channel subunit beta-1";"KCNMB1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Calcium-activated potassium channel subunit beta-1";"KCNMB1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Calcium-activated potassium channel subunit beta-1";"KCNMB1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Calcium-activated potassium channel subunit beta-1";"KCNMB1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Calcium-activated potassium channel subunit beta-1";"KCNMB1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Calcium-activated potassium channel subunit beta-1";"KCNMB1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Calcium-activated potassium channel subunit beta-2";"KCNMB2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Calcium-activated potassium channel subunit beta-2";"KCNMB2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Calcium-activated potassium channel subunit beta-2";"KCNMB2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Calcium-activated potassium channel subunit beta-2";"KCNMB2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Calcium-activated potassium channel subunit beta-2";"KCNMB2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Calcium-activated potassium channel subunit beta-2";"KCNMB2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Calcium-activated potassium channel subunit beta-2";"KCNMB2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Calcium-activated potassium channel subunit beta-3";"KCNMB3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Calcium-activated potassium channel subunit beta-3";"KCNMB3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Calcium-activated potassium channel subunit beta-3";"KCNMB3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Calcium-activated potassium channel subunit beta-3";"KCNMB3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Calcium-activated potassium channel subunit beta-3";"KCNMB3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Calcium-activated potassium channel subunit beta-3";"KCNMB3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Calcium-activated potassium channel subunit beta-3";"KCNMB3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Calcium-activated potassium channel subunit beta-4";"KCNMB4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Calcium-activated potassium channel subunit beta-4";"KCNMB4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Calcium-activated potassium channel subunit beta-4";"KCNMB4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Calcium-activated potassium channel subunit beta-4";"KCNMB4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Calcium-activated potassium channel subunit beta-4";"KCNMB4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Calcium-activated potassium channel subunit beta-4";"KCNMB4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Calcium-activated potassium channel subunit beta-4";"KCNMB4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Small conductance calcium-activated potassium channel protein 1";"KCNN1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Small conductance calcium-activated potassium channel protein 1";"KCNN1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Small conductance calcium-activated potassium channel protein 1";"KCNN1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Small conductance calcium-activated potassium channel protein 1";"KCNN1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Small conductance calcium-activated potassium channel protein 1";"KCNN1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Small conductance calcium-activated potassium channel protein 1";"KCNN1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Small conductance calcium-activated potassium channel protein 1";"KCNN1";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Small conductance calcium-activated potassium channel protein 2";"KCNN2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Small conductance calcium-activated potassium channel protein 2";"KCNN2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Small conductance calcium-activated potassium channel protein 2";"KCNN2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Small conductance calcium-activated potassium channel protein 2";"KCNN2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Small conductance calcium-activated potassium channel protein 2";"KCNN2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Small conductance calcium-activated potassium channel protein 2";"KCNN2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Small conductance calcium-activated potassium channel protein 2";"KCNN2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Small conductance calcium-activated potassium channel protein 3";"KCNN3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Small conductance calcium-activated potassium channel protein 3";"KCNN3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Small conductance calcium-activated potassium channel protein 3";"KCNN3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Small conductance calcium-activated potassium channel protein 3";"KCNN3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Small conductance calcium-activated potassium channel protein 3";"KCNN3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Small conductance calcium-activated potassium channel protein 3";"KCNN3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Small conductance calcium-activated potassium channel protein 3";"KCNN3";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A01AB09";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"A07AC01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"J02AB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"S02AA13";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Miconazole";"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC52";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Cefuroxime";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O";"Approximately 80 minutes following intramuscular or intravenous injection.";"S01AA27";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefuroxime";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O";"Approximately 80 minutes following intramuscular or intravenous injection.";"J01DC02";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefuroxime";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O";"Approximately 80 minutes following intramuscular or intravenous injection.";"J01RA03";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Papaverine";"COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1";"0.5-2 hours";"G04BE02";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Papaverine";"COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1";"0.5-2 hours";"G04BE52";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Papaverine";"COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1";"0.5-2 hours";"A03AD01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Papaverine";"COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1";"0.5-2 hours";"G04BE02";"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A";"PDE10A";"unknown";"inhibitor"
"Papaverine";"COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1";"0.5-2 hours";"G04BE52";"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A";"PDE10A";"unknown";"inhibitor"
"Papaverine";"COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1";"0.5-2 hours";"A03AD01";"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A";"PDE10A";"unknown";"inhibitor"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB54";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB54";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB04";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB54";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB04";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB54";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Chlorphenamine";"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1";"21-27 hours";"R06AB04";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08CA55";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Nifedipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC";"2 hours";"C08GA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Trimethaphan";"O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1";"";"C02BA01";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"yes";"antagonist"
"Atovaquone";"OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O";"2.2 to 3.2 days";"P01AX06";"Cytochrome b";"MT-CYB";"yes";"inhibitor"
"Atovaquone";"OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O";"2.2 to 3.2 days";"P01AX06";"Dihydroorotate dehydrogenase (quinone), mitochondrial";"";"yes";"inhibitor"
"Atovaquone";"OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O";"2.2 to 3.2 days";"P01AX06";"Dihydroorotate dehydrogenase (quinone), mitochondrial";"DHODH";"unknown";"inhibitor"
"Amiodarone";"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1";"58 days (range 15-142 days)";"C01BD01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Amiodarone";"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1";"58 days (range 15-142 days)";"C01BD01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Amiodarone";"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1";"58 days (range 15-142 days)";"C01BD01";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"unknown";"inhibitor"
"Amiodarone";"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1";"58 days (range 15-142 days)";"C01BD01";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"yes";"inhibitor"
"Amiodarone";"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1";"58 days (range 15-142 days)";"C01BD01";"Thyroid hormone receptor alpha";"THRA";"unknown";""
"Amiodarone";"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1";"58 days (range 15-142 days)";"C01BD01";"Thyroid hormone receptor beta";"THRB";"unknown";""
"Amiodarone";"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1";"58 days (range 15-142 days)";"C01BD01";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"V03AH01";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inducer"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"C02DA01";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inducer"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"G01AE10";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inducer"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"V03AH01";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"C02DA01";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"G01AE10";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"V03AH01";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"C02DA01";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"G01AE10";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"V03AH01";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"other"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"C02DA01";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"other"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"G01AE10";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"other"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"V03AH01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"C02DA01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"G01AE10";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"other"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"V03AH01";"Solute carrier family 12 member 3";"SLC12A3";"unknown";"unknown"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"C02DA01";"Solute carrier family 12 member 3";"SLC12A3";"unknown";"unknown"
"Diazoxide";"CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2";"28 &plusmn;8.3 hours in normal adults.";"G01AE10";"Solute carrier family 12 member 3";"SLC12A3";"unknown";"unknown"
"Gliclazide";"CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1";"10.4 hours. Duration of action is 10-24 hours.";"A10BB09";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"binder"
"Gliclazide";"CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1";"10.4 hours. Duration of action is 10-24 hours.";"A10BB09";"Vascular endothelial growth factor A";"VEGFA";"unknown";"other/unknown"
"Phenacemide";"NC(=O)NC(=O)CC1=CC=CC=C1";"22-25 hours.";"N03AX07";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Ambenonium";"CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl";"";"N07AA30";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Tolbutamide";"CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1";"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.";"V04CA01";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Tolbutamide";"CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1";"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.";"A10BB03";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Tolbutamide";"CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1";"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.";"V04CA01";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"unknown";"inhibitor"
"Tolbutamide";"CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1";"Approximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.";"A10BB03";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"unknown";"inhibitor"
"Dutasteride";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F";"5 weeks";"G04CB02";"3-oxo-5-alpha-steroid 4-dehydrogenase 2";"SRD5A2";"yes";"inhibitor"
"Dutasteride";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F";"5 weeks";"G04CA52";"3-oxo-5-alpha-steroid 4-dehydrogenase 2";"SRD5A2";"yes";"inhibitor"
"Dutasteride";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F";"5 weeks";"G04CB02";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Dutasteride";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F";"5 weeks";"G04CA52";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Econazole";"ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF05";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonist"
"Econazole";"ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC03";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonist"
"Econazole";"ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF20";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonist"
"Econazole";"ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Econazole";"ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"D01AC03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Econazole";"ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"";"G01AF20";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Bicalutamide";"CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F";"5.9 days";"L02BB03";"Androgen receptor";"AR";"yes";"antagonist"
"Rabeprazole";"COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1";"1-2 hours (in plasma)";"A02BC04";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Rabeprazole";"COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1";"1-2 hours (in plasma)";"M01AA05";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Rabeprazole";"COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1";"1-2 hours (in plasma)";"M02AA03";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Rabeprazole";"COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1";"1-2 hours (in plasma)";"A02BC54";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Prednicarbate";"[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"";"D07AC18";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Proguanil";"CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1";"Approximately 20 hours";"P01BB51";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Proguanil";"CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1";"Approximately 20 hours";"P01BB01";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Proguanil";"CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1";"Approximately 20 hours";"P01BB51";"Bifunctional dihydrofolate reductase-thymidylate synthase";"";"unknown";"inhibitor"
"Proguanil";"CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1";"Approximately 20 hours";"P01BB01";"Bifunctional dihydrofolate reductase-thymidylate synthase";"";"unknown";"inhibitor"
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD12";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD09";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BG03";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD06";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD05";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD12";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD09";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BG03";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD06";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD05";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD12";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD09";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BG03";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD06";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD05";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD12";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD09";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BG03";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD06";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Pioglitazone";"CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1";"The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from 3 to 7 hours and 16 to 24 hours, respectively [FDA Label].";"A10BD05";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Tiludronic acid";"OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O";"Half-life in healthy subjects is 50 hours following administration of a 400 mg single oral dose. Half-life in pagetic patients is about 150 hours following administration of 400 mg tiludronate a day for 12 days. In patients with renal insufficiency (creatinine clearance between 11 and 18 mL per minute [mL/min]), half-life is 205 hours from plasma after administration of a single, oral dose equivalent to 400 mg tiludronate.";"M05BA05";"V-type proton ATPase catalytic subunit A";"ATP6V1A";"unknown";"inhibitor"
"Tiludronic acid";"OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O";"Half-life in healthy subjects is 50 hours following administration of a 400 mg single oral dose. Half-life in pagetic patients is about 150 hours following administration of 400 mg tiludronate a day for 12 days. In patients with renal insufficiency (creatinine clearance between 11 and 18 mL per minute [mL/min]), half-life is 205 hours from plasma after administration of a single, oral dose equivalent to 400 mg tiludronate.";"M05BA05";"Tyrosine-protein phosphatase non-receptor type 1";"PTPN1";"unknown";"inhibitor"
"Doxacurium chloride";"[Cl-].[Cl-].COC1=CC(C[C@@H]2C3=C(OC)C(OC)=C(OC)C=C3CC[N@@+]2(C)CCCOC(=O)CCC(=O)OCCC[N@@+]2(C)CCC3=C([C@@H]2CC2=CC(OC)=C(OC)C(OC)=C2)C(OC)=C(OC)C(OC)=C3)=CC(OC)=C1OC";"99 minutes in normal healthy adults.";"M03AC07";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Doxacurium chloride";"[Cl-].[Cl-].COC1=CC(C[C@@H]2C3=C(OC)C(OC)=C(OC)C=C3CC[N@@+]2(C)CCCOC(=O)CCC(=O)OCCC[N@@+]2(C)CCC3=C([C@@H]2CC2=CC(OC)=C(OC)C(OC)=C2)C(OC)=C(OC)C(OC)=C3)=CC(OC)=C1OC";"99 minutes in normal healthy adults.";"M03AC07";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"NADH dehydrogenase [ubiquinone] 1 subunit C2";"NDUFC2";"unknown";"inhibitor"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Vascular endothelial growth factor A";"VEGFA";"unknown";"other"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Natriuretic peptides B";"NPPB";"unknown";"other"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Gap junction alpha-1 protein";"GJA1";"unknown";"other"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Vascular cell adhesion protein 1";"VCAM1";"unknown";"inhibitor"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"E-selectin";"SELE";"unknown";"inhibitor"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Hypoxia-inducible factor 1-alpha";"HIF1A";"unknown";"modulator"
"Carvedilol";"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2";"7-10 hours";"C07AG02";"Inward rectifier potassium channel 4";"KCNJ4";"unknown";""
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"A02BD10";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"J01RA05";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"S01AE05";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"J01MA12";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"A02BD10";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"J01RA05";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"S01AE05";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"J01MA12";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"A02BD10";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"J01RA05";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"S01AE05";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Levofloxacin";"C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"6-8 hours";"J01MA12";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Sulfinpyrazone";"O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1";"Approximately 4-6 hours";"M04AB02";"Canalicular multispecific organic anion transporter 1";"ABCC2";"yes";"inhibitor"
"Sulfinpyrazone";"O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1";"Approximately 4-6 hours";"M04AB02";"Multidrug resistance-associated protein 1";"ABCC1";"yes";"inhibitor"
"Sulfinpyrazone";"O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1";"Approximately 4-6 hours";"M04AB02";"Solute carrier family 22 member 12";"SLC22A12";"yes";"inhibitor"
"Sulfinpyrazone";"O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1";"Approximately 4-6 hours";"M04AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Cefapirin";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O";"";"J01DB08";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefadroxil";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"1.5 hours";"J01DB05";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Cefadroxil";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"1.5 hours";"J01DB05";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefadroxil";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"1.5 hours";"J01DB05";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Cefadroxil";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"1.5 hours";"J01DB05";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Micafungin";"CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O";"14-17 hours";"J02AX05";"1,3-beta-glucan synthase component FKS1";"fksA";"yes";"inhibitor"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"binder"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Histamine H4 receptor";"HRH4";"unknown";"binder"
"Doxepin";"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12";"Half life of doxepin ranges from 6 to 24.5 hours. The mean distribution half-life of doxepin was 2.0 hrs and the mean elimination half-life ranges from 15.3 to 17.9 hrs [A1945, L1347]. The apparent terminal half-life of desmethyldoxepin was 31 hours [L1347].";"N06AA12";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Amifostine";"NCCCNCCSP(O)(O)=O";"8 minutes";"V03AF05";"Alkaline phosphatase, placental-like";"ALPPL2";"yes";"inducer"
"Amifostine";"NCCCNCCSP(O)(O)=O";"8 minutes";"V03AF05";"Ectonucleotide pyrophosphatase/phosphodiesterase family member 1";"ENPP1";"unknown";"inducer"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"S01EC02";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"S01EC02";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"S01EC02";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 4";"CA4";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"S01EC02";"Carbonic anhydrase 7";"CA7";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 7";"CA7";"yes";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"S01EC02";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Diclofenamide";"NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Sulfoxone";"OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1";"3-8 hours";"J04BA03";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Diphenylpyraline";"CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1";"";"R06AA57";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Diphenylpyraline";"CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1";"";"R06AA07";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Diphenylpyraline";"CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1";"";"R06AA57";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Diphenylpyraline";"CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1";"";"R06AA07";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CF02";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CR50";"Beta-lactamase";"ampC";"unknown";"inducer"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CF02";"Beta-lactamase";"ampC";"unknown";"inducer"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CF02";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CF02";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CR50";"Penicillin-binding protein 3";"pbpB";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CF02";"Penicillin-binding protein 3";"pbpB";"yes";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CR50";"D-alanyl-D-alanine carboxypeptidase DacA";"dacA";"unknown";"inhibitor"
"Cloxacillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O";"";"J01CF02";"D-alanyl-D-alanine carboxypeptidase DacA";"dacA";"unknown";"inhibitor"
"Flavoxate";"CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1";"";"G04BD02";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Flavoxate";"CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1";"";"G04BD02";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"other/unknown"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Nefazodone";"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1";"2-4 hours";"N06AX06";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"antagonist"
"Cefprozil";"[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"1.3 hours";"J01DC10";"Penicillin-binding protein 1A";"ponA";"yes";"inhibitor"
"Cefprozil";"[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"1.3 hours";"J01DC10";"Penicillin-binding protein 2x";"pbpX";"yes";"inhibitor"
"Cefprozil";"[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O";"1.3 hours";"J01DC10";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"other"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Sphingomyelin phosphodiesterase";"SMPD1";"unknown";"inhibitor"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Alpha-1 adrenergic receptors";"ADRA1A";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Alpha-1 adrenergic receptors";"ADRA1B";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Alpha-1 adrenergic receptors";"ADRA1D";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"binder"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"binder"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"D(2) dopamine receptor";"DRD2";"unknown";"binder"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";"binder"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";"binder"
"Desipramine";"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12";"7-60+ hours; 70% eliminated renally";"N06AA01";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";"binder"
"Sertaconazole";"ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl";"";"D01AC14";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Sertaconazole";"ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl";"";"G01AF20";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Sertaconazole";"ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl";"";"G01AF19";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Thiamylal";"CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O";"Although no studies have been performed on humans, the half-life in cats is 14.3 hours.";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Thiamylal";"CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O";"Although no studies have been performed on humans, the half-life in cats is 14.3 hours.";"N05CB01";"ATP-sensitive inward rectifier potassium channel 8";"KCNJ8";"yes";"inhibitor"
"Thiamylal";"CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O";"Although no studies have been performed on humans, the half-life in cats is 14.3 hours.";"N05CB01";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"yes";"inhibitor"
"Gemifloxacin";"CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O";"7 (&plusmn; 2) hours";"J01MA15";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Gemifloxacin";"CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O";"7 (&plusmn; 2) hours";"J01MA15";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Bupropion";"CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1";"24 hours";"A08AA62";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Bupropion";"CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1";"24 hours";"N06AX12";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Bupropion";"CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1";"24 hours";"A08AA62";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Bupropion";"CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1";"24 hours";"N06AX12";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Bupropion";"CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1";"24 hours";"A08AA62";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"antagonist"
"Bupropion";"CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1";"24 hours";"N06AX12";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"antagonist"
"Trimetrexate";"COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC";"11 to 20 hours";"P01AX07";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Potassium channel subfamily K member 3";"KCNK3";"yes";"binder"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Potassium channel subfamily K member 9";"KCNK9";"yes";"binder"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";"antagonist"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Glutamate receptor ionotropic, NMDA 3B";"GRIN3B";"unknown";"antagonist"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"antagonist"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";"allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Rhodopsin";"RHO";"unknown";"other"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"G protein-activated inward rectifier potassium channel 2";"KCNJ6";"unknown";"inhibitor"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"G protein-activated inward rectifier potassium channel 1";"KCNJ3";"unknown";"inhibitor"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"NADH-ubiquinone oxidoreductase chain 1";"MT-ND1";"unknown";"inhibitor"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Intermediate conductance calcium-activated potassium channel protein 4";"KCNN4";"unknown";"inhibitor"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"ATP synthase subunit delta, mitochondrial";"ATP5D";"unknown";"other/unknown"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"unknown";"other/unknown"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";"other/unknown"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2";"GNG2";"unknown";"other/unknown"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"Neuropeptide S receptor";"NPSR1";"unknown";"other/unknown"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Halothane";"FC(F)(F)C(Cl)Br";"";"N01AB01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Chloroprocaine";"CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1";"21 +/- 2 seconds";"N01BA04";"Sodium channel protein type 10 subunit alpha";"SCN10A";"yes";"inhibitor"
"Chloroprocaine";"CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1";"21 +/- 2 seconds";"N01BA04";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";"antagonist"
"Chloroprocaine";"CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1";"21 +/- 2 seconds";"N01BA04";"Neuronal acetylcholine receptor subunit alpha-10";"CHRNA10";"unknown";"antagonist"
"Chloroprocaine";"CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1";"21 +/- 2 seconds";"N01BA04";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Chloroprocaine";"CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1";"21 +/- 2 seconds";"N01BA04";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Terazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1";"12 hours";"G04CA03";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Terazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1";"12 hours";"G04CA03";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Terazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1";"12 hours";"G04CA03";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Terazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1";"12 hours";"G04CA03";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Terazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1";"12 hours";"G04CA03";"Potassium voltage-gated channel subfamily H member 6";"KCNH6";"unknown";"inhibitor"
"Terazosin";"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1";"12 hours";"G04CA03";"Potassium voltage-gated channel subfamily H member 7";"KCNH7";"unknown";"inhibitor"
"Amdinocillin";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1";"Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.";"J01CA11";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Amdinocillin";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1";"Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.";"J01CA11";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Amdinocillin";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1";"Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.";"J01CA11";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Amdinocillin";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1";"Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.";"J01CA11";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Amdinocillin";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1";"Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.";"J01CA11";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Amdinocillin";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1";"Approximately 1 hour in patients with normal renal function. Increases to 3 to 6 hours in anephric patients.";"J01CA11";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Calcium Chloride";"[Cl-].[Cl-].[Ca++]";"";"A11GB01";"Protein S100-A13";"S100A13";"unknown";""
"Calcium Chloride";"[Cl-].[Cl-].[Ca++]";"";"A12AA07";"Protein S100-A13";"S100A13";"unknown";""
"Calcium Chloride";"[Cl-].[Cl-].[Ca++]";"";"B05XA07";"Protein S100-A13";"S100A13";"unknown";""
"Calcium Chloride";"[Cl-].[Cl-].[Ca++]";"";"G04BA03";"Protein S100-A13";"S100A13";"unknown";""
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"J01MA01";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"S02AA16";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"J01RA09";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"S01AE01";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"J01MA01";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"S02AA16";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"J01RA09";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"S01AE01";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"J01MA01";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"S02AA16";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"J01RA09";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Ofloxacin";"CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1";"9 hours";"S01AE01";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";"inhibitor"
"Cilostazol";"O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2";"11-13 hours.";"B01AC23";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Itraconazole";"CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"21 hours";"J02AC02";"Lanosterol 14-alpha demethylase";"CYP51A1";"yes";"inhibitor"
"Itraconazole";"CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1";"21 hours";"J02AC02";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Procarbazine";"CNNCC1=CC=C(C=C1)C(=O)NC(C)C";"10 minutes";"L01XB01";"Monoamine oxidase";"MAOA";"yes";"inhibitor"
"Procarbazine";"CNNCC1=CC=C(C=C1)C(=O)NC(C)C";"10 minutes";"L01XB01";"Monoamine oxidase";"MAOB";"yes";"inhibitor"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"yes";"inducer"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Thioredoxin reductase 1, cytoplasmic";"TXNRD1";"yes";"inhibitor"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Transcription factor AP-1";"JUN";"yes";"inducer"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"G1/S-specific cyclin-D1";"CCND1";"yes";"antagonist"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Mitogen-activated protein kinase 3";"MAPK3";"yes";"inducer"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Mitogen-activated protein kinase 1";"MAPK1";"yes";"inducer"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"RAC-alpha serine/threonine-protein kinase";"AKT1";"unknown";"inducer"
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Cyclin-dependent kinase inhibitor 1";"CDKN1A";"unknown";""
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Histone deacetylase 1";"HDAC1";"unknown";""
"Arsenic trioxide";"O=[As]O[As]=O";"";"L01XX27";"Protein PML";"PML";"unknown";""
"Guanethidine";"NC(N)=NCCN1CCCCCCC1";"1.5 days";"C02CC02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inducer"
"Guanethidine";"NC(N)=NCCN1CCCCCCC1";"1.5 days";"C02LF01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inducer"
"Guanethidine";"NC(N)=NCCN1CCCCCCC1";"1.5 days";"S01EX01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inducer"
"Moclobemide";"ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1";"1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted";"N06AG02";"Amine oxidase [flavin-containing] A";"MAOA";"yes";"antagonistinhibitor"
"Moclobemide";"ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1";"1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted";"N06AG02";"Monoamine oxidase";"MAOA";"unknown";"antagonist"
"Moclobemide";"ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1";"1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted";"N06AG02";"Monoamine oxidase";"MAOB";"unknown";"antagonist"
"Moclobemide";"ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1";"1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted";"N06AG02";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";"antagonist"
"Kanamycin";"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O";"2.5 hours";"J01GB04";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Kanamycin";"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O";"2.5 hours";"A07AA08";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Kanamycin";"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O";"2.5 hours";"S01AA24";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC51";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"N04AB02";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC01";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC51";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"N04AB02";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC01";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC51";"Glutamate receptor ionotropic, NMDA 3B";"GRIN3B";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"N04AB02";"Glutamate receptor ionotropic, NMDA 3B";"GRIN3B";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC01";"Glutamate receptor ionotropic, NMDA 3B";"GRIN3B";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC51";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"N04AB02";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC01";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC51";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"N04AB02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC51";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"N04AB02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC01";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC51";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";"inhibitor"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"N04AB02";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";"inhibitor"
"Orphenadrine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C";"13-20 hours";"M03BC01";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";"inhibitor"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N03AA02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Phenobarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1";"53 to 118 hours (mean 79 hours)";"N05CB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Escitalopram";"CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"27-32 hours";"N06AB10";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Escitalopram";"CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"27-32 hours";"N06AB10";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"inhibitor"
"Escitalopram";"CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"27-32 hours";"N06AB10";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Escitalopram";"CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"27-32 hours";"N06AB10";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Escitalopram";"CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"27-32 hours";"N06AB10";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Escitalopram";"CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1";"27-32 hours";"N06AB10";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Cyclizine";"CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"20 hours";"R06AE03";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Cyclizine";"CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"20 hours";"R06AE53";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Cyclizine";"CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"20 hours";"R06AE03";"Estrogen sulfotransferase";"SULT1E1";"unknown";"inhibitor"
"Cyclizine";"CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"20 hours";"R06AE53";"Estrogen sulfotransferase";"SULT1E1";"unknown";"inhibitor"
"Idarubicin";"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O";"22 hours";"L01DB06";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Chlormezanone";"CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O";"";"M03BB02";"Translocator protein";"TSPO";"yes";"agonist"
"Chlormezanone";"CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O";"";"M03BB72";"Translocator protein";"TSPO";"yes";"agonist"
"Chlormezanone";"CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O";"";"M03BB52";"Translocator protein";"TSPO";"yes";"agonist"
"Podofilox";"[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O";"1.0 to 4.5 hours.";"D06BB04";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Podofilox";"[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O";"1.0 to 4.5 hours.";"D06BB04";"Tubulin alpha-4A chain";"TUBA4A";"yes";"inhibitor"
"Podofilox";"[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O";"1.0 to 4.5 hours.";"D06BB04";"Tubulin beta chain";"TUBB";"yes";"inhibitor"
"Rescinnamine";"[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02AA01";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Rescinnamine";"[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA02";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Rescinnamine";"[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2";"";"C02LA52";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Ifosfamide";"ClCCNP1(=O)OCCCN1CCCl";"7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.";"L01AA06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Propafenone";"CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1";"2-10 hours";"C01BC03";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Propafenone";"CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1";"2-10 hours";"C01BC03";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Propafenone";"CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1";"2-10 hours";"C01BC03";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"antagonist"
"Propafenone";"CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1";"2-10 hours";"C01BC03";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Naloxone";"OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O";"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr";"V03AB15";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Naloxone";"OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O";"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr";"V03AB15";"Delta-type opioid receptor";"OPRD1";"yes";"antagonist"
"Naloxone";"OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O";"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr";"V03AB15";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Naloxone";"OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O";"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr";"V03AB15";"Cyclic AMP-responsive element-binding protein 1";"CREB1";"no";"other/unknown"
"Naloxone";"OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O";"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr";"V03AB15";"Estrogen receptor alpha";"ESR1";"no";"antagonistother/unknown"
"Naloxone";"OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O";"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr";"V03AB15";"Toll-like receptor 4";"TLR4";"unknown";"inhibitor"
"Naloxone";"OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O";"0.4mg IM injection = 1.24 hr
Nasal spray (one 2mg spray) = 1.85 hr
Nasal spray (one 4mg spray) = 2.08 hr";"V03AB15";"Liver carboxylesterase 1";"CES1";"unknown";""
"Domperidone";"ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2";"7 hours";"A03FA03";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Domperidone";"ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2";"7 hours";"A03FA03";"D(3) dopamine receptor";"DRD3";"yes";"antagonist"
"Fluoxymesterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"9.2 hours";"G03BA01";"Androgen receptor";"AR";"yes";"agonist"
"Fluoxymesterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"9.2 hours";"G03BA01";"Estrogen receptor alpha";"ESR1";"yes";"antagonist"
"Fluoxymesterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"9.2 hours";"G03BA01";"Prolactin receptor";"PRLR";"yes";"antagonist"
"Fluoxymesterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"9.2 hours";"G03BA01";"Glucocorticoid receptor";"NR3C1";"unknown";"antagonist"
"Fluoxymesterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"9.2 hours";"G03BA01";"Corticosteroid 11-beta-dehydrogenase isozyme 2";"HSD11B2";"unknown";"inhibitor"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"D(4) dopamine receptor";"DRD4";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Pergolide";"[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC";"27 hours";"N04BC02";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Ciclopirox";"CC1=CC(=O)N(O)C(=C1)C1CCCCC1";"1.7 hours for 1% topical solution.";"G01AX12";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"binder"
"Ciclopirox";"CC1=CC(=O)N(O)C(=C1)C1CCCCC1";"1.7 hours for 1% topical solution.";"D01AE14";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"binder"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"Glycine receptor subunit alpha-1";"GLRA1";"yes";"agonist"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"Glutamate receptor 1";"GRIA1";"yes";"antagonist"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"yes";"inducer"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"inhibitor"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"ATP synthase subunit delta, mitochondrial";"ATP5D";"unknown";"other/unknown"
"Desflurane";"FC(F)OC(F)C(F)(F)F";"";"N01AB07";"NADH-ubiquinone oxidoreductase chain 1";"MT-ND1";"unknown";"unknown"
"Clindamycin";"[H][C@@](C)(Cl)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O";"2.4 hours";"J01FF01";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clindamycin";"[H][C@@](C)(Cl)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O";"2.4 hours";"G01AA10";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clindamycin";"[H][C@@](C)(Cl)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O";"2.4 hours";"D10AF51";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clindamycin";"[H][C@@](C)(Cl)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O";"2.4 hours";"D10AF01";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Dexfenfluramine";"CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F";"17-20 hours";"A08AA04";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Dexfenfluramine";"CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F";"17-20 hours";"A08AA04";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Acebutolol";"CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1";"The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.";"C07AB04";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Acebutolol";"CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1";"The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.";"C07BB04";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Acebutolol";"CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1";"The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.";"C07AB04";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"partial agonist"
"Acebutolol";"CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1";"The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.";"C07BB04";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"partial agonist"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC54";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC04";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC54";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC04";"Carbonic anhydrase 1";"CA1";"unknown";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC54";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC04";"Carbonic anhydrase 4";"CA4";"unknown";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC54";"Carbonic anhydrase 5A, mitochondrial";"CA5A";"unknown";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC04";"Carbonic anhydrase 5A, mitochondrial";"CA5A";"unknown";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC54";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Brinzolamide";"CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O";"111 days";"S01EC04";"Carbonic anhydrase 3";"CA3";"unknown";"inhibitor"
"Flecainide";"FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1";"20 hours (range 12-27 hours)";"C01BC04";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Flecainide";"FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1";"20 hours (range 12-27 hours)";"C01BC04";"Sodium channel protein type 4 subunit alpha";"SCN4A";"yes";"inhibitor"
"Flecainide";"FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1";"20 hours (range 12-27 hours)";"C01BC04";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Estramustine";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]";"20 hours";"L01XX11";"Microtubule-associated protein 2";"MAP2";"yes";"antagonist"
"Estramustine";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]";"20 hours";"L01XX11";"Microtubule-associated protein 1A";"MAP1A";"yes";"antagonist"
"Estramustine";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]";"20 hours";"L01XX11";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estramustine";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]";"20 hours";"L01XX11";"Estrogen receptor beta";"ESR2";"yes";"other/unknown"
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09AA01";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09BA01";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09AA01";"72 kDa type IV collagenase";"MMP2";"unknown";"inhibitor"
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09BA01";"72 kDa type IV collagenase";"MMP2";"unknown";"inhibitor"
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09AA01";"Matrix metalloproteinase-9";"MMP9";"unknown";"inhibitor"
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09BA01";"Matrix metalloproteinase-9";"MMP9";"unknown";"inhibitor"
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09AA01";"Leukotriene A-4 hydrolase";"LTA4H";"unknown";""
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09BA01";"Leukotriene A-4 hydrolase";"LTA4H";"unknown";""
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09AA01";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Captopril";"C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O";"2 hours";"C09BA01";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Zopiclone";"CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.";"N05CF01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Zopiclone";"CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.";"N05CF01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Zopiclone";"CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.";"N05CF01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Zopiclone";"CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.";"N05CF01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Zopiclone";"CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1";"Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.";"N05CF01";"Translocator protein";"TSPO";"unknown";"agonist"
"Tubocurarine";"[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3";"1-2 hours";"M03AA02";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Tubocurarine";"[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3";"1-2 hours";"M03AA02";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Tubocurarine";"[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3";"1-2 hours";"M03AA02";"Acetylcholinesterase";"ACHE";"unknown";"inhibitor"
"Tubocurarine";"[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3";"1-2 hours";"M03AA02";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";""
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"G02CB01";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Bromocriptine";"[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C";"2-8 hours";"N04BC01";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Rifapentine";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O";"";"J04AB05";"DNA-directed RNA polymerase subunit beta'";"rpoC";"yes";"inhibitor"
"Levetiracetam";"CC[C@H](N1CCCC1=O)C(N)=O";"6-8 hours";"N03AX14";"Synaptic vesicle glycoprotein 2A";"SV2A";"yes";"agonist"
"Levetiracetam";"CC[C@H](N1CCCC1=O)C(N)=O";"6-8 hours";"N03AX14";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"yes";"inhibitor"
"Nadolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2";"14-24 hours";"C07AA12";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Nadolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2";"14-24 hours";"C07BA12";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Nadolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2";"14-24 hours";"C07AA12";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Nadolol";"CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2";"14-24 hours";"C07BA12";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Mitoxantrone";"OCCNCCNC1=C2C(=O)C3=C(O)C=CC(O)=C3C(=O)C2=C(NCCNCCO)C=C1";"75 hours";"L01DB07";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"antagonist"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"antagonist"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"antagonist"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Flumazenil";"CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1";"Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).";"V03AB25";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Lomustine";"ClCCN(N=O)C(=O)NC1CCCCC1";"Approximately 94 minutes, however the metabolites have a serum half-life of 16 to 48 hours.";"L01AD02";"Stathmin-4";"STMN4";"unknown";"antagonist"
"Sparfloxacin";"C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O";"Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance &lt;50 mL/min).";"J01MA09";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Sparfloxacin";"C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O";"Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance &lt;50 mL/min).";"J01MA09";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Sparfloxacin";"C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O";"Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance &lt;50 mL/min).";"J01MA09";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Dezocine";"[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N";"Elimination half-life following intramuscular administration averages 2.2 hours. Elimination half-life following a 5mg intravenous dose averages 1.7 to 2.6 hours (range 0.6 to 4.4 hours) while a 10mg dose averages 2.4 to 2.6 hours (range 1.2 to 7.4 hours). In patients with hepatic cirrhosis, the half-life is increased by 30 to 50%.";"N02AX03";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Dezocine";"[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N";"Elimination half-life following intramuscular administration averages 2.2 hours. Elimination half-life following a 5mg intravenous dose averages 1.7 to 2.6 hours (range 0.6 to 4.4 hours) while a 10mg dose averages 2.4 to 2.6 hours (range 1.2 to 7.4 hours). In patients with hepatic cirrhosis, the half-life is increased by 30 to 50%.";"N02AX03";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Levobunolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O";"20 hours";"S01ED03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Levobunolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O";"20 hours";"S01ED03";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD05";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD06";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"J01FA09";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD09";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD07";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD04";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD11";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD05";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD06";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"J01FA09";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD09";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD07";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD04";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD11";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD05";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD06";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"J01FA09";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD09";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD07";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD04";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD11";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD05";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD06";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"J01FA09";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD09";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD07";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD04";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Clarithromycin";"[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC";"3-4 hours";"A02BD11";"Solute carrier organic anion transporter family member 1B3";"SLCO1B3";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD04";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD54";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD04";"Solute carrier family 22 member 11";"SLC22A11";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD54";"Solute carrier family 22 member 11";"SLC22A11";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD04";"Solute carrier family 22 member 6";"SLC22A6";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD54";"Solute carrier family 22 member 6";"SLC22A6";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD04";"Solute carrier family 22 member 8";"SLC22A8";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD54";"Solute carrier family 22 member 8";"SLC22A8";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD04";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Ceftriaxone";"[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"5.8-8.7 hours";"J01DD54";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Fomepizole";"CC1=CNN=C1";"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.";"V03AB34";"Alcohol dehydrogenase 1A";"ADH1A";"yes";"inhibitor"
"Fomepizole";"CC1=CNN=C1";"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.";"V03AB34";"Alcohol dehydrogenase 1B";"ADH1B";"yes";"inhibitor"
"Fomepizole";"CC1=CNN=C1";"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.";"V03AB34";"Alcohol dehydrogenase 1C";"ADH1C";"yes";"inhibitor"
"Fomepizole";"CC1=CNN=C1";"The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.";"V03AB34";"Catalase";"CAT";"yes";"inhibitor"
"Metipranolol";"CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1";"";"C07BA68";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Metipranolol";"CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1";"";"S01ED54";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Metipranolol";"CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1";"";"S01ED04";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonist"
"Metipranolol";"CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1";"";"C07BA68";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metipranolol";"CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1";"";"S01ED54";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Metipranolol";"CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1";"";"S01ED04";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Estazolam";"ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1";"The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.";"N05CD04";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"D11AX10";"3-oxo-5-alpha-steroid 4-dehydrogenase 2";"SRD5A2";"yes";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"G04CB01";"3-oxo-5-alpha-steroid 4-dehydrogenase 2";"SRD5A2";"yes";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"G04CA51";"3-oxo-5-alpha-steroid 4-dehydrogenase 2";"SRD5A2";"yes";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"D11AX10";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"unknown";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"G04CB01";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"unknown";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"G04CA51";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"unknown";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"D11AX10";"3-oxo-5-beta-steroid 4-dehydrogenase";"AKR1D1";"unknown";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"G04CB01";"3-oxo-5-beta-steroid 4-dehydrogenase";"AKR1D1";"unknown";"inhibitor"
"Finasteride";"[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C";"4.5 hours (range 3.3-13.4 hours)";"G04CA51";"3-oxo-5-beta-steroid 4-dehydrogenase";"AKR1D1";"unknown";"inhibitor"
"Anastrozole";"CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N";"50 hours";"L02BG03";"Cytochrome P450 19A1";"CYP19A1";"yes";"inhibitor"
"Halofantrine";"CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F";"6-10 days";"P01BX01";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"yes";"inhibitor"
"Halofantrine";"CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F";"6-10 days";"P01BX01";"Plasmepsin-2";"";"unknown";"inhibitor"
"Dantrolene";"[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O";"The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.";"M03CA01";"Ryanodine receptor 1";"RYR1";"yes";"antagonist"
"Rifaximin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O";"Approximately 6 hours.";"A07AA11";"DNA-directed RNA polymerase subunit beta";"rpoB";"yes";"inhibitor"
"Rifaximin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O";"Approximately 6 hours.";"D06AX11";"DNA-directed RNA polymerase subunit beta";"rpoB";"yes";"inhibitor"
"Rifaximin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O";"Approximately 6 hours.";"A07AA11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"no";"agonist"
"Rifaximin";"CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O";"Approximately 6 hours.";"D06AX11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"no";"agonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"yes";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Substance-P receptor";"TACR1";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"D(2) dopamine receptor";"DRD2";"unknown";"agonistpartial agonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Delta-type opioid receptor";"OPRD1";"unknown";"binder"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Mu-type opioid receptor";"OPRM1";"unknown";"binder"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"binder"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"binder"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"binder"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"binder"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"binder"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 2";"HTR2A";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 2";"HTR2B";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 2";"HTR2C";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 1";"HTR1A";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 1";"HTR1B";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 1";"HTR1D";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 1";"HTR1E";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 1";"HTR1F";"unknown";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"potentiator"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Alpha-7 nicotinic cholinergic receptor subunit";"CHRNA7";"yes";"antagonist"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Cholinesterase";"BCHE";"yes";"inhibitor"
"Ketamine";"CNC1(CCCCC1=O)C1=CC=CC=C1Cl";"The reported half-life in preclinical studies for ketamine is 186 min.[A31883]";"N01AX03";"Nitric oxide synthase, brain";"NOS1";"yes";"inhibitor"
"Budesonide";"[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.";"R03AK07";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Budesonide";"[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.";"A07EA06";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Budesonide";"[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.";"R03BA02";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Budesonide";"[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.";"D07AC09";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Budesonide";"[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.";"R03AK12";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Budesonide";"[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"Following IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.";"R01AD05";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA20";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA55";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DB05";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA05";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA20";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA55";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DB05";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA05";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA20";"Adenosine receptor A3";"ADORA3";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA55";"Adenosine receptor A3";"ADORA3";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DB05";"Adenosine receptor A3";"ADORA3";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA05";"Adenosine receptor A3";"ADORA3";"yes";"antagonist"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA20";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA55";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DB05";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Aminophylline";"NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O";"7-9 hours";"R03DA05";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"other/unknown"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"other/unknown"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"other/unknown"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"other/unknown"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"other/unknown"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"D(1B) dopamine receptor";"DRD5";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Quetiapine";"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12";"6 hours";"N05AH04";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Mivacurium";"COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC";"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.";"M03AC10";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Mivacurium";"COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC";"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.";"M03AC10";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonistpartial agonist"
"Mivacurium";"COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC";"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.";"M03AC10";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Mivacurium";"COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC";"The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.";"M03AC10";"Cholinesterase";"BCHE";"unknown";""
"Levomethadyl Acetate";"CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"2.6 days";"N07BC03";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Levomethadyl Acetate";"CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"2.6 days";"N07BC03";"Neuronal acetylcholine receptor subunit beta-4";"CHRNB4";"unknown";"other/unknown"
"Levomethadyl Acetate";"CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1";"2.6 days";"N07BC03";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"antagonist"
"Encainide";"COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C";"1-2 hours";"C01BC08";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Paclitaxel";"[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C";"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.";"L01CD01";"Tubulin beta-1 chain";"TUBB1";"yes";"inhibitor"
"Paclitaxel";"[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C";"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.";"L01CD01";"Apoptosis regulator Bcl-2";"BCL2";"yes";"inhibitor"
"Paclitaxel";"[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C";"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.";"L01CD01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"inducer"
"Paclitaxel";"[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C";"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.";"L01CD01";"Microtubule-associated protein 4";"MAP4";"yes";""
"Paclitaxel";"[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C";"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.";"L01CD01";"Microtubule-associated protein 2";"MAP2";"yes";""
"Paclitaxel";"[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C";"When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.";"L01CD01";"Microtubule-associated protein tau";"MAPT";"yes";""
"Saquinavir";"[H][C@@](O)(CN1C[C@@]2([H])CCCC[C@@]2([H])C[C@@]1([H])C(O)=NC(C)(C)C)[C@]([H])(CC1=CC=CC=C1)N=C(O)[C@]([H])(CC(O)=N)NC(=O)C1=NC2=CC=CC=C2C=C1";"";"J05AE01";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Metoclopramide";"CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC";"5-6 hr";"A03FA01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Metoclopramide";"CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC";"5-6 hr";"A03FA01";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"agonist"
"Metoclopramide";"CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC";"5-6 hr";"A03FA01";"5-hydroxytryptamine receptor 4";"HTR4";"unknown";"agonist"
"Metoclopramide";"CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC";"5-6 hr";"A03FA01";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"agonist"
"Metoclopramide";"CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC";"5-6 hr";"A03FA01";"Acetylcholinesterase";"ACHE";"unknown";"inhibitor"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03CA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02CA06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01BA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"C05AA09";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CB01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"H02AB02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02BA06";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D10AA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"A01AC02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07XB05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07AB19";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07CB04";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03BA01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD53";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD03";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03CA01";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02CA06";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01BA01";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"C05AA09";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CB01";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"H02AB02";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02BA06";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D10AA03";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"A01AC02";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07XB05";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07AB19";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07CB04";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CA01";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03BA01";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD53";"Nuclear receptor subfamily 0 group B member 1";"NR0B1";"unknown";"stimulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD03";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03CA01";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02CA06";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01BA01";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"C05AA09";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CB01";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"H02AB02";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02BA06";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D10AA03";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"A01AC02";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07XB05";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07AB19";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07CB04";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CA01";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03BA01";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD53";"Annexin A1";"ANXA1";"unknown";"agonist"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD03";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03CA01";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02CA06";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01BA01";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"C05AA09";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CB01";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"H02AB02";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02BA06";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D10AA03";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"A01AC02";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07XB05";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07AB19";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07CB04";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CA01";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03BA01";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD53";"Nitric oxide synthase, inducible";"NOS2";"unknown";"negative modulator"
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03CA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02CA06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01BA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"C05AA09";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CB01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"H02AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S02BA06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D10AA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"A01AC02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07XB05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07AB19";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"D07CB04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S01CA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"S03BA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Dexamethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C";"36-54 hours";"R01AD53";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA03";"D(1A) dopamine receptor";"DRD1";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA02";"D(1A) dopamine receptor";"DRD1";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA01";"D(1A) dopamine receptor";"DRD1";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA03";"D(1B) dopamine receptor";"DRD5";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA02";"D(1B) dopamine receptor";"DRD5";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA01";"D(1B) dopamine receptor";"DRD5";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA03";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA02";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA01";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA03";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA02";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA01";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA03";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA02";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Levodopa";"N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O";"50 to 90 minutes";"N04BA01";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"Glycine receptor subunit alpha-1";"GLRA1";"yes";"agonist"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"Glutamate receptor 1";"GRIA1";"yes";"antagonist"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"yes";"inducer"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"inhibitor"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"ATP synthase subunit delta, mitochondrial";"ATP5D";"unknown";"other/unknown"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"NADH-ubiquinone oxidoreductase chain 1";"MT-ND1";"unknown";"unknown"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Sevoflurane";"FCOC(C(F)(F)F)C(F)(F)F";"15-23 hours";"N01AB08";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Bromodiphenhydramine";"CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1";"1 to 4 hours";"R06AA01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"D(2) dopamine receptor";"DRD2";"yes";"antagonistpartial agonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonistpartial agonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 1E";"HTR1E";"unknown";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonistpartial agonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"D(1B) dopamine receptor";"DRD5";"unknown";"antagonistpartial agonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"D(3) dopamine receptor";"DRD3";"unknown";"antagonistpartial agonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"D(4) dopamine receptor";"DRD4";"unknown";"antagonistpartial agonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Histamine H1 receptor";"HRH1";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Alpha-1A adrenergic receptor";"ADRA1A";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Alpha-1B adrenergic receptor";"ADRA1B";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Alpha-2A adrenergic receptor";"ADRA2A";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Alpha-2B adrenergic receptor";"ADRA2B";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Alpha-2C adrenergic receptor";"ADRA2C";"no";"antagonistother/unknown"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Aripiprazole";"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl";"75-146 hours";"N05AX12";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"D(3) dopamine receptor";"DRD3";"yes";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"Muscarinic acetylcholine receptor M2";"CHRM2";"no";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"Muscarinic acetylcholine receptor M3";"CHRM3";"no";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Chlorprothixene";"[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2";"8 to 12 hours";"N05AF03";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Epoprostenol";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O";"The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.";"B01AC09";"P2Y purinoceptor 12";"P2RY12";"yes";"agonist"
"Epoprostenol";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O";"The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.";"B01AC09";"Prostacyclin receptor";"PTGIR";"yes";"agonist"
"Epoprostenol";"[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O";"The in vitro half-life of epoprostenol in human blood at 37&deg;C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.";"B01AC09";"Prostacyclin synthase";"PTGIS";"yes";"inducer"
"Gemfibrozil";"CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1";"1.5 hours";"C10AB04";"Peroxisome proliferator-activated receptor alpha";"PPARA";"yes";"agonist"
"Clomipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2";"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).";"N06AA04";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Clomipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2";"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).";"N06AA04";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Clomipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2";"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).";"N06AA04";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"antagonist"
"Clomipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2";"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).";"N06AA04";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Clomipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2";"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).";"N06AA04";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Clomipramine";"CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2";"Following oral administration of a single 150 mg dose of clomipramine, the average elimination half-life of clomipramine was 32 hours (range: 19-37 hours) and of desmethylclomipramine was 69 hours (range: 54-77 hours). Elimination half-life may vary substantially with different doses due to saturable kinetics (i.e. metabolism).";"N06AA04";"Glutathione S-transferase P";"GSTP1";"unknown";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Voltage-dependent P/Q-type calcium channel subunit alpha-1A";"CACNA1A";"yes";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"yes";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Voltage-dependent calcium channel subunit alpha-2/delta-2";"CACNA2D2";"yes";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Potassium voltage-gated channel subfamily KQT member 1";"KCNQ1";"unknown";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"unknown";"other"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Calmodulin";"CALM1";"unknown";"binder"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B";"PDE1B";"unknown";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A";"PDE1A";"unknown";"inhibitor"
"Bepridil";"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1";"24-50 hours";"C08EA02";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Alimemazine";"CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12";"";"R06AD01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Isocarboxazid";"CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1";"The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor.[T117] These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.[T114]";"N06AF01";"Amine oxidase [flavin-containing] A";"MAOA";"yes";"inhibitor"
"Isocarboxazid";"CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1";"The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor.[T117] These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.[T114]";"N06AF01";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"inhibitor"
"Docetaxel";"[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1";"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.";"L01CD02";"Tubulin beta-1 chain";"TUBB1";"yes";""
"Docetaxel";"[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1";"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.";"L01CD02";"Apoptosis regulator Bcl-2";"BCL2";"unknown";""
"Docetaxel";"[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1";"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.";"L01CD02";"Microtubule-associated protein 2";"MAP2";"yes";""
"Docetaxel";"[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1";"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.";"L01CD02";"Microtubule-associated protein 4";"MAP4";"yes";""
"Docetaxel";"[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1";"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.";"L01CD02";"Microtubule-associated protein tau";"MAPT";"yes";""
"Docetaxel";"[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1";"Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.";"L01CD02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"binder"
"Olsalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O";"Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.";"A07EC03";"Thiopurine S-methyltransferase";"TPMT";"yes";"inhibitor"
"Olsalazine";"OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O";"Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.";"A07EC03";"Interferon gamma";"IFNG";"yes";""
"Gliquidone";"COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O";"The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours)";"A10BB08";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Gliquidone";"COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O";"The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours)";"A10BB08";"ATP-sensitive inward rectifier potassium channel 8";"KCNJ8";"yes";"inhibitor"
"Mitiglinide";"[H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O";"";"A10BX08";"ATP-binding cassette sub-family C member 8";"ABCC8";"yes";"inhibitor"
"Mitiglinide";"[H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O";"";"A10BX08";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"agonist"
"Ergonovine";"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO";"t<sub>1/2 &alpha;</sub>=10 minutes; t<sub>1/2 &beta;</sub>=2 hours";"G02AB03";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase ABL1";"ABL1";"yes";"multitarget"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Proto-oncogene tyrosine-protein kinase Src";"SRC";"yes";"multitarget"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Ephrin type-A receptor 2";"EPHA2";"yes";"antagonist"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase Lck";"LCK";"yes";"multitarget"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase Yes";"YES1";"yes";"inhibitor"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Mast/stem cell growth factor receptor Kit";"KIT";"unknown";"antagonist"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Platelet-derived growth factor receptor beta";"PDGFRB";"unknown";"antagonist"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Signal transducer and activator of transcription 5B";"STAT5B";"unknown";"inhibitor"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Abelson tyrosine-protein kinase 2";"ABL2";"unknown";"multitarget"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase Fyn";"FYN";"unknown";"multitarget"
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase BTK";"BTK";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Nuclear receptor subfamily 4 group A member 3";"NR4A3";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Breakpoint cluster region protein";"BCR";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase CSK";"CSK";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Ephrin type-A receptor 5";"EPHA5";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Ephrin type-B receptor 4";"EPHB4";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase Fgr";"FGR";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase FRK";"FRK";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Heat shock cognate 71 kDa protein";"HSPA8";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Tyrosine-protein kinase Lyn";"LYN";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Mitogen-activated protein kinase kinase kinase MLT";"ZAK";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Mitogen-activated protein kinase 14";"MAPK14";"unknown";""
"Dasatinib";"CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1";"The overall mean terminal half-life of dasatinib is 3-5 hours.";"L01XE06";"Amidophosphoribosyltransferase";"PPAT";"unknown";""
"Lisdexamfetamine";"C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN";"The plasma elimination half-life of lisdexamfetamine typically averaged less 
than one hour.";"N06BA12";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Lisdexamfetamine";"C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN";"The plasma elimination half-life of lisdexamfetamine typically averaged less 
than one hour.";"N06BA12";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Retapamulin";"[H][C@]12CC[C@]([H])(C[C@]([H])(C1)SCC(=O)O[C@]1([H])C[C@@](C)(C=C)[C@@]([H])(O)[C@]([H])(C)[C@]34CCC(=O)[C@@]3([H])[C@@]1(C)[C@]([H])(C)CC4)N2C";"";"D06AX13";"50S ribosomal protein L3";"rplC";"yes";"inhibitor"
"Lapatinib";"CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1";"Single-dose terminal half life: 14.2 hours
Effective multiple-dose half life: 24 hours";"L01XE07";"Epidermal growth factor receptor";"EGFR";"yes";"antagonist"
"Lapatinib";"CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1";"Single-dose terminal half life: 14.2 hours
Effective multiple-dose half life: 24 hours";"L01XE07";"Receptor tyrosine-protein kinase erbB-2";"ERBB2";"yes";"antagonist"
"Desonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"";"D07BB02";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Desonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"";"D07AB08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Desonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO";"";"S01BA11";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Sitagliptin";"N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F";"12.4 hours";"A10BH51";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Sitagliptin";"N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F";"12.4 hours";"A10BD12";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Sitagliptin";"N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F";"12.4 hours";"A10BH01";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Sitagliptin";"N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F";"12.4 hours";"A10BD07";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Decitabine";"NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1";"The terminal phase elimination half-life is 0.51 &plusmn; 0.31 hours.";"L01BC08";"DNA (cytosine-5)-methyltransferase 1";"DNMT1";"yes";"inhibitor"
"Posaconazole";"[H][C@@](C)(O)[C@]([H])(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@]2([H])CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1";"Posaconazole is eliminated with a mean half-life (t&frac12;) of 35 hours (range 20 to 66 hours).";"J02AC04";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"antagonist"
"Darunavir";"[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1";"The terminal elimination half-life of darunavir was approximately 15 hours when combined with ritonavir.";"J05AR14";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Darunavir";"[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1";"The terminal elimination half-life of darunavir was approximately 15 hours when combined with ritonavir.";"J05AE10";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Darunavir";"[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1";"The terminal elimination half-life of darunavir was approximately 15 hours when combined with ritonavir.";"G01AE10";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Telbivudine";"CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O";"Approximately 15 hours.";"J05AF11";"Protein P";"P";"yes";""
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Histamine H1 receptor";"HRH1";"unknown";"agonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"D(4) dopamine receptor";"DRD4";"yes";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"D(3) dopamine receptor";"DRD3";"yes";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Cytochrome P450 2D6";"CYP2D6";"unknown";""
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"Cytochrome P450 3A5";"CYP3A5";"unknown";""
"Paliperidone";"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1";"The terminal elimination half-life of paliperidone is approximately 23 hours.";"N05AX13";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";""
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Platelet-derived growth factor receptor beta";"PDGFRB";"yes";"inhibitor"
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Vascular endothelial growth factor receptor 1";"FLT1";"yes";"inhibitor"
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Mast/stem cell growth factor receptor Kit";"KIT";"yes";"inhibitor"
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"inhibitor"
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Vascular endothelial growth factor receptor 3";"FLT4";"yes";"inhibitor"
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Receptor-type tyrosine-protein kinase FLT3";"FLT3";"yes";"inhibitor"
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Macrophage colony-stimulating factor 1 receptor";"CSF1R";"yes";"inhibitor"
"Sunitinib";"CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C";"Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.";"L01XE04";"Platelet-derived growth factor receptor alpha";"PDGFRA";"yes";"inhibitor"
"Varenicline";"[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21";"The elimination half-life of varenicline is approximately 24 hours";"N07BA03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"yes";"partial agonist"
"Varenicline";"[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21";"The elimination half-life of varenicline is approximately 24 hours";"N07BA03";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"agonist"
"Varenicline";"[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21";"The elimination half-life of varenicline is approximately 24 hours";"N07BA03";"Neuronal acetylcholine receptor subunit alpha-3";"CHRNA3";"unknown";"partial agonist"
"Varenicline";"[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21";"The elimination half-life of varenicline is approximately 24 hours";"N07BA03";"Neuronal acetylcholine receptor subunit alpha-6";"CHRNA6";"unknown";"partial agonist"
"Varenicline";"[H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21";"The elimination half-life of varenicline is approximately 24 hours";"N07BA03";"Neuronal acetylcholine receptor subunit beta-2";"CHRNB2";"unknown";"partial agonist"
"Hydralazine";"NNC1=NN=CC2=CC=CC=C12";"3 to 7 hours";"C02DB02";"Membrane primary amine oxidase";"AOC3";"yes";"inhibitor"
"Hydralazine";"NNC1=NN=CC2=CC=CC=C12";"3 to 7 hours";"C02LG02";"Membrane primary amine oxidase";"AOC3";"yes";"inhibitor"
"Hydralazine";"NNC1=NN=CC2=CC=CC=C12";"3 to 7 hours";"C02DB02";"Prolyl 4-hydroxylase subunit alpha-1";"P4HA1";"unknown";"inhibitor"
"Hydralazine";"NNC1=NN=CC2=CC=CC=C12";"3 to 7 hours";"C02LG02";"Prolyl 4-hydroxylase subunit alpha-1";"P4HA1";"unknown";"inhibitor"
"Nelarabine";"COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"Nelarabine and ara-G are rapidly eliminated from plasma with a half-life of approximately 30 minutes and 3 hours.";"L01BB07";"DNA polymerase alpha catalytic subunit";"POLA1";"unknown";"inhibitor"
"Carbetocin";"[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC";"40 minutes";"H01BB03";"Oxytocin receptor";"OXTR";"yes";"agonist"
"Lumiracoxib";"CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1";"Terminal half-life is approximately 4 hours.";"M01AH06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Lumiracoxib";"CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1";"Terminal half-life is approximately 4 hours.";"M01AH06";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Tetracosactide";"CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O";"About 15 minutes following intravenous administration.";"H01AA02";"Adrenocorticotropic hormone receptor";"MC2R";"yes";"antagonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03AL01";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03AC04";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03CC04";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"G02CA03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03AL01";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03AC04";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03CC04";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"G02CA03";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03AL01";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03AC04";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"R03CC04";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Fenoterol";"CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1";"";"G02CA03";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Glisoxepide";"CC1=CC(=NO1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1";"";"A10BB11";"ATP-sensitive inward rectifier potassium channel 8";"KCNJ8";"yes";"inhibitor"
"Pirbuterol";"CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1";"The plasma half-life measured after oral administration is about two hours.";"R03CC07";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Pirbuterol";"CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1";"The plasma half-life measured after oral administration is about two hours.";"R03AC08";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Pirbuterol";"CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1";"The plasma half-life measured after oral administration is about two hours.";"R03CC07";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Pirbuterol";"CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1";"The plasma half-life measured after oral administration is about two hours.";"R03AC08";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Bevantolol";"COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1";"";"C07AB06";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bevantolol";"COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1";"";"C07BB06";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bevantolol";"COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1";"";"C07AB06";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Bevantolol";"COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1";"";"C07BB06";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Bevantolol";"COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1";"";"C07AB06";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Bevantolol";"COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1";"";"C07BB06";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Glucosamine";"N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O";"";"M01AX05";"Matrix metalloproteinase-9";"MMP9";"yes";"antagonist"
"Glucosamine";"N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O";"";"M01AX05";"Nuclear factor NF-kappa-B p100 subunit";"NFKB2";"unknown";"antagonist"
"Glucosamine";"N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O";"";"M01AX05";"Tumor necrosis factor";"TNF";"unknown";""
"Glucosamine";"N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O";"";"M01AX05";"Interferon gamma";"IFNG";"unknown";""
"Glucosamine";"N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O";"";"M01AX05";"Chitosanase";"csn";"unknown";""
"Practolol";"CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1";"";"C07AB01";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Sulfacytine";"CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O";"";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfadoxine";"COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC";"";"G01AE10";"Dihydropteroate synthetase";"";"yes";""
"Sulfadoxine";"COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC";"";"G01AE10";"Bifunctional dihydrofolate reductase-thymidylate synthase";"";"unknown";"inhibitor"
"Rolitetracycline";"[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C";"";"J01AA20";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Rolitetracycline";"[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C";"";"J01AA09";"30S ribosomal protein S9";"rpsI";"yes";"inhibitor"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DB02";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA20";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA02";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DB02";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA02";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DB02";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA20";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA02";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DB02";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA20";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA02";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DB02";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA20";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Oxtriphylline";"C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O";"The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.";"R03DA02";"Histone deacetylase 2";"HDAC2";"yes";"activator"
"Fosamprenavir";"CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1";"The plasma elimination half-life of amprenavir (the active metabolite) is approximately 7.7 hours.";"J05AE07";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Fosphenytoin";"OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1";"Fosphenytoin has a half-life of approximately 15 minutes.";"N03AB05";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Josamycin";"CO[C@H]1[C@H](OC(=O)C)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@H](N(C)C)[C@H]1O";"";"J01FA07";"50S ribosomal protein L4";"rplD";"yes";"inhibitor"
"Polythiazide";"CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AA05";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Polythiazide";"CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"C03AB05";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Polythiazide";"CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O";"";"G01AE10";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BA02";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BB02";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BA02";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BB02";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BA02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BB02";"Solute carrier family 12 member 1";"SLC12A1";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BA02";"Solute carrier family 12 member 2";"SLC12A2";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BB02";"Solute carrier family 12 member 2";"SLC12A2";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BA02";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Quinethazone";"CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O";"";"C03BB02";"Solute carrier family 12 member 3";"SLC12A3";"yes";"inhibitor"
"Cefamandole";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O";"The half-life after an intravenous dose is 32 minutes; after intramuscular administration, the half-life is 60 minutes.";"J01DC03";"Penicillin-binding protein 2";"pbpA";"yes";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Penicillin-binding protein 1C";"pbpC";"yes";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Serum paraoxonase/arylesterase 1";"PON1";"unknown";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Interleukin-15";"IL15";"unknown";"inhibitor"
"Cefazolin";"[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O";"The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.";"J01DB04";"Interleukin-2";"IL2";"unknown";"inhibitor"
"Cefonicid";"[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O";"4.5 hours";"J01DC06";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefonicid";"[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O";"4.5 hours";"J01DC06";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefonicid";"[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O";"4.5 hours";"J01DC06";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Cefonicid";"[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O";"4.5 hours";"J01DC06";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"yes";"inhibitor"
"Cefonicid";"[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O";"4.5 hours";"J01DC06";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"Penicillin-binding protein 1B";"ponB";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"Penicillin-binding protein 1B";"ponB";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"D-alanyl-D-alanine carboxypeptidase DacC";"dacC";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"D-alanyl-D-alanine carboxypeptidase DacC";"dacC";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"D-alanyl-D-alanine carboxypeptidase DacA";"dacA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"D-alanyl-D-alanine carboxypeptidase DacA";"dacA";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD12";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"yes";"inhibitor"
"Cefoperazone";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O";"The mean serum half-life is approximately 2.0 hours, independent of the route of administration.";"J01DD62";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"yes";"inhibitor"
"Cefotetan";"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O";"In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged";"J01DC05";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"D-alanyl-D-alanine carboxypeptidase DacC";"dacC";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"D-alanyl-D-alanine carboxypeptidase DacA";"dacA";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"D-alanyl-D-alanine endopeptidase";"pbpG";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Cefoxitin";"[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O";"The half-life after an intravenous dose is 41 to 59 minutes.";"J01DC01";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Ceftizoxime";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"";"J01DD07";"MecA PBP2' (penicillin binding protein 2')";"mecA";"yes";"inhibitor"
"Ceftizoxime";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"";"J01DD07";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Ceftizoxime";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"";"J01DD07";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Ceftizoxime";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"";"J01DD07";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefradine";"[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O";"";"J01DB09";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Pancuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1";"1.5 to 2.7 hours.";"M03AC01";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Pancuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1";"1.5 to 2.7 hours.";"M03AC01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Pancuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1";"1.5 to 2.7 hours.";"M03AC01";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Pipecuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1";"Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]";"M03AC06";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Pipecuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1";"Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]";"M03AC06";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Pipecuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1";"Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]";"M03AC06";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Vecuronium";"[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1";"51–80 minutes";"M03AC03";"Neuronal acetylcholine receptor subunit alpha-2";"CHRNA2";"yes";"antagonist"
"Cilazapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O";"Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.";"C09BA08";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Cilazapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O";"Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.";"C09AA08";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Potassium";"[K]";"";"C03AB02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03BB07";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB04";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB03";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03CB02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB06";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB07";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"B05XA17";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03BB03";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03BB04";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB01";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03CB01";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB05";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB08";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03BB02";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03BB05";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Potassium";"[K]";"";"C03AB09";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Spirapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2";"30 to 35 hours";"C09AA11";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Tasosartan";"CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1";"";"C09CA05";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Tasosartan";"CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1";"";"C09CA05";"Type-2 angiotensin II receptor";"AGTR2";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CA02";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Amobarbital";"CCC1(CCC(C)C)C(=O)NC(=O)NC1=O";"";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Aprobarbital";"CC(C)C1(CC=C)C(=O)NC(=O)NC1=O";"";"N05CA05";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Butethal";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"37 hours";"N05CA03";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Heptabarbital";"CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1";"";"N05CA11";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N01AF02";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CA16";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Hexobarbital";"CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1";"";"N05CB01";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Lithium";"[Li+]";"";"D11AX04";"Glycogen synthase kinase-3 beta";"GSK3B";"unknown";"inhibitor"
"Lithium";"[Li+]";"";"N05AN01";"Glycogen synthase kinase-3 beta";"GSK3B";"unknown";"inhibitor"
"Lithium";"[Li+]";"";"D11AX04";"Inositol monophosphatase 1";"IMPA1";"unknown";"inhibitor"
"Lithium";"[Li+]";"";"N05AN01";"Inositol monophosphatase 1";"IMPA1";"unknown";"inhibitor"
"Lithium";"[Li+]";"";"D11AX04";"Inositol monophosphatase 2";"IMPA2";"unknown";"inhibitor"
"Lithium";"[Li+]";"";"N05AN01";"Inositol monophosphatase 2";"IMPA2";"unknown";"inhibitor"
"Lithium";"[Li+]";"";"D11AX04";"Glutamate receptor 3";"GRIA3";"unknown";"potentiator"
"Lithium";"[Li+]";"";"N05AN01";"Glutamate receptor 3";"GRIA3";"unknown";"potentiator"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07CA23";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonistpartial agonist"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07AA23";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonistpartial agonist"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07CA23";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonistpartial agonist"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07AA23";"Beta-2 adrenergic receptor";"ADRB2";"yes";"antagonistpartial agonist"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07CA23";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07AA23";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07CA23";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Penbutolol";"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1";"Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.";"C07AA23";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AA03";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inverse agonist"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"C01CA26";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inverse agonist"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AB05";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inverse agonist"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R03CA02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inverse agonist"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"A08AA56";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inverse agonist"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"S01FB02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inverse agonist"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AA03";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"C01CA26";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AB05";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R03CA02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"A08AA56";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"S01FB02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AA03";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";"inhibitor"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"C01CA26";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";"inhibitor"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AB05";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";"inhibitor"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R03CA02";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";"inhibitor"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"A08AA56";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";"inhibitor"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"S01FB02";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";"inhibitor"
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AA03";"Acetylcholinesterase";"ACHE";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"C01CA26";"Acetylcholinesterase";"ACHE";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R01AB05";"Acetylcholinesterase";"ACHE";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"R03CA02";"Acetylcholinesterase";"ACHE";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"A08AA56";"Acetylcholinesterase";"ACHE";"unknown";""
"Ephedrine";"CN[C@@H](C)[C@H](O)C1=CC=CC=C1";"3-6 hours";"S01FB02";"Acetylcholinesterase";"ACHE";"unknown";""
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Alpha adrenergic receptor";"ADRA1A";"yes";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Alpha adrenergic receptor";"ADRA1B";"yes";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Alpha adrenergic receptor";"ADRA1D";"yes";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Alpha adrenergic receptor";"ADRA2A";"yes";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Alpha adrenergic receptor";"ADRA2B";"yes";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Alpha adrenergic receptor";"ADRA2C";"yes";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Beta adrenergic receptor";"ADRB1";"unknown";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Beta adrenergic receptor";"ADRB2";"unknown";"agonist"
"Mephentermine";"CNC(C)(C)CC1=CC=CC=C1";"17 to 18 hours.";"C01CA11";"Beta adrenergic receptor";"ADRB3";"unknown";"agonist"
"Procaterol";"CC[C@H](NC(C)C)[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1";"";"R03AC16";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Procaterol";"CC[C@H](NC(C)C)[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1";"";"R03CC08";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Rasagiline";"C#CCN[C@@H]1CCC2=CC=CC=C12";"Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.";"N04BD02";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"inhibitor"
"Rasagiline";"C#CCN[C@@H]1CCC2=CC=CC=C12";"Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.";"N04BD02";"Apoptosis regulator Bcl-2";"BCL2";"yes";"activator"
"Aluminium";"[Al]";"";"A02AB03";"Serotransferrin";"TF";"unknown";""
"Aluminium";"[Al]";"";"A02AB03";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";"binder"
"Aluminium";"[Al]";"";"A02AB03";"Kallikrein-1";"KLK1";"unknown";"inhibitor"
"Aluminium";"[Al]";"";"A02AB03";"Amyloid beta A4 protein";"APP";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"ligand"
"Calcium";"[Ca]";"";"M05BB02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"ligand"
"Calcium";"[Ca]";"";"A11GB01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"ligand"
"Calcium";"[Ca]";"";"M05BB04";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"ligand"
"Calcium";"[Ca]";"";"M05BB05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"ligand"
"Calcium";"[Ca]";"";"A11AA02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"ligand"
"Calcium";"[Ca]";"";"M05BB01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"ligand"
"Calcium";"[Ca]";"";"M05BB08";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB02";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"agonist"
"Calcium";"[Ca]";"";"A11GB01";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB04";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB05";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"agonist"
"Calcium";"[Ca]";"";"A11AA02";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB01";"Calcium-transporting ATPase type 2C member 1";"ATP2C1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB08";"Troponin C, skeletal muscle";"TNNC2";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB02";"Troponin C, skeletal muscle";"TNNC2";"yes";"agonist"
"Calcium";"[Ca]";"";"A11GB01";"Troponin C, skeletal muscle";"TNNC2";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB04";"Troponin C, skeletal muscle";"TNNC2";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB05";"Troponin C, skeletal muscle";"TNNC2";"yes";"agonist"
"Calcium";"[Ca]";"";"A11AA02";"Troponin C, skeletal muscle";"TNNC2";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB01";"Troponin C, skeletal muscle";"TNNC2";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB08";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB02";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"agonist"
"Calcium";"[Ca]";"";"A11GB01";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB04";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB05";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"agonist"
"Calcium";"[Ca]";"";"A11AA02";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB01";"Troponin C, slow skeletal and cardiac muscles";"TNNC1";"yes";"agonist"
"Calcium";"[Ca]";"";"M05BB08";"Spectrin beta chain, non-erythrocytic 1";"SPTBN1";"unknown";"agonist"
"Calcium";"[Ca]";"";"M05BB02";"Spectrin beta chain, non-erythrocytic 1";"SPTBN1";"unknown";"agonist"
"Calcium";"[Ca]";"";"A11GB01";"Spectrin beta chain, non-erythrocytic 1";"SPTBN1";"unknown";"agonist"
"Calcium";"[Ca]";"";"M05BB04";"Spectrin beta chain, non-erythrocytic 1";"SPTBN1";"unknown";"agonist"
"Calcium";"[Ca]";"";"M05BB05";"Spectrin beta chain, non-erythrocytic 1";"SPTBN1";"unknown";"agonist"
"Calcium";"[Ca]";"";"A11AA02";"Spectrin beta chain, non-erythrocytic 1";"SPTBN1";"unknown";"agonist"
"Calcium";"[Ca]";"";"M05BB01";"Spectrin beta chain, non-erythrocytic 1";"SPTBN1";"unknown";"agonist"
"Calcium";"[Ca]";"";"M05BB08";"Protein S100-B";"S100B";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Protein S100-B";"S100B";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Protein S100-B";"S100B";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Protein S100-B";"S100B";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Protein S100-B";"S100B";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Protein S100-B";"S100B";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Protein S100-B";"S100B";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Calpastatin";"CAST";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Calpastatin";"CAST";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Calpastatin";"CAST";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Calpastatin";"CAST";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Calpastatin";"CAST";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Calpastatin";"CAST";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Calpastatin";"CAST";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Cartilage oligomeric matrix protein";"COMP";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Cartilage oligomeric matrix protein";"COMP";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Cartilage oligomeric matrix protein";"COMP";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Cartilage oligomeric matrix protein";"COMP";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Cartilage oligomeric matrix protein";"COMP";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Cartilage oligomeric matrix protein";"COMP";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Cartilage oligomeric matrix protein";"COMP";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Calmodulin";"CALM1";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Calmodulin";"CALM1";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Calmodulin";"CALM1";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Calmodulin";"CALM1";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Calmodulin";"CALM1";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Calmodulin";"CALM1";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Calmodulin";"CALM1";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Amiloride-sensitive amine oxidase [copper-containing]";"AOC1";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Protein S100-A13";"S100A13";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Protein S100-A13";"S100A13";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Protein S100-A13";"S100A13";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Protein S100-A13";"S100A13";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Protein S100-A13";"S100A13";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Protein S100-A13";"S100A13";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Protein S100-A13";"S100A13";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Alkaline phosphatase, placental type";"ALPP";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Alkaline phosphatase, placental type";"ALPP";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Alkaline phosphatase, placental type";"ALPP";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Alkaline phosphatase, placental type";"ALPP";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Alkaline phosphatase, placental type";"ALPP";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Alkaline phosphatase, placental type";"ALPP";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Alkaline phosphatase, placental type";"ALPP";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Protein S100-A8";"S100A8";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Protein S100-A8";"S100A8";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Protein S100-A8";"S100A8";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Protein S100-A8";"S100A8";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Protein S100-A8";"S100A8";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Protein S100-A8";"S100A8";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Protein S100-A8";"S100A8";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Protein S100-A9";"S100A9";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Protein S100-A9";"S100A9";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Protein S100-A9";"S100A9";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Protein S100-A9";"S100A9";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Protein S100-A9";"S100A9";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Protein S100-A9";"S100A9";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Protein S100-A9";"S100A9";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Protein S100-A2";"S100A2";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Protein S100-A2";"S100A2";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Protein S100-A2";"S100A2";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Protein S100-A2";"S100A2";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Protein S100-A2";"S100A2";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Protein S100-A2";"S100A2";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Protein S100-A2";"S100A2";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Ceruloplasmin";"CP";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Ceruloplasmin";"CP";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Ceruloplasmin";"CP";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Ceruloplasmin";"CP";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Ceruloplasmin";"CP";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Ceruloplasmin";"CP";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Ceruloplasmin";"CP";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Bone morphogenetic protein 4";"BMP4";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Bone morphogenetic protein 4";"BMP4";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Bone morphogenetic protein 4";"BMP4";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Bone morphogenetic protein 4";"BMP4";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Bone morphogenetic protein 4";"BMP4";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Bone morphogenetic protein 4";"BMP4";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Bone morphogenetic protein 4";"BMP4";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Matrix Gla protein";"MGP";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Matrix Gla protein";"MGP";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Matrix Gla protein";"MGP";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Matrix Gla protein";"MGP";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Matrix Gla protein";"MGP";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Matrix Gla protein";"MGP";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Matrix Gla protein";"MGP";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Protocadherin-19";"PCDH19";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Protocadherin-19";"PCDH19";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Protocadherin-19";"PCDH19";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Protocadherin-19";"PCDH19";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Protocadherin-19";"PCDH19";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Protocadherin-19";"PCDH19";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Protocadherin-19";"PCDH19";"unknown";""
"Calcium";"[Ca]";"";"M05BB08";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Calcium";"[Ca]";"";"M05BB02";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Calcium";"[Ca]";"";"A11GB01";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Calcium";"[Ca]";"";"M05BB04";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Calcium";"[Ca]";"";"M05BB05";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Calcium";"[Ca]";"";"A11AA02";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Calcium";"[Ca]";"";"M05BB01";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Magnesium";"[Mg++]";"";"A12CC07";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Magnesium";"[Mg++]";"";"A12CC06";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"unknown";""
"Cortisone acetate";"[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"";"H02AB10";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Cortisone acetate";"[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"";"S01BA03";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Glycodiazine";"COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1";"4 hours.";"A10BC01";"ATP-sensitive inward rectifier potassium channel 1";"KCNJ1";"yes";"other/unknown"
"Glycodiazine";"COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1";"4 hours.";"A10BC01";"ATP-binding cassette sub-family C member 8";"ABCC8";"unknown";"inducer"
"Paramethasone";"[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@]([H])(F)C2=CC(=O)C=C[C@]12C";"";"H02AB05";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit beta-3";"CACNB3";"yes";"inhibitor"
"Mibefradil";"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C";"17 to 25 hours at steady state.";"C08CX01";"Voltage-dependent L-type calcium channel subunit beta-4";"CACNB4";"yes";"inhibitor"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"partial agonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"5-hydroxytryptamine receptor 1D";"HTR1D";"unknown";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"ATP-sensitive potassium channel";"KCNJ1";"unknown";""
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"ATP-sensitive potassium channel";"KCNJ10";"unknown";""
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"ATP-sensitive potassium channel";"KCNJ11";"unknown";""
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"ATP-sensitive potassium channel";"KCNJ12";"unknown";""
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"ATP-sensitive potassium channel";"KCNJ14";"unknown";""
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"ATP-sensitive potassium channel";"KCNJ15";"unknown";""
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"ATP-sensitive potassium channel";"KCNJ8";"unknown";""
"Yohimbine";"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2";"Elimination half-life is approximately 36 minutes.";"G04BE04";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"antagonist"
"Bezafibrate";"CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O";"1-2 hours";"C10AB02";"Peroxisome proliferator-activated receptor alpha";"PPARA";"yes";"agonist"
"Bezafibrate";"CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O";"1-2 hours";"C10AB02";"Peroxisome proliferator-activated receptor delta";"PPARD";"yes";"agonist"
"Bezafibrate";"CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O";"1-2 hours";"C10AB02";"Peroxisome proliferator-activated receptor gamma";"PPARG";"yes";"agonist"
"Bezafibrate";"CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O";"1-2 hours";"C10AB02";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Bezafibrate";"CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O";"1-2 hours";"C10AB02";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";"agonist"
"Bezafibrate";"CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O";"1-2 hours";"C10AB02";"Retinoic acid receptor RXR-beta";"RXRB";"unknown";"agonist"
"Bezafibrate";"CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O";"1-2 hours";"C10AB02";"Retinoic acid receptor RXR-gamma";"RXRG";"unknown";"agonist"
"Colchicine";"COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O";"Elimination half-life is approximately 1 hour in healthy subjects, although a study with an extended sampling time reported mean terminal elimination half-life values of approximately 9 to 10.5 hours. Other studies have reported half-life values of approximately 2 hours in patients with alcoholic cirrhosis and approximately 2.5 hours in patients with familial Mediterranean fever.";"M04AC01";"Tubulin beta-1 chain";"TUBB1";"yes";"inhibitor"
"Colchicine";"COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O";"Elimination half-life is approximately 1 hour in healthy subjects, although a study with an extended sampling time reported mean terminal elimination half-life values of approximately 9 to 10.5 hours. Other studies have reported half-life values of approximately 2 hours in patients with alcoholic cirrhosis and approximately 2.5 hours in patients with familial Mediterranean fever.";"M04AC01";"Tubulin beta chain";"TUBB";"yes";"inhibitor"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03FA17";"Progesterone receptor";"PGR";"yes";"agonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03AC10";"Progesterone receptor";"PGR";"yes";"agonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03AA12";"Progesterone receptor";"PGR";"yes";"agonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03FA17";"Mineralocorticoid receptor";"NR3C2";"yes";"antagonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03AC10";"Mineralocorticoid receptor";"NR3C2";"yes";"antagonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03AA12";"Mineralocorticoid receptor";"NR3C2";"yes";"antagonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03FA17";"Androgen receptor";"AR";"yes";"antagonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03AC10";"Androgen receptor";"AR";"yes";"antagonist"
"Drospirenone";"[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21";"30 hours";"G03AA12";"Androgen receptor";"AR";"yes";"antagonist"
"Digitoxin";"[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1";"";"C01AA04";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"inhibitor"
"Salsalate";"OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O";"The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.";"N02BA06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Salsalate";"OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O";"The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.";"N02BA06";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Neostigmine";"CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C";"The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.";"N07AA51";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Neostigmine";"CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C";"The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.";"S01EB06";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Neostigmine";"CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C";"The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.";"N07AA01";"Acetylcholinesterase";"ACHE";"yes";"inhibitor"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"D(1B) dopamine receptor";"DRD5";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Methotrimeprazine";"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1";"Approximately 20 hours.";"N05AA02";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Temafloxacin";"CC1CN(CCN1)C1=C(F)C=C2C(=O)C(=CN(C2=C1)C1=C(F)C=C(F)C=C1)C(O)=O";"Approximately 8 hours in patients with normal renal function.";"J01MA05";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Temafloxacin";"CC1CN(CCN1)C1=C(F)C=C2C(=O)C(=CN(C2=C1)C1=C(F)C=C(F)C=C1)C(O)=O";"Approximately 8 hours in patients with normal renal function.";"J01MA05";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Danazol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3";"Approximately 24 hours.";"G03XA01";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Danazol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3";"Approximately 24 hours.";"G03XA01";"Androgen receptor";"AR";"yes";"agonist"
"Danazol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3";"Approximately 24 hours.";"G03XA01";"Progesterone receptor";"PGR";"yes";"agonist"
"Danazol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3";"Approximately 24 hours.";"G03XA01";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"negative modulator"
"Danazol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3";"Approximately 24 hours.";"G03XA01";"Putative gonadotropin-releasing hormone II receptor";"GNRHR2";"yes";"negative modulator"
"Danazol";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3";"Approximately 24 hours.";"G03XA01";"C-C motif chemokine 2";"CCL2";"unknown";"inhibitor"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03CC13";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03AC14";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03CC13";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03AC14";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"agonist"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03CC13";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03AC14";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"agonist"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03CC13";"Beta-nerve growth factor";"NGF";"unknown";"stimulator"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03AC14";"Beta-nerve growth factor";"NGF";"unknown";"stimulator"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03CC13";"Tumor necrosis factor";"TNF";"unknown";"other/unknown"
"Clenbuterol";"CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1";"36-39 hours";"R03AC14";"Tumor necrosis factor";"TNF";"unknown";"other/unknown"
"Bambuterol";"CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C";"13 hours for bambuterol and 21 hours for the primary active metabolite terbutaline.";"R03CC12";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03AL06";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB04";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB54";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03AL06";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB04";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB54";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03AL06";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB04";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB54";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03AL06";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";""
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB04";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";""
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB54";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";""
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03AL06";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";""
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB04";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";""
"Tiotropium";"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1";"5-6 days";"R03BB54";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";""
"Ciclesonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C";"";"R03BA08";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Ciclesonide";"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C";"";"R01AD13";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Pranlukast";"O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1";"";"R03DC02";"Cysteinyl leukotriene receptor 1";"CYSLTR1";"yes";"antagonist"
"Pranlukast";"O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1";"";"R03DC02";"Tumor necrosis factor";"TNF";"unknown";"other/unknown"
"Pranlukast";"O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1";"";"R03DC02";"Interleukin-5";"IL5";"unknown";"antagonist"
"Pranlukast";"O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1";"";"R03DC02";"Eosinophil cationic protein";"RNASE3";"unknown";"other/unknown"
"Pranlukast";"O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1";"";"R03DC02";"Nuclear factor NF-kappa-B p105 subunit";"NFKB1";"unknown";"other/unknown"
"Pranlukast";"O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1";"";"R03DC02";"Mucin-2";"MUC2";"unknown";"other/unknown"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA20";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA07";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA57";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"C03BD01";"Adenosine receptor A1";"ADORA1";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA20";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA07";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA57";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"C03BD01";"Adenosine receptor A2a";"ADORA2A";"yes";"antagonist"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA20";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA07";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"R03DA57";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Theobromine";"CN1C=NC2=C1C(=O)NC(=O)N2C";"";"C03BD01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01RA06";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01DE01";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01RA06";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01DE01";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01RA06";"Penicillin-binding protein 3";"pbpB";"yes";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01DE01";"Penicillin-binding protein 3";"pbpB";"yes";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01RA06";"Penicillin-binding protein 2";"pbpA";"yes";"inhibitor"
"Cefepime";"CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1";"2.0 (&plusmn; 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (&plusmn; 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (&plusmn; 2.0) hours.";"J01DE01";"Penicillin-binding protein 2";"pbpA";"yes";"inhibitor"
"Cefacetrile";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC#N)C(O)=O";"1.2 hours";"J01DB10";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Cefacetrile";"[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC#N)C(O)=O";"1.2 hours";"J01DB10";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Ceftibuten";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O";"";"J01DD14";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Ceftibuten";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O";"";"J01DD14";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Ceftibuten";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O";"";"J01DD14";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Ceftibuten";"[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O";"";"J01DD14";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Cefpodoxime";"[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O";"2.09 to 2.84 hours";"J01DD13";"Peptidoglycan synthase FtsI";"ftsI";"yes";"inhibitor"
"Acenocoumarol";"CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O";"8 to 11 hours.";"B01AA07";"Vitamin K epoxide reductase complex subunit 1";"VKORC1";"yes";"inhibitor"
"Paromomycin";"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O";"";"A07AA06";"30S ribosomal protein S10";"rpsJ";"yes";"inhibitor"
"Nitroxoline";"OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O";"";"J01XX07";"Methionine aminopeptidase 2";"METAP2";"yes";"inhibitor"
"Alizapride";"COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C";"3 hours";"A03FA05";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Ajmaline";"CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H](C2[C@H]4O)N3[C@@H]1O";"";"C01BA05";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Amrinone";"NC1=CC(=CNC1=O)C1=CC=NC=C1";"5 to 8 hours";"C01CE01";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Amrinone";"NC1=CC(=CNC1=O)C1=CC=NC=C1";"5 to 8 hours";"C01CE01";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Amrinone";"NC1=CC(=CNC1=O)C1=CC=NC=C1";"5 to 8 hours";"C01CE01";"Tumor necrosis factor";"TNF";"unknown";"inhibitor"
"Aprindine";"CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C1=CC=CC=C1";"";"C01BB04";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"inhibitor"
"Aprindine";"CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C1=CC=CC=C1";"";"C01BB04";"Calmodulin";"CALM1";"unknown";"inhibitor"
"Almitrine";"FC1=CC=C(C=C1)C(N1CCN(CC1)C1=NC(NCC=C)=NC(NCC=C)=N1)C1=CC=C(F)C=C1";"";"R07AB07";"Sodium/potassium-transporting ATPase subunit alpha-1";"ATP1A1";"yes";"binder"
"Allylestrenol";"[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"";"G03DC01";"Progesterone receptor";"PGR";"yes";"agonist"
"Allylestrenol";"[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]";"";"G03DC01";"Estrogen receptor alpha";"ESR1";"unknown";"agonist"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"N02BB51";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"N02BB01";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"N02BB71";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"S02DA03";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"N02BB51";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"N02BB01";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"N02BB71";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Antipyrine";"CN1N(C(=O)C=C1C)C1=CC=CC=C1";"";"S02DA03";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Alfacalcidol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"";"A11CC03";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Alfacalcidol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"";"M05BB06";"Vitamin D3 receptor";"VDR";"yes";"agonist"
"Alfacalcidol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"";"A11CC03";"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial";"CYP27B1";"unknown";""
"Alfacalcidol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"";"M05BB06";"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial";"CYP27B1";"unknown";""
"Alfacalcidol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"";"A11CC03";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Alfacalcidol";"CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C";"";"M05BB06";"Retinoic acid receptor RXR-alpha";"RXRA";"unknown";""
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Glutethimide";"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1";"10-12 hours";"N05CE01";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Phenazopyridine";"NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1";"7.35 hours";"G04BX06";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Heroin";"[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2OC(C)=O";"<10 minutes";"N07BC06";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Heroin";"[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2OC(C)=O";"<10 minutes";"N07BC06";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Heroin";"[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2OC(C)=O";"<10 minutes";"N07BC06";"Delta-type opioid receptor";"OPRD1";"unknown";"agonist"
"Heroin";"[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2OC(C)=O";"<10 minutes";"N07BC06";"Liver carboxylesterase 1";"CES1";"unknown";""
"Fencamfamine";"CCNC1C2CCC(C2)C1C1=CC=CC=C1";"";"N06BA06";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Ethylmorphine";"[H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"";"R05DA01";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Ethylmorphine";"[H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"";"S01XA06";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Neuronal acetylcholine receptor subunit alpha-4";"CHRNA4";"unknown";"antagonist"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";"antagonist"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Glutamate receptor 2";"GRIA2";"unknown";"antagonist"
"Barbital";"CCC1(CC)C(=O)NC(=O)NC1=O";"";"N05CA04";"Glutamate receptor ionotropic, kainate 2";"GRIK2";"unknown";"antagonist"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Translocator protein";"TSPO";"yes";"agonist"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"agonist"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";"agonist"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"unknown";"agonist"
"Flunitrazepam";"CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F";"18-26 hours";"N05CD03";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"unknown";"agonist"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Bromazepam";"BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1";"10-20 hours";"N05BA08";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Clotiazepam";"CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl";"4 hours";"N05BA21";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Fludiazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F";"";"N05BA17";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Dextroamphetamine";"C[C@H](N)CC1=CC=CC=C1";"10-28 hours (average is approximately 12 hours)";"N06BA02";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inducer"
"Dextroamphetamine";"C[C@H](N)CC1=CC=CC=C1";"10-28 hours (average is approximately 12 hours)";"N06BA02";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"negative modulator"
"Dextroamphetamine";"C[C@H](N)CC1=CC=CC=C1";"10-28 hours (average is approximately 12 hours)";"N06BA02";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"negative modulator"
"Dextroamphetamine";"C[C@H](N)CC1=CC=CC=C1";"10-28 hours (average is approximately 12 hours)";"N06BA02";"Trace amine-associated receptor 1";"TAAR1";"unknown";"agonist"
"Dextroamphetamine";"C[C@H](N)CC1=CC=CC=C1";"10-28 hours (average is approximately 12 hours)";"N06BA02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Dextroamphetamine";"C[C@H](N)CC1=CC=CC=C1";"10-28 hours (average is approximately 12 hours)";"N06BA02";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"negative modulator"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"negative modulator"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"negative modulator"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Chromaffin granule amine transporter";"SLC18A1";"yes";"inhibitor"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Trace amine-associated receptor 1";"TAAR1";"yes";"agonist"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Amine oxidase [flavin-containing] A";"MAOA";"yes";"inhibitor"
"Methamphetamine";"CN[C@@H](C)CC1=CC=CC=C1";"The biological half-life has been reported in the range of 4 to 5 hours.";"N06BA03";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"inhibitor"
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07CA02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07BA02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07AA02";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07CA02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07BA02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07AA02";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07CA02";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07BA02";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Oxprenolol";"CC(C)NCC(O)COC1=CC=CC=C1OCC=C";"1-2 hours";"C07AA02";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Sulfamerazine";"CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1";"";"J01EE07";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamerazine";"CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1";"";"D06BA06";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamerazine";"CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1";"";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamerazine";"CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1";"";"J01ED07";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethazine";"CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1";"";"J01EE05";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethazine";"CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1";"";"J01EB03";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfamethazine";"CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1";"";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Ursodeoxycholic acid";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O";"";"A05AA02";"Aldo-keto reductase family 1 member C2";"AKR1C2";"yes";"inducer"
"Ursodeoxycholic acid";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O";"";"A05AA02";"Bile acid receptor";"NR1H4";"unknown";""
"Ketazolam";"CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1";"26-200 hours";"N05BA10";"Translocator protein";"TSPO";"yes";"agonist"
"Ketazolam";"CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1";"26-200 hours";"N05BA10";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Ketazolam";"CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1";"26-200 hours";"N05BA10";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Ketazolam";"CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1";"26-200 hours";"N05BA10";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Ketazolam";"CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1";"26-200 hours";"N05BA10";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Ketazolam";"CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1";"26-200 hours";"N05BA10";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Prazepam";"ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1";"36-200 hours";"N05BA11";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRA1";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRA2";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRA3";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRA4";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRA5";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRA6";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRB1";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRB2";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRB3";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRD";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRE";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRG1";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRG2";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRG3";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRP";"yes";"positive allosteric modulator"
"Quazepam";"FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2";"39 hours";"N05CD10";"GABA-A receptor (anion channel)";"GABRQ";"yes";"positive allosteric modulator"
"Everolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC";"~30 hours.";"L01XE10";"Serine/threonine-protein kinase mTOR";"MTOR";"yes";"inhibitor"
"Everolimus";"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC";"~30 hours.";"L04AA18";"Serine/threonine-protein kinase mTOR";"MTOR";"yes";"inhibitor"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04BD08";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04CA53";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04BD08";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04CA53";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04BD08";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04CA53";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04BD08";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04CA53";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04BD08";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Solifenacin";"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1";"The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.";"G04CA53";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Iron";"[Fe]";"";"B03AE01";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Transferrin receptor protein 1";"TFRC";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Egl nine homolog 1";"EGLN1";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AE02";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AD02";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AA10";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AA01";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AE03";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"A11AA01";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AA02";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AE04";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AA03";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AA06";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Iron";"[Fe]";"";"B03AE01";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Alpha-hemoglobin-stabilizing protein";"AHSP";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Frataxin, mitochondrial";"FXN";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Ferritin heavy chain";"FTH1";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Flap endonuclease 1";"FEN1";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Endonuclease 8-like 2";"NEIL2";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"DNA polymerase beta";"POLB";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Ceruloplasmin";"CP";"unknown";""
"Iron";"[Fe]";"";"B03AE01";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AE02";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AD02";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AA10";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AA01";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AE03";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"A11AA01";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AA02";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AE04";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AA03";"Serotransferrin";"TF";"unknown";""
"Iron";"[Fe]";"";"B03AA06";"Serotransferrin";"TF";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"B1 bradykinin receptor";"BDKRB1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Methylated-DNA--protein-cysteine methyltransferase";"MGMT";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Methylated-DNA--protein-cysteine methyltransferase";"MGMT";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Fructose-bisphosphate aldolase A";"ALDOA";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Fructose-bisphosphate aldolase A";"ALDOA";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Elongation factor 1-alpha 1";"EEF1A1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Elongation factor 1-alpha 1";"EEF1A1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Alpha-enolase";"ENO1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Alpha-enolase";"ENO1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific";"GAPDHS";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific";"GAPDHS";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Nucleoside diphosphate kinase A";"NME1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Nucleoside diphosphate kinase A";"NME1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Protein disulfide-isomerase";"P4HB";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Protein disulfide-isomerase";"P4HB";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Protein disulfide-isomerase A3";"PDIA3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Protein disulfide-isomerase A3";"PDIA3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Peroxiredoxin-1";"PRDX1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Peroxiredoxin-1";"PRDX1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Phosphoserine phosphatase";"PSPH";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Phosphoserine phosphatase";"PSPH";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Triosephosphate isomerase";"TPI1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Triosephosphate isomerase";"TPI1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Elongation factor Tu, mitochondrial";"TUFM";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Elongation factor Tu, mitochondrial";"TUFM";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Estrogen receptor alpha";"ESR1";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Estrogen receptor alpha";"ESR1";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Interleukin-3";"IL3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Interleukin-3";"IL3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Metallothionein-2";"MT2A";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Metallothionein-2";"MT2A";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Copper chaperone for superoxide dismutase";"CCS";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Copper chaperone for superoxide dismutase";"CCS";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Histone deacetylase 1";"HDAC1";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Histone deacetylase 1";"HDAC1";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Histone deacetylase 4";"HDAC4";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Histone deacetylase 4";"HDAC4";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"DNA-3-methyladenine glycosylase";"MPG";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"DNA-3-methyladenine glycosylase";"MPG";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Semenogelin-1";"SEMG1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Semenogelin-1";"SEMG1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Superoxide dismutase [Cu-Zn]";"SOD1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Histone deacetylase 8";"HDAC8";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Apoptosis regulatory protein Siva";"SIVA1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Apoptosis regulatory protein Siva";"SIVA1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"E3 ubiquitin-protein ligase Mdm2";"MDM2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"E3 ubiquitin-protein ligase Mdm2";"MDM2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Insulin";"INS";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Insulin";"INS";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Utrophin";"UTRN";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Utrophin";"UTRN";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Aspartoacylase";"ASPA";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Aspartoacylase";"ASPA";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Protein S100-A8";"S100A8";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Protein S100-A8";"S100A8";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Protein S100-A9";"S100A9";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Protein S100-A9";"S100A9";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Matrix metalloproteinase-9";"MMP9";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Matrix metalloproteinase-9";"MMP9";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Tumor protein p73";"TP73";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Tumor protein p73";"TP73";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Protein S100-A2";"S100A2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Protein S100-A2";"S100A2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Cellular tumor antigen p53";"TP53";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Cellular tumor antigen p53";"TP53";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Metallothionein-3";"MT3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Metallothionein-3";"MT3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Programmed cell death protein 6";"PDCD6";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"DAN domain family member 5";"DAND5";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"DAN domain family member 5";"DAND5";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Metallothionein-1A";"MT1A";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Metallothionein-1A";"MT1A";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Alpha-1B-glycoprotein";"A1BG";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Alpha-1B-glycoprotein";"A1BG";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Alpha-2-macroglobulin";"A2M";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Alpha-2-macroglobulin";"A2M";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Angiotensinogen";"AGT";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Angiotensinogen";"AGT";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Alpha-2-HS-glycoprotein";"AHSG";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Alpha-2-HS-glycoprotein";"AHSG";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Serum amyloid P-component";"APCS";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Serum amyloid P-component";"APCS";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Apolipoprotein A-I";"APOA1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Apolipoprotein A-I";"APOA1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Apolipoprotein A-II";"APOA2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Apolipoprotein A-II";"APOA2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Apolipoprotein A-IV";"APOA4";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Apolipoprotein A-IV";"APOA4";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Apolipoprotein B receptor";"APOBR";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Apolipoprotein B receptor";"APOBR";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Apolipoprotein E";"APOE";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Apolipoprotein E";"APOE";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Apolipoprotein L1";"APOL1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Apolipoprotein L1";"APOL1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement C1q subcomponent subunit B";"C1QB";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement C1q subcomponent subunit B";"C1QB";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement C1q subcomponent subunit C";"C1QC";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement C1q subcomponent subunit C";"C1QC";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement C1r subcomponent";"C1R";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement C1r subcomponent";"C1R";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement C1s subcomponent";"C1S";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement C1s subcomponent";"C1S";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement C3";"C3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement C3";"C3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement C4-B";"C4B";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement C4-B";"C4B";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"C4b-binding protein alpha chain";"C4BPA";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"C4b-binding protein alpha chain";"C4BPA";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"C4b-binding protein beta chain";"C4BPB";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"C4b-binding protein beta chain";"C4BPB";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement C5";"C5";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement C5";"C5";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Lys-63-specific deubiquitinase BRCC36";"BRCC3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Lys-63-specific deubiquitinase BRCC36";"BRCC3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement component C8 alpha chain";"C8A";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement component C8 alpha chain";"C8A";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement component C8 beta chain";"C8B";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement component C8 beta chain";"C8B";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement component C8 gamma chain";"C8G";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement component C8 gamma chain";"C8G";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement factor B";"CFB";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement factor B";"CFB";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement factor H";"CFH";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement factor H";"CFH";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Complement factor I";"CFI";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Complement factor I";"CFI";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Clusterin";"CLU";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Clusterin";"CLU";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Ceruloplasmin";"CP";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Ceruloplasmin";"CP";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Carboxypeptidase N catalytic chain";"CPN1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Carboxypeptidase N catalytic chain";"CPN1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Carboxypeptidase N subunit 2";"CPN2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Carboxypeptidase N subunit 2";"CPN2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Dermcidin";"DCD";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Dermcidin";"DCD";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Desmoplakin";"DSP";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Desmoplakin";"DSP";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Coagulation factor XII";"F12";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Coagulation factor XII";"F12";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Coagulation factor XIII B chain";"F13B";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Coagulation factor XIII B chain";"F13B";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Prothrombin";"F2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Prothrombin";"F2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Ficolin-3";"FCN3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Ficolin-3";"FCN3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Fibrinogen alpha chain";"FGA";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Fibrinogen alpha chain";"FGA";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Fibronectin";"FN1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Fibronectin";"FN1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Gelsolin";"GSN";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Gelsolin";"GSN";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Hemoglobin subunit beta";"HBB";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Hemoglobin subunit beta";"HBB";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Haptoglobin-related protein";"HPR";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Haptoglobin-related protein";"HPR";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Hornerin";"HRNR";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Hornerin";"HRNR";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Insulin-like growth factor-binding protein complex acid labile subunit";"IGFALS";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Insulin-like growth factor-binding protein complex acid labile subunit";"IGFALS";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Ig alpha-1 chain C region";"IGHA1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Ig alpha-1 chain C region";"IGHA1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Ig mu chain C region";"IGHM";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Ig mu chain C region";"IGHM";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Immunoglobulin kappa variable 1-17";"IGKV1-17";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Immunoglobulin kappa variable 1-17";"IGKV1-17";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Ig kappa chain V-III region GOL";"";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Ig kappa chain V-III region GOL";"";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Immunoglobulin lambda variable 3-21";"IGLV3-21";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Immunoglobulin lambda variable 3-21";"IGLV3-21";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Inter-alpha-trypsin inhibitor heavy chain H1";"ITIH1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Inter-alpha-trypsin inhibitor heavy chain H1";"ITIH1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Inter-alpha-trypsin inhibitor heavy chain H2";"ITIH2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Inter-alpha-trypsin inhibitor heavy chain H2";"ITIH2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Inter-alpha-trypsin inhibitor heavy chain H3";"ITIH3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Inter-alpha-trypsin inhibitor heavy chain H3";"ITIH3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Inter-alpha-trypsin inhibitor heavy chain H4";"ITIH4";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Inter-alpha-trypsin inhibitor heavy chain H4";"ITIH4";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Immunoglobulin J chain";"JCHAIN";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Immunoglobulin J chain";"JCHAIN";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Junction plakoglobin";"JUP";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Junction plakoglobin";"JUP";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Plasma kallikrein";"KLKB1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Plasma kallikrein";"KLKB1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Kininogen-1";"KNG1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Kininogen-1";"KNG1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type II cytoskeletal 1";"KRT1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type II cytoskeletal 1";"KRT1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type I cytoskeletal 10";"KRT10";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type I cytoskeletal 10";"KRT10";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type I cytoskeletal 14";"KRT14";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type I cytoskeletal 14";"KRT14";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type I cytoskeletal 16";"KRT16";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type I cytoskeletal 16";"KRT16";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type II cytoskeletal 2 epidermal";"KRT2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type II cytoskeletal 2 epidermal";"KRT2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type II cytoskeletal 5";"KRT5";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type II cytoskeletal 5";"KRT5";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type II cytoskeletal 6A";"KRT6A";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type II cytoskeletal 6A";"KRT6A";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Keratin, type I cytoskeletal 9";"KRT9";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Keratin, type I cytoskeletal 9";"KRT9";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Alpha-1-acid glycoprotein 2";"ORM2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"N-acetylmuramoyl-L-alanine amidase";"PGLYRP2";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"N-acetylmuramoyl-L-alanine amidase";"PGLYRP2";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Serum paraoxonase/arylesterase 1";"PON1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Serum paraoxonase/arylesterase 1";"PON1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Pregnancy zone protein";"PZP";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Pregnancy zone protein";"PZP";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Protein S100-A7";"S100A7";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Protein S100-A7";"S100A7";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Selenoprotein P";"SEPP1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Selenoprotein P";"SEPP1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Alpha-1-antitrypsin";"SERPINA1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Alpha-1-antitrypsin";"SERPINA1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Alpha-1-antichymotrypsin";"SERPINA3";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Alpha-1-antichymotrypsin";"SERPINA3";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Kallistatin";"SERPINA4";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Kallistatin";"SERPINA4";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Corticosteroid-binding globulin";"SERPINA6";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Corticosteroid-binding globulin";"SERPINA6";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Heparin cofactor 2";"SERPIND1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Heparin cofactor 2";"SERPIND1";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Serotransferrin";"TF";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Serotransferrin";"TF";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Transthyretin";"TTR";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Transthyretin";"TTR";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Vitronectin";"VTN";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Vitronectin";"VTN";"unknown";""
"Zinc";"[Zn]";"";"A16AX05";"Amyloid-like protein 1";"APLP1";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Amyloid-like protein 1";"APLP1";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Amyloid-like protein 2";"APLP2";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Amyloid-like protein 2";"APLP2";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Amyloid beta A4 protein";"APP";"unknown";"cofactor"
"Zinc";"[Zn]";"";"B05XA12";"Amyloid beta A4 protein";"APP";"unknown";"cofactor"
"Zinc";"[Zn]";"";"A16AX05";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";""
"Zinc";"[Zn]";"";"B05XA12";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";""
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Cinolazepam";"OC1N=C(C2=CC=CC=C2F)C2=C(C=CC(Cl)=C2)N(CCC#N)C1=O";"9 hours";"N05CD13";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit alpha-4";"GABRA4";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit alpha-6";"GABRA6";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit beta-1";"GABRB1";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit beta-2";"GABRB2";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit beta-3";"GABRB3";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit gamma-1";"GABRG1";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit gamma-3";"GABRG3";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit delta";"GABRD";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit epsilon";"GABRE";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit pi";"GABRP";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit rho-1";"GABRR1";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit rho-2";"GABRR2";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit rho-3";"GABRR3";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Gamma-aminobutyric acid receptor subunit theta";"GABRQ";"yes";"potentiator"
"Nitrazepam";"[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1";"15-38 hours (mean elimination half life 26 hours).";"N05CD02";"Sodium channel protein type 1 subunit alpha";"SCN1A";"unknown";"other/unknown"
"Imipenem";"[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour";"J01DH51";"Penicillin-binding protein 2";"mrdA";"yes";"inhibitor"
"Imipenem";"[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour";"J01DH51";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Imipenem";"[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour";"J01DH51";"Penicillin-binding protein 1A";"mrcA";"yes";"inhibitor"
"Imipenem";"[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour";"J01DH51";"Penicillin-binding protein 3";"pbpC";"yes";"inhibitor"
"Imipenem";"[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour";"J01DH51";"Beta-lactamase";"blaZ";"yes";"other/unknown"
"Probucol";"CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C";"Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.";"C10AX02";"ATP-binding cassette sub-family A member 1";"ABCA1";"yes";"inhibitor"
"Probucol";"CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C";"Ranges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.";"C10AX02";"Liver carboxylesterase 1";"CES1";"unknown";""
"Tiaprofenic acid";"CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1";"1.5-2.5 hours";"M01AE11";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Tiaprofenic acid";"CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1";"1.5-2.5 hours";"M01AE11";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Lopinavir";"CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1";"";"J05AR10";"Human immunodeficiency virus type 1 protease";"pol";"yes";"inhibitor"
"Bacampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OC(C)OC(=O)OCC";"";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Bacampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OC(C)OC(=O)OCC";"";"J01CA06";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CR50";"MecA PBP2' (penicillin binding protein 2')";"mecA";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CF03";"MecA PBP2' (penicillin binding protein 2')";"mecA";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CF03";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CR50";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CF03";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CF03";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CF03";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Meticillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O";"25-60 minutes";"J01CF03";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Pivampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)C(C)(C)C";"Approximately 1 hour.";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Pivampicillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)C(C)(C)C";"Approximately 1 hour.";"J01CA02";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Pivmecillinam";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1";"";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Pivmecillinam";"[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1";"";"J01CA08";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Tazobactam";"[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O";"";"J01CR50";"Beta-lactamase SHV-1";"bla";"unknown";"inhibitor"
"Tazobactam";"[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O";"";"J01CG02";"Beta-lactamase SHV-1";"bla";"unknown";"inhibitor"
"Tazobactam";"[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O";"";"J01CR50";"Beta-lactamase TEM";"bla";"yes";"inhibitor"
"Tazobactam";"[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O";"";"J01CG02";"Beta-lactamase TEM";"bla";"yes";"inhibitor"
"Ticarcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O";"1.1 hours";"J01CR03";"Penicillin binding protein 2a";"mecA";"yes";"inhibitor"
"Ticarcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O";"1.1 hours";"J01CR50";"Penicillin binding protein 2a";"mecA";"yes";"inhibitor"
"Ticarcillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O";"1.1 hours";"J01CA13";"Penicillin binding protein 2a";"mecA";"yes";"inhibitor"
"Propericiazine";"OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1";"";"N05AC01";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Propericiazine";"OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1";"";"N05AC01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Propericiazine";"OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1";"";"N05AC01";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Propericiazine";"OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1";"";"N05AC01";"Androgen receptor";"AR";"unknown";""
"Hydroxychloroquine";"CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1";"Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.";"P01BA02";"Toll-like receptor 7";"TLR7";"yes";"antagonist"
"Hydroxychloroquine";"CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1";"Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.";"P01BA02";"Toll-like receptor 9";"TLR9";"yes";"antagonist"
"Amyl Nitrite";"CCCCCON=O";"";"V03AB22";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Erythrityl Tetranitrate";"[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O";"";"C01DA13";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Erythrityl Tetranitrate";"[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O";"";"C01DA63";"Atrial natriuretic peptide receptor 1";"NPR1";"yes";"agonist"
"Erythrityl Tetranitrate";"[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O";"";"C01DA13";"Atrial natriuretic peptide receptor 2";"NPR2";"yes";"agonist"
"Erythrityl Tetranitrate";"[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O";"";"C01DA63";"Atrial natriuretic peptide receptor 2";"NPR2";"yes";"agonist"
"Acepromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O";"3 hours in horses.";"N05AA04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Acepromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O";"3 hours in horses.";"N05AA04";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Acepromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O";"3 hours in horses.";"N05AA04";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Acepromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O";"3 hours in horses.";"N05AA04";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Acepromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O";"3 hours in horses.";"N05AA04";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Acepromazine";"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O";"3 hours in horses.";"N05AA04";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Alverine";"CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1";"The plasma half-life averages 0.8 hours for alverine and 5.7 hours for the active primary metabolite.";"A03AX58";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Alverine";"CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1";"The plasma half-life averages 0.8 hours for alverine and 5.7 hours for the active primary metabolite.";"A03AX08";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Molindone";"CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2";"";"N05AE02";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Molindone";"CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2";"";"N05AE02";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Molindone";"CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2";"";"N05AE02";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Molindone";"CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2";"";"N05AE02";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"other/unknown"
"Phenindamine";"CN1CCC2=C(C1)C(C1=CC=CC=C21)C1=CC=CC=C1";"";"R06AX04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Pheniramine";"CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1";"";"R06AB05";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Pheniramine";"CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1";"";"D04AA16";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Pheniramine";"CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1";"";"R06AB05";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Pheniramine";"CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1";"";"D04AA16";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Pipotiazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1";"";"N05AC04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Pipotiazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1";"";"N05AC04";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Pipotiazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1";"";"N05AC04";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Pipotiazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1";"";"N05AC04";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Thioproperazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"N05AB08";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Thioproperazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"N05AB08";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Thioproperazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"N05AB08";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Thioproperazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"N05AB08";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Thioproperazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"N05AB08";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Thioproperazine";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1";"";"N05AB08";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Thiothixene";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1";"10-20 hours";"N05AF04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Thiothixene";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1";"10-20 hours";"N05AF04";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Thiothixene";"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1";"10-20 hours";"N05AF04";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Zuclopenthixol";"OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.";"N05AF05";"D(1A) dopamine receptor";"DRD1";"yes";"antagonist"
"Zuclopenthixol";"OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.";"N05AF05";"D(1B) dopamine receptor";"DRD5";"yes";"antagonist"
"Zuclopenthixol";"OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.";"N05AF05";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Zuclopenthixol";"OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.";"N05AF05";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Zuclopenthixol";"OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.";"N05AF05";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Zuclopenthixol";"OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.";"N05AF05";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Zuclopenthixol";"OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1";"20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.";"N05AF05";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Isopropamide";"CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C";"";"A03CA01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Isopropamide";"CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C";"";"A03AB09";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Isopropamide";"CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C";"";"A03CA01";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Isopropamide";"CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C";"";"A03AB09";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Pargyline";"CN(CC#C)CC1=CC=CC=C1";"";"C02LL01";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"inhibitor"
"Pargyline";"CN(CC#C)CC1=CC=CC=C1";"";"C02KC01";"Amine oxidase [flavin-containing] B";"MAOB";"yes";"inhibitor"
"Pargyline";"CN(CC#C)CC1=CC=CC=C1";"";"C02LL01";"Amine oxidase [flavin-containing] A";"MAOA";"unknown";"inhibitor"
"Pargyline";"CN(CC#C)CC1=CC=CC=C1";"";"C02KC01";"Amine oxidase [flavin-containing] A";"MAOA";"unknown";"inhibitor"
"Lincomycin";"[H][C@](C)(O)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O";"The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function.";"J01FF02";"50S ribosomal protein L10";"rplJ";"yes";"inhibitor"
"Etoricoxib";"CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O";"22 hours";"M01AH05";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AG07";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AD18";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"V04CC01";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"B05CX02";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AG07";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AD18";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"V04CC01";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"B05CX02";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AG07";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AD18";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"V04CC01";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"B05CX02";"Xylose isomerase";"xylA";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AG07";"Malate synthase G";"glcB";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"A06AD18";"Malate synthase G";"glcB";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"V04CC01";"Malate synthase G";"glcB";"unknown";""
"Sorbitol";"OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"";"B05CX02";"Malate synthase G";"glcB";"unknown";""
"Roflumilast";"FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl";"Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).";"R03DX07";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"unknown";"inhibitor"
"Roflumilast";"FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl";"Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).";"R03DX07";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"unknown";"inhibitor"
"Roflumilast";"FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl";"Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).";"R03DX07";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"unknown";"inhibitor"
"Roflumilast";"FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl";"Plasma half-life of roflumilast is 17 hours and its metabolite is 30 hours (oral dose).";"R03DX07";"cAMP-specific 3',5'-cyclic phosphodiesterase 4C";"PDE4C";"unknown";"inhibitor"
"Fumaric Acid";"OC(=O)\C=C\C(O)=O";"";"D05AX01";"Malate dehydrogenase";"mdh";"unknown";""
"Fumaric Acid";"OC(=O)\C=C\C(O)=O";"";"D05AX01";"Fumarate reductase flavoprotein subunit";"fccA";"unknown";""
"Fumaric Acid";"OC(=O)\C=C\C(O)=O";"";"D05AX01";"Fumarate reductase flavoprotein subunit";"";"unknown";""
"Fumaric Acid";"OC(=O)\C=C\C(O)=O";"";"D05AX01";"NAD-dependent malic enzyme, mitochondrial";"ME2";"unknown";""
"Fumaric Acid";"OC(=O)\C=C\C(O)=O";"";"D05AX01";"Fumarylacetoacetase";"FAH";"unknown";""
"Rutin";"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O";"";"C05CA01";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";""
"Rutin";"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O";"";"C05CA51";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";""
"Rutin";"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O";"";"C05CA01";"Carbonyl reductase [NADPH] 1";"CBR1";"unknown";""
"Rutin";"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O";"";"C05CA51";"Carbonyl reductase [NADPH] 1";"CBR1";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Estrogen receptor alpha";"ESR1";"unknown";"binder"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Estrogen receptor alpha";"ESR1";"unknown";"binder"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Estrogen receptor beta";"ESR2";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Estrogen receptor beta";"ESR2";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRA1";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRA1";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRA2";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRA2";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRA3";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRA3";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRA4";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRA4";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRA5";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRA5";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRA6";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRA6";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRB1";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRB1";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRB2";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRB2";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRB3";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRB3";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRD";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRD";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRE";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRE";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRG1";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRG1";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRG2";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRG2";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRG3";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRG3";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRP";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRP";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"GABA-A receptor (anion channel)";"GABRQ";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"GABA-A receptor (anion channel)";"GABRQ";"unknown";"antagonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"NMDA receptor";"GRIN1";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"NMDA receptor";"GRIN1";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"NMDA receptor";"GRIN2A";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"NMDA receptor";"GRIN2A";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"NMDA receptor";"GRIN2B";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"NMDA receptor";"GRIN2B";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"NMDA receptor";"GRIN2C";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"NMDA receptor";"GRIN2C";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"NMDA receptor";"GRIN2D";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"NMDA receptor";"GRIN2D";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"NMDA receptor";"GRIN3A";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"NMDA receptor";"GRIN3A";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"NMDA receptor";"GRIN3B";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"NMDA receptor";"GRIN3B";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Androgen receptor";"AR";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Androgen receptor";"AR";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Estradiol 17-beta-dehydrogenase 1";"HSD17B1";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Estradiol 17-beta-dehydrogenase 1";"HSD17B1";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Bile salt sulfotransferase";"SULT2A1";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Bile salt sulfotransferase";"SULT2A1";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Sulfotransferase family cytosolic 2B member 1";"SULT2B1";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Sulfotransferase family cytosolic 2B member 1";"SULT2B1";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";"agonist"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"activator"
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Steroid Delta-isomerase";"ksi";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Steroid Delta-isomerase";"ksi";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"A14AA07";"Cholesterol oxidase";"choB";"unknown";""
"Prasterone";"[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C";"12 hours";"G03EA03";"Cholesterol oxidase";"choB";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"D08AJ02";"Cyclopropane mycolic acid synthase MmaA2";"mmaA2";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"D11AC01";"Cyclopropane mycolic acid synthase MmaA2";"mmaA2";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"D08AJ04";"Cyclopropane mycolic acid synthase MmaA2";"mmaA2";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"R02AA17";"Cyclopropane mycolic acid synthase MmaA2";"mmaA2";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"D08AJ02";"Cyclopropane mycolic acid synthase 1";"cmaA1";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"D11AC01";"Cyclopropane mycolic acid synthase 1";"cmaA1";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"D08AJ04";"Cyclopropane mycolic acid synthase 1";"cmaA1";"unknown";""
"Cetrimonium";"CCCCCCCCCCCCCCCC[N+](C)(C)C";"";"R02AA17";"Cyclopropane mycolic acid synthase 1";"cmaA1";"unknown";""
"Camphor";"[H][C@@]12CC[C@@](C)(C(=O)C1)C2(C)C";"";"C01EB02";"Camphor 5-monooxygenase";"camC";"unknown";""
"Pantothenic acid";"CC(C)(CO)C(O)C(=O)NCCC(O)=O";"";"D03AX04";"Pantothenate kinase";"coaA";"unknown";""
"Pantothenic acid";"CC(C)(CO)C(O)C(=O)NCCC(O)=O";"";"A11HA31";"Pantothenate kinase";"coaA";"unknown";""
"Flufenamic Acid";"OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F";"";"M01AG03";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";""
"Flufenamic Acid";"OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F";"";"M01AG03";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Flufenamic Acid";"OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F";"";"M01AG03";"Aldo-keto reductase family 1 member C3";"AKR1C3";"unknown";""
"Flufenamic Acid";"OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F";"";"M01AG03";"Androgen receptor";"AR";"unknown";""
"Flufenamic Acid";"OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F";"";"M01AG03";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";"activator"
"Flufenamic Acid";"OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F";"";"M01AG03";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"agonist"
"Calcipotriol";"O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1";"";"D05AX02";"Vitamin D3 receptor";"VDR";"unknown";"antagonist"
"Calcipotriol";"O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1";"";"D05AX52";"Vitamin D3 receptor";"VDR";"unknown";"antagonist"
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"mRNA-capping enzyme";"RNGTT";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"FMN-dependent NADH-azoreductase";"azoR";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Transcription termination/antitermination protein NusG";"nusG";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase";"ADI1";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"GTP cyclohydrolase 1";"GCH1";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Growth/differentiation factor 5";"GDF5";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Subtilisin BPN'";"apr";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Ig kappa chain V-IV region Len";"";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Ribonuclease pancreatic";"RNASE1";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Pectate lyase";"pelA";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Trypsin-2";"PRSS2";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Gag polyprotein";"gag";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Aldehyde oxidoreductase";"mop";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Ganglioside GM2 activator";"GM2A";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Thermolysin";"nprS";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Scaffolding dockerin binding protein A";"sdbA";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Chitotriosidase-1";"CHIT1";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Alr1529 protein";"";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"L-xylulose reductase";"DCXR";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Peroxiredoxin-6";"PRDX6";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Hydrolase, TatD family";"";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Tumor necrosis factor";"TNF";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Tartrate-resistant acid phosphatase type 5";"ACP5";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Adenosylhomocysteinase";"AHCY";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Spliceosome RNA helicase DDX39B";"DDX39B";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"DNA mismatch repair protein MutL";"mutL";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Gag-Pro-Pol polyprotein";"gag-pro-pol";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Lysozyme";"R";"unknown";""
"Isopropyl Alcohol";"CC(C)O";"";"D08AX05";"Glucarate dehydratase";"gudD";"unknown";""
"Carbenoxolone";"[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O";"";"A02BX71";"3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase";"";"unknown";""
"Carbenoxolone";"[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O";"";"A02BX51";"3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase";"";"unknown";""
"Carbenoxolone";"[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O";"";"A02BX01";"3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase";"";"unknown";""
"Carbenoxolone";"[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O";"";"A02BX71";"Corticosteroid 11-beta-dehydrogenase isozyme 1";"HSD11B1";"unknown";"inhibitor"
"Carbenoxolone";"[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O";"";"A02BX51";"Corticosteroid 11-beta-dehydrogenase isozyme 1";"HSD11B1";"unknown";"inhibitor"
"Carbenoxolone";"[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O";"";"A02BX01";"Corticosteroid 11-beta-dehydrogenase isozyme 1";"HSD11B1";"unknown";"inhibitor"
"Aminobenzoic acid";"NC1=CC=C(C=C1)C(O)=O";"";"D02BA01";"p-hydroxybenzoate hydroxylase";"pobA";"unknown";""
"Aminobenzoic acid";"NC1=CC=C(C=C1)C(O)=O";"";"D02BA01";"p-hydroxybenzoate hydroxylase";"pobA";"unknown";""
"Tolrestat";"COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F";"";"A10XA01";"Aldose reductase";"AKR1B1";"unknown";"inhibitor"
"Tolrestat";"COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F";"";"A10XA01";"Alcohol dehydrogenase [NADP(+)]";"AKR1A1";"unknown";""
"Tolrestat";"COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F";"";"A10XA01";"Aldo-keto reductase family 1 member B10";"AKR1B10";"unknown";""
"Vorinostat";"ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1";"2 hours";"L01XX38";"Histone deacetylase 1";"HDAC1";"yes";"inhibitor"
"Vorinostat";"ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1";"2 hours";"L01XX38";"Histone deacetylase 2";"HDAC2";"yes";"inhibitor"
"Vorinostat";"ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1";"2 hours";"L01XX38";"Histone deacetylase 3";"HDAC3";"yes";"inhibitor"
"Vorinostat";"ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1";"2 hours";"L01XX38";"Histone deacetylase 6";"HDAC6";"yes";"inhibitor"
"Vorinostat";"ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1";"2 hours";"L01XX38";"Histone deacetylase 8";"HDAC8";"unknown";""
"Vorinostat";"ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1";"2 hours";"L01XX38";"Acetoin utilization protein";"acuC1";"unknown";""
"Terlipressin";"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O";"";"H01BA04";"Vasopressin V2 receptor";"AVPR2";"yes";"agonist"
"Terlipressin";"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O";"";"H01BA04";"Vasopressin V1b receptor";"AVPR1B";"unknown";""
"Terlipressin";"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O";"";"H01BA04";"Vasopressin V1a receptor";"AVPR1A";"unknown";"stimulator"
"Fumagillin";"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O";"";"P01AX10";"Methionine aminopeptidase 2";"METAP2";"unknown";"ligand"
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Ferrochelatase, mitochondrial";"FECH";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Alcohol dehydrogenase 1C";"ADH1C";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Estrogen-related receptor gamma";"ESRRG";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Gastrotropin";"FABP6";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 4 isoform 1, mitochondrial";"COX4I1";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 1";"MT-CO1";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 2";"MT-CO2";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 3";"MT-CO3";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 5A, mitochondrial";"COX5A";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 5B, mitochondrial";"COX5B";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 6C";"COX6C";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 7B, mitochondrial";"COX7B";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 7C, mitochondrial";"COX7C";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 8A, mitochondrial";"COX8A";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 6A2, mitochondrial";"COX6A2";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 6B1";"COX6B1";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Cytochrome c oxidase subunit 7A1, mitochondrial";"COX7A1";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Phospholipase A2";"PLA2G1B";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Liver carboxylesterase 1";"CES1";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Ferrochelatase";"DKFZp686P18130";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Choloylglycine hydrolase";"cbh";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"Bile acid receptor";"NR1H4";"unknown";""
"Cholic Acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C";"";"A05AA03";"G-protein coupled bile acid receptor 1";"GPBAR1";"unknown";""
"Nicotinamide";"NC(=O)C1=CC=CN=C1";"";"A11HA01";"Exotoxin A";"eta";"unknown";""
"Nicotinamide";"NC(=O)C1=CC=CN=C1";"";"A11HA01";"L-lactate dehydrogenase A chain";"LDHA";"unknown";""
"Nicotinamide";"NC(=O)C1=CC=CN=C1";"";"A11HA01";"Poly [ADP-ribose] polymerase 1";"PARP1";"unknown";"binder"
"Nicotinamide";"NC(=O)C1=CC=CN=C1";"";"A11HA01";"NAD-dependent protein deacylase sirtuin-5, mitochondrial";"SIRT5";"unknown";""
"Nicotinamide";"NC(=O)C1=CC=CN=C1";"";"A11HA01";"ADP-ribosyl cyclase 2";"BST1";"unknown";""
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"J01XC01";"Elongation factor G";"fusA";"yes";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"D09AA02";"Elongation factor G";"fusA";"yes";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"D06AX01";"Elongation factor G";"fusA";"yes";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"S01AA13";"Elongation factor G";"fusA";"yes";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"J01XC01";"Chloramphenicol acetyltransferase";"cat";"unknown";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"D09AA02";"Chloramphenicol acetyltransferase";"cat";"unknown";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"D06AX01";"Chloramphenicol acetyltransferase";"cat";"unknown";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"S01AA13";"Chloramphenicol acetyltransferase";"cat";"unknown";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"J01XC01";"Chloramphenicol acetyltransferase 3";"cat3";"unknown";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"D09AA02";"Chloramphenicol acetyltransferase 3";"cat3";"unknown";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"D06AX01";"Chloramphenicol acetyltransferase 3";"cat3";"unknown";"inhibitor"
"Fusidic Acid";"O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C";"Approximately 5 to 6 hours in adults.";"S01AA13";"Chloramphenicol acetyltransferase 3";"cat3";"unknown";"inhibitor"
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"A14AA01";"Estradiol 17-beta-dehydrogenase 1";"HSD17B1";"unknown";""
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"G03BB02";"Estradiol 17-beta-dehydrogenase 1";"HSD17B1";"unknown";""
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"A14AA01";"Androgen receptor";"AR";"unknown";""
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"G03BB02";"Androgen receptor";"AR";"unknown";""
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"A14AA01";"Estrogen receptor alpha";"ESR1";"unknown";""
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"G03BB02";"Estrogen receptor alpha";"ESR1";"unknown";""
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"A14AA01";"Mineralocorticoid receptor";"NR3C2";"unknown";""
"Stanolone";"[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C";"";"G03BB02";"Mineralocorticoid receptor";"NR3C2";"unknown";""
"Piretanide";"NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O";"";"C03CA03";"Solute carrier family 12 member 1";"SLC12A1";"unknown";"inhibitor"
"Oxitriptan";"N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O";"";"N06AX01";"Tryptophan--tRNA ligase 2";"trpS2";"unknown";""
"Acetylcholine";"CC(=O)OCC[N+](C)(C)C";"";"S01EB09";"Acetylcholinesterase";"ACHE";"unknown";""
"Acetylcholine";"CC(=O)OCC[N+](C)(C)C";"";"S01EB09";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";""
"Acetylcholine";"CC(=O)OCC[N+](C)(C)C";"";"S01EB09";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";""
"Acetylcholine";"CC(=O)OCC[N+](C)(C)C";"";"S01EB09";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Acetylcholine";"CC(=O)OCC[N+](C)(C)C";"";"S01EB09";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";""
"Acetylcholine";"CC(=O)OCC[N+](C)(C)C";"";"S01EB09";"Neuronal acetylcholine receptor subunit alpha-7";"CHRNA7";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"D08AE03";"Thermolysin";"nprS";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"C05BB05";"Thermolysin";"nprS";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"R02AA19";"Thermolysin";"nprS";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"N01BX03";"Thermolysin";"nprS";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"D08AE03";"Lysozyme";"E";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"C05BB05";"Lysozyme";"E";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"R02AA19";"Lysozyme";"E";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"N01BX03";"Lysozyme";"E";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"D08AE03";"Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase";"cobT";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"C05BB05";"Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase";"cobT";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"R02AA19";"Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase";"cobT";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"N01BX03";"Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase";"cobT";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"D08AE03";"Serum albumin";"ALB";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"C05BB05";"Serum albumin";"ALB";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"R02AA19";"Serum albumin";"ALB";"unknown";""
"Phenol";"OC1=CC=CC=C1";"";"N01BX03";"Serum albumin";"ALB";"unknown";""
"Oxyphenbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1";"";"S01BC02";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";""
"Oxyphenbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1";"";"M01AA03";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";""
"Oxyphenbutazone";"CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1";"";"M02AA04";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";""
"Methylcobalamin";"C1(CC[C@@]2([C@@H](CC(N)=O)[C@@]3([C@@]4([N+]5=C([C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C(C)=C4[N+]6=C(C=C7[N+]8=C([C@H](C7(C)C)CCC(N)=O)C(C)=C2N3[Co-3]568([N+]2=CN([C@H]3O[C@@H]([C@@H](OP(O[C@@H](CN1)C)([O-])=O)[C@H]3O)CO)C1=CC(C)=C(C=C21)C)C)[C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C)[H])C)=O";"";"B03BA05";"Methionine synthase";"metH";"unknown";""
"Ribostamycin";"[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(O)[C@]([H])(N)C[C@]([H])(N)[C@@]2([H])O[C@@]2([H])O[C@]([H])(CN)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])N)[C@]([H])(O)[C@]1([H])O";"";"J01GB10";"Aminoglycoside N(6')-acetyltransferase type 1";"";"unknown";""
"Ribostamycin";"[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(O)[C@]([H])(N)C[C@]([H])(N)[C@@]2([H])O[C@@]2([H])O[C@]([H])(CN)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])N)[C@]([H])(O)[C@]1([H])O";"";"J01GB10";"Aminoglycoside 2'-N-acetyltransferase";"aac";"unknown";""
"Ribostamycin";"[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(O)[C@]([H])(N)C[C@]([H])(N)[C@@]2([H])O[C@@]2([H])O[C@]([H])(CN)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])N)[C@]([H])(O)[C@]1([H])O";"";"J01GB10";"Protein disulfide-isomerase";"P4HB";"unknown";""
"Ribostamycin";"[H][C@]1(CO)O[C@@]([H])(O[C@]2([H])[C@@]([H])(O)[C@]([H])(N)C[C@]([H])(N)[C@@]2([H])O[C@@]2([H])O[C@]([H])(CN)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])N)[C@]([H])(O)[C@]1([H])O";"";"J01GB10";"30S ribosomal protein S12";"rpsL";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Autolysin";"lytA";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Autolysin";"lytA";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Cytochrome c4";"cc4";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Cytochrome c4";"cc4";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Soluble calcium-activated nucleotidase 1";"CANT1";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Soluble calcium-activated nucleotidase 1";"CANT1";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Lipoprotein NlpI";"nlpI";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Lipoprotein NlpI";"nlpI";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"DNA protection during starvation protein";"dps";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"DNA protection during starvation protein";"dps";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Putative glucose-6-phosphate 1-epimerase";"";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Putative glucose-6-phosphate 1-epimerase";"";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Endonuclease 8-like 1";"NEIL1";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Cholera enterotoxin subunit B";"ctxB";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Cholera enterotoxin subunit B";"ctxB";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"S-adenosylmethionine decarboxylase proenzyme";"AMD1";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"S-adenosylmethionine decarboxylase proenzyme";"AMD1";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Biotin synthase";"bioB";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Biotin synthase";"bioB";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Vascular endothelial growth factor A";"VEGFA";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Vascular endothelial growth factor A";"VEGFA";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"6-phosphogluconolactonase";"pgl";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"6-phosphogluconolactonase";"pgl";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05BB03";"Decorin";"DCN";"unknown";""
"Tromethamine";"NC(CO)(CO)CO";"";"B05XX02";"Decorin";"DCN";"unknown";""
"Phenacetin";"CCOC1=CC=C(NC(C)=O)C=C1";"";"N02BE73";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Phenacetin";"CCOC1=CC=C(NC(C)=O)C=C1";"";"N02BE53";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Phenacetin";"CCOC1=CC=C(NC(C)=O)C=C1";"";"N02BE03";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Hydrogen peroxide-inducible genes activator";"oxyR";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Hydrogen peroxide-inducible genes activator";"oxyR";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"HTH-type transcriptional regulator MalT";"malT";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"HTH-type transcriptional regulator MalT";"malT";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Tautomerase PptA";"pptA";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Tautomerase PptA";"pptA";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"D-amino-acid oxidase";"DAO";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"D-amino-acid oxidase";"DAO";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Ribonuclease UK114";"HRSP12";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Ribonuclease UK114";"HRSP12";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Chlorocatechol 1,2-dioxygenase";"clcA";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Chlorocatechol 1,2-dioxygenase";"clcA";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Ras-related protein Rab-9A";"RAB9A";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Ras-related protein Rab-9A";"RAB9A";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase";"cumD";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase";"cumD";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Non-heme chloroperoxidase";"cpo";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Non-heme chloroperoxidase";"cpo";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Oxygen-insensitive NAD(P)H nitroreductase";"nfsB";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Oxygen-insensitive NAD(P)H nitroreductase";"nfsB";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Hydroxyquinol 1,2-dioxygenase";"chqB";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Hydroxyquinol 1,2-dioxygenase";"chqB";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Replication protein";"repA";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Replication protein";"repA";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Peroxiredoxin-5, mitochondrial";"PRDX5";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Peroxiredoxin-5, mitochondrial";"PRDX5";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Heat-labile enterotoxin B chain";"eltB";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Heat-labile enterotoxin B chain";"eltB";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Cocaine esterase";"cocE";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Cocaine esterase";"cocE";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"V04CG30";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Benzoic Acid";"OC(=O)C1=CC=CC=C1";"";"A16AX11";"Solute carrier family 15 member 1";"SLC15A1";"unknown";""
"Fotemustine";"CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O";"";"L01AD05";"Thioredoxin reductase 1, cytoplasmic";"TXNRD1";"unknown";""
"Valpromide";"CCCC(CCC)C(N)=O";"";"N03AG02";"Limonene-1,2-epoxide hydrolase";"limA";"unknown";""
"Fructose";"OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O";"";"V06DC02";"Maltoporin";"lamB";"unknown";""
"Fructose";"OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O";"";"V06DC02";"Bis(5'-adenosyl)-triphosphatase";"FHIT";"unknown";""
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"R02AA02";"Acriflavine resistance protein B";"acrB";"unknown";""
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"G01AC05";"Acriflavine resistance protein B";"acrB";"unknown";""
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"D08AH01";"Acriflavine resistance protein B";"acrB";"unknown";""
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"R02AA02";"HTH-type transcriptional regulator QacR";"qacR";"unknown";""
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"G01AC05";"HTH-type transcriptional regulator QacR";"qacR";"unknown";""
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"D08AH01";"HTH-type transcriptional regulator QacR";"qacR";"unknown";""
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"R02AA02";"E3 ubiquitin-protein ligase XIAP";"XIAP";"yes";"antagonistinhibitor"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"G01AC05";"E3 ubiquitin-protein ligase XIAP";"XIAP";"yes";"antagonistinhibitor"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"D08AH01";"E3 ubiquitin-protein ligase XIAP";"XIAP";"yes";"antagonistinhibitor"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"R02AA02";"cGMP-gated cation channel alpha-1";"CNGA1";"unknown";"blocker"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"G01AC05";"cGMP-gated cation channel alpha-1";"CNGA1";"unknown";"blocker"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"D08AH01";"cGMP-gated cation channel alpha-1";"CNGA1";"unknown";"blocker"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"R02AA02";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"G01AC05";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Dequalinium";"CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2";"";"D08AH01";"Calcium-activated potassium channel subunit alpha-1";"KCNMA1";"unknown";"inhibitor"
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"KHG/KDPG aldolase";"eda";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Molybdenum cofactor guanylyltransferase";"mobA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Fumarate hydratase class II";"fumC";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"6-phosphogluconolactonase";"pgl";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Oxygen-insensitive NAD(P)H nitroreductase";"nfsB";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Gag-Pro-Pol polyprotein";"gag-pro-pol";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"L-amino-acid oxidase";"IL4I1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Macrophage migration inhibitory factor";"MIF";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1";"CTDSP1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"1-deoxy-D-xylulose 5-phosphate reductoisomerase";"dxr";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Tryptophan synthase alpha chain";"trpA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Sialidase";"nedA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Cytochrome c peroxidase";"";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Hepatocyte growth factor-regulated tyrosine kinase substrate";"HGS";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Invasin";"";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Intron-associated endonuclease 1";"ITEVIR";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Short tail fiber protein";"12";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Malate dehydrogenase, mitochondrial";"MDH2";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"N5-carboxyaminoimidazole ribonucleotide mutase";"purE";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"50S ribosomal protein L4";"rplD";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Carboxypeptidase B";"CPB1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Hexon protein";"";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Riboflavin biosynthesis protein RibF";"";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Beta-fructosidase";"bfrA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Putative stringent starvation protein A";"sspA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Citrate synthase";"cit";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"RNA 3'-terminal phosphate cyclase";"rtcA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"U6 snRNA-associated Sm-like protein LSm6";"LSM6";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Pleckstrin homology domain-containing family A member 1";"PLEKHA1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Fe(3+)-binding periplasmic protein";"fbpA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Signal recognition particle receptor FtsY";"ftsY";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Nicotinate-nucleotide adenylyltransferase";"nadD";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"N utilization substance protein B homolog";"nusB";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Complement component C8 gamma chain";"C8G";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Ribonucleoside-diphosphate reductase subunit beta";"nrdF";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Glutamine synthetase 1";"glnA1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Glutamine synthetase 1";"glnA1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Citrate synthase";"gltA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Prostaglandin F synthase";"";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Cell division protein FtsZ";"ftsZ";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Adenine phosphoribosyltransferase";"APRT";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Angiogenin";"ANG";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Glucose-1-phosphate thymidylyltransferase";"rmlA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Beta-lactamase 2";"blm";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Glyoxalase family protein";"";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Uridine-cytidine kinase 2";"UCK2";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Tumor necrosis factor ligand superfamily member 13B";"TNFSF13B";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Laccase domain protein YfiH";"yfiH";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Betaine--homocysteine S-methyltransferase 1";"BHMT";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Ribose-5-phosphate isomerase A";"rpiA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Tryptophan--tRNA ligase";"trpS";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"GMP synthase [glutamine-hydrolyzing]";"guaA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Aldose reductase";"AKR1B1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Inosine triphosphate pyrophosphatase";"ITPA";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Citrate synthase, mitochondrial";"CS";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Lysozyme";"17";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Heparan sulfate glucosamine 3-O-sulfotransferase 3A1";"HS3ST3A1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Glycerol uptake operon antiterminator regulatory protein";"";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"3-carboxy-cis,cis-muconate cycloisomerase";"pcaB";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Proto-oncogene tyrosine-protein kinase Src";"SRC";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Pyruvate decarboxylase";"pdc";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Ribonuclease pancreatic";"RNASE1";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Isocitrate dehydrogenase [NADP]";"icd";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Glycine N-methyltransferase";"GNMT";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Eosinophil cationic protein";"RNASE3";"unknown";""
"Citric Acid";"OC(=O)CC(O)(CC(O)=O)C(O)=O";"";"A09AB04";"Beta-lactamase";"penP";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"G01AX02";"IAG-nucleoside hydrolase";"";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"D06BB05";"IAG-nucleoside hydrolase";"";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"S01XA10";"IAG-nucleoside hydrolase";"";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"G01AX02";"Purine nucleoside phosphorylase";"PNP";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"D06BB05";"Purine nucleoside phosphorylase";"PNP";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"S01XA10";"Purine nucleoside phosphorylase";"PNP";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"G01AX02";"Purine nucleoside phosphorylase DeoD-type";"deoD";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"D06BB05";"Purine nucleoside phosphorylase DeoD-type";"deoD";"unknown";""
"Inosine";"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O";"";"S01XA10";"Purine nucleoside phosphorylase DeoD-type";"deoD";"unknown";""
"Carbocisteine";"N[C@@H](CSCC(O)=O)C(O)=O";"";"R05CB03";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Lactic Acid";"CC(O)C(O)=O";"";"G01AD01";"Bifunctional protein PutA";"putA";"unknown";""
"Lactic Acid";"CC(O)C(O)=O";"";"G01AD01";"NimA-related protein";"";"unknown";""
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M02AA17";"Phospholipase A2";"PLA2G1B";"yes";"inhibitor"
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M01AX02";"Phospholipase A2";"PLA2G1B";"yes";"inhibitor"
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M02AA17";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M01AX02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M02AA17";"Chloride channel protein ClC-Ka";"CLCNKA";"unknown";"inducer"
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M01AX02";"Chloride channel protein ClC-Ka";"CLCNKA";"unknown";"inducer"
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M02AA17";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M01AX02";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M02AA17";"Cytosolic phospholipase A2";"PLA2G4A";"unknown";""
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M01AX02";"Cytosolic phospholipase A2";"PLA2G4A";"unknown";""
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M02AA17";"UDP-glucuronosyltransferase 1-9";"UGT1A9";"unknown";""
"Niflumic Acid";"OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1";"2.5 hours";"M01AX02";"UDP-glucuronosyltransferase 1-9";"UGT1A9";"unknown";""
"Latamoxef";"[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O";"1.6 hours";"J01DD06";"Penicillin-binding protein 3";"pbpC";"yes";"inhibitor"
"Latamoxef";"[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O";"1.6 hours";"J01DD06";"Penicillin-binding protein 1A";"mrcA";"unknown";"inhibitor"
"Latamoxef";"[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O";"1.6 hours";"J01DD06";"Penicillin-binding protein 1B";"mrcB";"unknown";"inhibitor"
"Latamoxef";"[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O";"1.6 hours";"J01DD06";"D-alanyl-D-alanine carboxypeptidase DacB";"dacB";"unknown";"inhibitor"
"Estriol";"[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"";"G03CC06";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estriol";"[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"";"G03CA04";"Estrogen receptor alpha";"ESR1";"yes";"agonist"
"Estriol";"[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"";"G03CC06";"Estrogen receptor beta";"ESR2";"unknown";"agonist"
"Estriol";"[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"";"G03CA04";"Estrogen receptor beta";"ESR2";"unknown";"agonist"
"Estriol";"[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"";"G03CC06";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Estriol";"[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3";"";"G03CA04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Fleroxacin";"CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN(CCF)C2=C1F)C(O)=O";"";"J01MA08";"DNA topoisomerase 2-alpha";"TOP2A";"yes";"inhibitor"
"Fleroxacin";"CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN(CCF)C2=C1F)C(O)=O";"";"J01MA08";"DNA gyrase subunit A";"gyrA";"yes";"inhibitor"
"Fleroxacin";"CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN(CCF)C2=C1F)C(O)=O";"";"J01MA08";"DNA topoisomerase 4 subunit A";"parC";"yes";"inhibitor"
"Aniracetam";"COC1=CC=C(C=C1)C(=O)N1CCCC1=O";"1-2.5 hours";"N06BX11";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";""
"Aniracetam";"COC1=CC=C(C=C1)C(=O)N1CCCC1=O";"1-2.5 hours";"N06BX11";"D(2) dopamine receptor";"DRD2";"unknown";""
"Aniracetam";"COC1=CC=C(C=C1)C(=O)N1CCCC1=O";"1-2.5 hours";"N06BX11";"Glutamate receptor 2";"GRIA2";"unknown";""
"Aniracetam";"COC1=CC=C(C=C1)C(=O)N1CCCC1=O";"1-2.5 hours";"N06BX11";"Glutamate receptor 3";"GRIA3";"unknown";""
"Aldosterone";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C=O)C(=O)CO";"";"H02AA01";"Mineralocorticoid receptor";"NR3C2";"unknown";""
"Aldosterone";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C=O)C(=O)CO";"";"H02AA01";"Glucocorticoid receptor";"NR3C1";"unknown";""
"Choline alfoscerate";"[H][C@@](O)(CO)COP([O-])(=O)OCC[N+](C)(C)C";"";"N07AX02";"Ganglioside GM2 activator";"GM2A";"unknown";""
"Nimesulide";"CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O";"1.8–4.7 hours";"M02AA26";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Nimesulide";"CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O";"1.8–4.7 hours";"M01AX17";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Nimesulide";"CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O";"1.8–4.7 hours";"M02AA26";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";""
"Nimesulide";"CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O";"1.8–4.7 hours";"M01AX17";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";""
"Nimesulide";"CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O";"1.8–4.7 hours";"M02AA26";"Lactotransferrin";"LTF";"unknown";""
"Nimesulide";"CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O";"1.8–4.7 hours";"M01AX17";"Lactotransferrin";"LTF";"unknown";""
"Suramin";"CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O";"Approximately 36 to 60 days";"P01CX02";"P2Y purinoceptor 2";"P2RY2";"yes";"antagonist"
"Suramin";"CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O";"Approximately 36 to 60 days";"P01CX02";"NAD-dependent protein deacylase sirtuin-5, mitochondrial";"SIRT5";"yes";"inhibitor"
"Suramin";"CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O";"Approximately 36 to 60 days";"P01CX02";"Follicle-stimulating hormone receptor";"FSHR";"yes";"antagonist"
"Suramin";"CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O";"Approximately 36 to 60 days";"P01CX02";"Ryanodine receptor 1";"RYR1";"unknown";"agonist"
"Suramin";"CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O";"Approximately 36 to 60 days";"P01CX02";"Prothrombin";"F2";"unknown";"inhibitor"
"Suramin";"CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O";"Approximately 36 to 60 days";"P01CX02";"Phospholipase A2, membrane associated";"PLA2G2A";"unknown";"inhibitor"
"Suramin";"CC1=C(NC(=O)C2=CC(NC(=O)NC3=CC=CC(=C3)C(=O)NC3=C(C)C=CC(=C3)C(=O)NC3=C4C(C=C(C=C4S(O)(=O)=O)S(O)(=O)=O)=C(C=C3)S(O)(=O)=O)=CC=C2)C=C(C=C1)C(=O)NC1=C2C(C=C(C=C2S(O)(=O)=O)S(O)(=O)=O)=C(C=C1)S(O)(=O)=O";"Approximately 36 to 60 days";"P01CX02";"Complement control protein C3";"";"unknown";""
"Bifonazole";"C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1";"1-2 hours";"D01AC60";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Bifonazole";"C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1";"1-2 hours";"D01AC10";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Bifonazole";"C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1";"1-2 hours";"D01AC60";"Cytochrome P450 2B6";"CYP2B6";"unknown";""
"Bifonazole";"C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1";"1-2 hours";"D01AC10";"Cytochrome P450 2B6";"CYP2B6";"unknown";""
"Metamizole";"[Na+].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1";"";"N02BB02";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Metamizole";"[Na+].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1";"";"N02BB72";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Metamizole";"[Na+].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1";"";"N02BB52";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";""
"Nialamide";"O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1";"";"N06AF02";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Nialamide";"O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1";"";"N06AF02";"Amine oxidase [flavin-containing] A";"MAOA";"unknown";""
"Nialamide";"O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1";"";"N06AF02";"Catechol O-methyltransferase";"COMT";"unknown";""
"Nomifensine";"CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2";"";"N06AX04";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Nomifensine";"CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2";"";"N06AX04";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";""
"Nomifensine";"CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2";"";"N06AX04";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";""
"Nomifensine";"CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2";"";"N06AX04";"Amine oxidase [flavin-containing] A";"MAOA";"unknown";""
"Nomifensine";"CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2";"";"N06AX04";"Myeloperoxidase";"MPO";"unknown";""
"Nomifensine";"CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2";"";"N06AX04";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";""
"Nomifensine";"CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2";"";"N06AX04";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";""
"Phenolphthalein";"OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1";"";"A06AB04";"UDP-glucuronosyltransferase 1-9";"UGT1A9";"unknown";""
"Phenolphthalein";"OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1";"";"A06AB04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Phenolphthalein";"OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1";"";"A06AB04";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";""
"Phenolphthalein";"OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1";"";"A06AB04";"Estrogen receptor alpha";"ESR1";"unknown";"agonist"
"Phenolphthalein";"OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1";"";"A06AB04";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Prenylamine";"CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1";"";"C01DX52";"Calmodulin";"CALM1";"unknown";""
"Prenylamine";"CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1";"";"C01DX02";"Calmodulin";"CALM1";"unknown";""
"Prenylamine";"CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1";"";"C01DX52";"Myosin light chain kinase 2, skeletal/cardiac muscle";"MYLK2";"unknown";""
"Prenylamine";"CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1";"";"C01DX02";"Myosin light chain kinase 2, skeletal/cardiac muscle";"MYLK2";"unknown";""
"Zomepirac";"CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1";"";"M01AB04";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";""
"Zimelidine";"CN(C)CC=C(C1=CC=C(Br)C=C1)C1=CN=CC=C1";"8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.";"N06AB02";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";""
"Zimelidine";"CN(C)CC=C(C1=CC=C(Br)C=C1)C1=CN=CC=C1";"8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.";"N06AB02";"Amine oxidase [flavin-containing] B";"MAOB";"unknown";"inhibitor"
"Zimelidine";"CN(C)CC=C(C1=CC=C(Br)C=C1)C1=CN=CC=C1";"8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.";"N06AB02";"Amine oxidase [flavin-containing] A";"MAOA";"unknown";"inhibitor"
"Maraviroc";"[H][C@@](CCN1[C@@]2([H])CC[C@]1([H])C[C@]([H])(C2)N1C(C)=NN=C1C(C)C)(N=C(O)C1CCC(F)(F)CC1)C1=CC=CC=C1";"14-18 hours";"J05AX09";"C-C chemokine receptor type 5";"CCR5";"yes";"antagonist"
"Amineptine";"[Cl-].OC(=O)CCCCCC[NH2+]C1C2=CC=CC=C2CCC2=CC=CC=C12";"48 minutes for the parent drug and 2.5 hours for the metabolites.";"N06AA19";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";""
"Amineptine";"[Cl-].OC(=O)CCCCCC[NH2+]C1C2=CC=CC=C2CCC2=CC=CC=C12";"48 minutes for the parent drug and 2.5 hours for the metabolites.";"N06AA19";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";""
"Clofedanol";"CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl";"";"R05DB10";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Cyclandelate";"CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1";"";"C04AX01";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"unknown";"inhibitor"
"Cyclandelate";"CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1";"";"C04AX01";"Liver carboxylesterase 1";"CES1";"unknown";""
"Cyproterone acetate";"[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]";"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.";"G03HB01";"Androgen receptor";"AR";"yes";"antagonist"
"Cyproterone acetate";"[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]";"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.";"G03HA01";"Androgen receptor";"AR";"yes";"antagonist"
"Cyproterone acetate";"[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]";"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.";"G03HB01";"Prostate-specific antigen";"KLK3";"unknown";""
"Cyproterone acetate";"[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]";"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.";"G03HA01";"Prostate-specific antigen";"KLK3";"unknown";""
"Debrisoquin";"NC(=N)N1CCC2=CC=CC=C2C1";"";"C02CC04";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inducer"
"Flunarizine";"FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1";"18 days";"N07CA03";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Flunarizine";"FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1";"18 days";"N07CA03";"Voltage-dependent T-type calcium channel subunit alpha-1H";"CACNA1H";"yes";"inhibitor"
"Flunarizine";"FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1";"18 days";"N07CA03";"Voltage-dependent T-type calcium channel subunit alpha-1I";"CACNA1I";"yes";"inhibitor"
"Flunarizine";"FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1";"18 days";"N07CA03";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Flunarizine";"FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1";"18 days";"N07CA03";"Calmodulin";"CALM1";"unknown";""
"Fluspirilene";"FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1";"";"N05AG01";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Fluspirilene";"FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1";"";"N05AG01";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Fluspirilene";"FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1";"";"N05AG01";"Voltage-dependent calcium channel gamma-1 subunit";"CACNG1";"unknown";"inhibitor"
"Mepenzolate";"C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"";"A03AB12";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Mepenzolate";"C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1";"";"A03AB12";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Tetrabenazine";"COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1";"α-HTBZ = 7 hours; 
β-HTBZ = 5 hours;
9-desmethyl-β-DHTBZ = 12 hours.";"N07XX06";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Tetrabenazine";"COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1";"α-HTBZ = 7 hours; 
β-HTBZ = 5 hours;
9-desmethyl-β-DHTBZ = 12 hours.";"N07XX06";"D(2) dopamine receptor";"DRD2";"unknown";"inhibitor"
"Ixabepilone";"[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1";"52 hours";"L01DC04";"Tubulin beta-3 chain";"TUBB3";"yes";"inhibitor"
"Celiprolol";"CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O";"5 hours";"C07AB08";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Celiprolol";"CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O";"5 hours";"C07AB08";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Cediranib";"COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1";"12 to 35 hours";"L01XE32";"Vascular endothelial growth factor receptor 2";"KDR";"unknown";""
"Febuxostat";"CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N";"~5-8 hours.";"M04AA03";"Xanthine dehydrogenase/oxidase";"XDH";"yes";"inhibitor"
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Beta-1 adrenergic receptor";"ADRB1";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit beta-1";"CACNB1";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit beta-3";"CACNB3";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Voltage-dependent L-type calcium channel subunit beta-4";"CACNB4";"unknown";""
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Sodium channel protein type 1 subunit alpha";"SCN1A";"unknown";"inhibitor"
"Dronedarone";"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2";"Elimination half-life: 13-19 hours";"C01BD07";"Potassium channel subfamily K member 2";"KCNK2";"unknown";"inhibitor"
"Nebivolol";"OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2";"10 hours";"C07FB12";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Nebivolol";"OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2";"10 hours";"C07AB12";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Nebivolol";"OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2";"10 hours";"C07BB12";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Nebivolol";"OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2";"10 hours";"C07FB12";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Nebivolol";"OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2";"10 hours";"C07AB12";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Nebivolol";"OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2";"10 hours";"C07BB12";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Omacetaxine mepesuccinate";"[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]";"Homoharringtonine has a half life of about 6 hours after subcutaneous administration.";"L01XX40";"50S ribosomal protein L2";"rpl2";"yes";"antagonist"
"Omacetaxine mepesuccinate";"[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]";"Homoharringtonine has a half life of about 6 hours after subcutaneous administration.";"L01XX40";"60S ribosomal protein L3";"RPL3";"yes";"antagonist"
"Nilotinib";"CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F";"15 hours";"L01XE08";"Tyrosine-protein kinase ABL1";"ABL1";"yes";"inhibitor"
"Nilotinib";"CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F";"15 hours";"L01XE08";"Mast/stem cell growth factor receptor Kit";"KIT";"unknown";"antagonist"
"Lorcaserin";"C[C@H]1CNCCC2=CC=C(Cl)C=C12";"The plasma half life is approximately 11 hours.";"A08AA11";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";""
"Vildagliptin";"OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N";"The elimination half-life is approximately 90 minutes.";"A10BH02";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Vildagliptin";"OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N";"The elimination half-life is approximately 90 minutes.";"A10BD08";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Voglibose";"OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O";"";"A10BF03";"Maltase-glucoamylase, intestinal";"MGAM";"yes";"inhibitor"
"Enoximone";"CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1";"4-10 hours";"C01CE03";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"yes";"inhibitor"
"Dapoxetine";"CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1";"Initial half-life of 1-2 hours.";"G04BX14";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";""
"Dapoxetine";"CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1";"Initial half-life of 1-2 hours.";"G04BX14";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";""
"Dapoxetine";"CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1";"Initial half-life of 1-2 hours.";"G04BX14";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";""
"Cilansetron";"CC1=NC=CN1C[C@H]1CCC2=C(C3=CC=CC4=C3N2CCC4)C1=O";"The elimination half-life after 4- and 8-mg oral doses administered 3 times daily for 6 days was reported to be 1.6 to 1.9 hours.";"A03AE03";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";""
"Vapreotide";"[H][C@@](N)(CC1=CC=CC=C1)C(O)=N[C@@]1([H])CSSC[C@]([H])(N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CCCCN)N=C(O)[C@@]([H])(CC2=CNC3=CC=CC=C23)N=C(O)[C@]([H])(CC2=CC=C(O)C=C2)N=C1O)C(C)C)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N";"30 minutes";"H01CB04";"Somatostatin receptor type 2";"SSTR2";"yes";"inducer"
"Vapreotide";"[H][C@@](N)(CC1=CC=CC=C1)C(O)=N[C@@]1([H])CSSC[C@]([H])(N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CCCCN)N=C(O)[C@@]([H])(CC2=CNC3=CC=CC=C23)N=C(O)[C@]([H])(CC2=CC=C(O)C=C2)N=C1O)C(C)C)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N";"30 minutes";"H01CB04";"Somatostatin receptor type 5";"SSTR5";"yes";"agonist"
"Vapreotide";"[H][C@@](N)(CC1=CC=CC=C1)C(O)=N[C@@]1([H])CSSC[C@]([H])(N=C(O)[C@@]([H])(N=C(O)[C@]([H])(CCCCN)N=C(O)[C@@]([H])(CC2=CNC3=CC=CC=C23)N=C(O)[C@]([H])(CC2=CC=C(O)C=C2)N=C1O)C(C)C)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N";"30 minutes";"H01CB04";"Substance-P receptor";"TACR1";"unknown";"antagonist"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"NMDA receptor";"GRIN1";"unknown";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"NMDA receptor";"GRIN2A";"unknown";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"NMDA receptor";"GRIN2B";"unknown";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"NMDA receptor";"GRIN2C";"unknown";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"NMDA receptor";"GRIN2D";"unknown";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"NMDA receptor";"GRIN3A";"unknown";"inhibitor"
"Milnacipran";"CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1";"The terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).";"N06AX17";"NMDA receptor";"GRIN3B";"unknown";"inhibitor"
"Ximelagatran";"CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1";"3-5 hours";"B01AE05";"Prothrombin";"F2";"yes";"inhibitor"
"Flibanserin";"FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1";"≈11 hours";"G02CX02";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonist"
"Flibanserin";"FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1";"≈11 hours";"G02CX02";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Flibanserin";"FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1";"≈11 hours";"G02CX02";"D(4) dopamine receptor";"DRD4";"yes";"antagonist"
"Ceftobiprole";"[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCNC1";"";"J01DI01";"MecA";"mecA";"unknown";""
"Ceftobiprole";"[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCNC1";"";"J01DI01";"Penicillin-binding protein 2x";"pbpX";"unknown";""
"Ceftobiprole";"[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCNC1";"";"J01DI01";"Peptidoglycan synthase FtsI";"ftsI";"unknown";""
"Clevidipine";"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC";"1 minute";"C08CA16";"Voltage-dependent L-type calcium channel subunit alpha-1F";"CACNA1F";"unknown";""
"Clevidipine";"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC";"1 minute";"C08CA16";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";""
"Clevidipine";"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC";"1 minute";"C08CA16";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"unknown";""
"Clevidipine";"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC";"1 minute";"C08CA16";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";""
"Itopride";"COC1=C(OC)C=C(C=C1)C(=O)NCC1=CC=C(OCCN(C)C)C=C1";"";"A03FA07";"D(2) dopamine receptor";"DRD2";"unknown";""
"Itopride";"COC1=C(OC)C=C(C=C1)C(=O)NCC1=CC=C(OCCN(C)C)C=C1";"";"A03FA07";"Muscarinic acetylcholine receptor M3";"CHRM3";"unknown";""
"Permethrin";"CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1";"";"P03AC54";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Permethrin";"CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1";"";"P03AC04";"Sodium channel protein type 1 subunit alpha";"SCN1A";"yes";"inhibitor"
"Permethrin";"CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1";"";"P03AC54";"Estrogen receptor alpha";"ESR1";"unknown";""
"Permethrin";"CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1";"";"P03AC04";"Estrogen receptor alpha";"ESR1";"unknown";""
"Permethrin";"CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1";"";"P03AC54";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Permethrin";"CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1";"";"P03AC04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Afamelanotide";"CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O";"The plasma half-lives following SC dosing (0.08 to 0.21 mg/kg) ranged from 0.07 to 0.79 h for the absorption phase and from 0.8 to 1.7 h for the beta-phase.";"D02BB02";"Melanocyte-stimulating hormone receptor";"MC1R";"unknown";""
"Ospemifene";"OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1";"Terminal half-life = 26 hours .";"G03XC05";"Estrogen receptor alpha";"ESR1";"yes";"antagonistagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Iloperidone";"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O";"The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.";"N05AX14";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Lofexidine";"CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1";"11 hours";"N07BC04";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Pirfenidone";"CC1=CN(C(=O)C=C1)C1=CC=CC=C1";"2-2.5 hours";"L04AX05";"Furin";"FURIN";"unknown";""
"Ezogabine";"CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1";"Terminal half-life = 7.5 hours";"N03AX21";"Potassium voltage-gated channel subfamily KQT member 2";"KCNQ2";"unknown";""
"Ezogabine";"CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1";"Terminal half-life = 7.5 hours";"N03AX21";"Potassium voltage-gated channel subfamily KQT member 3";"KCNQ3";"unknown";""
"Ezogabine";"CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1";"Terminal half-life = 7.5 hours";"N03AX21";"Potassium voltage-gated channel subfamily KQT member 4";"KCNQ4";"unknown";""
"Ezogabine";"CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1";"Terminal half-life = 7.5 hours";"N03AX21";"Potassium voltage-gated channel subfamily KQT member 5";"KCNQ5";"unknown";""
"Ingenol Mebutate";"OCC1=C[C@]2([H])C(=O)[C@]3(C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@@H]1O)[C@H](C)C[C@@]1([H])C(C)(C)[C@@]21[H]";"There is no half-life quantity since ingenol mebutate is a topical treatment.";"D06BX02";"Protein kinase C delta type";"PRKCD";"unknown";"ligand"
"Ingenol Mebutate";"OCC1=C[C@]2([H])C(=O)[C@]3(C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@@H]1O)[C@H](C)C[C@@]1([H])C(C)(C)[C@@]21[H]";"There is no half-life quantity since ingenol mebutate is a topical treatment.";"D06BX02";"Protein kinase C alpha type";"PRKCA";"unknown";"ligand"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC1";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC10";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC11";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC2";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC3";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC4";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC5";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC6";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC7";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC8";"yes";"inhibitor"
"Belinostat";"ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1";"Displays a three-compartment pharmacokinetic property with elimination half life of 1.1 hours";"L01XX49";"Histone deacetylase";"HDAC9";"yes";"inhibitor"
"Indacaterol";"CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1";"Indacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.";"R03AL04";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Indacaterol";"CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1";"Indacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.";"R03AC18";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Pleconaril";"CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C2=NOC(=N2)C(F)(F)F)=C1";"";"J05AX06";"Polyprotein";"";"unknown";""
"Vintafolide";"[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"";"L01CA06";"Folate receptor beta";"FOLR2";"unknown";""
"Vintafolide";"[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"";"L01CA06";"Folate receptor gamma";"FOLR3";"unknown";""
"Vintafolide";"[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC";"";"L01CA06";"Folate receptor alpha";"FOLR1";"unknown";""
"Beraprost";"[Na+].[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C1=CC=CC(CCCC([O-])=O)=C1O2";"35–40 minutes";"B01AC19";"Prostacyclin receptor";"PTGIR";"unknown";""
"Methsuximide";"CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1";"1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.";"N03AD03";"Voltage-dependent T-type calcium channel subunit alpha-1G";"CACNA1G";"yes";"inhibitor"
"Ibudilast";"CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C";"19 hours";"R03DC04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Ibudilast";"CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C";"19 hours";"R03DC04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"inhibitor"
"Ibudilast";"CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C";"19 hours";"R03DC04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4C";"PDE4C";"yes";"inhibitor"
"Ibudilast";"CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C";"19 hours";"R03DC04";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"unknown";"inhibitor"
"Ibudilast";"CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C";"19 hours";"R03DC04";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"unknown";"inhibitor"
"Rotigotine";"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1";"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.";"N04BC09";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Rotigotine";"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1";"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.";"N04BC09";"D(4) dopamine receptor";"DRD4";"yes";"agonist"
"Rotigotine";"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1";"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.";"N04BC09";"D(2) dopamine receptor";"DRD2";"yes";"agonist"
"Rotigotine";"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1";"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.";"N04BC09";"D(1B) dopamine receptor";"DRD5";"unknown";"agonist"
"Rotigotine";"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1";"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.";"N04BC09";"D(1A) dopamine receptor";"DRD1";"unknown";"agonist"
"Rotigotine";"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1";"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.";"N04BC09";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Rotigotine";"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1";"After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours. The pharmacokinetic profile showed a biphasic elimination with an initial half-life of 3 hours.";"N04BC09";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Vandetanib";"COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1";"Median half life of 19 days.";"L01XE12";"Vascular endothelial growth factor A";"VEGFA";"unknown";"inhibitor"
"Vandetanib";"COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1";"Median half life of 19 days.";"L01XE12";"Epidermal growth factor receptor";"EGFR";"unknown";"inhibitor"
"Vandetanib";"COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1";"Median half life of 19 days.";"L01XE12";"Protein-tyrosine kinase 6";"PTK6";"unknown";"inhibitor"
"Vandetanib";"COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1";"Median half life of 19 days.";"L01XE12";"Angiopoietin-1 receptor";"TEK";"unknown";"inhibitor"
"Vandetanib";"COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1";"Median half life of 19 days.";"L01XE12";"Proto-oncogene tyrosine-protein kinase receptor Ret";"RET";"unknown";""
"Dexlansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1";"Dexlansoprazole is eliminated with a half-life of approximately one to two hours in healthy subjects and in patients with symptomatic GERD.";"A02BC06";"Potassium-transporting ATPase alpha chain 1";"ATP4A";"yes";"inhibitor"
"Dexlansoprazole";"CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1";"Dexlansoprazole is eliminated with a half-life of approximately one to two hours in healthy subjects and in patients with symptomatic GERD.";"A02BC06";"Potassium-transporting ATPase subunit beta";"ATP4B";"yes";"inhibitor"
"Histamine";"NCCC1=CNC=N1";"";"L03AX14";"Histamine H1 receptor";"HRH1";"yes";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"V04CG03";"Histamine H1 receptor";"HRH1";"yes";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"L03AX14";"Histamine H2 receptor";"HRH2";"yes";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"V04CG03";"Histamine H2 receptor";"HRH2";"yes";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"L03AX14";"Histamine H3 receptor";"HRH3";"yes";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"V04CG03";"Histamine H3 receptor";"HRH3";"yes";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"L03AX14";"Histamine H4 receptor";"HRH4";"unknown";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"V04CG03";"Histamine H4 receptor";"HRH4";"unknown";"agonist"
"Histamine";"NCCC1=CNC=N1";"";"L03AX14";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";""
"Histamine";"NCCC1=CNC=N1";"";"V04CG03";"Synaptic vesicular amine transporter";"SLC18A2";"unknown";""
"Iodine";"II";"";"D08AG03";"NADH-ubiquinone oxidoreductase chain 5";"MT-ND5";"unknown";""
"Telaprevir";"[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1";"Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state [FDA Label].";"J05AE11";"NS3/4A protein";"NS3/4A";"yes";"inhibitor"
"Telaprevir";"[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1";"Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state [FDA Label].";"J05AE11";"Solute carrier organic anion transporter family member 1B1";"SLCO1B1";"unknown";"inhibitor"
"Telaprevir";"[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1";"Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state [FDA Label].";"J05AE11";"Solute carrier organic anion transporter family member 2B1";"SLCO2B1";"unknown";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Synaptic vesicle glycoprotein 2A";"SV2A";"yes";"unknown"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN1A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN10A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN11A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN2A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN3A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN4A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN5A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN7A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN8A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN9A";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN1B";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN2B";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN3B";"yes";"inhibitor"
"Brivaracetam";"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1";"7-8h [A19180].";"N03AX23";"Sodium channel protein";"SCN4B";"yes";"inhibitor"
"Sodium stibogluconate";"O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[H][C@@]1(O[Sb]2(O)(O[Sb]34([O-])O[C@@H](C([O-])=O)[C@@]([H])(O3)[C@]([H])(O4)[C@H](O)CO)O[C@@H](C([O-])=O)[C@@]1([H])O2)[C@H](O)CO";"";"P01CB02";"DNA topoisomerase 1";"TOP1";"yes";"inhibitor"
"Apremilast";"[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1";"6-9 hours.";"L04AA32";"cAMP-specific 3',5'-cyclic phosphodiesterase 4D";"PDE4D";"yes";"antagonist"
"Apremilast";"[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1";"6-9 hours.";"L04AA32";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"antagonist"
"Apremilast";"[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1";"6-9 hours.";"L04AA32";"cAMP-specific 3',5'-cyclic phosphodiesterase 4B";"PDE4B";"yes";"antagonist"
"Apremilast";"[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1";"6-9 hours.";"L04AA32";"Tumor necrosis factor";"TNF";"unknown";""
"Apremilast";"[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1";"6-9 hours.";"L04AA32";"Interleukin-2";"IL2";"unknown";""
"Apremilast";"[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1";"6-9 hours.";"L04AA32";"Interferon gamma";"IFNG";"unknown";""
"Apremilast";"[H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1";"6-9 hours.";"L04AA32";"Nitric oxide synthase, endothelial";"NOS3";"unknown";""
"Abiraterone";"[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C";"Terminal elimination half-life = 5-14 hours";"L02BX03";"Steroid 17-alpha-hydroxylase/17,20 lyase";"CYP17A1";"yes";"inhibitor"
"Obeticholic acid";"[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C";"Steady state half life: ~4 days";"A05AA04";"Bile acid receptor";"NR1H4";"yes";"agonist"
"Cariprazine";"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1";"~1 week for the combined drug.";"N05AX15";"D(3) dopamine receptor";"DRD3";"yes";"agonistpartial agonist"
"Cariprazine";"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1";"~1 week for the combined drug.";"N05AX15";"D(2) dopamine receptor";"DRD2";"yes";"agonistpartial agonist"
"Cariprazine";"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1";"~1 week for the combined drug.";"N05AX15";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonistpartial agonist"
"Cariprazine";"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1";"~1 week for the combined drug.";"N05AX15";"5-hydroxytryptamine receptor 2B";"HTR2B";"yes";"antagonist"
"Cariprazine";"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1";"~1 week for the combined drug.";"N05AX15";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Cariprazine";"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1";"~1 week for the combined drug.";"N05AX15";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"5-hydroxytryptamine receptor 6";"HTR6";"yes";"antagonist"
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"inhibitor"
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";""
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";""
"Sertindole";"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2";"3 days";"N05AE03";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";""
"Spiramycin";"[H]\C1=C(\[H])/C(/[H])=C([H])/[C@]([H])(O[C@@]2([H])CC[C@]([H])(N(C)C)[C@]([H])(C)O2)[C@]([H])(C)C[C@]([H])(CC=O)[C@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@@]3([H])C[C@@](C)(O)[C@@]([H])(O)[C@]([H])(C)O3)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(OC)[C@]([H])(O)CC(=O)O[C@]([H])(C)C1";"Intravenous:
Young persons (18 to 32 years of age): Approximately 4.5 to 6.2 hours.
Elderly persons (73 to 85 years of age): Approximately 9.8 to 13.5 hours. 

Oral: 5.5-8 hours, Rectal in children: 8 hours";"J01FA02";"50S ribosomal protein L3";"rplC";"yes";"antagonistinhibitor"
"Spiramycin";"[H]\C1=C(\[H])/C(/[H])=C([H])/[C@]([H])(O[C@@]2([H])CC[C@]([H])(N(C)C)[C@]([H])(C)O2)[C@]([H])(C)C[C@]([H])(CC=O)[C@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@@]3([H])C[C@@](C)(O)[C@@]([H])(O)[C@]([H])(C)O3)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(OC)[C@]([H])(O)CC(=O)O[C@]([H])(C)C1";"Intravenous:
Young persons (18 to 32 years of age): Approximately 4.5 to 6.2 hours.
Elderly persons (73 to 85 years of age): Approximately 9.8 to 13.5 hours. 

Oral: 5.5-8 hours, Rectal in children: 8 hours";"J01RA04";"50S ribosomal protein L3";"rplC";"yes";"antagonistinhibitor"
"Sulfathiazole";"NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1";"";"J01EB07";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfathiazole";"NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1";"";"D06BA02";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfathiazole";"NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1";"";"G01AE10";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Sodium-dependent noradrenaline transporter";"SLC6A2";"unknown";"inhibitor"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Histamine H4 receptor";"HRH4";"unknown";"binder"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"blocker"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"binder"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"5-hydroxytryptamine receptor 1F";"HTR1F";"unknown";"binder"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"D(3) dopamine receptor";"DRD3";"unknown";"binder"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Kappa-type opioid receptor";"OPRK1";"unknown";"agonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Sodium-dependent dopamine transporter";"SLC6A3";"unknown";"binder"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"binder"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";"antagonist"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"D(1) dopamine receptor";"DRD1";"unknown";"binder"
"Mianserin";"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21";"10-17 hours";"N06AX03";"D(1) dopamine receptor";"DRD5";"unknown";"binder"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Glutathione synthetase";"GSS";"yes";"stimulator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Glutathione synthetase";"GSS";"yes";"stimulator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Glutathione synthetase";"GSS";"yes";"stimulator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Cystine/glutamate transporter";"SLC7A11";"yes";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Cystine/glutamate transporter";"SLC7A11";"yes";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Cystine/glutamate transporter";"SLC7A11";"yes";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Aminoacylase-1";"ACY1";"unknown";"ligand"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Aminoacylase-1";"ACY1";"unknown";"ligand"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Aminoacylase-1";"ACY1";"unknown";"ligand"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";"inhibitor"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";"inhibitor"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Inhibitor of nuclear factor kappa-B kinase subunit beta";"IKBKB";"unknown";"inhibitor"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Inhibitor of nuclear factor kappa-B kinase subunit alpha";"CHUK";"unknown";"inhibitor"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Glutamate receptor ionotropic, NMDA 2A";"GRIN2A";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Glutamate receptor ionotropic, NMDA 2D";"GRIN2D";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"V03AB23";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"R05CB01";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";"activator"
"Acetylcysteine";"CC(=O)N[C@@H](CS)C(O)=O";"5.6 hours (adults), 11 hours (neonates)";"S01XA08";"Glutamate receptor ionotropic, NMDA 3A";"GRIN3A";"unknown";"activator"
"Rimonabant";"CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1";"6 to 9 days with normal BMI and 16 days if BMI is greater than 30";"A08AX01";"Cannabinoid receptor 1";"CNR1";"yes";"antagonist"
"Rimonabant";"CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1";"6 to 9 days with normal BMI and 16 days if BMI is greater than 30";"A08AX01";"G-protein coupled receptor 55";"GPR55";"unknown";""
"Noscapine";"[H][C@@]1(OC(=O)C2=C1C=CC(OC)=C2OC)[C@]1([H])N(C)CCC2=CC3=C(OCO3)C(OC)=C12";"";"R05DA07";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"unknown";""
"Romidepsin";"[H]\C(C)=C1\N=C(O)[C@@]2([H])CSSCCC([H])=C([H])[C@]([H])(CC(O)=N[C@]([H])(C(C)C)C(O)=N2)OC(=O)[C@@]([H])(N=C1O)C(C)C";"Approximately 3 hours";"L01XX39";"Histone deacetylase 1";"HDAC1";"yes";"antagonistinhibitor"
"Romidepsin";"[H]\C(C)=C1\N=C(O)[C@@]2([H])CSSCCC([H])=C([H])[C@]([H])(CC(O)=N[C@]([H])(C(C)C)C(O)=N2)OC(=O)[C@@]([H])(N=C1O)C(C)C";"Approximately 3 hours";"L01XX39";"Histone deacetylase 2";"HDAC2";"yes";"antagonistinhibitor"
"Romidepsin";"[H]\C(C)=C1\N=C(O)[C@@]2([H])CSSCCC([H])=C([H])[C@]([H])(CC(O)=N[C@]([H])(C(C)C)C(O)=N2)OC(=O)[C@@]([H])(N=C1O)C(C)C";"Approximately 3 hours";"L01XX39";"Histone deacetylase 4";"HDAC4";"no";"inhibitor"
"Romidepsin";"[H]\C(C)=C1\N=C(O)[C@@]2([H])CSSCCC([H])=C([H])[C@]([H])(CC(O)=N[C@]([H])(C(C)C)C(O)=N2)OC(=O)[C@@]([H])(N=C1O)C(C)C";"Approximately 3 hours";"L01XX39";"Histone deacetylase 6";"HDAC6";"no";"inhibitor"
"Romidepsin";"[H]\C(C)=C1\N=C(O)[C@@]2([H])CSSCCC([H])=C([H])[C@]([H])(CC(O)=N[C@]([H])(C(C)C)C(O)=N2)OC(=O)[C@@]([H])(N=C1O)C(C)C";"Approximately 3 hours";"L01XX39";"Multidrug resistance-associated protein 1";"ABCC1";"unknown";""
"Icatibant";"[H][C@]12CC(N(C(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)C3C[C@@H](O)CN3C(=O)C3CCCN3C(=O)C(CCCN=C(N)N)NC(=O)[C@H](N)CCCN=C(N)N)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O";"After subcutaneous administration, mean elimination half-life was 1.4 ± 0.4 hours.";"B06AC02";"B2 bradykinin receptor";"BDKRB2";"yes";"antagonist"
"Icatibant";"[H][C@]12CC(N(C(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)C3C[C@@H](O)CN3C(=O)C3CCCN3C(=O)C(CCCN=C(N)N)NC(=O)[C@H](N)CCCN=C(N)N)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O";"After subcutaneous administration, mean elimination half-life was 1.4 ± 0.4 hours.";"B06AC02";"Aminopeptidase N";"ANPEP";"unknown";"inhibitor"
"Rufinamide";"NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1";"Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.";"N03AF03";"Metabotropic glutamate receptor 5";"GRM5";"unknown";"inhibitor"
"Rufinamide";"NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1";"Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.";"N03AF03";"Sodium channel protein type 9 subunit alpha";"SCN9A";"unknown";"modulator"
"Lasofoxifene";"[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1";"Elimination half-life is approximately 6 days [A19178].";"G03XC03";"Estrogen receptor alpha";"ESR1";"yes";"antagonistagonistnegative modulator"
"Lasofoxifene";"[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1";"Elimination half-life is approximately 6 days [A19178].";"G03XC03";"Estrogen receptor beta";"ESR2";"yes";"agonist"
"Lasofoxifene";"[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1";"Elimination half-life is approximately 6 days [A19178].";"G03XC03";"Cannabinoid receptor 2";"CNR2";"unknown";"inverse agonist"
"Alogliptin";"CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O";"Terminal half-life = 21 hours";"A10BD13";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Alogliptin";"CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O";"Terminal half-life = 21 hours";"A10BD09";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Alogliptin";"CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O";"Terminal half-life = 21 hours";"A10BH04";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Tapentadol";"CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1";"Elimination half-life, IV: 4 hours.";"N02AX06";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Tapentadol";"CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1";"Elimination half-life, IV: 4 hours.";"N02AX06";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Tapentadol";"CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1";"Elimination half-life, IV: 4 hours.";"N02AX06";"Kappa-type opioid receptor";"OPRK1";"unknown";""
"Tapentadol";"CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1";"Elimination half-life, IV: 4 hours.";"N02AX06";"Delta-type opioid receptor";"OPRD1";"unknown";""
"Tapentadol";"CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1";"Elimination half-life, IV: 4 hours.";"N02AX06";"5-hydroxytryptamine receptor 3A";"HTR3A";"unknown";""
"Tapentadol";"CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1";"Elimination half-life, IV: 4 hours.";"N02AX06";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Silodosin";"C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F";"Silodosin = 13.3 ± 8.07 hours;
KMD-3213G = 24 hours;";"G04CA04";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Silodosin";"C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F";"Silodosin = 13.3 ± 8.07 hours;
KMD-3213G = 24 hours;";"G04CA04";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"antagonist"
"Silodosin";"C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F";"Silodosin = 13.3 ± 8.07 hours;
KMD-3213G = 24 hours;";"G04CA04";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"antagonist"
"Prasugrel";"CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1";"The active metabolite has an elimination half-life of about 7.4 hours (range 2-15 hours).";"B01AC22";"P2Y purinoceptor 12";"P2RY12";"yes";"antagonist"
"Eltrombopag";"CC1=NN(C(=O)\C1=N/NC1=C(O)C(=CC=C1)C1=CC=CC(=C1)C(O)=O)C1=CC=C(C)C(C)=C1";"About 21-32 hours in healthy patients.
About 26-35 hours in patients with idiopathic thrombocytopenic purpura.";"B02BX05";"Thrombopoietin receptor";"MPL";"unknown";"agonist"
"Doripenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour, in healthy non-elderly adults.";"J01DH04";"Penicillin-binding protein 1A";"mrcA";"yes";"antagonistinhibitor"
"Doripenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour, in healthy non-elderly adults.";"J01DH04";"Penicillin-binding protein 1B";"mrcB";"yes";"antagonistinhibitor"
"Doripenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour, in healthy non-elderly adults.";"J01DH04";"Penicillin-binding protein 2";"mrdA";"yes";"antagonistinhibitor"
"Doripenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour, in healthy non-elderly adults.";"J01DH04";"Penicillin-binding protein 3";"pbpB";"yes";"antagonistinhibitor"
"Doripenem";"[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O";"1 hour, in healthy non-elderly adults.";"J01DH04";"Penicillin-binding protein 4";"pbp4";"yes";"antagonistinhibitor"
"Tolvaptan";"CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2";"Terminal half life, oral dose = 12 hours.";"C03XA01";"Vasopressin V2 receptor";"AVPR2";"yes";"antagonist"
"Tolvaptan";"CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2";"Terminal half life, oral dose = 12 hours.";"C03XA01";"Vasopressin V1a receptor";"AVPR1A";"no";"antagonist"
"Regadenoson";"CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1";"Initial phase: 2-4 minutes;
Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); 
Terminal phase: 2 hours";"C01EB21";"Adenosine receptor A2a";"ADORA2A";"yes";"agonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 2C";"HTR2C";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 5A";"HTR5A";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Alpha-2B adrenergic receptor";"ADRA2B";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Histamine H2 receptor";"HRH2";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"antagonist"
"Asenapine";"OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1";"24 hours (range of 13.4 - 39.2 hours)";"N05AH05";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Vernakalant";"COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1";"Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.";"C01BG11";"Sodium channel protein type 5 subunit alpha";"SCN5A";"yes";"blocker"
"Vernakalant";"COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1";"Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.";"C01BG11";"Potassium voltage-gated channel subfamily A member 5";"KCNA5";"yes";"blocker"
"Vernakalant";"COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1";"Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.";"C01BG11";"Potassium voltage-gated channel subfamily D member 3";"KCND3";"yes";"blocker"
"Vernakalant";"COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1";"Elimination half life in CYP2D6 extensive metabolizers is 3 hours and 5.5 hours in poor metabolizers.";"C01BG11";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";"blocker"
"Lacosamide";"COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1";"13 Hours";"N03AX18";"Sodium channel protein type 9 subunit alpha";"SCN9A";"unknown";""
"Lacosamide";"COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1";"13 Hours";"N03AX18";"Sodium channel protein type 3 subunit alpha";"SCN3A";"unknown";""
"Lacosamide";"COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1";"13 Hours";"N03AX18";"Sodium channel protein type 10 subunit alpha";"SCN10A";"unknown";""
"Rivaroxaban";"ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O";"The terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.";"B01AF01";"Coagulation factor X";"F10";"yes";"antagonist"
"Nalmefene";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C";"The terminal half-life is approximately 12.5 hours following oral administration [L1024]. After intravenous administration of 1 mg in adult males, the terminal half life was 10.8 ± 5.2 hours [FDA Label].";"N07BB05";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Nalmefene";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C";"The terminal half-life is approximately 12.5 hours following oral administration [L1024]. After intravenous administration of 1 mg in adult males, the terminal half life was 10.8 ± 5.2 hours [FDA Label].";"N07BB05";"Kappa-type opioid receptor";"OPRK1";"yes";"partial agonist"
"Nalmefene";"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C";"The terminal half-life is approximately 12.5 hours following oral administration [L1024]. After intravenous administration of 1 mg in adult males, the terminal half life was 10.8 ± 5.2 hours [FDA Label].";"N07BB05";"Delta-type opioid receptor";"OPRD1";"yes";"antagonist"
"Ridaforolimus";"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O";"";"L01XE19";"Serine/threonine-protein kinase mTOR";"MTOR";"unknown";""
"Maribavir";"CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O";"";"J05AX10";"Serine/threonine protein kinase UL97";"UL97";"unknown";""
"Maribavir";"CC(C)NC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O";"";"J05AX10";"Serine/threonine protein kinase UL97";"UL97";"unknown";""
"Avanafil";"COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1";"Mean elimination half-life = 5.36 - 10.66 hours";"G04BE10";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Eflornithine";"NCCCC(N)(C(F)F)C(O)=O";"8 hours";"D11AX16";"Ornithine decarboxylase";"ODC1";"yes";"antagonistblocker"
"Eflornithine";"NCCCC(N)(C(F)F)C(O)=O";"8 hours";"P01CX03";"Ornithine decarboxylase";"ODC1";"yes";"antagonistblocker"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Alpha-1D adrenergic receptor";"ADRA1D";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Beta-1 adrenergic receptor";"ADRB1";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Droxidopa";"N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O";"2-3 hours.";"C01CA27";"Phenylalanine-4-hydroxylase";"PAH";"no";"inhibitor"
"Amrubicin";"[H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1";"20-30 h [A32143]

In a study of dogs, Amrubicin plasma concentrations followed a biphasic pattern with peak concentrations observed immediately after dosing followed by α and β half-lives (t1/2) ± SD of 0.06 ± 0.01 and 2.0 ± 0.3 hours, respectively [L1710].";"L01DB10";"DNA topoisomerase 2-alpha";"TOP2A";"unknown";""
"Lonidamine";"OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=C1C=CC=C2";"";"L01XX07";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";""
"Lonidamine";"OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=C1C=CC=C2";"";"L01XX07";"Hexokinase-1";"HK1";"unknown";""
"Udenafil";"CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C";"";"G04BE11";"cGMP-specific 3',5'-cyclic phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Sitaxentan";"CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl";"10 hours";"C02KX03";"Endothelin-1 receptor";"EDNRA";"yes";"antagonist"
"Sitaxentan";"CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl";"10 hours";"C02KX03";"Endothelin B receptor";"EDNRB";"unknown";"antagonist"
"Alvimopan";"C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1";"10 to 17 hours (gut metabolite: 10 to 18 hours)";"A06AH02";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Alvimopan";"C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1";"10 to 17 hours (gut metabolite: 10 to 18 hours)";"A06AH02";"Kappa-type opioid receptor";"OPRK1";"unknown";"antagonist"
"Alvimopan";"C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1";"10 to 17 hours (gut metabolite: 10 to 18 hours)";"A06AH02";"Delta-type opioid receptor";"OPRD1";"unknown";"antagonist"
"Levocetirizine";"OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"8-9 hours.";"R06AE09";"Histamine H1 receptor";"HRH1";"yes";"antagonistinhibitor"
"Temsirolimus";"OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC";"Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.";"L01XE09";"Serine/threonine-protein kinase mTOR";"MTOR";"yes";"inhibitor"
"Amisulpride";"CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC";"Approximately 12 hours";"N05AL05";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Amisulpride";"CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC";"Approximately 12 hours";"N05AL05";"D(3) dopamine receptor";"DRD3";"unknown";"antagonist"
"Amisulpride";"CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC";"Approximately 12 hours";"N05AL05";"5-hydroxytryptamine receptor 7";"HTR7";"yes";"antagonist"
"Amisulpride";"CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC";"Approximately 12 hours";"N05AL05";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"antagonist"
"Simeprevir";"[H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1";"The elimination half-life of simeprevir following 200mg dose administration is about 41 hours in HCV-positive patients and 10 to 13 hours in individuals without HCV infection.";"J05AE14";"NS3 protease";"";"yes";"inhibitor"
"Simeprevir";"[H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1";"The elimination half-life of simeprevir following 200mg dose administration is about 41 hours in HCV-positive patients and 10 to 13 hours in individuals without HCV infection.";"G01AE10";"NS3 protease";"";"yes";"inhibitor"
"Dapagliflozin";"CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1";"13.8 hours with the consumption of a 50 mg dose.";"A10BX09";"Sodium/glucose cotransporter 2";"SLC5A2";"yes";"antagonist"
"Dapagliflozin";"CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1";"13.8 hours with the consumption of a 50 mg dose.";"A10BD15";"Sodium/glucose cotransporter 2";"SLC5A2";"yes";"antagonist"
"Dapagliflozin";"CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1";"13.8 hours with the consumption of a 50 mg dose.";"A10BD21";"Sodium/glucose cotransporter 2";"SLC5A2";"yes";"antagonist"
"Saxagliptin";"N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2";"Saxagliptin = 2.5 hours;
5-hydroxy saxagliptin = 3.1 hours;";"A10BD10";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Saxagliptin";"N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2";"Saxagliptin = 2.5 hours;
5-hydroxy saxagliptin = 3.1 hours;";"A10BH03";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Saxagliptin";"N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2";"Saxagliptin = 2.5 hours;
5-hydroxy saxagliptin = 3.1 hours;";"A10BD21";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Iclaprim";"COC1=CC(CC2=CN=C(N)N=C2N)=C2C=CC(OC2=C1OC)C1CC1";"";"J01EA03";"Dihydrofolate reductase";"DHFR";"unknown";""
"Xaliproden";"FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC3=CC=CC=C3C=C2)CC1";"";"N07XX03";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";""
"Bazedoxifene";"CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1";"~30 hours.";"G03CC07";"Estrogen receptor alpha";"ESR1";"yes";"antagonistagonist"
"Bazedoxifene";"CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1";"~30 hours.";"G03XC02";"Estrogen receptor alpha";"ESR1";"yes";"antagonistagonist"
"Bazedoxifene";"CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1";"~30 hours.";"G03CC07";"Estrogen receptor beta";"ESR2";"unknown";""
"Bazedoxifene";"CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1";"~30 hours.";"G03XC02";"Estrogen receptor beta";"ESR2";"unknown";""
"Ambrisentan";"COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1";"Ambrisentan has a terminal half-life of 15 hours. It is thought that steady state is achieved after around 4 days of repeat-dosing.";"C02KX02";"Endothelin-1 receptor";"EDNRA";"yes";"antagonist"
"Ambrisentan";"COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1";"Ambrisentan has a terminal half-life of 15 hours. It is thought that steady state is achieved after around 4 days of repeat-dosing.";"C02KX02";"Endothelin B receptor";"EDNRB";"no";"antagonist"
"Doxercalciferol";"[H]\C(\C(\[H])=C1/CCC[C@@]2(C)[C@@]1([H])CC[C@]2([H])[C@]([H])(C)C(\[H])=C(/[H])[C@]([H])(C)C(C)C)=C1/C[C@@]([H])(O)C[C@]([H])(O)C1=C";"32 to 37 hours.";"H05BX03";"Vitamin D3 receptor";"VDR";"unknown";"suppressor"
"Oxymetholone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O";"";"A14AA05";"Androgen receptor";"AR";"yes";"agonistactivator"
"Oxymetholone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O";"";"A14AA05";"Natriuretic peptides B";"NPPB";"unknown";""
"Armodafinil";"NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1";"Terminal half-life is approximately 15 hours.";"N06BA13";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"antagonistinhibitor"
"Etravirine";"CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N";"Half life of 9.05-41 hours.";"J05AG04";"Gag-Pol polyprotein";"gag-pol";"unknown";""
"Etravirine";"CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N";"Half life of 9.05-41 hours.";"J05AG04";"Gag-Pol polyprotein";"gag-pol";"unknown";""
"Cangrelor";"CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1";"The average elimination half-life of cangrelor is about 3-6 minutes.";"B01AC25";"P2Y purinoceptor 12";"P2RY12";"yes";"inhibitor"
"clomethiazole";"CC1=C(CCCl)SC=N1";"";"N05CX04";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";""
"clomethiazole";"CC1=C(CCCl)SC=N1";"";"N05CM02";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"unknown";""
"Propentofylline";"CCCN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C";"";"N06BC02";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"unknown";""
"Prucalopride";"COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1";"Terminal half-life is 24–30 hours.";"A06AX05";"5-hydroxytryptamine receptor 4";"HTR4";"yes";"agonist"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Vascular endothelial growth factor receptor 1";"FLT1";"yes";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Vascular endothelial growth factor receptor 3";"FLT4";"yes";""
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Platelet-derived growth factor receptor alpha";"PDGFRA";"yes";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Platelet-derived growth factor receptor beta";"PDGFRB";"yes";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Mast/stem cell growth factor receptor Kit";"KIT";"yes";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Fibroblast growth factor receptor 3";"FGFR3";"unknown";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Tyrosine-protein kinase ITK/TSK";"ITK";"unknown";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"Fibroblast growth factor 1";"FGF1";"unknown";"inhibitor"
"Pazopanib";"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1";"35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.";"L01XE11";"SH2B adapter protein 3";"SH2B3";"unknown";"inhibitor"
"Agomelatine";"COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1";"<2 hours";"N06AX22";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Agomelatine";"COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1";"<2 hours";"N06AX22";"Melatonin receptor type 1A";"MTNR1A";"yes";"agonist"
"Agomelatine";"COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1";"<2 hours";"N06AX22";"Melatonin receptor type 1B";"MTNR1B";"yes";"agonist"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC1";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC10";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC11";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC2";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC3";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC4";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC5";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC6";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC7";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC8";"yes";"inhibitor"
"Panobinostat";"[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO";"30 hours";"L01XX42";"Histone deacetylase";"HDAC9";"yes";"inhibitor"
"Apixaban";"COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O";"If administered orally, the half life is 12 hours (due to prolonged absorption). If administerd by I.V., the half-life is about 5 hours.";"B01AF02";"Coagulation factor X";"F10";"yes";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Breakpoint cluster region protein";"BCR";"yes";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Tyrosine-protein kinase ABL1";"ABL1";"yes";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Tyrosine-protein kinase Lyn";"LYN";"unknown";""
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Tyrosine-protein kinase HCK";"HCK";"unknown";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Proto-oncogene tyrosine-protein kinase Src";"SRC";"unknown";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Cyclin-dependent kinase 2";"CDK2";"unknown";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Dual specificity mitogen-activated protein kinase kinase 1";"MAP2K1";"unknown";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Dual specificity mitogen-activated protein kinase kinase 2";"MAP2K2";"unknown";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Mitogen-activated protein kinase kinase kinase 2";"MAP3K2";"unknown";"inhibitor"
"Bosutinib";"COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl";"Terminal phase elimination half-life, single oral dose, fed-state = 22.5 hours";"L01XE14";"Calcium/calmodulin-dependent protein kinase type II subunit gamma";"CAMK2G";"unknown";"inhibitor"
"Flupirtine";"CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1";"6.5 hrs (average), 11.2-16.8 hrs (average 14 hrs) (elderly), 8.7-10.9 hrs (average 9.8 hrs) (in those with moderate-level renal impairment).";"N02BG07";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";""
"Axitinib";"[H]\C(=C(\[H])C1=CC=CC=N1)C1=C2C=CC(SC3=CC=CC=C3C(O)=NC)=CC2=NN1";"Axitinib has a half life of 2.5 to 6.1 hours.";"L01XE17";"Vascular endothelial growth factor receptor 1";"FLT1";"yes";"inhibitor"
"Axitinib";"[H]\C(=C(\[H])C1=CC=CC=N1)C1=C2C=CC(SC3=CC=CC=C3C(O)=NC)=CC2=NN1";"Axitinib has a half life of 2.5 to 6.1 hours.";"L01XE17";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"inhibitor"
"Axitinib";"[H]\C(=C(\[H])C1=CC=CC=N1)C1=C2C=CC(SC3=CC=CC=C3C(O)=NC)=CC2=NN1";"Axitinib has a half life of 2.5 to 6.1 hours.";"L01XE17";"Vascular endothelial growth factor receptor 3";"FLT4";"yes";"inhibitor"
"Casopitant";"C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F";"";"A04AD13";"Cytochrome P450 3A4";"CYP3A4";"unknown";""
"Casopitant";"C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F";"";"A04AD13";"Substance-P receptor";"TACR1";"unknown";""
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 1";"KCNA1";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 2";"KCNA2";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 3";"KCNA3";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 4";"KCNA4";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 5";"KCNA5";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 6";"KCNA6";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 7";"KCNA7";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily A member 10";"KCNA10";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily B member 1";"KCNB1";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily B member 2";"KCNB2";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily C member 1";"KCNC1";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily C member 2";"KCNC2";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily C member 3";"KCNC3";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily D member 1";"KCND1";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily D member 2";"KCND2";"yes";"antagonist"
"Dalfampridine";"NC1=CC=NC=C1";"Immediate release form = 3.5 hours;
Extended release form = 5.47 hours;";"N07XX07";"Potassium voltage-gated channel subfamily D member 3";"KCND3";"yes";"antagonist"
"Pasireotide";"NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1";"The half-life is 12 hours.";"H01CB05";"Somatostatin receptor type 1";"SSTR1";"unknown";""
"Pasireotide";"NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1";"The half-life is 12 hours.";"H01CB05";"Somatostatin receptor type 2";"SSTR2";"unknown";""
"Pasireotide";"NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1";"The half-life is 12 hours.";"H01CB05";"Somatostatin receptor type 3";"SSTR3";"unknown";""
"Pasireotide";"NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1";"The half-life is 12 hours.";"H01CB05";"Somatostatin receptor type 5";"SSTR5";"unknown";""
"Vilazodone";"NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1";"25.4h";"N06AX24";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"agonist"
"Ethanolamine Oleate";"NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O";"";"C05BB01";"Coagulation factor XII";"F12";"unknown";"activator"
"Mepyramine";"COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1";"";"R06AC01";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Mepyramine";"COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1";"";"D04AA02";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA53";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB06";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA07";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA03";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA53";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB06";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA07";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA03";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA53";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB06";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA07";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA03";"Alpha-2B adrenergic receptor";"ADRA2B";"yes";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA53";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB06";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA07";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA03";"Alpha-1B adrenergic receptor";"ADRA1B";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA53";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB06";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA07";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA03";"Alpha-1D adrenergic receptor";"ADRA1D";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA53";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AB06";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"R01AA07";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Xylometazoline";"CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C";"";"S01GA03";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"agonist"
"Dabigatran etexilate";"CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1";"12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery.";"B01AE07";"Prothrombin";"F2";"yes";"inhibitor"
"Arbekacin";"NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O";"3 hours";"J01GB12";"30S ribosomal protein S12";"rpsL";"yes";"inhibitor"
"Betahistine";"CNCCC1=CC=CC=N1";"3-4 hours";"N07CA01";"Histamine H1 receptor";"HRH1";"yes";"agonist"
"Betahistine";"CNCCC1=CC=CC=N1";"3-4 hours";"N07CA01";"Histamine H3 receptor";"HRH3";"yes";"antagonist"
"Degarelix";"CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O";"Terminal half-life: 41.5 - 70.2 days; 
Absorption half-life: 32.9 hours; 
Half-life from injection site: 1.17 days.";"L02BX02";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"antagonist"
"Desvenlafaxine";"CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1";"The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.";"N06AX23";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Desvenlafaxine";"CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1";"The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment.";"N06AX23";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Dexmethylphenidate";"COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1";"2-4 hours";"N06BA11";"Sodium-dependent dopamine transporter";"SLC6A3";"yes";"inhibitor"
"Dexmethylphenidate";"COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1";"2-4 hours";"N06BA11";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Dexmethylphenidate";"COC(=O)[C@@H]([C@H]1CCCCN1)C1=CC=CC=C1";"2-4 hours";"N06BA11";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";"inhibitor"
"Fesoterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C";"7-8 hours for the active metabolite 5-hydroxymethyl tolterodine";"G04BD11";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Fesoterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C";"7-8 hours for the active metabolite 5-hydroxymethyl tolterodine";"G04BD11";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Fesoterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C";"7-8 hours for the active metabolite 5-hydroxymethyl tolterodine";"G04BD11";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Fesoterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C";"7-8 hours for the active metabolite 5-hydroxymethyl tolterodine";"G04BD11";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Fesoterodine";"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C";"7-8 hours for the active metabolite 5-hydroxymethyl tolterodine";"G04BD11";"Muscarinic acetylcholine receptor M5";"CHRM5";"unknown";"antagonist"
"Isometheptene";"CNC(C)CCC=C(C)C";"";"A03AX10";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Isometheptene";"CNC(C)CCC=C(C)C";"";"A03AX10";"Synaptic vesicular amine transporter";"SLC18A2";"yes";"inhibitor"
"Methyltestosterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"G03EA01";"Androgen receptor";"AR";"yes";"agonist"
"Methyltestosterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"G03BA02";"Androgen receptor";"AR";"yes";"agonist"
"Methyltestosterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"G03EK01";"Androgen receptor";"AR";"yes";"agonist"
"Methyltestosterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"G03EA01";"Estrogen receptor alpha";"ESR1";"unknown";""
"Methyltestosterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"G03BA02";"Estrogen receptor alpha";"ESR1";"unknown";""
"Methyltestosterone";"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"6-8 hours";"G03EK01";"Estrogen receptor alpha";"ESR1";"unknown";""
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"R01AB02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"S01GA51";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"S01GA01";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"R01AA08";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"R01AB02";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"S01GA51";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"S01GA01";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Naphazoline";"C(C1=NCCN1)C1=CC=CC2=CC=CC=C12";"";"R01AA08";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Nilvadipine";"COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N";"";"C08CA10";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"inhibitor"
"Nilvadipine";"COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N";"";"C08CA10";"Voltage-dependent calcium channel subunit alpha-2/delta-1";"CACNA2D1";"yes";"inhibitor"
"Nilvadipine";"COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N";"";"C08CA10";"Voltage-dependent L-type calcium channel subunit beta-2";"CACNB2";"yes";"inhibitor"
"Nilvadipine";"COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N";"";"C08CA10";"Voltage-dependent L-type calcium channel subunit alpha-1D";"CACNA1D";"unknown";"inhibitor"
"Nilvadipine";"COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N";"";"C08CA10";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"unknown";"inhibitor"
"Nilvadipine";"COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N";"";"C08CA10";"Voltage-dependent calcium channel subunit alpha-2/delta-3";"CACNA2D3";"unknown";"inhibitor"
"Norelgestromin";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO";"";"G03AA13";"Progesterone receptor";"PGR";"yes";"agonist"
"Norelgestromin";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO";"";"G03AA13";"Serum albumin";"ALB";"unknown";""
"Norelgestromin";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO";"";"G03AA13";"Androgen receptor";"AR";"unknown";"partial agonist"
"Lornoxicam";"CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O";"3-5 hours";"M01AC05";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Lornoxicam";"CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O";"3-5 hours";"M01AC05";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Sulfaphenazole";"NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1";"";"J01ED08";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfaphenazole";"NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1";"";"S01AB05";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfaphenazole";"NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1";"";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Gestodene";"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C";"16 to 18 hrs.";"G03AA10";"Probable G-protein coupled receptor 133";"ADGRD1";"unknown";""
"Gestodene";"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C";"16 to 18 hrs.";"G03AB06";"Probable G-protein coupled receptor 133";"ADGRD1";"unknown";""
"Aceclofenac";"OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"The mean plasma elimination half-life is approximately 4 hours [L868].";"M01AB16";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Aceclofenac";"OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"The mean plasma elimination half-life is approximately 4 hours [L868].";"M02AA25";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Aceclofenac";"OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"The mean plasma elimination half-life is approximately 4 hours [L868].";"M01AB16";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Aceclofenac";"OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl";"The mean plasma elimination half-life is approximately 4 hours [L868].";"M02AA25";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"Kappa-type opioid receptor";"OPRK1";"yes";"agonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"Delta-type opioid receptor";"OPRD1";"yes";"agonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"NMDA receptor";"GRIN1";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"NMDA receptor";"GRIN2A";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"NMDA receptor";"GRIN2B";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"NMDA receptor";"GRIN2C";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"NMDA receptor";"GRIN2D";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"NMDA receptor";"GRIN3A";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AG02";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Ketobemidone";"CCC(=O)C1(CCN(C)CC1)C1=CC(O)=CC=C1";"Plasma half-life: 2.42 +/- 0.41 h (m +/- SD).
Elimination half-life: 3.27 +/- 0.32 h";"N02AB01";"NMDA receptor";"GRIN3B";"unknown";"antagonist"
"Seratrodast";"CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O";"";"R03DX06";"Thromboxane A2 receptor";"TBXA2R";"unknown";"antagonist"
"Drotaverine";"CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1";"7 to 12 hours";"A03AD02";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"yes";"inhibitor"
"Drotaverine";"CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1";"7 to 12 hours";"A03AD02";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"unknown";"inhibitor"
"Glycine betaine";"C[N+](C)(C)CC([O-])=O";"14 hours";"A09AB02";"Apoptosis regulator Bcl-2";"BCL2";"unknown";""
"Glycine betaine";"C[N+](C)(C)CC([O-])=O";"14 hours";"A16AA06";"Apoptosis regulator Bcl-2";"BCL2";"unknown";""
"Tetryzoline";"C1CN=C(N1)C1CCCC2=CC=CC=C12";"";"S01GA02";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Tetryzoline";"C1CN=C(N1)C1CCCC2=CC=CC=C12";"";"S01GA52";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Tetryzoline";"C1CN=C(N1)C1CCCC2=CC=CC=C12";"";"R01AA06";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Tetryzoline";"C1CN=C(N1)C1CCCC2=CC=CC=C12";"";"R01AB03";"Alpha-1A adrenergic receptor";"ADRA1A";"yes";"agonist"
"Alcaftadine";"CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=CC=CC=C12";"The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration.";"S01GX11";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Besifloxacin";"N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O";"The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.";"S01AE08";"DNA topoisomerase 4 subunit A";"parC";"yes";"antagonist"
"Besifloxacin";"N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O";"The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.";"S01AE08";"DNA topoisomerase 4 subunit A";"parC";"yes";"antagonist"
"Besifloxacin";"N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O";"The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.";"S01AE08";"DNA gyrase subunit A";"gyrA";"yes";"antagonist"
"Besifloxacin";"N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O";"The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.";"S01AE08";"DNA gyrase subunit A";"gyrA";"yes";"antagonist"
"Cabazitaxel";"[H][C@@](O)([C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1)C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O";"Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.";"L01CD04";"Tubulin alpha-4A chain";"TUBA4A";"yes";"binder"
"Cabazitaxel";"[H][C@@](O)([C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1)C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O";"Following a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.";"L01CD04";"Tubulin beta-1 chain";"TUBB1";"yes";"binder"
"Capsaicin";"COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1";"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].";"M02AB01";"Transient receptor potential cation channel subfamily V member 1";"TRPV1";"yes";"agonist"
"Capsaicin";"COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1";"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].";"N01BX04";"Transient receptor potential cation channel subfamily V member 1";"TRPV1";"yes";"agonist"
"Capsaicin";"COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1";"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].";"M02AB01";"Prohibitin-2";"PHB2";"unknown";""
"Capsaicin";"COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1";"Following oral ingestion of equipotent dose of 26.6 mg of pure capsaicin, the half life was approximately 24.9 ± 5.0 min [A32319]. Following topical application of 3% solution of capsaicin, the half-life of capsaicin was approximately 24 h [A32319]. The mean population elimination half-life was 1.64 h following application of a topical patch containing 179 mg of capsaicin [A32319].";"N01BX04";"Prohibitin-2";"PHB2";"unknown";""
"Carglumic Acid";"NC(=O)N[C@@H](CCC(O)=O)C(O)=O";"Median values for the terminal half-life was 5.6 hours (range 4.3-9.5).";"A16AA05";"Carbamoyl-phosphate synthase [ammonia], mitochondrial";"CPS1";"yes";"allosteric modulator"
"Chenodeoxycholic acid";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O";"";"A05AA01";"Bile acid receptor";"NR1H4";"unknown";"other"
"Chenodeoxycholic acid";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O";"";"A05AA01";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Chenodeoxycholic acid";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O";"";"A05AA01";"G-protein coupled bile acid receptor 1";"GPBAR1";"unknown";""
"Chenodeoxycholic acid";"[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O";"";"A05AA01";"Aldo-keto reductase family 1 member C2";"AKR1C2";"unknown";"substrate"
"Difluprednate";"[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"";"D07AC19";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Dimercaprol";"OCC(S)CS";"The drug has a short half life.";"V03AB09";"Amyloid beta A4 protein";"APP";"unknown";""
"Ganirelix";"CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O";"16.2 hours.";"H01CC01";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"antagonist"
"Halcinonide";"[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"";"D07AD02";"Smoothened homolog";"SMO";"unknown";"agonistactivator"
"Hexocyclium";"C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1";"";"A03AB10";"Muscarinic acetylcholine receptor M1";"CHRM1";"unknown";"antagonist"
"Hexocyclium";"C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1";"";"A03AB10";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Hexocyclium";"C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1";"";"A03AB10";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Hexocyclium";"C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1";"";"A03AB10";"Muscarinic acetylcholine receptor M4";"CHRM4";"unknown";"antagonist"
"Histrelin";"CC(O)=O.CC(O)=O.[H][C@@](CO)(N=C(O)[C@]([H])(CC1=CNC2=CC=CC=C12)N=C(O)[C@]([H])(CC1=CN=CN1)N=C(O)[C@]1([H])CCC(O)=N1)C(O)=N[C@@]([H])(CC1=CC=C(O)C=C1)C(O)=N[C@]([H])(CC1=CN(CC2=CC=CC=C2)C=N1)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(=O)N1CCC[C@@]1([H])C(O)=NCC";"";"L02AE05";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"agonist"
"Hydroxyprogesterone caproate";"[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Half-life = 16 days (±6 days). (3)";"G03DA03";"Progesterone receptor";"PGR";"unknown";"agonist"
"Hydroxyprogesterone caproate";"[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Half-life = 16 days (±6 days). (3)";"G03FA02";"Progesterone receptor";"PGR";"unknown";"agonist"
"Lanreotide";"[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]";"Half-life is approximately 22 days (5)";"H01CB03";"Somatostatin receptor type 2";"SSTR2";"unknown";"agonist"
"Lanreotide";"[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]";"Half-life is approximately 22 days (5)";"H01CB03";"Somatostatin receptor type 5";"SSTR5";"unknown";"agonist"
"Mafenide";"NCC1=CC=C(C=C1)S(N)(=O)=O";"";"D06BA03";"Carbonic anhydrase 6";"CA6";"unknown";"antagonist"
"Mafenide";"NCC1=CC=C(C=C1)S(N)(=O)=O";"";"G01AE10";"Carbonic anhydrase 6";"CA6";"unknown";"antagonist"
"Methylnaltrexone";"C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35";"terminal: 8.89 ± 2.59 h (intravenous) 
terminal: 6.14- 8.83 h (subcutaneous)";"A06AH01";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Methylnaltrexone";"C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35";"terminal: 8.89 ± 2.59 h (intravenous) 
terminal: 6.14- 8.83 h (subcutaneous)";"A06AH01";"Kappa-type opioid receptor";"OPRK1";"no";"antagonist"
"Nepafenac";"NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N";"";"S01BC10";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Nepafenac";"NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N";"";"S01BC10";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"inhibitor"
"Plerixafor";"C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1";"Terminal elimination half-life, NHL patients: 4.4 hours;
Terminal elimination half-life, MM patients: 5.6 hours;
Terminal elimination half-life, Hodgkin's lymphoma patients: 3.5 hours; 
Distribution half-life: 0.3 hours";"L03AX16";"C-X-C chemokine receptor type 4";"CXCR4";"yes";"antagonist"
"Pralatrexate";"NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1";"12-18 hours";"L01BA05";"Dihydrofolate reductase";"DHFR";"yes";"inhibitor"
"Pralatrexate";"NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1";"12-18 hours";"L01BA05";"Thymidylate synthase";"TYMS";"yes";"inhibitor"
"Raltegravir";"CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1";"9 hours";"J05AX08";"Integrase";"pol";"yes";"inhibitor"
"Raltegravir";"CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1";"9 hours";"J05AR16";"Integrase";"pol";"yes";"inhibitor"
"Phenylbutyric acid";"OC(=O)CCCC1=CC=CC=C1";"For sodium phenylbutyrate the half life  is 0.77 hours. For phenylacetate the half life is 1.15 hours.";"A16AX03";"Aromatic-amino-acid aminotransferase";"tyrB";"unknown";""
"Phenylbutyric acid";"OC(=O)CCCC1=CC=CC=C1";"For sodium phenylbutyrate the half life  is 0.77 hours. For phenylacetate the half life is 1.15 hours.";"A16AX03";"Thermolysin";"npr";"unknown";""
"Sulfameter";"COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1";"";"J01ED04";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Sulfameter";"COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1";"";"G01AE10";"Dihydropteroate synthase";"folP";"yes";"inhibitor"
"Triptorelin";"CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O";"The pharmacokinetics of triptorelin follows a 3 compartment model.  The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.";"L02AE04";"Gonadotropin-releasing hormone receptor";"GNRHR";"yes";"agonist"
"Hymecromone";"CC1=CC(=O)OC2=C1C=CC(O)=C2";"";"A05AX02";"Arylsulfate sulfotransferase";"assT";"unknown";""
"Felbinac";"OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1";"";"M02AA08";"Cathepsin L1";"CTSL";"unknown";""
"Dibromotyrosine";"[H][C@](N)(CC1=CC(Br)=C(O)C(Br)=C1)C(O)=O";"";"H03BX02";"Erythropoietin receptor";"EPOR";"unknown";""
"Sulthiame";"NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O";"";"N03AX03";"Carbonic anhydrase 2";"CA2";"unknown";""
"Parecoxib";"CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1";"22 minutes (parecoxib); 8 hours (valdecoxib)";"M01AH04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Parecoxib";"CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1";"22 minutes (parecoxib); 8 hours (valdecoxib)";"M01AH04";"Lactotransferrin";"LTF";"unknown";""
"Efaproxiral";"CC1=CC(NC(=O)CC2=CC=C(OC(C)(C)C(O)=O)C=C2)=CC(C)=C1";"";"L01XD06";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Efaproxiral";"CC1=CC(NC(=O)CC2=CC=C(OC(C)(C)C(O)=O)C=C2)=CC(C)=C1";"";"L01XD06";"Hemoglobin subunit beta";"HBB";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Enoyl-[acyl-carrier-protein] reductase [NADH] FabI";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Enoyl-[acyl-carrier-protein] reductase [NADH] FabI";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"inhA";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Enoyl-[acyl-carrier-protein] reductase [NADH] FabI";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Enoyl-[acyl-carrier-protein] reductase [NADH] FabI";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Enoyl-[acyl-carrier-protein] reductase [NADH]";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI";"fabI";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Androgen receptor";"AR";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Androgen receptor";"AR";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"inverse agonist"
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Nuclear receptor subfamily 1 group I member 3";"NR1I3";"unknown";"inverse agonist"
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D08AE04";"Thyroid peroxidase";"TPO";"unknown";"weak inhibitor"
"Triclosan";"OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1";"The terminal plasma half life of triclosan is 21 h (Sandborgh-Englund et al., 2006).";"D09AA06";"Thyroid peroxidase";"TPO";"unknown";"weak inhibitor"
"Thiamphenicol";"[H][C@](CO)(NC(=O)C(Cl)Cl)[C@]([H])(O)C1=CC=C(C=C1)S(C)(=O)=O";"";"J01BA52";"Dr hemagglutinin structural subunit";"draA";"unknown";""
"Thiamphenicol";"[H][C@](CO)(NC(=O)C(Cl)Cl)[C@]([H])(O)C1=CC=C(C=C1)S(C)(=O)=O";"";"J01BA02";"Dr hemagglutinin structural subunit";"draA";"unknown";""
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CE04";"Penicillin-binding protein 2a";"pbp2a";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CE04";"Penicillin-binding protein 1b";"pbp1b";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CE04";"Penicillin-binding protein 3";"pbp3";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CE04";"Penicillin-binding protein 1A";"pbpA";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CR50";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Azidocillin";"[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N=[N+]=[N-])C1=CC=CC=C1)C(O)=O";"";"J01CE04";"Penicillin-binding protein 2B";"penA";"yes";"inhibitor"
"Sulfamoxole";"CC1=C(C)N=C(NS(=O)(=O)C2=CC=C(N)C=C2)O1";"";"J01EE04";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfamoxole";"CC1=C(C)N=C(NS(=O)(=O)C2=CC=C(N)C=C2)O1";"";"J01EC03";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Sulfamoxole";"CC1=C(C)N=C(NS(=O)(=O)C2=CC=C(N)C=C2)O1";"";"G01AE10";"Dihydropteroate synthetase";"";"yes";"inhibitor"
"Antazoline";"C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1";"";"R01AC04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Antazoline";"C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1";"";"R06AX05";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Chloropyramine";"CN(C)CCN(CC1=CC=C(Cl)C=C1)C1=CC=CC=N1";"";"D04AA09";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Chloropyramine";"CN(C)CCN(CC1=CC=C(Cl)C=C1)C1=CC=CC=N1";"";"R06AC03";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Chloropyramine";"CN(C)CCN(CC1=CC=C(Cl)C=C1)C1=CC=CC=N1";"";"R06AC53";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Dimetindene";"CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1";"";"R06AB03";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Dimetindene";"CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1";"";"D04AA13";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Dimetindene";"CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1";"";"R06AB03";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Dimetindene";"CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1";"";"D04AA13";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Isothipendyl";"CC(CN1C2=CC=CC=C2SC2=C1N=CC=C2)N(C)C";"";"D04AA22";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Isothipendyl";"CC(CN1C2=CC=CC=C2SC2=C1N=CC=C2)N(C)C";"";"R06AD09";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Roxatidine acetate";"CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1";"5-6 hours";"A02BA06";"Histamine H2 receptor";"HRH2";"yes";"antagonist"
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07CA17";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07AA17";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07CA17";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"partial agonist"
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07AA17";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"partial agonist"
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07CA17";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";""
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07AA17";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";""
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07CA17";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";""
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07AA17";"5-hydroxytryptamine receptor 1B";"HTR1B";"unknown";""
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07CA17";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Bopindolol";"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1";"";"C07AA17";"Beta-3 adrenergic receptor";"ADRB3";"unknown";""
"Bupranolol";"CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1";"2-4 hours";"C07AA19";"Beta-1 adrenergic receptor";"ADRB1";"yes";"antagonist"
"Bupranolol";"CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1";"2-4 hours";"C07AA19";"Beta-2 adrenergic receptor";"ADRB2";"unknown";"antagonist"
"Bupranolol";"CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1";"2-4 hours";"C07AA19";"Beta-3 adrenergic receptor";"ADRB3";"unknown";"antagonist"
"Tofisopam";"CCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1";"6-8 hours";"N05BA23";"cAMP-specific 3',5'-cyclic phosphodiesterase 4A";"PDE4A";"unknown";"inhibitor"
"Tofisopam";"CCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1";"6-8 hours";"N05BA23";"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A";"PDE10A";"unknown";"inhibitor"
"Tofisopam";"CCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1";"6-8 hours";"N05BA23";"cGMP-inhibited 3',5'-cyclic phosphodiesterase A";"PDE3A";"unknown";"inhibitor"
"Tofisopam";"CCC1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC(OC)=C(OC)C=C1";"6-8 hours";"N05BA23";"cGMP-dependent 3',5'-cyclic phosphodiesterase";"PDE2A";"unknown";"inhibitor"
"Triflusal";"CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O";"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]";"B01AC18";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"antagonist"
"Triflusal";"CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O";"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]";"B01AC18";"Nuclear factor NF-kappa-B p105 subunit";"NFKB1";"yes";"antagonist"
"Triflusal";"CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O";"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]";"B01AC18";"Nitric oxide synthase, inducible";"NOS2";"yes";"agonist"
"Triflusal";"CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O";"In the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.[L1186]";"B01AC18";"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A";"PDE10A";"yes";"antagonist"
"Lurasidone";"O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12";"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours";"N05AE05";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Lurasidone";"O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12";"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours";"N05AE05";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Lurasidone";"O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12";"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours";"N05AE05";"5-hydroxytryptamine receptor 7";"HTR7";"unknown";"antagonist"
"Lurasidone";"O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12";"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours";"N05AE05";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Lurasidone";"O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12";"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours";"N05AE05";"Alpha-2C adrenergic receptor";"ADRA2C";"unknown";"antagonist"
"Lurasidone";"O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12";"40 mg dose= 18 hours 
120 mg - 160 mg dose = 29-37 hours";"N05AE05";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";""
"Ticagrelor";"CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1";"Ticagrelor has a half life of 7 hours, while its active metabolite has a half life of 9 hours.";"B01AC24";"P2Y purinoceptor 12";"P2RY12";"yes";"inhibitor"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"CD44 antigen";"CD44";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"CD44 antigen";"CD44";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"CD44 antigen";"CD44";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"CD44 antigen";"CD44";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"CD44 antigen";"CD44";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Intercellular adhesion molecule 1";"ICAM1";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Intercellular adhesion molecule 1";"ICAM1";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Intercellular adhesion molecule 1";"ICAM1";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Intercellular adhesion molecule 1";"ICAM1";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Intercellular adhesion molecule 1";"ICAM1";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Hyaluronan mediated motility receptor";"HMMR";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Hyaluronan mediated motility receptor";"HMMR";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Hyaluronan mediated motility receptor";"HMMR";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Hyaluronan mediated motility receptor";"HMMR";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Hyaluronan mediated motility receptor";"HMMR";"yes";""
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Neurocan core protein";"NCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Neurocan core protein";"NCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Neurocan core protein";"NCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Neurocan core protein";"NCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Neurocan core protein";"NCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Versican core protein";"VCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Versican core protein";"VCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Versican core protein";"VCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Versican core protein";"VCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Versican core protein";"VCAN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Complement component 1 Q subcomponent-binding protein, mitochondrial";"C1QBP";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Complement component 1 Q subcomponent-binding protein, mitochondrial";"C1QBP";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Complement component 1 Q subcomponent-binding protein, mitochondrial";"C1QBP";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Complement component 1 Q subcomponent-binding protein, mitochondrial";"C1QBP";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Complement component 1 Q subcomponent-binding protein, mitochondrial";"C1QBP";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Hyaluronan and proteoglycan link protein 1";"HAPLN1";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Hyaluronan and proteoglycan link protein 1";"HAPLN1";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Hyaluronan and proteoglycan link protein 1";"HAPLN1";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Hyaluronan and proteoglycan link protein 1";"HAPLN1";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Hyaluronan and proteoglycan link protein 1";"HAPLN1";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Hyaluronan and proteoglycan link protein 3";"HAPLN3";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Hyaluronan and proteoglycan link protein 3";"HAPLN3";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Hyaluronan and proteoglycan link protein 3";"HAPLN3";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Hyaluronan and proteoglycan link protein 3";"HAPLN3";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Hyaluronan and proteoglycan link protein 3";"HAPLN3";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Hyaluronan and proteoglycan link protein 4";"HAPLN4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Hyaluronan and proteoglycan link protein 4";"HAPLN4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Hyaluronan and proteoglycan link protein 4";"HAPLN4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Hyaluronan and proteoglycan link protein 4";"HAPLN4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Hyaluronan and proteoglycan link protein 4";"HAPLN4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Hyaluronan-binding protein 2";"HABP2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Hyaluronan-binding protein 2";"HABP2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Hyaluronan-binding protein 2";"HABP2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Hyaluronan-binding protein 2";"HABP2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Hyaluronan-binding protein 2";"HABP2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Layilin";"LAYN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Layilin";"LAYN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Layilin";"LAYN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Layilin";"LAYN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Layilin";"LAYN";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Stabilin-2";"STAB2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Stabilin-2";"STAB2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Stabilin-2";"STAB2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Stabilin-2";"STAB2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Stabilin-2";"STAB2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Tumor necrosis factor-inducible gene 6 protein";"TNFAIP6";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Tumor necrosis factor-inducible gene 6 protein";"TNFAIP6";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Tumor necrosis factor-inducible gene 6 protein";"TNFAIP6";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Tumor necrosis factor-inducible gene 6 protein";"TNFAIP6";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Tumor necrosis factor-inducible gene 6 protein";"TNFAIP6";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Interphotoreceptor matrix proteoglycan 2";"IMPG2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Interphotoreceptor matrix proteoglycan 2";"IMPG2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Interphotoreceptor matrix proteoglycan 2";"IMPG2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Interphotoreceptor matrix proteoglycan 2";"IMPG2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Interphotoreceptor matrix proteoglycan 2";"IMPG2";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA01";"Intracellular hyaluronan-binding protein 4";"HABP4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"R01AX09";"Intracellular hyaluronan-binding protein 4";"HABP4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"S01KA51";"Intracellular hyaluronan-binding protein 4";"HABP4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"M09AX01";"Intracellular hyaluronan-binding protein 4";"HABP4";"unknown";"binder"
"Hyaluronic acid";"CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O";"";"D03AX05";"Intracellular hyaluronan-binding protein 4";"HABP4";"unknown";"binder"
"Tafluprost";"CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1";"";"S01EE05";"Prostaglandin F2-alpha receptor";"PTGFR";"yes";"agonist"
"Ivacaftor";"CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C";"The apparent terminal half-life was approximately 12 hours following a single dose [FDA Label].";"R07AX30";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"yes";"potentiator"
"Ivacaftor";"CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C";"The apparent terminal half-life was approximately 12 hours following a single dose [FDA Label].";"R07AX02";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"yes";"potentiator"
"Azilsartan medoxomil";"CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1";"The half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.";"C09CA09";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Azilsartan medoxomil";"CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1";"The half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.";"C09DA09";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Lomitapide";"FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12";"Lomitapide half-life is about 39.7 hours.";"C10AX12";"Microsomal triglyceride transfer protein large subunit";"MTTP";"yes";"antagonist"
"Vismodegib";"CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1";"The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.";"L01XX43";"Smoothened homolog";"SMO";"yes";"antagonist"
"Spaglumic Acid";"CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O";"";"R01AC05";"Glutamate carboxypeptidase 2";"FOLH1";"unknown";"ligand"
"Spaglumic Acid";"CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O";"";"S01GX03";"Glutamate carboxypeptidase 2";"FOLH1";"unknown";"ligand"
"Temocapril";"CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1";"13.1 hours in patients with normal liver function.";"C09AA14";"Angiotensin-converting enzyme";"ACE";"unknown";"inhibitor"
"Pitavastatin";"O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O";"Plasma elimination half-lfie = 12 hours";"C10AA08";"3-hydroxy-3-methylglutaryl-coenzyme A reductase";"HMGCR";"yes";"inhibitor"
"Rilpivirine";"CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1";"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]";"J05AR19";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Rilpivirine";"CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1";"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]";"J05AG05";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Rilpivirine";"CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1";"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]";"J05AR08";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Rilpivirine";"CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1";"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]";"J05AR19";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Rilpivirine";"CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1";"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]";"J05AG05";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Rilpivirine";"CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1";"Plasma drug elimination is really slow, giving rilpivirine a half-life of 34-55 hours after oral administration.[A31331]";"J05AR08";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"agonist"
"Crizotinib";"C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl";"Plasma terminal half-life, patients = 42 hours";"L01XE16";"ALK tyrosine kinase receptor";"ALK";"yes";"inhibitor"
"Crizotinib";"C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl";"Plasma terminal half-life, patients = 42 hours";"L01XE16";"Hepatocyte growth factor receptor";"MET";"yes";"inhibitor"
"Ulipristal";"CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12";"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours";"G03AD02";"Progesterone receptor";"PGR";"yes";"modulator"
"Ulipristal";"CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12";"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours";"G03XB02";"Progesterone receptor";"PGR";"yes";"modulator"
"Ulipristal";"CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12";"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours";"G03AD02";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Ulipristal";"CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12";"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours";"G03XB02";"Glucocorticoid receptor";"NR3C1";"yes";"antagonist"
"Ulipristal";"CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12";"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours";"G03AD02";"Androgen receptor";"AR";"unknown";""
"Ulipristal";"CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12";"Mean elimination half-life, single oral dose, healthy subject = 32.4 ± 6.3 hours";"G03XB02";"Androgen receptor";"AR";"unknown";""
"Fingolimod";"CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1";"6-9 days";"L04AA27";"Sphingosine 1-phosphate receptor 5";"S1PR5";"yes";"modulator"
"Fingolimod";"CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1";"6-9 days";"L04AA27";"Histone deacetylase 1";"HDAC1";"unknown";"inhibitor"
"Tesamorelin";"CC\C=C\CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O";"26 and 38 minutes in healthy subjects and HIV-infected patients, respectively.";"H01AC06";"Growth hormone-releasing hormone receptor";"GHRHR";"yes";"binder"
"Eribulin";"[H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC";"about 40 hours";"L01XX41";"Apoptosis regulator Bcl-2";"BCL2";"unknown";""
"Eribulin";"[H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC";"about 40 hours";"L01XX41";"Tubulin beta-1 chain";"TUBB1";"unknown";""
"Boceprevir";"[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C";"Boceprevir has a mean half-life of elimination of 3.4 hours [FDA Label].";"J05AE12";"NS3/4A protein";"NS3/4A";"yes";"inhibitor"
"Fidaxomicin";"CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\C(=O)OC(C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O";"200 mg, healthy subjects = 11.7 hours";"A07AA12";"RNA polymerase sigma factor";"sigA1";"yes";"inhibitor"
"Cabozantinib";"COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2";"Cabozantinib has a long half-life of 55 hours.";"L01XE26";"Hepatocyte growth factor receptor";"MET";"yes";"antagonist"
"Cabozantinib";"COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2";"Cabozantinib has a long half-life of 55 hours.";"L01XE26";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"antagonist"
"Cabozantinib";"COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2";"Cabozantinib has a long half-life of 55 hours.";"L01XE26";"Proto-oncogene tyrosine-protein kinase receptor Ret";"RET";"yes";"antagonist"
"Ruxolitinib";"N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1";"Mean elimination half-life, 15 mg, healthy subject = 2.8 hours.";"L01XE18";"Tyrosine-protein kinase JAK1";"JAK1";"yes";"inhibitor"
"Ruxolitinib";"N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1";"Mean elimination half-life, 15 mg, healthy subject = 2.8 hours.";"L01XE18";"Tyrosine-protein kinase JAK2";"JAK2";"yes";"inhibitor"
"Teriflunomide";"C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F";"The median half-life is 18 to 19 days.";"L04AA31";"Dihydroorotate dehydrogenase (quinone), mitochondrial";"DHODH";"unknown";"inhibitor"
"Vemurafenib";"CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1";"The elimination half-life of Vemurafenib is estimated to be 57 hours (range of 30-120 hours).[A31274]";"L01XE15";"Serine/threonine-protein kinase B-raf";"BRAF";"yes";"inhibitor"
"Linagliptin";"CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1";"Terminal half life = 131 hours. Because of this long half-life, inhibition of DPP-4 activity is sustained which indicates that once-daily dosing is appropriate. Effective half-life for accumulation of drug is 12 hours when multiple oral doses of 5 mg are given.";"A10BH05";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Linagliptin";"CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1";"Terminal half life = 131 hours. Because of this long half-life, inhibition of DPP-4 activity is sustained which indicates that once-daily dosing is appropriate. Effective half-life for accumulation of drug is 12 hours when multiple oral doses of 5 mg are given.";"A10BD19";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Linagliptin";"CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1";"Terminal half life = 131 hours. Because of this long half-life, inhibition of DPP-4 activity is sustained which indicates that once-daily dosing is appropriate. Effective half-life for accumulation of drug is 12 hours when multiple oral doses of 5 mg are given.";"A10BD11";"Dipeptidyl peptidase 4";"DPP4";"yes";"inhibitor"
"Perampanel";"O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1";"Perampanel has a long elmination half-life of about 105 hours.";"N03AX22";"Glutamate receptor 1";"GRIA1";"yes";"antagonist"
"Carfilzomib";"CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1";"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.";"L01XX45";"Proteasome subunit beta type-5";"PSMB5";"yes";"inhibitor"
"Carfilzomib";"CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1";"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.";"L01XX45";"Proteasome subunit beta type-8";"PSMB8";"yes";"inhibitor"
"Carfilzomib";"CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1";"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.";"L01XX45";"Proteasome subunit beta type-1";"PSMB1";"yes";"inhibitor"
"Carfilzomib";"CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1";"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.";"L01XX45";"Proteasome subunit beta type-9";"PSMB9";"yes";"inhibitor"
"Carfilzomib";"CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1";"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.";"L01XX45";"Proteasome subunit beta type-2";"PSMB2";"yes";"inhibitor"
"Carfilzomib";"CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1";"Following intravenous administration of doses ≥ 15 mg/m^2, carfilzomib was rapidly cleared from the systemic circulation with a half-life of ≤ 1 hour on Day 1 of Cycle 1.";"L01XX45";"Proteasome subunit beta type-10";"PSMB10";"yes";"inhibitor"
"Linaclotide";"[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O";"Because linaclotide is not systemically absorbed, half life cannot be calculated.";"A06AX04";"Heat-stable enterotoxin receptor";"GUCY2C";"yes";"agonist"
"Mirabegron";"NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1";"Terminal elimination half-life = 50 hours";"G04BD12";"Beta-3 adrenergic receptor";"ADRB3";"yes";"agonist"
"Tofacitinib";"[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N";"~3 hours";"L04AA29";"Tyrosine-protein kinase JAK1";"JAK1";"yes";"inhibitor"
"Tofacitinib";"[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N";"~3 hours";"L04AA29";"Tyrosine-protein kinase JAK2";"JAK2";"yes";"antagonistinhibitor"
"Tofacitinib";"[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N";"~3 hours";"L04AA29";"Tyrosine-protein kinase JAK3";"JAK3";"yes";"inhibitor"
"Tofacitinib";"[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N";"~3 hours";"L04AA29";"Non-receptor tyrosine-protein kinase TYK2";"TYK2";"unknown";""
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Vascular endothelial growth factor receptor 1";"FLT1";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Vascular endothelial growth factor receptor 3";"FLT4";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Mast/stem cell growth factor receptor Kit";"KIT";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Platelet-derived growth factor receptor alpha";"PDGFRA";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Platelet-derived growth factor receptor beta";"PDGFRB";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Fibroblast growth factor receptor 1";"FGFR1";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Fibroblast growth factor receptor 2";"FGFR2";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Angiopoietin-1 receptor";"TEK";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Discoidin domain-containing receptor 2";"DDR2";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"High affinity nerve growth factor receptor";"NTRK1";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Ephrin type-A receptor 2";"EPHA2";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"RAF proto-oncogene serine/threonine-protein kinase";"RAF1";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Serine/threonine-protein kinase B-raf";"BRAF";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Mitogen-activated protein kinase 11";"MAPK11";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Tyrosine-protein kinase FRK";"FRK";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Tyrosine-protein kinase ABL1";"ABL1";"yes";"inhibitor"
"Regorafenib";"CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1";"Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); 
M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); 
M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);";"L01XE21";"Proto-oncogene tyrosine-protein kinase receptor Ret";"RET";"yes";"inhibitor"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03AL05";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03BB05";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03AL05";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03BB05";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03AL05";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03BB05";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03AL05";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03BB05";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03AL05";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Aclidinium";"OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1";"Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). 
Effective half-life = 5-8 hours.";"R03BB05";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Enzalutamide";"CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F";"The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.";"L02BB04";"Androgen receptor";"AR";"yes";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Tyrosine-protein kinase ABL1";"ABL1";"yes";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Breakpoint cluster region protein";"BCR";"yes";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Mast/stem cell growth factor receptor Kit";"KIT";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Proto-oncogene tyrosine-protein kinase receptor Ret";"RET";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Angiopoietin-1 receptor";"TEK";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Receptor-type tyrosine-protein kinase FLT3";"FLT3";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Fibroblast growth factor receptor 1";"FGFR1";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Fibroblast growth factor receptor 2";"FGFR2";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Fibroblast growth factor receptor 3";"FGFR3";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Fibroblast growth factor receptor 4";"FGFR4";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Tyrosine-protein kinase Lck";"LCK";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Proto-oncogene tyrosine-protein kinase Src";"SRC";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Tyrosine-protein kinase Lyn";"LYN";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Vascular endothelial growth factor receptor 2";"KDR";"unknown";"inhibitor"
"Ponatinib";"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1";"After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).";"L01XE24";"Platelet-derived growth factor receptor alpha";"PDGFRA";"unknown";"inhibitor"
"Bedaquiline";"COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2";"Terminal elimination half-life, bedaquiline and M2 = 5.5 months. This long half-life suggests slow release of bedaquiline and M2 from peripheral tissues.";"J04AK05";"ATP synthase subunit c";"atpE";"yes";"inhibitor"
"Fluticasone furoate";"[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"Elimination phase half-life, IV dose = 15.1 hours;
Elimination phase half-life, inhaled = 17 - 24 hours;";"R03AK10";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluticasone furoate";"[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"Elimination phase half-life, IV dose = 15.1 hours;
Elimination phase half-life, inhaled = 17 - 24 hours;";"R01AD12";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Fluticasone furoate";"[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"Elimination phase half-life, IV dose = 15.1 hours;
Elimination phase half-life, inhaled = 17 - 24 hours;";"R03BA09";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Canagliflozin";"[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1";"The apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.";"A10BD16";"Sodium/glucose cotransporter 2";"SLC5A2";"yes";"inhibitor"
"Canagliflozin";"[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1";"The apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.";"A10BX11";"Sodium/glucose cotransporter 2";"SLC5A2";"yes";"inhibitor"
"Canagliflozin";"[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1";"The apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.";"A10BD16";"Sodium/glucose cotransporter 1";"SLC5A1";"unknown";"inhibitor"
"Canagliflozin";"[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1";"The apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.";"A10BX11";"Sodium/glucose cotransporter 1";"SLC5A1";"unknown";"inhibitor"
"Dimethyl fumarate";"[H]\C(=C(\[H])C(=O)OC)C(=O)OC";"MMF has a short half life of about 1 hour, and MMF does not accumulate after repeated doses of dimethyl fumarate.";"N07XX09";"Kelch-like ECH-associated protein 1";"KEAP1";"yes";"binder"
"Dimethyl fumarate";"[H]\C(=C(\[H])C(=O)OC)C(=O)OC";"MMF has a short half life of about 1 hour, and MMF does not accumulate after repeated doses of dimethyl fumarate.";"N07XX09";"Transcription factor p65";"RELA";"unknown";""
"Pomalidomide";"NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O";"Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours.";"L04AX06";"Protein cereblon";"CRBN";"yes";"inhibitor"
"Pomalidomide";"NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O";"Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours.";"L04AX06";"Tumor necrosis factor";"TNF";"yes";"inhibitor"
"Pomalidomide";"NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O";"Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours.";"L04AX06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Trametinib";"CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1";"Elimination half-life = 3.9-4.8 days.";"L01XE25";"Dual specificity mitogen-activated protein kinase kinase 1";"MAP2K1";"yes";"inhibitor"
"Trametinib";"CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1";"Elimination half-life = 3.9-4.8 days.";"L01XE25";"Dual specificity mitogen-activated protein kinase kinase 2";"MAP2K2";"yes";"inhibitor"
"Dabrafenib";"CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1";"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.";"L01XE23";"Serine/threonine-protein kinase B-raf";"BRAF";"yes";"inhibitor"
"Dabrafenib";"CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1";"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.";"L01XE23";"RAF proto-oncogene serine/threonine-protein kinase";"RAF1";"yes";"inhibitor"
"Dabrafenib";"CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1";"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.";"L01XE23";"Serine/threonine-protein kinase SIK1";"SIK1";"unknown";"inhibitor"
"Dabrafenib";"CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1";"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.";"L01XE23";"Serine/threonine-protein kinase Nek11";"NEK11";"unknown";"inhibitor"
"Dabrafenib";"CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1";"Dabrafenib = 8 hours; 
Hydroxy-dabrafenib = 10 hours;
Carboxy-dabrafenib = 21-22 hours;
Desmethyl-dabrafenib = 21- 22 hours.";"L01XE23";"LIM domain kinase 1";"LIMK1";"unknown";"inhibitor"
"Afatinib";"CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1";"Cancer patients, repeat dosing = 37 hours";"L01XE13";"Epidermal growth factor receptor";"EGFR";"yes";"inhibitor"
"Afatinib";"CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1";"Cancer patients, repeat dosing = 37 hours";"L01XE13";"Receptor tyrosine-protein kinase erbB-2";"ERBB2";"yes";"inhibitor"
"Afatinib";"CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1";"Cancer patients, repeat dosing = 37 hours";"L01XE13";"Receptor tyrosine-protein kinase erbB-4";"ERBB4";"yes";"inhibitor"
"Dolutegravir";"[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2";"The half-life of dolutegravir is 14 hours.[A7514]";"J05AR13";"Integrase";"pol";"yes";"inhibitor"
"Dolutegravir";"[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2";"The half-life of dolutegravir is 14 hours.[A7514]";"J05AX12";"Integrase";"pol";"yes";"inhibitor"
"Riociguat";"COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2";"About 12 hours in patients and 7 hours in healthy subjects.";"C02KX05";"Guanylate cyclase soluble subunit alpha-2";"GUCY1A2";"yes";"agoniststimulator"
"Macitentan";"CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1";"The half life of macitentan is 16 hours, and the half life of it's active metabolite is 48 hours.";"C02KX04";"Endothelin-1 receptor";"EDNRA";"yes";"antagonist"
"Macitentan";"CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1";"The half life of macitentan is 16 hours, and the half life of it's active metabolite is 48 hours.";"C02KX04";"Endothelin B receptor";"EDNRB";"yes";"antagonist"
"Luliconazole";"ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1";"The half life of luliconazole has yet to be determined.";"D01AC18";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Sofosbuvir";"CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1";"Sofosbuvir has a terminal half life of 0.4 hours [FDA Label].";"J05AX65";"RNA-dependent RNA-polymerase";"NS5b";"yes";"inhibitor"
"Sofosbuvir";"CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1";"Sofosbuvir has a terminal half life of 0.4 hours [FDA Label].";"J05AX15";"RNA-dependent RNA-polymerase";"NS5b";"yes";"inhibitor"
"Chlorcyclizine";"CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1";"about 12 h.";"R06AE04";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Inositol nicotinate";"O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1";"Mean elimination half life in healthy human adults is approximately one hour [A19550].";"C04AC03";"Hydroxycarboxylic acid receptor 3";"HCAR3";"yes";"agonist"
"Inositol nicotinate";"O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1";"Mean elimination half life in healthy human adults is approximately one hour [A19550].";"C04AC03";"Hydroxycarboxylic acid receptor 2";"HCAR2";"yes";"agonist"
"Indoramin";"OC(=NC1CCN(CCC2=CNC3=CC=CC=C23)CC1)C1=CC=CC=C1";"";"C02CA02";"Alpha-1A adrenergic receptor";"ADRA1A";"unknown";"antagonist"
"Ifenprodil";"CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1";"";"C04AX28";"Glutamate receptor ionotropic, NMDA 1";"GRIN1";"yes";"antagonist"
"Ifenprodil";"CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1";"";"C04AX28";"Glutamate receptor ionotropic, NMDA 2B";"GRIN2B";"yes";"antagonist"
"Gemeprost";"CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC";"";"G02AD03";"Prostaglandin E2 receptor EP2 subtype";"PTGER2";"unknown";"agonist"
"Gemeprost";"CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC";"";"G02AD03";"Prostaglandin E2 receptor EP3 subtype";"PTGER3";"yes";"agonist"
"Diosmin";"COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1";"";"C05CA53";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Diosmin";"COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1";"";"C05CA03";"Aryl hydrocarbon receptor";"AHR";"unknown";"agonist"
"Dimetacrine";"CN(C)CCCN1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12";"Approximately 10 hours. (PMID 5312397)";"N06AA18";"Acetylcholinesterase";"ACHE";"yes";"antagonist"
"Befunolol";"CC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O";"";"S01ED06";"Beta-1 adrenergic receptor";"ADRB1";"unknown";""
"Befunolol";"CC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O";"";"S01ED06";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Captodiame";"CCCCSC1=CC=C(C=C1)C(SCCN(C)C)C1=CC=CC=C1";"";"N05BB02";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"antagonist"
"Captodiame";"CCCCSC1=CC=C(C=C1)C(SCCN(C)C)C1=CC=CC=C1";"";"N05BB02";"Sigma non-opioid intracellular receptor 1";"SIGMAR1";"yes";"agonist"
"Captodiame";"CCCCSC1=CC=C(C=C1)C(SCCN(C)C)C1=CC=CC=C1";"";"N05BB02";"D(3) dopamine receptor";"DRD3";"yes";"agonist"
"Bromopride";"CCN(CC)CCN=C(O)C1=C(OC)C=C(N)C(Br)=C1";"";"A03FA04";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Aliskiren";"COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1";"Approximate accumulation half‐life of 24 hours.";"C09DX02";"Renin";"REN";"yes";"inhibitor"
"Aliskiren";"COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1";"Approximate accumulation half‐life of 24 hours.";"C09XA02";"Renin";"REN";"yes";"inhibitor"
"Aliskiren";"COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1";"Approximate accumulation half‐life of 24 hours.";"C09XA52";"Renin";"REN";"yes";"inhibitor"
"Aliskiren";"COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1";"Approximate accumulation half‐life of 24 hours.";"C09XA53";"Renin";"REN";"yes";"inhibitor"
"Aliskiren";"COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1";"Approximate accumulation half‐life of 24 hours.";"C09XA54";"Renin";"REN";"yes";"inhibitor"
"Ledipasvir";"[H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F";"The median terminal half-life of ledipasvir is 47 hours [FDA Label].";"J05AX65";"Nonstructural protein 5A";"NS5A";"yes";"inhibitor"
"Vorapaxar";"[H]\C(=C(\[H])[C@]1([H])[C@]2([H])[C@@]([H])(C)OC(=O)[C@]2([H])C[C@]2([H])C[C@@]([H])(CC[C@@]12[H])N=C(O)OCC)C1=NC=C(C=C1)C1=CC(F)=CC=C1";"Vorapaxar has an effective half life of 3-4 days and an apparent terminal half life of 8 days.";"B01AC26";"Proteinase-activated receptor 1";"F2R";"yes";"antagonist"
"Miltefosine";"CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C";"The primary elimination half life is 7.05 days (range: 5.45-9.10 days) and the terminal half-life is 30.9 days (range: 30.8-31.2 days).";"L01XX09";"Multidrug resistance protein 1";"ABCB1";"unknown";""
"Empagliflozin";"[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1";"Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.";"A10BD20";"Sodium/glucose cotransporter 2";"SLC5A2";"unknown";"antagonistinhibitor"
"Empagliflozin";"[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1";"Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.";"A10BD19";"Sodium/glucose cotransporter 2";"SLC5A2";"unknown";"antagonistinhibitor"
"Empagliflozin";"[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1";"Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.";"A10BX12";"Sodium/glucose cotransporter 2";"SLC5A2";"unknown";"antagonistinhibitor"
"Eliglustat";"[H][C@](CN1CCCC1)(N=C(O)CCCCCCC)[C@]([H])(O)C1=CC2=C(OCCO2)C=C1";"6.5 hours in EM (extensive metabolizers) and 8.9 hours in PM (poor metabolizers).";"A16AX10";"Ceramide glucosyltransferase";"UGCG";"yes";"antagonist"
"Efinaconazole";"C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1";"29.9 hours in healthy patients.";"D01AC19";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Naloxegol";"COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5";"6-11 hours.";"A06AH03";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Ceftolozane";"CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=NSC(N)=N1)C2=O)C([O-])=O";"2.77 hours on day 1 of treatment.
3.12 hours on day 10 of treatment.";"J01DI54";"Penicillin-binding protein 1B";"ponB";"yes";"inhibitor"
"Ceftolozane";"CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=NSC(N)=N1)C2=O)C([O-])=O";"2.77 hours on day 1 of treatment.
3.12 hours on day 10 of treatment.";"J01DI54";"Penicillin-binding protein 3";"pbpB";"yes";"inhibitor"
"Ibrutinib";"NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1";"The elimination half-life of ibrutinib is of approximately 4-6 hours.[T148]";"L01XE27";"Tyrosine-protein kinase BTK";"BTK";"yes";"inhibitor"
"Ceritinib";"CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1";"The terminal half life is 41 hours.";"L01XE28";"ALK tyrosine kinase receptor";"ALK";"yes";"antagonist"
"Ciprofibrate";"CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O";"";"C10AB08";"Peroxisome proliferator-activated receptor alpha";"PPARA";"unknown";""
"Vortioxetine";"CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1";"Mean terminal half­life is approximately 66 hours";"N06AX26";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Vortioxetine";"CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1";"Mean terminal half­life is approximately 66 hours";"N06AX26";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Vortioxetine";"CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1";"Mean terminal half­life is approximately 66 hours";"N06AX26";"5-hydroxytryptamine receptor 7";"HTR7";"yes";"antagonist"
"Vortioxetine";"CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1";"Mean terminal half­life is approximately 66 hours";"N06AX26";"5-hydroxytryptamine receptor 1B";"HTR1B";"yes";"partial agonist"
"Vortioxetine";"CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1";"Mean terminal half­life is approximately 66 hours";"N06AX26";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonist"
"Vortioxetine";"CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1";"Mean terminal half­life is approximately 66 hours";"N06AX26";"Beta-1 adrenergic receptor";"ADRB1";"unknown";"ligand"
"Trimetazidine";"COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1";"Half life of the modified release (MR) formulation was reported to be ∼8 h in young volunteers (25 ± 8) and ∼12 h in elderly (72 ± 4) (Barré et al. 2003).";"C01EB15";"3-ketoacyl-CoA thiolase, peroxisomal";"ACAA1";"yes";"inhibitor"
"Tibolone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H]";"The elimination half-life is approximately 45 h [L1720].";"G03CX01";"Estrogen receptor alpha";"ESR1";"yes";"antagonistagonist"
"Tasimelteon";"[H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1";"The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.";"N05CH03";"Melatonin receptor type 1A";"MTNR1A";"yes";"agonist"
"Tasimelteon";"[H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1";"The observed mean elimination half-life for tasimelteon is 1.3 ± 0.4 hours.";"N05CH03";"Melatonin receptor type 1B";"MTNR1B";"yes";"agonist"
"Palbociclib";"CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O";"The mean plasma elimination half-life is 29 hours.";"L01XE33";"Cyclin-dependent kinase 4";"CDK4";"yes";"inhibitor"
"Palbociclib";"CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O";"The mean plasma elimination half-life is 29 hours.";"L01XE33";"Cyclin-dependent kinase 6";"CDK6";"yes";"inhibitor"
"Olaparib";"OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12";"11.9 hours, standard deviation 4.8 hours.";"L01XX46";"Poly [ADP-ribose] polymerase 1";"PARP1";"yes";"inhibitor"
"Olaparib";"OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12";"11.9 hours, standard deviation 4.8 hours.";"L01XX46";"Poly [ADP-ribose] polymerase 2";"PARP2";"yes";"inhibitor"
"Olaparib";"OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12";"11.9 hours, standard deviation 4.8 hours.";"L01XX46";"Poly [ADP-ribose] polymerase 3";"PARP3";"yes";"inhibitor"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03BB07";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03AL03";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03BB07";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03AL03";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03BB07";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03AL03";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03BB07";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03AL03";"Muscarinic acetylcholine receptor M4";"CHRM4";"no";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03BB07";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Umeclidinium";"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2";"The effective half-life after once daily dosing is 11 hours.";"R03AL03";"Muscarinic acetylcholine receptor M5";"CHRM5";"no";"antagonist"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Vascular endothelial growth factor receptor 1";"FLT1";"yes";"inhibitor"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"inhibitor"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Vascular endothelial growth factor receptor 3";"FLT4";"yes";"inhibitor"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Fibroblast growth factor receptor 1";"FGFR1";"yes";"inhibitor"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Fibroblast growth factor receptor 2";"FGFR2";"yes";"inhibitor"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Fibroblast growth factor receptor 3";"FGFR3";"yes";"inhibitor"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Fibroblast growth factor receptor 4";"FGFR4";"yes";"inhibitor"
"Lenvatinib";"COC1=C(C=C2C(OC3=CC(Cl)=C(NC(O)=NC4CC4)C=C3)=CC=NC2=C1)C(O)=N";"The terminal elimination half­life of lenvatinib is approximately 28 hours.";"L01XE29";"Mast/stem cell growth factor receptor Kit";"KIT";"yes";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Vascular endothelial growth factor receptor 1";"FLT1";"yes";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Vascular endothelial growth factor receptor 2";"KDR";"yes";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Vascular endothelial growth factor receptor 3";"FLT4";"yes";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Fibroblast growth factor receptor 1";"FGFR1";"yes";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Fibroblast growth factor receptor 2";"FGFR2";"yes";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Fibroblast growth factor receptor 3";"FGFR3";"yes";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Receptor-type tyrosine-protein kinase FLT3";"FLT3";"unknown";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Tyrosine-protein kinase Lck";"LCK";"unknown";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Tyrosine-protein kinase Lyn";"LYN";"unknown";"inhibitor"
"Nintedanib";"COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(O)=N2";"9.5 hours";"L01XE31";"Proto-oncogene tyrosine-protein kinase Src";"SRC";"unknown";"inhibitor"
"Olodaterol";"COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1";"The terminal half-life following intravenous administration is 22 hours. The terminal half-life following inhalation in contrast is about 45 hours, indicating that the latter is determined by absorption rather than by elimination processes.";"R03AL06";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Olodaterol";"COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1";"The terminal half-life following intravenous administration is 22 hours. The terminal half-life following inhalation in contrast is about 45 hours, indicating that the latter is determined by absorption rather than by elimination processes.";"R03AC19";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Vilanterol";"[H][C@](O)(CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl)C1=CC(CO)=C(O)C=C1";"21.3 hr";"R03AK10";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Vilanterol";"[H][C@](O)(CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl)C1=CC(CO)=C(O)C=C1";"21.3 hr";"R03AL03";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"D04AB06";"Ryanodine receptor 1";"RYR1";"yes";"modulator"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"N01BA03";"Ryanodine receptor 1";"RYR1";"yes";"modulator"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"S01HA03";"Ryanodine receptor 1";"RYR1";"yes";"modulator"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"C05AD02";"Ryanodine receptor 1";"RYR1";"yes";"modulator"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"D04AB06";"Ryanodine receptor 2";"RYR2";"yes";"modulator"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"N01BA03";"Ryanodine receptor 2";"RYR2";"yes";"modulator"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"S01HA03";"Ryanodine receptor 2";"RYR2";"yes";"modulator"
"Tetracaine";"CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C";"Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.";"C05AD02";"Ryanodine receptor 2";"RYR2";"yes";"modulator"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Mu-type opioid receptor";"OPRM1";"yes";"agonist"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNA1C";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNA1D";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNA1F";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNA1S";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNB1";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNB2";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNB3";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage dependent L type calcium channel";"CACNB4";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNMA1";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNMB1";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNMB2";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNMB3";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNMB4";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNN4";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNN1";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNN2";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Calcium-activated potassium channel";"KCNN3";"yes";"inhibitor"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage-dependent T-type calcium channel";"CACNA1G";"unknown";"activator"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage-dependent T-type calcium channel";"CACNA1H";"unknown";"activator"
"Trimebutine";"CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1";"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].";"A03AA05";"Voltage-dependent T-type calcium channel";"CACNA1I";"unknown";"activator"
"Pinaverium";"COC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1";"The mean elimination half life is approximately 1.5 hours [L873].";"A03AX04";"Voltage-dependent L-type calcium channel subunit alpha-1S";"CACNA1S";"yes";"antagonistinhibitor"
"Tixocortol";"[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Tixocortol presents a shorter half-life than cortisol.[A31447]";"A07EA05";"Glucocorticoid receptor";"NR3C1";"yes";"binder"
"Tixocortol";"[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Tixocortol presents a shorter half-life than cortisol.[A31447]";"R01AD07";"Glucocorticoid receptor";"NR3C1";"yes";"binder"
"Tixocortol";"[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Tixocortol presents a shorter half-life than cortisol.[A31447]";"R01AD57";"Glucocorticoid receptor";"NR3C1";"yes";"binder"
"Tixocortol";"[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Tixocortol presents a shorter half-life than cortisol.[A31447]";"A07EA05";"Histone deacetylase 2";"HDAC2";"yes";"stimulator"
"Tixocortol";"[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Tixocortol presents a shorter half-life than cortisol.[A31447]";"R01AD07";"Histone deacetylase 2";"HDAC2";"yes";"stimulator"
"Tixocortol";"[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C";"Tixocortol presents a shorter half-life than cortisol.[A31447]";"R01AD57";"Histone deacetylase 2";"HDAC2";"yes";"stimulator"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"R03DA20";"60S ribosomal protein L3";"RPL3";"no";"binder"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"C04AD02";"60S ribosomal protein L3";"RPL3";"no";"binder"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"R03DA20";"NAD(P) transhydrogenase, mitochondrial";"NNT";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"C04AD02";"NAD(P) transhydrogenase, mitochondrial";"NNT";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"R03DA20";"Glyceraldehyde-3-phosphate dehydrogenase";"GAPDH";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"C04AD02";"Glyceraldehyde-3-phosphate dehydrogenase";"GAPDH";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"R03DA20";"Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial";"IDH3A";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"C04AD02";"Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial";"IDH3A";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"R03DA20";"2-oxoglutarate dehydrogenase, mitochondrial";"OGDH";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"C04AD02";"2-oxoglutarate dehydrogenase, mitochondrial";"OGDH";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"R03DA20";"Malate dehydrogenase, mitochondrial";"MDH2";"yes";"cofactor"
"Xanthinol";"CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C";"The reported elimination half-life of xanthinol is 1.67h.";"C04AD02";"Malate dehydrogenase, mitochondrial";"MDH2";"yes";"cofactor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"S01AA02";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA03";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA20";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"A01AB21";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"D06AA02";"30S ribosomal protein S3";"rpsC";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"S01AA02";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA03";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA20";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"A01AB21";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"D06AA02";"30S ribosomal protein S8";"rpsH";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"S01AA02";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA03";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA20";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"A01AB21";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"D06AA02";"30S ribosomal protein S19";"rpsS";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"S01AA02";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA03";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA20";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"A01AB21";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"D06AA02";"30S ribosomal protein S14";"rpsN";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"S01AA02";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA03";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"J01AA20";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"A01AB21";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Chlortetracycline";"[H][C@]12C[C@@]3([H])[C@]([H])(N(C)C)C(O)=C(C(O)=N)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C(O)C=CC(Cl)=C1[C@@]2(C)O";"The half-life of Chlortetracycline is 5.6 hours [A1424].";"D06AA02";"30S ribosomal protein S7";"rpsG";"yes";"inhibitor"
"Difluocortolone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459]";"D07XC04";"Annexin A3";"ANXA3";"yes";"inducer"
"Difluocortolone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459]";"D07AC06";"Annexin A3";"ANXA3";"yes";"inducer"
"Difluocortolone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459]";"D07BC04";"Annexin A3";"ANXA3";"yes";"inducer"
"Difluocortolone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459]";"D07XC04";"Glucocorticoid receptor";"NR3C1";"yes";"binder"
"Difluocortolone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459]";"D07AC06";"Glucocorticoid receptor";"NR3C1";"yes";"binder"
"Difluocortolone";"[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C";"The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459]";"D07BC04";"Glucocorticoid receptor";"NR3C1";"yes";"binder"
"Quinagolide";"[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC";"The terminal half-life for parent drug is 11.5 hours following single dose and 17 hours at steady state.";"G02CB04";"D(2) dopamine receptor";"DRD2";"unknown";"agonist"
"Quinagolide";"[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC";"The terminal half-life for parent drug is 11.5 hours following single dose and 17 hours at steady state.";"G02CB04";"D(1) dopamine receptor";"DRD1";"unknown";"agonist"
"Quinagolide";"[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC";"The terminal half-life for parent drug is 11.5 hours following single dose and 17 hours at steady state.";"G02CB04";"D(1) dopamine receptor";"DRD5";"unknown";"agonist"
"Elvitegravir";"[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2";"The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.";"J05AR18";"Integrase";"pol";"yes";"inhibitor"
"Elvitegravir";"[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2";"The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.";"J05AR09";"Integrase";"pol";"yes";"inhibitor"
"Elvitegravir";"[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2";"The median terminal plasma half-life following administration of elvitegravir and ritonavir was approximately 8.7 hours.";"J05AX11";"Integrase";"pol";"yes";"inhibitor"
"Nitrous acid";"ON=O";"Half life of 0.4-0.78h [A19444].";"V03AB08";"Hemoglobin subunit alpha";"HBA1";"yes";"oxidizer"
"Nitrous acid";"ON=O";"Half life of 0.4-0.78h [A19444].";"V03AB08";"Hemoglobin subunit beta";"HBB";"yes";"oxidizer"
"Nitrous acid";"ON=O";"Half life of 0.4-0.78h [A19444].";"V03AB08";"Myoglobin";"MB";"unknown";"oxidizer"
"Calcium carbimide";"[Ca++].[N-]=C=[N-]";"Calcium carbimide is metabolized and eliminated very rapidly so the apparent half-life is of 92.4 minutes.[L1114]";"N07BB02";"Aldehyde dehydrogenase family 3 member B2";"ALDH3B2";"yes";"antagonistinhibitor"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRA1";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRA2";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRA3";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRA4";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRA5";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRA6";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRB1";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRB2";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRB3";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRD";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRE";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRG1";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRG2";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRG3";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRP";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"GABA-A receptor (anion channel)";"GABRQ";"yes";"agonistpositive allosteric modulator"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"L-lactate dehydrogenase A chain";"LDHA";"yes";"inhibitor"
"Stiripentol";"CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1";"Elimination half life is approximately ranges from 4.5 to 13 hours, in a dose-dependent manner [L880].";"N03AX17";"L-lactate dehydrogenase B chain";"LDHB";"yes";"inhibitor"
"Eslicarbazepine acetate";"CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12";"The apparent plasma half-life of eslicarbazepine is 10-20 hours in healthy subjects and 13-20 hours in epilepsy patients. Steady-state plasma concentrations are attained after 4 to 5 days of once daily dosing.";"N03AF04";"P2X purinoceptor 4";"P2RX4";"yes";"antagonist"
"Zucapsaicin";"COC1=C(O)C=CC(CNC(=O)CCCC\C=C/C(C)C)=C1";"In rats, the elimination half life of zucapsaicin and its metabolites is approximately 7 to 11 hours [L877].";"M02AB02";"Transient receptor potential cation channel subfamily V member 1";"TRPV1";"yes";"agonistactivator"
"Aurothioglucose";"OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O";"The biological half-life of gold salts (like aurothioglucose) following a single 50 mg dose demonstrates a biological half-life of about 3-27 days, where the half-life seemingly increases with increased number of doses [T147]. Following successive weekly doses, the half-life increases and may become 14-40 days after the third dose and up to 168 days after the eleventh weekly dose [L1925].";"M01CB04";"Adenylate cyclase type 1";"ADCY1";"unknown";""
"Aurothioglucose";"OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O";"The biological half-life of gold salts (like aurothioglucose) following a single 50 mg dose demonstrates a biological half-life of about 3-27 days, where the half-life seemingly increases with increased number of doses [T147]. Following successive weekly doses, the half-life increases and may become 14-40 days after the third dose and up to 168 days after the eleventh weekly dose [L1925].";"M01CB04";"Adenylate cyclase type 2";"ADCY2";"unknown";""
"Aurothioglucose";"OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O";"The biological half-life of gold salts (like aurothioglucose) following a single 50 mg dose demonstrates a biological half-life of about 3-27 days, where the half-life seemingly increases with increased number of doses [T147]. Following successive weekly doses, the half-life increases and may become 14-40 days after the third dose and up to 168 days after the eleventh weekly dose [L1925].";"M01CB04";"Adenylate cyclase type 5";"ADCY5";"unknown";""
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03DB08";"Progesterone receptor";"PGR";"yes";"agonist"
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03AB08";"Progesterone receptor";"PGR";"yes";"agonist"
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03FA15";"Progesterone receptor";"PGR";"yes";"agonist"
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03AA16";"Progesterone receptor";"PGR";"yes";"agonist"
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03DB08";"Androgen receptor";"AR";"yes";"antagonist"
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03AB08";"Androgen receptor";"AR";"yes";"antagonist"
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03FA15";"Androgen receptor";"AR";"yes";"antagonist"
"Dienogest";"[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Elimination half-life of dienogest is around 9-10 hours. The half-life of urinary metabolites excretion is 14 hours [L931].";"G03AA16";"Androgen receptor";"AR";"yes";"antagonist"
"Medrogestone";"[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"The half-life of medrogestone is reported to be of 4 hours.[T79]";"G03FB07";"Progesterone receptor";"PGR";"yes";"ligand"
"Medrogestone";"[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C";"The half-life of medrogestone is reported to be of 4 hours.[T79]";"G03DB03";"Progesterone receptor";"PGR";"yes";"ligand"
"Brexpiprazole";"O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1";"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.";"N05AX16";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"agonistpartial agonist"
"Brexpiprazole";"O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1";"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.";"N05AX16";"D(2) dopamine receptor";"DRD2";"yes";"agonistpartial agonist"
"Brexpiprazole";"O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1";"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.";"N05AX16";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Brexpiprazole";"O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1";"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.";"N05AX16";"Alpha-2C adrenergic receptor";"ADRA2C";"yes";"antagonist"
"Brexpiprazole";"O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1";"Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.";"N05AX16";"Alpha-1B adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Oxygen";"O=O";"Approximately 122.24 seconds";"V03AN01";"Cytochrome c oxidase subunit 1";"MT-CO1";"unknown";"agonistactivator"
"Oxygen";"O=O";"Approximately 122.24 seconds";"V03AN01";"NADPH oxidase 1";"NOX1";"unknown";"agonistactivator"
"Oxygen";"O=O";"Approximately 122.24 seconds";"V03AN01";"Hemoglobin subunit alpha";"HBA1";"unknown";""
"Oxygen";"O=O";"Approximately 122.24 seconds";"V03AN01";"Hemoglobin subunit beta";"HBB";"unknown";""
"Sonidegib";"[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1";"Half-life ~ 28 days (2)";"L01XX48";"Smoothened homolog";"SMO";"unknown";"antagonist"
"Iron saccharate";"O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O";"6 hours.";"B03AB02";"Hemoglobin subunit alpha";"HBA1";"yes";"component of"
"Iron saccharate";"O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O";"6 hours.";"V03AE05";"Hemoglobin subunit alpha";"HBA1";"yes";"component of"
"Florbetaben (18F)";"CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1";"1 hr";"V09AX06";"Amyloid beta A4 protein";"APP";"yes";"binder"
"Florbetapir (18F)";"[H]N(C1=C([H])C([H])=C(\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H]";"";"V09AX05";"Amyloid beta A4 protein";"APP";"yes";"binder"
"Flutemetamol (18F)";"CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1";"";"V09AX04";"Amyloid beta A4 protein";"APP";"yes";"binder"
"Etizolam";"CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl";"The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].";"N05BA19";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"agonist"
"Etizolam";"CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl";"The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].";"N05BA19";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"agonist"
"Etizolam";"CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl";"The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].";"N05BA19";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"agonist"
"Etizolam";"CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl";"The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].";"N05BA19";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"agonist"
"Etizolam";"CCC1=CC2=C(S1)N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl";"The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism [L884]. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours [A19776].";"N05BA19";"Platelet-activating factor receptor";"PTAFR";"unknown";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"5-hydroxytryptamine receptor 1A";"HTR1A";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Muscarinic acetylcholine receptor M1";"CHRM1";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Muscarinic acetylcholine receptor M2";"CHRM2";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Muscarinic acetylcholine receptor M4";"CHRM4";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Muscarinic acetylcholine receptor M5";"CHRM5";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Alpha-2 adrenergic receptors";"ADRA2A";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Alpha-2 adrenergic receptors";"ADRA2B";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Alpha-2 adrenergic receptors";"ADRA2C";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Alpha-1 adrenergic receptors";"ADRA1A";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Alpha-1 adrenergic receptors";"ADRA1B";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Alpha-1 adrenergic receptors";"ADRA1D";"yes";"antagonist"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Dosulepin";"CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12";"The elimination half life is approximately 20.4 hours following oral administration of 25mg dosulepin [L881].";"N06AA16";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"inhibitor"
"Dasabuvir";"COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C";"The half-life of elimination of dasabuvir is 5.5 to 6 hours [FDA Label].";"J05AX16";"Nonstructural protein 5B (NS5B)";"NS5b";"yes";"inhibitor"
"Dasabuvir";"COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C";"The half-life of elimination of dasabuvir is 5.5 to 6 hours [FDA Label].";"J05AX66";"Nonstructural protein 5B (NS5B)";"NS5b";"yes";"inhibitor"
"Viloxazine";"CCOC1=CC=CC=C1OCC1CNCCO1";"Elimination half life is approximately 3-4 hours [A19786].";"N06AX09";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"inhibitor"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Alpha-2 adrenergic receptors";"ADRA2A";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Alpha-2 adrenergic receptors";"ADRA2B";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Alpha-2 adrenergic receptors";"ADRA2C";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Histamine H1 receptor";"HRH1";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Muscarinic acetylcholine receptor";"CHRM1";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Muscarinic acetylcholine receptor";"CHRM2";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Muscarinic acetylcholine receptor";"CHRM3";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Muscarinic acetylcholine receptor";"CHRM4";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"Muscarinic acetylcholine receptor";"CHRM5";"unknown";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Etoperidone";"CCN1C(=O)N(CCCN2CCN(CC2)C2=CC=CC(Cl)=C2)N=C1CC";"After oral administration of etoperidone the terminal half-life was 21.7 hours.[A31350]";"N06AB09";"5-hydroxytryptamine receptor 2C";"HTR2C";"yes";"agonist"
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"C01CA08";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"S01GA06";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"S01GA56";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"C01CA08";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"S01GA06";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"S01GA56";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"C01CA08";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"S01GA06";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";""
"Synephrine";"CNCC(O)C1=CC=C(O)C=C1";"";"S01GA56";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";""
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"C04AX10";"Alpha adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"G04BE06";"Alpha adrenergic receptor";"ADRA1A";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"C04AX10";"Alpha adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"G04BE06";"Alpha adrenergic receptor";"ADRA1B";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"C04AX10";"Alpha adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"G04BE06";"Alpha adrenergic receptor";"ADRA1D";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"C04AX10";"Alpha adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"G04BE06";"Alpha adrenergic receptor";"ADRA2A";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"C04AX10";"Alpha adrenergic receptor";"ADRA2B";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"G04BE06";"Alpha adrenergic receptor";"ADRA2B";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"C04AX10";"Alpha adrenergic receptor";"ADRA2C";"yes";"antagonist"
"Moxisylyte";"CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1";"The half-life of moxisylyte was of 1-2 hours.[L1174]";"G04BE06";"Alpha adrenergic receptor";"ADRA2C";"yes";"antagonist"
"Pholcodine";"[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"After oral administration of 60 mg of pholcodine, the half-life in plasma, saliva and urine are 45, 55 and 45 hours respectively.[A31738]";"R05DA08";"Mu-type opioid receptor";"OPRM1";"yes";"antagonist"
"Pholcodine";"[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"After oral administration of 60 mg of pholcodine, the half-life in plasma, saliva and urine are 45, 55 and 45 hours respectively.[A31738]";"R05DA08";"Kappa-type opioid receptor";"OPRK1";"yes";"antagonist"
"Pholcodine";"[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O";"After oral administration of 60 mg of pholcodine, the half-life in plasma, saliva and urine are 45, 55 and 45 hours respectively.[A31738]";"R05DA08";"Delta-type opioid receptor";"OPRD1";"unknown";"antagonist"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"inhibitor"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Apoptosis regulator Bcl-2";"BCL2";"unknown";"negative modulator"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Thrombomodulin";"THBD";"unknown";"modulator"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Tissue-type plasminogen activator";"PLAT";"unknown";"modulator"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Fatty acid-binding protein, intestinal";"FABP2";"unknown";"binder"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";"activator"
"Dexibuprofen";"[H][C@@](C)(C(O)=O)C1=CC=C(CC(C)C)C=C1";"Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours [A19254].";"M01AE14";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"unknown";"inhibitor"
"Dexketoprofen";"[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"1.65 h [L1299]";"M02AA27";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"antagonist"
"Dexketoprofen";"[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"1.65 h [L1299]";"M01AE17";"Prostaglandin G/H synthase 1";"PTGS1";"unknown";"antagonist"
"Dexketoprofen";"[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"1.65 h [L1299]";"M02AA27";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"antagonist"
"Dexketoprofen";"[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1";"1.65 h [L1299]";"M01AE17";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";"antagonist"
"Droxicam";"CN1C2=C(OC(=O)N(C2=O)C2=CC=CC=N2)C2=CC=CC=C2S1(=O)=O";"Data not available for prodrug. See [DB00554] for information on the active compound.";"M01AC04";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"inhibitor"
"Droxicam";"CN1C2=C(OC(=O)N(C2=O)C2=CC=CC=N2)C2=CC=CC=C2S1(=O)=O";"Data not available for prodrug. See [DB00554] for information on the active compound.";"M01AC04";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"inhibitor"
"Tolfenamic Acid";"CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O";"The estimated half-life of tolfenamic acid is 8.01-13.50 hours.[A31842] When tested intravenously, the reported half-life was 6.1h.[A31849]";"M01AG02";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"antagonist"
"Tolfenamic Acid";"CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O";"The estimated half-life of tolfenamic acid is 8.01-13.50 hours.[A31842] When tested intravenously, the reported half-life was 6.1h.[A31849]";"M01AG02";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"antagonist"
"Nicorandil";"[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1";"The elimination half life is approximately 1 hour [A20328].";"C01DX16";"ATP-binding cassette sub-family C member 9";"ABCC9";"yes";"activator"
"Melperone";"CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1";"Approximately 3-4 hours after oral administration [A31862]. After intramuscular injection, the half-life has been found to be approximately 6 hours [A31862].";"N05AD03";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"D(1) dopamine receptor";"DRD1";"yes";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"D(1) dopamine receptor";"DRD5";"yes";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"D(2) dopamine receptor";"DRD2";"yes";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"5-hydroxytryptamine receptor 2A";"HTR2A";"yes";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"5-hydroxytryptamine receptor 6";"HTR6";"unknown";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"5-hydroxytryptamine receptor 7";"HTR7";"yes";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"Sodium-dependent noradrenaline transporter";"SLC6A2";"yes";"antagonist"
"Zotepine";"CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12";"The half-life of zotepine is reported to be of 21 hours.[A31893]";"N05AX11";"Sodium-dependent serotonin transporter";"SLC6A4";"yes";"antagonist"
"Barnidipine";"COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2=CC=CC=C2)C1";"In a two-compartment analytical model, the median terminal elimination half life of barnidipine was 20 hours after repeated administration [L1131].";"C08CA12";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNA1C";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNA1D";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNA1F";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNA1S";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNB1";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNB2";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNB3";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage dependent L type calcium channel";"CACNB4";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage-dependent T-type calcium channel";"CACNA1G";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage-dependent T-type calcium channel";"CACNA1H";"yes";"antagonist"
"Benidipine";"COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1";"The elimination half-life of benidipine is registered to be of approximate 1 hour.[A31950]";"C08CA15";"Voltage-dependent T-type calcium channel";"CACNA1I";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage-dependent N-type calcium channel subunit alpha-1B";"CACNA1B";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNA1C";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNA1D";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNA1F";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNA1S";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNB1";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNB2";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNB3";"yes";"antagonist"
"Cilnidipine";"COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1";"The half-life of the hypotensive effect for cilnidipine is of about 20.4 min.[A32004]";"C08CA14";"Voltage dependent L type calcium channel";"CACNB4";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNA1C";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNA1D";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNA1F";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNA1S";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNB1";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNB2";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNB3";"yes";"antagonist"
"Lacidipine";"CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC";"The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [L1126].";"C08CA09";"Voltage dependent L type calcium channel";"CACNB4";"yes";"antagonist"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNA1C";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNA1C";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNA1D";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNA1D";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNA1F";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNA1F";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNA1S";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNA1S";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNB1";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNB1";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNB2";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNB2";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNB3";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNB3";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage dependent L type calcium channel";"CACNB4";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage dependent L type calcium channel";"CACNB4";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage-dependent T-type calcium channel";"CACNA1G";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage-dependent T-type calcium channel";"CACNA1G";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage-dependent T-type calcium channel";"CACNA1H";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage-dependent T-type calcium channel";"CACNA1H";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C08CA11";"Voltage-dependent T-type calcium channel";"CACNA1I";"yes";"blocker"
"Manidipine";"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1";"The half life of elimination has been observed to be dose dependent [A7845]. Doses of 5, 10, and 20 mg produced half lives of 3.94, 5.02, and 7.95 h respectively.";"C09BB12";"Voltage-dependent T-type calcium channel";"CACNA1I";"yes";"blocker"
"Methylene blue";"[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1";"5–6.5 hours (after IV dose).";"V03AB17";"Guanylate cyclase soluble subunit alpha-2";"GUCY1A2";"yes";"antagonist"
"Methylene blue";"[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1";"5–6.5 hours (after IV dose).";"V04CG05";"Guanylate cyclase soluble subunit alpha-2";"GUCY1A2";"yes";"antagonist"
"Methylene blue";"[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1";"5–6.5 hours (after IV dose).";"V03AB17";"Nitric oxide synthase, brain";"NOS1";"yes";"antagonist"
"Methylene blue";"[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1";"5–6.5 hours (after IV dose).";"V04CG05";"Nitric oxide synthase, brain";"NOS1";"yes";"antagonist"
"Moxonidine";"COC1=NC(C)=NC(Cl)=C1NC1=NCCN1";"Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. [FDA label]";"C02LC05";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Moxonidine";"COC1=NC(C)=NC(Cl)=C1NC1=NCCN1";"Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. [FDA label]";"C02AC05";"Alpha-2A adrenergic receptor";"ADRA2A";"yes";"agonist"
"Moxonidine";"COC1=NC(C)=NC(Cl)=C1NC1=NCCN1";"Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. [FDA label]";"C02LC05";"Nischarin";"NISCH";"yes";"agonist"
"Moxonidine";"COC1=NC(C)=NC(Cl)=C1NC1=NCCN1";"Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. [FDA label]";"C02AC05";"Nischarin";"NISCH";"yes";"agonist"
"Toloxatone";"CC1=CC(=CC=C1)N1CC(CO)OC1=O";"1-3 h [A31957]";"N06AG03";"Amine oxidase [flavin-containing] A";"MAOA";"unknown";"antagonist"
"Lixisenatide";"[V].[H][C@](C)(O)[C@]([H])(N=C(O)CN=C(O)[C@]([H])(CCC(O)=O)N=C(O)CN=C(O)[C@@]([H])(N)CC1=CN=CN1)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCSC)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(O)=N)C(O)=NCC(O)=NCC(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=NCC(O)=N[C@@]([H])(C)C(=O)N1CCC[C@@]1([H])C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N)[C@@]([H])(C)CC)[C@@]([H])(C)O";"3h [FDA Label]";"A10BX10";"Glucagon-like peptide 1 receptor";"GLP1R";"yes";"agonist"
"Ubidecarenone";"COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O";"The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[A31414]";"C01EB09";"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial";"NDUFV3";"yes";"cofactor"
"Ubidecarenone";"COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O";"The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[A31414]";"C01EB09";"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial";"SDHA";"yes";"cofactor"
"Doxofylline";"CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O";"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].";"R03DA20";"Phosphodiesterase 2A, cGMP-stimulated";"PDE2A";"yes";"inhibitor"
"Doxofylline";"CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O";"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].";"R03DA11";"Phosphodiesterase 2A, cGMP-stimulated";"PDE2A";"yes";"inhibitor"
"Doxofylline";"CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O";"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].";"R03DA20";"Adenosine receptor A2a";"ADORA2A";"unknown";"antagonist"
"Doxofylline";"CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O";"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].";"R03DA11";"Adenosine receptor A2a";"ADORA2A";"unknown";"antagonist"
"Doxofylline";"CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O";"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].";"R03DA20";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Doxofylline";"CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O";"Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours [L1169].";"R03DA11";"Beta-2 adrenergic receptor";"ADRB2";"yes";"agonist"
"Artesunate";"[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4";"Half life of elimination after intravenous bolus was observed to be less than 5 min for artesunate and 21-64 min for DHA [L891]. Half life after intramuscular administration is 48 min in children and 41 min in adults.";"P01BF03";"Malaria protein EXP-1";"EXP-1";"yes";"inhibitor"
"Artesunate";"[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4";"Half life of elimination after intravenous bolus was observed to be less than 5 min for artesunate and 21-64 min for DHA [L891]. Half life after intramuscular administration is 48 min in children and 41 min in adults.";"P01BF04";"Malaria protein EXP-1";"EXP-1";"yes";"inhibitor"
"Artesunate";"[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4";"Half life of elimination after intravenous bolus was observed to be less than 5 min for artesunate and 21-64 min for DHA [L891]. Half life after intramuscular administration is 48 min in children and 41 min in adults.";"P01BF02";"Malaria protein EXP-1";"EXP-1";"yes";"inhibitor"
"Artesunate";"[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4";"Half life of elimination after intravenous bolus was observed to be less than 5 min for artesunate and 21-64 min for DHA [L891]. Half life after intramuscular administration is 48 min in children and 41 min in adults.";"P01BE03";"Malaria protein EXP-1";"EXP-1";"yes";"inhibitor"
"Artesunate";"[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4";"Half life of elimination after intravenous bolus was observed to be less than 5 min for artesunate and 21-64 min for DHA [L891]. Half life after intramuscular administration is 48 min in children and 41 min in adults.";"P01BF06";"Malaria protein EXP-1";"EXP-1";"yes";"inhibitor"
"Bismuth Subcitrate";"[K+].[K+].[K+].[Bi+3].OC(=O)CC(O)(CC([O-])=O)C(O)=O.OC(=O)CC(O)(CC([O-])=O)C(O)=O";"The elimination half-life of bismuth is approximately 5 days";"A02BD08";"ATP-dependent Clp protease ATP-binding subunit ClpX";"clpX";"unknown";"antagonist"
"Bismuth Subcitrate";"[K+].[K+].[K+].[Bi+3].OC(=O)CC(O)(CC([O-])=O)C(O)=O.OC(=O)CC(O)(CC([O-])=O)C(O)=O";"The elimination half-life of bismuth is approximately 5 days";"A02BX05";"ATP-dependent Clp protease ATP-binding subunit ClpX";"clpX";"unknown";"antagonist"
"Fimasartan";"CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1";"The half life of elimination is 7-10 h [A20319].";"C09CA10";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Lumacaftor";"CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O";"The half-life of lumacaftor is approximately 26 hours [FDA Label].";"R07AX30";"Cystic fibrosis transmembrane conductance regulator";"CFTR";"yes";"modulator"
"Molsidomine";"CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1";"";"C01DX12";"Guanylate cyclase soluble subunit alpha-2";"GUCY1A2";"unknown";"agonist"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE1A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE1B";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE1C";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE10A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE4A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE4B";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE4C";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE4D";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE7B";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE2A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE3A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE3B";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE5A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE6C";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE11A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE7A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE8A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE8B";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE9A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE6A";"yes";"inhibitor"
"Trapidil";"CCN(CC)C1=CC(C)=NC2=NC=NN12";"The half life of elimination is 1.31 h for a single dose and 1.14 h for steady state dosing [A19770].";"C01DX11";"Cyclic nucleotide phosphodiesterase";"PDE6B";"yes";"inhibitor"
"Morniflumate";"FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OCCN2CCOCC2)=CC=C1";"2h [L1498]";"M01AX22";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"antagonist"
"Morniflumate";"FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OCCN2CCOCC2)=CC=C1";"2h [L1498]";"M01AX22";"Prostaglandin G/H synthase 2";"PTGS2";"unknown";""
"Morniflumate";"FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OCCN2CCOCC2)=CC=C1";"2h [L1498]";"M01AX22";"Leukotriene B4 receptor 1";"LTB4R";"unknown";"antagonist"
"Morniflumate";"FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OCCN2CCOCC2)=CC=C1";"2h [L1498]";"M01AX22";"Thromboxane A2 receptor";"TBXA2R";"unknown";""
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"D(2) dopamine receptor";"DRD2";"unknown";"antagonist"
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"agonist"
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"Alpha-1 adrenergic receptors";"ADRA1A";"unknown";"antagonist"
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"Alpha-1 adrenergic receptors";"ADRA1B";"unknown";"antagonist"
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"Alpha-1 adrenergic receptors";"ADRA1D";"unknown";"antagonist"
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"D(4) dopamine receptor";"DRD4";"unknown";"antagonist"
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"D(1A) dopamine receptor";"DRD1";"unknown";"antagonist"
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"D(3) dopamine receptor";"DRD3";"unknown";""
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"5-hydroxytryptamine receptor 2B";"HTR2B";"unknown";""
"Pipamperone";"NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1";"17-26h [L1522]";"N05AD05";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";"antagonist"
"Propacetamol";"CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1";"The half-life of propacetamol is of 3.6 h.[L1509]";"N02BE05";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"antagonist"
"Propacetamol";"CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1";"The half-life of propacetamol is of 3.6 h.[L1509]";"N02BE05";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"antagonist"
"Propacetamol";"CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1";"The half-life of propacetamol is of 3.6 h.[L1509]";"N02BE05";"Transient receptor potential cation channel subfamily V member 1";"TRPV1";"yes";"antagonist"
"Propacetamol";"CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1";"The half-life of propacetamol is of 3.6 h.[L1509]";"N02BE05";"Cannabinoid receptor 1";"CNR1";"yes";"antagonist"
"Tianeptine";"CN1C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=C(C=C(Cl)C=C2)S1(=O)=O";"2.5h [L14529]";"N06AX14";"Sodium-dependent serotonin transporter";"SLC6A4";"unknown";""
"Tianeptine";"CN1C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=C(C=C(Cl)C=C2)S1(=O)=O";"2.5h [L14529]";"N06AX14";"5-hydroxytryptamine receptor 1A";"HTR1A";"unknown";"antagonist"
"Tianeptine";"CN1C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=C(C=C(Cl)C=C2)S1(=O)=O";"2.5h [L14529]";"N06AX14";"Glutamate receptor 1";"GRIA1";"unknown";""
"Sacubitril";"[H][C@@](CC1=CC=C(C=C1)C1=CC=CC=C1)(C[C@@]([H])(C)C(=O)OCC)NC(=O)CCC(O)=O";"The half life of sacubitril is 1.1 to 3.6 hours, and the half life of it's metabolite LBQ657 is 9.9 to 11.1 hours.";"C09DX04";"Neprilysin";"MME";"yes";"antagonistinhibitor"
"Ombitasvir";"COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1";"Ombitasvir has a half life of elimination of 21-25 hours [FDA Label]";"J05AX67";"Nonstructural protein 5A";"NS5A";"yes";"inhibitor"
"Ombitasvir";"COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1";"Ombitasvir has a half life of elimination of 21-25 hours [FDA Label]";"J05AX66";"Nonstructural protein 5A";"NS5A";"yes";"inhibitor"
"Paritaprevir";"[H][C@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=NC=C(C)N=C1)OC1=NC2=CC=CC=C2C2=CC=CC=C12)C(=O)NS(=O)(=O)C1CC1";"5.5 hr [FDA Label]";"J05AX67";"NS3/4A protein";"NS3/4A";"yes";"inhibitor"
"Paritaprevir";"[H][C@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=NC=C(C)N=C1)OC1=NC2=CC=CC=C2C2=CC=CC=C12)C(=O)NS(=O)(=O)C1CC1";"5.5 hr [FDA Label]";"J05AX66";"NS3/4A protein";"NS3/4A";"yes";"inhibitor"
"Tenofovir alafenamide";"CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1";"0.51 h";"J05AR19";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir alafenamide";"CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1";"0.51 h";"J05AR18";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Tenofovir alafenamide";"CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1";"0.51 h";"J05AR17";"Reverse transcriptase/RNaseH";"pol";"yes";"inhibitor"
"Butylscopolamine";"CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"The half life of elimination is 1-5 hours [A7905].";"A03BB01";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Butylscopolamine";"CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"The half life of elimination is 1-5 hours [A7905].";"A03DB04";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Butylscopolamine";"CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"The half life of elimination is 1-5 hours [A7905].";"A03BB01";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Butylscopolamine";"CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1";"The half life of elimination is 1-5 hours [A7905].";"A03DB04";"Muscarinic acetylcholine receptor M2";"CHRM2";"unknown";"antagonist"
"Benzathine benzylpenicillin";"[H][N+]([H])(CC[N+]([H])([H])CC1=CC=CC=C1)CC1=CC=CC=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O";"In adults with normal renal function is reportedly 0.4–0.9 hours.";"J01CR50";"Penicillin-binding protein 2";"penA";"unknown";"binding"
"Benzathine benzylpenicillin";"[H][N+]([H])(CC[N+]([H])([H])CC1=CC=CC=C1)CC1=CC=CC=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O";"In adults with normal renal function is reportedly 0.4–0.9 hours.";"J01CE08";"Penicillin-binding protein 2";"penA";"unknown";"binding"
"Benzathine benzylpenicillin";"[H][N+]([H])(CC[N+]([H])([H])CC1=CC=CC=C1)CC1=CC=CC=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O";"In adults with normal renal function is reportedly 0.4–0.9 hours.";"J01CR50";"Beta-lactam-inducible penicillin-binding protein";"pbp";"unknown";"binding"
"Benzathine benzylpenicillin";"[H][N+]([H])(CC[N+]([H])([H])CC1=CC=CC=C1)CC1=CC=CC=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C([O-])=O";"In adults with normal renal function is reportedly 0.4–0.9 hours.";"J01CE08";"Beta-lactam-inducible penicillin-binding protein";"pbp";"unknown";"binding"
"Sulbactam";"[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O";"~1 hr";"J01CR50";"Beta-lactamase";"blaZ";"yes";"inhibitor"
"Sulbactam";"[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O";"~1 hr";"J01CG01";"Beta-lactamase";"blaZ";"yes";"inhibitor"
"Iopodic acid";"CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I";"";"V08AC10";"Thyroxine 5-deiodinase";"DIO3";"yes";"antagonist"
"Iopodic acid";"CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I";"";"V08AC08";"Thyroxine 5-deiodinase";"DIO3";"yes";"antagonist"
"Mersalyl";"COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O";"";"C03BC01";"Alkaline phosphatase, tissue-nonspecific isozyme";"ALPL";"unknown";"antagonist"
"Mersalyl";"COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O";"";"C03BC01";"Aquaporin-1";"AQP1";"unknown";""
"Mersalyl";"COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O";"";"C03BC01";"Monocarboxylate transporter 1";"SLC16A1";"unknown";"antagonist"
"Dexpanthenol";"CC(C)(CO)[C@@H](O)C(=O)NCCCO";"Half life have not been reported";"D03AX03";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Dexpanthenol";"CC(C)(CO)[C@@H](O)C(=O)NCCCO";"Half life have not been reported";"A11HA30";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Dexpanthenol";"CC(C)(CO)[C@@H](O)C(=O)NCCCO";"Half life have not been reported";"S01XA12";"Muscarinic acetylcholine receptor M3";"CHRM3";"yes";"antagonist"
"Norethynodrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3";"";"G03FA09";"Estrogen receptor alpha";"ESR1";"unknown";""
"Norethynodrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3";"";"G03FA09";"Androgen receptor";"AR";"unknown";""
"Norethynodrel";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3";"";"G03FA09";"Sex hormone-binding globulin";"SHBG";"unknown";""
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03FB01";"Progesterone receptor";"PGR";"yes";"binder"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03AA06";"Progesterone receptor";"PGR";"yes";"binder"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03FA10";"Progesterone receptor";"PGR";"yes";"binder"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03FB01";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03AA06";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03FA10";"3-oxo-5-alpha-steroid 4-dehydrogenase 1";"SRD5A1";"yes";"inhibitor"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03FB01";"Androgen receptor";"AR";"unknown";"agonist"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03AA06";"Androgen receptor";"AR";"unknown";"agonist"
"Norgestrel";"CCC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C";"";"G03FA10";"Androgen receptor";"AR";"unknown";"agonist"
"Protirelin";"[H][C@@](CC1=CN=CN1)(NC(=O)[C@]1([H])CCC(=O)N1)C(=O)N1CCC[C@@]1([H])C(N)=O";"";"V04CJ02";"Thyrotropin Releasing Hormone Receptor";"TRHR";"yes";"ligand"
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Peroxisome proliferator-activated receptor delta";"PPARD";"yes";"agonist"
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Peroxisome proliferator-activated receptor delta";"PPARD";"yes";"agonist"
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Hematopoietic prostaglandin D synthase";"HPGDS";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Endoglucanase G";"celCCG";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Endoglucanase G";"celCCG";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Glutathione S-transferase P";"GSTP1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Group IIE secretory phospholipase A2";"PLA2G2E";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Inositol-3-phosphate synthase 1";"ISYNA1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Inositol-3-phosphate synthase 1";"ISYNA1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"C4-dicarboxylate transport transcriptional regulatory protein DctD";"dctD";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"C4-dicarboxylate transport transcriptional regulatory protein DctD";"dctD";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Alcohol dehydrogenase 1B";"ADH1B";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Alcohol dehydrogenase 1B";"ADH1B";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Inositol 1,4,5-trisphosphate receptor type 1";"ITPR1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Inositol 1,4,5-trisphosphate receptor type 1";"ITPR1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Glycodelin";"PAEP";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Glycodelin";"PAEP";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Alpha-N-acetylgalactosaminidase";"NAGA";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Alpha-N-acetylgalactosaminidase";"NAGA";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Cytochrome c4";"cc4";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Cytochrome c4";"cc4";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Bacterioferritin";"bfr";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Bacterioferritin";"bfr";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"TGF-beta receptor type-2";"TGFBR2";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"TGF-beta receptor type-2";"TGFBR2";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Argininosuccinate synthase";"argG";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Argininosuccinate synthase";"argG";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Enolase";"eno";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Enolase";"eno";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"ADP-ribosylation factor 1";"ARF1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"ADP-ribosylation factor 1";"ARF1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Multidrug resistance protein MexA";"mexA";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Multidrug resistance protein MexA";"mexA";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1";"PAPSS1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1";"PAPSS1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Histidinol dehydrogenase";"hisD";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Histidinol dehydrogenase";"hisD";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"DNA mismatch repair protein MutL";"mutL";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"DNA mismatch repair protein MutL";"mutL";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Glycerol uptake facilitator protein";"glpF";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Glycerol uptake facilitator protein";"glpF";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"Ribonucleoside-diphosphate reductase 1 subunit beta";"nrdB";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"Ribonucleoside-diphosphate reductase 1 subunit beta";"nrdB";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"A/G-specific adenine glycosylase";"mutY";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"A/G-specific adenine glycosylase";"mutY";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AG04";"tRNA (cytosine(38)-C(5))-methyltransferase";"TRDMT1";"unknown";""
"Glycerin";"OCC(O)CO";"30 - 45 minutes";"A06AX01";"tRNA (cytosine(38)-C(5))-methyltransferase";"TRDMT1";"unknown";""
"Sodium sulfate";"[Na+].[Na+].[O-]S([O-])(=O)=O";"Serum sulfate: 8.5 hours";"A12CA02";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Sodium sulfate";"[Na+].[Na+].[O-]S([O-])(=O)=O";"Serum sulfate: 8.5 hours";"A06AD13";"Carbonic anhydrase 2";"CA2";"yes";"inhibitor"
"Sodium sulfate";"[Na+].[Na+].[O-]S([O-])(=O)=O";"Serum sulfate: 8.5 hours";"A12CA02";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Sodium sulfate";"[Na+].[Na+].[O-]S([O-])(=O)=O";"Serum sulfate: 8.5 hours";"A06AD13";"Carbonic anhydrase 1";"CA1";"yes";"inhibitor"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A02AA01";"Glutamate (NMDA) receptor";"GRIN1";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"V03AE04";"Glutamate (NMDA) receptor";"GRIN1";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A06AD01";"Glutamate (NMDA) receptor";"GRIN1";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A02AA01";"Glutamate (NMDA) receptor";"GRIN2A";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"V03AE04";"Glutamate (NMDA) receptor";"GRIN2A";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A06AD01";"Glutamate (NMDA) receptor";"GRIN2A";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A02AA01";"Glutamate (NMDA) receptor";"GRIN2B";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"V03AE04";"Glutamate (NMDA) receptor";"GRIN2B";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A06AD01";"Glutamate (NMDA) receptor";"GRIN2B";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A02AA01";"Glutamate (NMDA) receptor";"GRIN2C";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"V03AE04";"Glutamate (NMDA) receptor";"GRIN2C";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A06AD01";"Glutamate (NMDA) receptor";"GRIN2C";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A02AA01";"Glutamate (NMDA) receptor";"GRIN2D";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"V03AE04";"Glutamate (NMDA) receptor";"GRIN2D";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A06AD01";"Glutamate (NMDA) receptor";"GRIN2D";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A02AA01";"Glutamate (NMDA) receptor";"GRIN3A";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"V03AE04";"Glutamate (NMDA) receptor";"GRIN3A";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A06AD01";"Glutamate (NMDA) receptor";"GRIN3A";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A02AA01";"Glutamate (NMDA) receptor";"GRIN3B";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"V03AE04";"Glutamate (NMDA) receptor";"GRIN3B";"unknown";"blocker"
"Magnesium carbonate";"[Mg++].[O-]C([O-])=O";"Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [L593].";"A06AD01";"Glutamate (NMDA) receptor";"GRIN3B";"unknown";"blocker"
"Acrivastine";"[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O";"The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.";"R06AX18";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Hydroquinone";"OC1=CC=C(O)C=C1";"";"D11AX11";"Tyrosinase";"TYR";"yes";"inhibitor"
"Phenyl salicylate";"OC1=CC=CC=C1C(=O)OC1=CC=CC=C1";"";"G04BX12";"Estrogen receptor alpha";"ESR1";"unknown";""
"Aluminum chloride";"Cl[Al](Cl)Cl";"";"D10AX01";"Glutamate dehydrogenase 1, mitochondrial";"GLUD1";"unknown";"inactivator"
"Resorcinol";"OC1=CC(O)=CC=C1";"";"S01AX06";"Thyroid peroxidase";"TPO";"unknown";""
"Resorcinol";"OC1=CC(O)=CC=C1";"";"D10AX02";"Thyroid peroxidase";"TPO";"unknown";""
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Extracellular calcium-sensing receptor";"CASR";"yes";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Extracellular calcium-sensing receptor";"CASR";"yes";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calreticulin";"CALR";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calreticulin";"CALR";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calcium and integrin-binding protein 1";"CIB1";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calcium and integrin-binding protein 1";"CIB1";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Programmed cell death protein 6";"PDCD6";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Programmed cell death protein 6";"PDCD6";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Sorcin";"SRI";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Sorcin";"SRI";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calcineurin B homologous protein 1";"CHP1";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calcineurin B homologous protein 1";"CHP1";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"SPARC";"SPARC";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"SPARC";"SPARC";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calnexin";"CANX";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calnexin";"CANX";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Fibrillin-2";"FBN2";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Fibrillin-2";"FBN2";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Protein S100-B";"S100B";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Protein S100-B";"S100B";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calsequestrin-2";"CASQ2";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calsequestrin-2";"CASQ2";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Regucalcin";"RGN";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Regucalcin";"RGN";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Peflin";"PEF1";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Peflin";"PEF1";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Protein S100-A6";"S100A6";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Protein S100-A6";"S100A6";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Translationally-controlled tumor protein";"TPT1";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Translationally-controlled tumor protein";"TPT1";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calcium and integrin-binding family member 2";"CIB2";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calcium and integrin-binding family member 2";"CIB2";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Protein S100-A13";"S100A13";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Protein S100-A13";"S100A13";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calsequestrin-1";"CASQ1";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calsequestrin-1";"CASQ1";"no";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Nucleobindin-1";"NUCB1";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Nucleobindin-1";"NUCB1";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Nucleobindin-2";"NUCB2";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Nucleobindin-2";"NUCB2";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calmodulin";"CALM1";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calmodulin";"CALM1";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Fibrillin-3";"FBN3";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Fibrillin-3";"FBN3";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Grancalcin";"GCA";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Grancalcin";"GCA";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calcium-dependent secretion activator 1";"CADPS";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calcium-dependent secretion activator 1";"CADPS";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calmodulin-2";"CALM2";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calmodulin-2";"CALM2";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calmodulin-3";"CALM3";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calmodulin-3";"CALM3";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Protein S100-A16";"S100A16";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Protein S100-A16";"S100A16";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calretinin";"CALB2";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calretinin";"CALB2";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calcyphosin";"CAPS";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calcyphosin";"CAPS";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calcium-dependent secretion activator 2";"CADPS2";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calcium-dependent secretion activator 2";"CADPS2";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Calreticulin-3";"CALR3";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Calreticulin-3";"CALR3";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Neurexin-1";"NRXN1";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Neurexin-1";"NRXN1";"unknown";"agonist"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A11GB01";"Neuronal calcium sensor 1";"NCS1";"unknown";"ligand"
"Calcium Citrate";"[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O";"";"A12AA13";"Neuronal calcium sensor 1";"NCS1";"unknown";"ligand"
"Pyrantel";"[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1";"In pigs, following intravenous administration, pyrantel exhibited a half-life of 1.75 +/- 0.19 h [A32291].";"P02CC01";"G-protein coupled receptor 35";"GPR35";"unknown";""
"Pyrantel";"[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1";"In pigs, following intravenous administration, pyrantel exhibited a half-life of 1.75 +/- 0.19 h [A32291].";"P02CC01";"Muscarinic acetylcholine receptor M1";"CHRM1";"no";"antagonistagonist"
"Anthralin";"OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2";"";"D05AC51";"Keratin, type II cytoskeletal 2 epidermal";"KRT2";"yes";"antagonist"
"Anthralin";"OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2";"";"D05AC01";"Keratin, type II cytoskeletal 2 epidermal";"KRT2";"yes";"antagonist"
"Anthralin";"OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2";"";"D05AC51";"C-Jun-amino-terminal kinase-interacting protein 1";"MAPK8IP1";"unknown";"agonist"
"Anthralin";"OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2";"";"D05AC01";"C-Jun-amino-terminal kinase-interacting protein 1";"MAPK8IP1";"unknown";"agonist"
"Anthralin";"OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2";"";"D05AC51";"Keratin, type I cytoskeletal 12";"KRT12";"yes";"antagonist"
"Anthralin";"OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2";"";"D05AC01";"Keratin, type I cytoskeletal 12";"KRT12";"yes";"antagonist"
"Homatropine";"[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C";"";"S01FA05";"Liver carboxylesterase 1";"CES1";"unknown";""
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Extracellular calcium-sensing receptor";"CASR";"yes";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Extracellular calcium-sensing receptor";"CASR";"yes";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calreticulin";"CALR";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calreticulin";"CALR";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calcium and integrin-binding protein 1";"CIB1";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calcium and integrin-binding protein 1";"CIB1";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Programmed cell death protein 6";"PDCD6";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Programmed cell death protein 6";"PDCD6";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Sorcin";"SRI";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Sorcin";"SRI";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calcineurin B homologous protein 1";"CHP1";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calcineurin B homologous protein 1";"CHP1";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"SPARC";"SPARC";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"SPARC";"SPARC";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calnexin";"CANX";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calnexin";"CANX";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Fibrillin-2";"FBN2";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Fibrillin-2";"FBN2";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Protein S100-B";"S100B";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Protein S100-B";"S100B";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calsequestrin-2";"CASQ2";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calsequestrin-2";"CASQ2";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Regucalcin";"RGN";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Regucalcin";"RGN";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Peflin";"PEF1";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Peflin";"PEF1";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Protein S100-A6";"S100A6";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Protein S100-A6";"S100A6";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Translationally-controlled tumor protein";"TPT1";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Translationally-controlled tumor protein";"TPT1";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calcium and integrin-binding family member 2";"CIB2";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calcium and integrin-binding family member 2";"CIB2";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Protein S100-A13";"S100A13";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Protein S100-A13";"S100A13";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calsequestrin-1";"CASQ1";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calsequestrin-1";"CASQ1";"no";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Nucleobindin-1";"NUCB1";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Nucleobindin-1";"NUCB1";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Nucleobindin-2";"NUCB2";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Nucleobindin-2";"NUCB2";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calmodulin";"CALM1";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calmodulin";"CALM1";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Fibrillin-3";"FBN3";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Fibrillin-3";"FBN3";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Grancalcin";"GCA";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Grancalcin";"GCA";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calcium-dependent secretion activator 1";"CADPS";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calcium-dependent secretion activator 1";"CADPS";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calmodulin-2";"CALM2";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calmodulin-2";"CALM2";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calmodulin-3";"CALM3";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calmodulin-3";"CALM3";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Protein S100-A16";"S100A16";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Protein S100-A16";"S100A16";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calretinin";"CALB2";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calretinin";"CALB2";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calcyphosin";"CAPS";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calcyphosin";"CAPS";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calcium-dependent secretion activator 2";"CADPS2";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calcium-dependent secretion activator 2";"CADPS2";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Calreticulin-3";"CALR3";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Calreticulin-3";"CALR3";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Neurexin-1";"NRXN1";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Neurexin-1";"NRXN1";"unknown";"agonist"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A11GB01";"Neuronal calcium sensor 1";"NCS1";"unknown";"ligand"
"Calcium Phosphate";"[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O";"";"A12AA01";"Neuronal calcium sensor 1";"NCS1";"unknown";"ligand"
"Selexipag";"CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1";"Selexipag's terminal half life is 0.8-2.5 hours. The active metabolite's terminal half life is 6.2-13.5 hours.";"B01AC27";"Prostacyclin receptor";"PTGIR";"yes";"agonist"
"Cefroxadine";"[H][C@]12SCC(OC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O";"The serum half life is 0.9-1.1 h [A20320].";"J01DB11";"Penicillin-binding protein 1B";"mrcB";"yes";"inhibitor"
"Chlorobutanol";"CC(C)(O)C(Cl)(Cl)Cl";"";"A04AD04";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Chlorobutanol";"CC(C)(O)C(Cl)(Cl)Cl";"";"A04AD54";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"unknown";""
"Lesinurad";"OC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2";"";"M04AB05";"Solute carrier family 22 member 12";"SLC22A12";"yes";"inhibitor"
"Lesinurad";"OC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2";"";"M04AB05";"Solute carrier family 22 member 11";"SLC22A11";"yes";"inhibitor"
"Indigotindisulfonic Acid";"OS(=O)(=O)C1=CC2=C(N\C(C2=O)=C2\NC3=C(C=C(C=C3)S(O)(=O)=O)C2=O)C=C1";"";"V04CH02";"Aryl hydrocarbon receptor";"AHR";"unknown";""
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRA1";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRA1";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRA2";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRA2";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRA3";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRA3";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRA4";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRA4";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRA5";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRA5";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRA6";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRA6";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRB1";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRB1";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRB2";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRB2";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRB3";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRB3";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRD";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRD";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRE";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRE";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRG1";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRG1";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRG2";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRG2";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRG3";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRG3";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRP";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRP";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"GABA-A receptor (anion channel)";"GABRQ";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"GABA-A receptor (anion channel)";"GABRQ";"yes";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"Glycine receptor subunit alpha-1";"GLRA1";"unknown";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX55";"Tumor necrosis factor ligand superfamily member 11";"TNFSF11";"unknown";"antagonist"
"Thiocolchicoside";"COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC";"Approximately 7.7h [L1670].";"M03BX05";"Tumor necrosis factor ligand superfamily member 11";"TNFSF11";"unknown";"antagonist"
"Asunaprevir";"[H][C@@](N=C(O)OC(C)(C)C)(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=NC=C(OC)C2=C1C=C(Cl)C=C2)C(C)(C)C";"";"J05AE15";"Hepatitis C virus NS3 protease/helicase";"NS3";"yes";"antagonist"
"Thimerosal";"CC[Hg]SC1=CC=CC=C1C(=O)O[Na]";"A study was done to study the pharmacokinetics of Thimerosal in mice. Estimated half-lives (in days) were 8.8 for blood, 10.7 for brain, 7.8 for heart, 7.7 for liver and 45.2 for kidney [L1685].

The the long half-life of ethylmercury (~50 days on average in humans) results in accumulation that may be harmful to the developing fetal brain, as it is more susceptible to organomercurial compounds than the adult brain [L1687].";"D08AK06";"Methionine synthase";"MTR";"unknown";"antagonist"
"Thimerosal";"CC[Hg]SC1=CC=CC=C1C(=O)O[Na]";"A study was done to study the pharmacokinetics of Thimerosal in mice. Estimated half-lives (in days) were 8.8 for blood, 10.7 for brain, 7.8 for heart, 7.7 for liver and 45.2 for kidney [L1685].

The the long half-life of ethylmercury (~50 days on average in humans) results in accumulation that may be harmful to the developing fetal brain, as it is more susceptible to organomercurial compounds than the adult brain [L1687].";"D08AK06";"Cystine/glutamate transporter";"SLC7A11";"unknown";"antagonist"
"Thimerosal";"CC[Hg]SC1=CC=CC=C1C(=O)O[Na]";"A study was done to study the pharmacokinetics of Thimerosal in mice. Estimated half-lives (in days) were 8.8 for blood, 10.7 for brain, 7.8 for heart, 7.7 for liver and 45.2 for kidney [L1685].

The the long half-life of ethylmercury (~50 days on average in humans) results in accumulation that may be harmful to the developing fetal brain, as it is more susceptible to organomercurial compounds than the adult brain [L1687].";"D08AK06";"Sodium/potassium-transporting ATPase subunit gamma";"FXYD2";"unknown";"antagonist"
"Bilastine";"CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1";"The mean half life of elimination is 14.5h [FDA Label].";"R06AX29";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Levoleucovorin";"NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1";"The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.";"V03AF04";"Serine hydroxymethyltransferase";"glyA";"unknown";""
"Levoleucovorin";"NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1";"The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.";"V03AF10";"Serine hydroxymethyltransferase";"glyA";"unknown";""
"Levoleucovorin";"NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1";"The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.";"V03AF04";"Dihydrofolate reductase";"folA";"unknown";""
"Levoleucovorin";"NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1";"The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.";"V03AF10";"Dihydrofolate reductase";"folA";"unknown";""
"Rupatadine";"CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1";"The half life of elimination is 15.9 h in children 2-5 years old, 12.3 h in children 6-11 years old, 5.9 h in adults, and 8.7 h in geriatric patients [FDA Label].";"R06AX28";"Platelet-activating factor receptor";"PTAFR";"yes";"antagonist"
"Rupatadine";"CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1";"The half life of elimination is 15.9 h in children 2-5 years old, 12.3 h in children 6-11 years old, 5.9 h in adults, and 8.7 h in geriatric patients [FDA Label].";"R06AX28";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Gestrinone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Plasma half-life is 24 hr [L1695].";"G03XA02";"Sex hormone-binding globulin";"SHBG";"unknown";"antagonist"
"Gestrinone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Plasma half-life is 24 hr [L1695].";"G03XA02";"Progesterone receptor";"PGR";"unknown";"antagonistagonist"
"Gestrinone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Plasma half-life is 24 hr [L1695].";"G03XA02";"Glucocorticoid receptor";"NR3C1";"unknown";"antagonist"
"Gestrinone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Plasma half-life is 24 hr [L1695].";"G03XA02";"Androgen receptor";"AR";"unknown";"antagonist"
"Gestrinone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Plasma half-life is 24 hr [L1695].";"G03XA02";"Gonadotropin-releasing hormone receptor";"GNRHR";"unknown";"antagonist"
"Gestrinone";"[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]";"Plasma half-life is 24 hr [L1695].";"G03XA02";"Estrogen receptor alpha";"ESR1";"unknown";"antagonistagonist"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"Lanosterol 14-alpha demethylase";"ERG11";"yes";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"Voltage-dependent L-type calcium channel subunit alpha-1C";"CACNA1C";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"G protein-activated inward rectifier potassium channel 2";"KCNJ6";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"G protein-activated inward rectifier potassium channel 3";"KCNJ9";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"ATP-sensitive inward rectifier potassium channel 11";"KCNJ11";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"Potassium voltage-gated channel subfamily A member 5";"KCNA5";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"Potassium voltage-gated channel subfamily D member 3";"KCND3";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"Potassium voltage-gated channel subfamily KQT member 1";"KCNQ1";"no";"inhibitor"
"Isavuconazole";"[H][C@](C)(C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1";"Based on a population pharmacokinetics analysis of healthy subjects and patients, the mean plasma half-life of isavuconazole was 130 hours [FDA label]. The mean half life following oral and intravenous administration of 400 mg isavuconazole was 110 and 115 hours, respectively [L1482].";"J02AC05";"Sodium channel protein type 5 subunit alpha";"SCN5A";"no";"inhibitor"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Actin, cytoplasmic 2";"ACTG1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Actin, cytoplasmic 2";"ACTG1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Alpha-aminoadipic semialdehyde dehydrogenase";"ALDH7A1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Alpha-aminoadipic semialdehyde dehydrogenase";"ALDH7A1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Annexin A2";"ANXA2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Annexin A2";"ANXA2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"ATP synthase subunit alpha, mitochondrial";"ATP5A1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"ATP synthase subunit alpha, mitochondrial";"ATP5A1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"ATP synthase subunit g, mitochondrial";"ATP5L";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"ATP synthase subunit g, mitochondrial";"ATP5L";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"ATP synthase subunit O, mitochondrial";"ATP5O";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"ATP synthase subunit O, mitochondrial";"ATP5O";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Calpastatin";"CAST";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Calpastatin";"CAST";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"T-complex protein 1 subunit gamma";"CCT3";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"T-complex protein 1 subunit gamma";"CCT3";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Cofilin-1";"CFL1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Cofilin-1";"CFL1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Chloride intracellular channel protein 1";"CLIC1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Chloride intracellular channel protein 1";"CLIC1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Cysteine and glycine-rich protein 1";"CSRP1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Cysteine and glycine-rich protein 1";"CSRP1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Dihydropyrimidinase-related protein 2";"DPYSL2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Dihydropyrimidinase-related protein 2";"DPYSL2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Desmoplakin";"DSP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Desmoplakin";"DSP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Elongation factor 1-alpha 1";"EEF1A1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Elongation factor 1-alpha 1";"EEF1A1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Alpha-enolase";"ENO1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Alpha-enolase";"ENO1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Filamin-A";"FLNA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Filamin-A";"FLNA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Alpha-ketoglutarate-dependent dioxygenase FTO";"FTO";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Alpha-ketoglutarate-dependent dioxygenase FTO";"FTO";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glucose-6-phosphate 1-dehydrogenase";"G6PD";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glucose-6-phosphate 1-dehydrogenase";"G6PD";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific";"GAPDHS";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glyceraldehyde-3-phosphate dehydrogenase, testis-specific";"GAPDHS";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glucose-6-phosphate isomerase";"GPI";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glucose-6-phosphate isomerase";"GPI";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heterogeneous nuclear ribonucleoproteins A2/B1";"HNRNPA2B1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heterogeneous nuclear ribonucleoproteins A2/B1";"HNRNPA2B1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heterogeneous nuclear ribonucleoprotein D0";"HNRNPD";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heterogeneous nuclear ribonucleoprotein D0";"HNRNPD";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heterogeneous nuclear ribonucleoprotein K";"HNRNPK";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heterogeneous nuclear ribonucleoprotein K";"HNRNPK";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heterochromatin protein 1-binding protein 3";"HP1BP3";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heterochromatin protein 1-binding protein 3";"HP1BP3";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heat shock protein beta-1";"HSPB1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heat shock protein beta-1";"HSPB1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Ras GTPase-activating-like protein IQGAP1";"IQGAP1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Ras GTPase-activating-like protein IQGAP1";"IQGAP1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Far upstream element-binding protein 2";"KHSRP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Far upstream element-binding protein 2";"KHSRP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"L-lactate dehydrogenase A chain";"LDHA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"L-lactate dehydrogenase A chain";"LDHA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"L-lactate dehydrogenase B chain";"LDHB";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"L-lactate dehydrogenase B chain";"LDHB";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Galectin-1";"LGALS1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Galectin-1";"LGALS1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Microtubule-associated protein 4";"MAP4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Microtubule-associated protein 4";"MAP4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Malate dehydrogenase, cytoplasmic";"MDH1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Malate dehydrogenase, cytoplasmic";"MDH1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Puromycin-sensitive aminopeptidase";"NPEPPS";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Puromycin-sensitive aminopeptidase";"NPEPPS";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Profilin-1";"PFN1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Profilin-1";"PFN1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Phosphoglycerate kinase 1";"PGK1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Phosphoglycerate kinase 1";"PGK1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Pyruvate kinase PKM";"PKM";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Pyruvate kinase PKM";"PKM";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Peptidyl-prolyl cis-trans isomerase A";"PPIA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Peptidyl-prolyl cis-trans isomerase A";"PPIA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Peroxiredoxin-1";"PRDX1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Peroxiredoxin-1";"PRDX1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L10";"RPL10";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L10";"RPL10";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L14";"RPL14";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L14";"RPL14";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L18";"RPL18";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L18";"RPL18";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L23a";"RPL23A";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L23a";"RPL23A";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L35";"RPL35";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L35";"RPL35";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L4";"RPL4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L4";"RPL4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S13";"RPS13";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S13";"RPS13";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S17";"RPS17";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S17";"RPS17";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S18";"RPS18";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S18";"RPS18";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S19";"RPS19";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S19";"RPS19";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S28";"RPS28";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S28";"RPS28";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S5";"RPS5";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S5";"RPS5";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S6";"RPS6";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S6";"RPS6";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S8";"RPS8";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S8";"RPS8";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S9";"RPS9";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S9";"RPS9";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Splicing factor 1";"SF1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Splicing factor 1";"SF1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Splicing factor, proline- and glutamine-rich";"SFPQ";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Splicing factor, proline- and glutamine-rich";"SFPQ";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Small nuclear ribonucleoprotein Sm D2";"SNRPD2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Small nuclear ribonucleoprotein Sm D2";"SNRPD2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Signal recognition particle 14 kDa protein";"SRP14";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Signal recognition particle 14 kDa protein";"SRP14";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Serine/arginine-rich splicing factor 4";"SRSF4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Serine/arginine-rich splicing factor 4";"SRSF4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Transgelin-2";"TAGLN2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Transgelin-2";"TAGLN2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Triosephosphate isomerase";"TPI1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Triosephosphate isomerase";"TPI1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Tropomyosin alpha-1 chain";"TPM1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Tropomyosin alpha-1 chain";"TPM1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Tubulin alpha-1A chain";"TUBA1A";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Tubulin alpha-1A chain";"TUBA1A";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Vimentin";"VIM";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Vimentin";"VIM";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Zyxin";"ZYX";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Zyxin";"ZYX";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heat shock cognate 71 kDa protein";"HSPA8";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heat shock cognate 71 kDa protein";"HSPA8";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Tubulin beta-6 chain";"TUBB6";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Tubulin beta-6 chain";"TUBB6";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Tubulin beta-4A chain";"TUBB4A";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Tubulin beta-4A chain";"TUBB4A";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Tubulin beta chain";"TUBB";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Tubulin beta chain";"TUBB";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Fructose-bisphosphate aldolase A";"ALDOA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Fructose-bisphosphate aldolase A";"ALDOA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glyceraldehyde-3-phosphate dehydrogenase";"GAPDH";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glyceraldehyde-3-phosphate dehydrogenase";"GAPDH";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Cytochrome c";"CYCS";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Cytochrome c";"CYCS";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Phosphoglycerate mutase 1";"PGAM1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Phosphoglycerate mutase 1";"PGAM1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Myosin-9";"MYH9";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Myosin-9";"MYH9";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Protein disulfide-isomerase";"P4HB";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Protein disulfide-isomerase";"P4HB";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Probable ATP-dependent RNA helicase DDX5";"DDX5";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Probable ATP-dependent RNA helicase DDX5";"DDX5";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Serine hydroxymethyltransferase, mitochondrial";"SHMT2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Serine hydroxymethyltransferase, mitochondrial";"SHMT2";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Spliceosome RNA helicase DDX39B";"DDX39B";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Spliceosome RNA helicase DDX39B";"DDX39B";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Temporary name for P06748";"NPM1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Temporary name for P06748";"NPM1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Translationally-controlled tumor protein homolog";"TCTP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Translationally-controlled tumor protein homolog";"TCTP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"P-type Ca2+-transporting ATPase";"serca";"unknown";"antagonist"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"P-type Ca2+-transporting ATPase";"serca";"unknown";"antagonist"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Ornithine aminotransferase";"OAT";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Ornithine aminotransferase";"OAT";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Elongation factor 1-alpha";"MEF-1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Elongation factor 1-alpha";"MEF-1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Multidrug resistance protein";"MDR1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Multidrug resistance protein";"MDR1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Elongation factor 2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Elongation factor 2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Actin-1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Actin-1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glyceraldehyde-3-phosphate dehydrogenase";"GAPDH";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glyceraldehyde-3-phosphate dehydrogenase";"GAPDH";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Fructose-bisphosphate aldolase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Fructose-bisphosphate aldolase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Cell division cycle protein 48 homologue,putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Cell division cycle protein 48 homologue,putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heat shock protein 90";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heat shock protein 90";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Eukaryotic initiation factor 4A";"H45";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Eukaryotic initiation factor 4A";"H45";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Pyruvate kinase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Pyruvate kinase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"L-lactate dehydrogenase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"L-lactate dehydrogenase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Protein disulfide-isomerase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Protein disulfide-isomerase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Thioredoxin-related protein, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Thioredoxin-related protein, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Spermidine synthase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Spermidine synthase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Probable ATP-dependent 6-phosphofructokinase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Probable ATP-dependent 6-phosphofructokinase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glutamate dehydrogenase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glutamate dehydrogenase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Endoplasmin homolog, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Endoplasmin homolog, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Hypoxanthine-guanine-xanthine phosphoribosyltransferase";"LACZ";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Hypoxanthine-guanine-xanthine phosphoribosyltransferase";"LACZ";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Enolase";"ENO";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Enolase";"ENO";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Non-SERCA-type Ca2+-transporting P-ATPase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Non-SERCA-type Ca2+-transporting P-ATPase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Tubulin alpha chain";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Tubulin alpha chain";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Knob-associated histidine-rich protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Knob-associated histidine-rich protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"S-adenosylmethionine synthase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"S-adenosylmethionine synthase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"V-type H(+)-translocating pyrophosphatase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"V-type H(+)-translocating pyrophosphatase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L4";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L4";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Phosphoethanolamine N-methyltransferase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Phosphoethanolamine N-methyltransferase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S3a";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S3a";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Conserved Plasmodium membrane protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Conserved Plasmodium membrane protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"High molecular weight rhoptry protein 2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"High molecular weight rhoptry protein 2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Serine repeat antigen 5";"SERA5";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Serine repeat antigen 5";"SERA5";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S19";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S19";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glycophorin-binding protein";"GBP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glycophorin-binding protein";"GBP";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Calcium-transporting ATPase";"ATP6";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Calcium-transporting ATPase";"ATP6";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"V-type proton ATPase catalytic subunit A";"vapA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"V-type proton ATPase catalytic subunit A";"vapA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Acyl-CoA synthetase";"ACS3";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Acyl-CoA synthetase";"ACS3";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Plasmepsin IV";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Plasmepsin IV";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Plasmepsin-1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Plasmepsin-1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Chloroquine resistance transporter";"CRT";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Chloroquine resistance transporter";"CRT";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"14-3-3 protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"14-3-3 protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Isoleucine--tRNA ligase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Isoleucine--tRNA ligase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Plasmodium exported protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Plasmodium exported protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Tubulin beta chain";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Tubulin beta chain";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L27";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L27";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Sec62, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Sec62, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Autophagy-related protein 18, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Autophagy-related protein 18, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Mature parasite-infected erythrocyte surface antigen";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Mature parasite-infected erythrocyte surface antigen";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Importin-7, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Importin-7, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Peptidyl-prolyl cis-trans isomerase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Peptidyl-prolyl cis-trans isomerase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"DnaJ protein, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"DnaJ protein, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Merozoite surface protein 1";"MSP-1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Merozoite surface protein 1";"MSP-1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glutamate--tRNA ligase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glutamate--tRNA ligase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"T-complex protein 1 subunit eta";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"T-complex protein 1 subunit eta";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Plasmepsin-2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Plasmepsin-2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Chaperone, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Chaperone, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Rhoptry neck protein 3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Rhoptry neck protein 3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S5, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S5, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Skeleton-binding protein 1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Skeleton-binding protein 1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Purine nucleotide phosphorylase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Purine nucleotide phosphorylase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Adenosylhomocysteinase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Adenosylhomocysteinase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Adenosine deaminase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Adenosine deaminase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Methionine--tRNA ligase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Methionine--tRNA ligase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Carbamoyl phosphate synthetase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Carbamoyl phosphate synthetase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Aspartate carbamoyltransferase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Aspartate carbamoyltransferase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Signal recognition particle receptor, beta subunit";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Signal recognition particle receptor, beta subunit";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Parasite-infected erythrocyte surface protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Parasite-infected erythrocyte surface protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Coatomer alpha subunit, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Coatomer alpha subunit, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Hexokinase";"HK";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Hexokinase";"HK";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Proteasome subunit alpha type";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Proteasome subunit alpha type";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Haloacid dehalogenase-like hydrolase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Haloacid dehalogenase-like hydrolase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Insulinase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Insulinase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"40S ribosomal protein S21";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"40S ribosomal protein S21";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Ubiquitin-conjugating enzyme E2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Ubiquitin-conjugating enzyme E2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Eukaryotic translation initiation factor 3 subunit C";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Eukaryotic translation initiation factor 3 subunit C";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L24, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L24, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L23";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L23";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L17, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L17, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"HAP protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"HAP protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Heat shock protein 110, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Heat shock protein 110, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L10, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L10, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Lysophospholipase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Lysophospholipase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Polyadenylate-binding protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Polyadenylate-binding protein";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Ubiquitin-60S ribosomal protein L40";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Ubiquitin-60S ribosomal protein L40";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Thioredoxin peroxidase 1";"TPx1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Thioredoxin peroxidase 1";"TPx1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Protein transport protein SEC31";"Sec31p";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Protein transport protein SEC31";"Sec31p";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Dipeptidyl aminopeptidase 1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Dipeptidyl aminopeptidase 1";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Ring-infected erythrocyte surface antigen";"RESA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Ring-infected erythrocyte surface antigen";"RESA";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"ATP-dependent RNA helicase UAP56";"UAP56";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"ATP-dependent RNA helicase UAP56";"UAP56";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Calcium-dependent protein kinase 4";"CPK4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Calcium-dependent protein kinase 4";"CPK4";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"GTP-binding nuclear protein Ran";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"GTP-binding nuclear protein Ran";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Nucleoside transporter 2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Nucleoside transporter 2";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Anamorsin homolog";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Anamorsin homolog";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Glutamine synthetase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Glutamine synthetase, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L30e, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L30e, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Casein kinase 2, alpha subunit";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Casein kinase 2, alpha subunit";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Threonine--tRNA ligase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Threonine--tRNA ligase";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"cAMP-dependent protein kinase regulatory subunit";"PKAr";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"cAMP-dependent protein kinase regulatory subunit";"PKAr";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Elongation factor 1-gamma, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Elongation factor 1-gamma, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Thioredoxin-like protein";"tlp1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Thioredoxin-like protein";"tlp1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L21";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L21";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"60S ribosomal protein L14, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"60S ribosomal protein L14, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Inner membrane complex sub-compartment protein 3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Inner membrane complex sub-compartment protein 3";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"HSP40, subfamily A, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"HSP40, subfamily A, putative";"";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Pyridoxal 5'-phosphate synthase subunit Pdx1";"pdx1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Pyridoxal 5'-phosphate synthase subunit Pdx1";"pdx1";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BE05";"Serum albumin";"ALB";"unknown";"ligand"
"Artenimol";"[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)C([H])(O)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4";"Artenimol was reported to have a half life of elimination of approximately 1 h [FDA Label].";"P01BF05";"Serum albumin";"ALB";"unknown";"ligand"
"Pitolisant";"ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1";"Pitolisant has a plasma half-life of 10-12 hours [L1471].";"N07XX11";"Histamine H3 receptor";"HRH3";"yes";"antagonistinverse agonist"
"Pitolisant";"ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1";"Pitolisant has a plasma half-life of 10-12 hours [L1471].";"N07XX11";"Potassium voltage-gated channel subfamily H member 2";"KCNH2";"no";"blocker"
"Tropisetron";"[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C";"5.7 h.";"A04AA03";"5-hydroxytryptamine receptor 3A";"HTR3A";"yes";"antagonist"
"Rilmenidine";"C1CC1C(NC1=NCCO1)C1CC1";"";"C02AC06";"Alpha-2A adrenergic receptor";"ADRA2A";"unknown";""
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"Oxysterols receptor LXR-alpha";"NR1H3";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"Oxysterols receptor LXR-beta";"NR1H2";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"Arachidonate 5-lipoxygenase";"ALOX5";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"Cytochrome P450 1A2";"CYP1A2";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"CYP3A";"CYP3A4";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"CYP3A";"CYP3A43";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"CYP3A";"CYP3A5";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"CYP3A";"CYP3A7";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"Cytochrome P450 2E1";"CYP2E1";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"Cytochrome P450 2C9";"CYP2C9";"unknown";"inhibitor"
"Diacerein";"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O";"4-10h [A19300].";"M01AX21";"Cytochrome P450 2D6";"CYP2D6";"unknown";"inhibitor"
"Tulobuterol";"CC(C)(C)NCC(O)C1=CC=CC=C1Cl";"";"R03AC11";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Tulobuterol";"CC(C)(C)NCC(O)C1=CC=CC=C1Cl";"";"R03CC11";"Beta-2 adrenergic receptor";"ADRB2";"unknown";""
"Benzbromarone";"CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=CC=CC=C2O1";"";"M04AB03";"Cytochrome P450 2C9";"CYP2C9";"unknown";"inhibitor"
"Benzbromarone";"CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=CC=CC=C2O1";"";"M04AB03";"Cytochrome P450 2C19";"CYP2C19";"unknown";"inhibitor"
"Ketanserin";"FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1";"";"C02KD01";"5-hydroxytryptamine receptor 2A";"HTR2A";"unknown";"inverse agonist"
"Piribedil";"C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1";"";"N04BC08";"D(2) dopamine receptor";"DRD2";"unknown";""
"Piribedil";"C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1";"";"N04BC08";"D(3) dopamine receptor";"DRD3";"unknown";""
"Dinoprost";"[H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@@]([H])(O)C[C@@]([H])(O)[C@]1([H])C(\[H])=C(/[H])[C@@]([H])(O)CCCCC";"";"G02AD01";"Prostaglandin D2 receptor 2";"PTGDR2";"unknown";"agonist"
"Cortivazol";"C[C@@H]1C[C@H]2[C@@H]3C=C(C)C4=CC5=C(C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O)C=NN5C1=CC=CC=C1";"";"H02AB17";"Glucocorticoid receptor";"NR3C1";"unknown";""
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"D(2) dopamine receptor";"DRD2";"yes";"blocker"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"D(3) dopamine receptor";"DRD3";"yes";"blocker"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR1A";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR1B";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR1D";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR1E";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR1F";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR2A";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR2B";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR2C";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR3A";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR3B";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR3C";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR3D";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR3E";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR4";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR6";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Serotonin Receptors";"HTR7";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Alpha-1 adrenergic receptors";"ADRA1A";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Alpha-1 adrenergic receptors";"ADRA1B";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Alpha-1 adrenergic receptors";"ADRA1D";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Alpha-2 adrenergic receptors";"ADRA2A";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Alpha-2 adrenergic receptors";"ADRA2B";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Alpha-2 adrenergic receptors";"ADRA2C";"yes";"antagonist"
"Tiapride";"CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O";"2.9–3.6 hours";"N05AL03";"Histamine H1 receptor";"HRH1";"yes";"antagonist"
"Macimorelin";"CC(C)(N)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)NC=O";"The mean terminal half-life (T1/2) is 4.1 hours following administration of a single oral dose of 0.5 mg macimorelin/kg body weight in healthy subjects [FDA Label].";"V04CD06";"Growth hormone secretagogue receptor type 1";"GHSR";"unknown";"agonist"
"Clobetasone";"[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl";"N/A";"S01BA09";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Clobetasone";"[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl";"N/A";"S01CA11";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Clobetasone";"[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl";"N/A";"D07AB01";"Glucocorticoid receptor";"NR3C1";"yes";"agonist"
"Zofenopril";"[H][C@@](C)(CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@]([H])(C[C@@]1([H])C(O)=O)SC1=CC=CC=C1";"";"C09BA15";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Zofenopril";"[H][C@@](C)(CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@]([H])(C[C@@]1([H])C(O)=O)SC1=CC=CC=C1";"";"C09AA15";"Angiotensin-converting enzyme";"ACE";"yes";"inhibitor"
"Alclofenac";"OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1";"The plasma half-life varies between 1.5 and 5.5 hours.";"M01AB06";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"antagonist"
"Troleandomycin";"CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O";"";"J01FA08";"50S ribosomal protein L32";"rpmF";"yes";"inhibitor"
"Troleandomycin";"CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O";"";"J01FA08";"50S ribosomal protein L4";"rplD";"yes";"inhibitor"
"Troleandomycin";"CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O";"";"J01FA08";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"activator"
"Phosphocreatine";"CN(CC(O)=O)C(=N)NP(O)(O)=O";"";"C01EB06";"Guanidinoacetate N-methyltransferase";"GAMT";"yes";"product of"
"Phosphocreatine";"CN(CC(O)=O)C(=N)NP(O)(O)=O";"";"C01EB06";"Sodium- and chloride-dependent creatine transporter 1";"SLC6A8";"yes";""
"Phosphocreatine";"CN(CC(O)=O)C(=N)NP(O)(O)=O";"";"C01EB06";"Creatine kinase M-type";"CKM";"yes";"ligand"
"Phosphocreatine";"CN(CC(O)=O)C(=N)NP(O)(O)=O";"";"C01EB06";"Creatine kinase U-type, mitochondrial";"CKMT1A";"yes";"ligand"
"Phosphocreatine";"CN(CC(O)=O)C(=N)NP(O)(O)=O";"";"C01EB06";"Creatine kinase S-type, mitochondrial";"CKMT2";"yes";"ligand"
"Phosphocreatine";"CN(CC(O)=O)C(=N)NP(O)(O)=O";"";"C01EB06";"Creatine kinase B-type";"CKB";"yes";"ligand"
"Metergoline";"[H][C@]1(CN=C(O)OCC2=CC=CC=C2)CN(C)[C@]2([H])CC3=CN(C)C4=CC=CC(=C34)[C@@]2([H])C1";"";"G02CB05";"Sodium channel protein type 2 subunit alpha";"SCN2A";"unknown";"inhibitor"
"Mifamurtide";"O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC";"Following intravenous administration of 4 mg mifamurtide in healthy adult subjects, the half life was 2.05 ± 0.40 hours. In pediatric and adult patients with psteosarcoma, the half life was 2.04 ± 0.456 hours after intravenous infusion of 2 mg/m^2 [L1203].";"L03AX15";"Toll-like receptor 4";"TLR4";"yes";"ligand"
"Mifamurtide";"O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC";"Following intravenous administration of 4 mg mifamurtide in healthy adult subjects, the half life was 2.05 ± 0.40 hours. In pediatric and adult patients with psteosarcoma, the half life was 2.04 ± 0.456 hours after intravenous infusion of 2 mg/m^2 [L1203].";"L03AX15";"Nucleotide-binding oligomerization domain-containing protein 2";"NOD2";"yes";"ligand"
"Xamoterol";"OC(CNCCN=C(O)N1CCOCC1)COC1=CC=C(O)C=C1";"";"C01CX07";"Beta-1 adrenergic receptor";"ADRB1";"yes";"partial agonist"
"Acemetacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O";"The elimination half-life of acemetacin after steady-state is 4.5 hours.[A31356]";"M01AB11";"Prostaglandin G/H synthase 1";"PTGS1";"yes";"antagonist"
"Acemetacin";"COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O";"The elimination half-life of acemetacin after steady-state is 4.5 hours.[A31356]";"M01AB11";"Prostaglandin G/H synthase 2";"PTGS2";"yes";"antagonist"
"Lormetazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl";"The terminal phase half life is 11 h [L927].";"N05CD06";"Gamma-aminobutyric acid receptor subunit alpha-2";"GABRA2";"yes";"positive allosteric modulator"
"Lormetazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl";"The terminal phase half life is 11 h [L927].";"N05CD06";"Gamma-aminobutyric acid receptor subunit gamma-2";"GABRG2";"yes";"positive allosteric modulator"
"Lormetazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl";"The terminal phase half life is 11 h [L927].";"N05CD06";"Gamma-aminobutyric acid receptor subunit alpha-3";"GABRA3";"yes";"positive allosteric modulator"
"Lormetazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl";"The terminal phase half life is 11 h [L927].";"N05CD06";"Gamma-aminobutyric acid receptor subunit alpha-5";"GABRA5";"yes";"positive allosteric modulator"
"Lormetazepam";"CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl";"The terminal phase half life is 11 h [L927].";"N05CD06";"Gamma-aminobutyric acid receptor subunit alpha-1";"GABRA1";"yes";"positive allosteric modulator"
"Fenofibric acid";"CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O";"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].";"C10AB11";"Peroxisome proliferator-activated receptor alpha";"PPARA";"yes";"agonist"
"Fenofibric acid";"CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O";"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].";"C10AB11";"Metalloproteinase";"mmp20";"unknown";"unknown"
"Fenofibric acid";"CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O";"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].";"C10AB11";"Peroxisome proliferator-activated receptor gamma";"PPARG";"unknown";""
"Fenofibric acid";"CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O";"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].";"C10AB11";"Peroxisome proliferator-activated receptor delta";"PPARD";"unknown";"unknown"
"Fenofibric acid";"CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O";"Following once daily dosing, fenofibric acid demonstrates an elimination associated with a half-life of about 20 hours after absorption [FDA Label].";"C10AB11";"Nuclear receptor subfamily 1 group I member 2";"NR1I2";"unknown";"partial agonist"
"Candesartan";"CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1";"";"C09CA06";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Candesartan";"CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1";"";"C09DB07";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"
"Candesartan";"CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1";"";"C09DA06";"Type-1 angiotensin II receptor";"AGTR1";"yes";"antagonist"